A BILL 
To increase the Federal commitment to defeating the virus 
that 
causes 
COVID–19 
and 
prepare 
for 
future 
pandemics, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Commitment to Defeat 
4
the Virus and Keep America Healthy Act’’. 
5
SEC. 2. TABLE OF CONTENTS. 
6
The table of contents for this Act is as follows: 
7
19:08 Nov 24, 2020
H14
2 
•HR 14 IH
Sec. 1. Short title. 
Sec. 2. Table of contents. 
TITLE I—PANDEMIC PREPAREDNESS AND RESPONSE 
Subtitle A—Clarifying the Role of the Department of Health and Human 
Services During Public Health Emergencies 
Sec. 1001. Lead agency for Federal public health and medical response to pub-
lic health emergencies. 
Sec. 1002. Deployment by the Secretary of Health and Human Services of Na-
tional Strategic Stockpile. 
Sec. 1003. Authority and responsibilities of the Federal Emergency Manage-
ment Agency regarding the Strategic National Stockpile. 
Subtitle B—Reagan-Udall Foundation and Foundation for the National 
Institutes of Health 
Sec. 1011. Reagan-Udall Foundation and Foundation for the National Insti-
tutes of Health. 
Subtitle C—Protections for Good Samaritan Health Professionals 
Sec. 1021. Limitation on liability for volunteer health care professionals. 
Sec. 1022. Sense of the Congress. 
Subtitle D—Medical Sheltering 
Sec. 1031. Reducing the spread of COVID–19 through payments to States to 
lease hotels to temporarily house eligible individuals. 
Subtitle E—CDC Campaign on COVID–19 Awareness 
Sec. 1041. COVID–19 public awareness campaign. 
Subtitle F—Protecting Children From COVID–19 
Sec. 1051. Study on children’s role in transmitting SARS–CoV–2. 
Subtitle G—Ensuring Understanding of COVID–19 
Sec. 1061. Study on the impact of COVID–19. 
Subtitle H—Safeguarding Therapeutics 
Sec. 1071. Authority to destroy counterfeit devices. 
Sec. 1072. Determination of budgetary effects. 
Subtitle I—Advisory Committee on Immunization Practices 
Sec. 1081. Expedited meeting of ACIP for COVID–19 vaccines. 
Subtitle J—Improvements to Transparency of the Pricing of Diagnostic 
Testing for COVID–19 
Sec. 1091. Improvements to transparency of the pricing of diagnostic testing 
for COVID–19. 
TITLE II—DOMESTIC MANUFACTURING AND SUPPLY CHAIN 
19:08 Nov 24, 2020
H14
3 
•HR 14 IH
Subtitle A—Sustained On-Shore Manufacturing Capacity for Public Health 
Emergencies 
Sec. 2001. Sustained on-shore manufacturing capacity for public health emer-
gencies. 
Subtitle B—Manufacturing API, Drugs, and Excipients in America 
Sec. 2011. Report to Congress on barriers to domestic manufacturing of med-
ical products and supplies. 
Sec. 2012. Enhancing intra-agency coordination and public health assessment 
with regard to compliance activities. 
Sec. 2013. Encouraging international harmonization. 
Sec. 2014. Mutual recognition agreements for inspections and review activities. 
Sec. 2015. Enhancing transparency of drug facility inspection timelines. 
Sec. 2016. Advanced manufacturing technologies program. 
Subtitle C—Improving the American Drug Supply Chain 
Sec. 2021. Study and reporting on domestic and foreign production. 
Subtitle D—Essential Medicines Strategic Stockpile 
Sec. 2031. Pilot program on ensuring medication supply stability. 
Subtitle E—National Centers of Excellence in Continuous Pharmaceutical 
Manufacturing 
Sec. 2041. National Centers of Excellence in Continuous Pharmaceutical Manu-
facturing. 
TITLE III—STRATEGIC NATIONAL STOCKPILE IMPROVEMENTS 
Subtitle A—Stockpiling for America’s Future Endeavors 
Sec. 3001. Strategic National Stockpile. 
Subtitle B—Stockpile Inventory Modernization 
Sec. 3011. Reimbursable transfers. 
Subtitle C—Equipment Maintenance 
Sec. 3021. Equipment maintenance. 
Subtitle D—Medical Supplies for Pandemics 
Sec. 3031. Supply chain flexibility manufacturing pilot. 
Subtitle E—State Stockpile Readiness 
Sec. 3041. Grants for State strategic stockpiles. 
Subtitle F—Process Improvements and Reports 
Sec. 3051. GAO study on the feasibility and benefits of user fee agreements. 
Sec. 3052. Action reporting. 
Sec. 3053. Improved, transparent processes. 
Subtitle G—Strategic National Stockpile Funding 
19:08 Nov 24, 2020
H14
4 
•HR 14 IH
Sec. 3061. Authorization of appropriations. 
TITLE IV—PUBLIC HEALTH INFRASTRUCTURE IMPROVEMENTS 
Subtitle A—Public Health Infrastructure Modernization 
Sec. 4001. Public health data system transformation. 
Subtitle B—Modernizing Infectious Disease Data Collection 
Sec. 4011. Modernizing infectious disease data collection. 
Subtitle C—Diagnostic Testing for Public Health Labs 
Sec. 4021. Grants for public health laboratories to acquire high-throughput di-
agnostic equipment. 
Subtitle D—Rapid Testing for Communities 
Sec. 4031. Grants for same-day point-of-care clinical laboratory diagnostic test-
ing in communities. 
Subtitle E—Public Health Workforce Loan Repayment 
Sec. 4041. Public Health Workforce Loan Repayment Program. 
Subtitle F—Vaccine Awareness and Disease Prevention 
Sec. 4051. Improving awareness of disease prevention. 
Subtitle G—Protecting the Health of America’s Older Adults During COVID– 
19 & Beyond 
Sec. 4061. National COVID–19 Resource Center for Older Adults. 
Sec. 4062. Healthy Aging Program. 
Sec. 4063. Authorization of appropriations. 
Subtitle H—Expanding Capacity for Health Outcomes 
Sec. 4071. Expanding capacity for health outcomes. 
Subtitle I—Community Readiness 
Sec. 4081. Grants for research on, or establishing, wastewater surveillance and 
other early warning systems. 
TITLE V—ADDRESSING COVID–19 HEALTH DISPARITIES 
Subtitle A—Tribal Health Data Improvement 
Sec. 5001. Collection and availability of health data with respect to Indian 
Tribes. 
Sec. 5002. Improving health statistics reporting with respect to Indian Tribes. 
Subtitle B—Tribal Medical Supplies Stockpile Access 
Sec. 5011. Provision of items to Indian programs and facilities. 
Subtitle C—Native American Suicide Prevention 
Sec. 5021. Native American suicide prevention. 
19:08 Nov 24, 2020
H14
5 
•HR 14 IH
Subtitle D—Pursuing Equity in Mental Health 
PART 1—HEALTH EQUITY AND ACCOUNTABILITY 
Sec. 5031. Integrated Health Care Demonstration Program. 
Sec. 5032. Addressing racial and ethnic minority mental health disparities re-
search gaps. 
Sec. 5033. Health professions competencies to address racial and ethnic minor-
ity mental health disparities. 
Sec. 5034. Racial and ethnic minority behavioral and mental health outreach 
and education strategy. 
Sec. 5035. Additional funds for National Institutes of Health. 
Sec. 5036. Additional funds for National Institute on Minority Health and 
Health Disparities. 
PART 2—OTHER PROVISIONS 
Sec. 5037. Reauthorization of Minority Fellowship Program. 
Sec. 5038. Study on the Effects of Smartphone and Social Media Use on Ado-
lescents. 
Sec. 5039. Technical correction. 
Subtitle E—Maternal Health Quality Improvement 
Sec. 5041. Innovation for maternal health. 
Sec. 5042. Training for health care providers. 
Sec. 5043. Study on training to reduce and prevent discrimination. 
Sec. 5044. Perinatal quality collaboratives. 
Sec. 5045. Integrated services for pregnant and postpartum women. 
Sec. 5046. Improving rural maternal and obstetric care data. 
Sec. 5047. Rural obstetric network grants. 
Sec. 5048. Telehealth network and telehealth resource centers grant programs. 
Sec. 5049. Rural maternal and obstetric care training demonstration. 
TITLE VI—ADDRESSING THE IMPACTS OF COVID–19 ON MENTAL 
HEALTH 
Subtitle A—Creating Resources To Improve Situations of Inherent Severity 
Sec. 6001. Set-aside for evidence-based crisis care services. 
Subtitle B—Emergency Mental Health and Substance Use Training and 
Technical Assistance Center 
Sec. 6011. Emergency mental health and substance use training and technical 
assistance center. 
Subtitle C—Suicide Prevention Grants 
Sec. 6021. Syndromic surveillance of self-harm behaviors program. 
Sec. 6022. Grants to provide self-harm and suicide prevention services. 
Subtitle D—Effective Suicide Screening in the Emergency Department 
Sec. 6031. Program to improve the care provided to patients in the emergency 
department who are at risk of suicide. 
Subtitle E—Suicide Prevention Lifeline Improvement 
19:08 Nov 24, 2020
H14
6 
•HR 14 IH
Sec. 6041. Suicide Prevention Lifeline. 
Sec. 6042. Pilot program on innovative technologies. 
Sec. 6043. HHS study and report. 
Sec. 6044. GAO study and report. 
Sec. 6045. Definition. 
Subtitle F—Campaign To Prevent Suicide 
Sec. 6051. National Suicide Prevention Lifeline. 
Sec. 6052. National suicide prevention media campaign. 
Subtitle G—Helping Emergency Responders Overcome 
Sec. 6061. Data system to capture national public safety officer suicide inci-
dence. 
Sec. 6062. Peer-support behavioral health and wellness programs within fire de-
partments and emergency medical service agencies. 
Sec. 6063. Health care provider behavioral health and wellness programs. 
Sec. 6064. Development of resources for educating mental health professionals 
about treating fire fighters and emergency medical services 
personnel. 
Sec. 6065. Best practices and other resources for addressing posttraumatic 
stress disorder in public safety officers. 
Subtitle H—Behavioral Health Intervention Guidelines 
Sec. 6071. Best practices for behavioral intervention teams. 
Subtitle I—Suicide Training and Awareness Nationally Delivered for 
Universal Prevention 
Sec. 6081. Student suicide awareness and prevention training. 
Sec. 6082. Effective date. 
TITLE VII—ADDRESSING THE IMPACTS OF COVID–19 ON 
SUBSTANCE USE DISORDERS 
Subtitle A—Easy Medication Access and Treatment for Opioid Addiction 
Sec. 7001. Dispensation of narcotic drugs for the purpose of relieving acute 
withdrawal symptoms from opioid use disorder. 
Subtitle B—Access to Remote Behavioral Health Treatment 
Sec. 7011. Registration of qualified community mental health centers. 
Subtitle C—PDMP Pilot Program 
Sec. 7021. Pilot program for integrating substance use disorder and behavioral 
health treatment locator tool into State prescription drug moni-
toring programs. 
Subtitle D—Family Support Services for Addiction 
Sec. 7031. Family support services for individuals struggling with substance 
use disorder. 
Subtitle E—Block, Report, And Suspend Suspicious Shipments 
19:08 Nov 24, 2020
H14
7 
•HR 14 IH
Sec. 7041. Clarification of process for registrants to exercise due diligence upon 
discovering a suspicious order. 
Subtitle F—Debarment Enforcement of Bad Actor Registrants 
Sec. 7051. Debarment of certain registrants. 
Subtitle G—Ensuring Compliance Against Opioid Diversion 
Sec. 7061. Modification, transfer, and termination of registration to manufac-
ture, distribute, or dispense controlled substances. 
Subtitle H—Opioid Prescription Verification 
Sec. 7071. Materials for training pharmacists on certain circumstances under 
which a pharmacist may decline to fill a prescription. 
Sec. 7072. Incentivizing States to facilitate responsible, informed dispensing of 
controlled substances. 
Subtitle I—Suspicious Order Identification 
Sec. 7081. Strengthening ARCOS. 
Sec. 7082. Suspicious Orders Task Force. 
Subtitle J—Stop the Importation and Manufacturing of Synthetic Analogues 
Sec. 7091. Establishment of schedule A. 
Sec. 7092. Temporary and permanent scheduling of schedule A substances. 
Sec. 7093. Penalties. 
Sec. 7094. False labeling of schedule A controlled substances. 
Sec. 7095. Registration requirements for importers and exporters of schedule A 
substances. 
Sec. 7096. Additional conforming amendments. 
Sec. 7097. Sentencing review. 
Sec. 7098. Rules of construction. 
Sec. 7099. Clarification of certain registration requirements related to research. 
Sec. 7100. Review of research registration process. 
TITLE VIII—TAX INCENTIVES TO IMPROVE HEALTH CARE 
Sec. 8001. Domestic medical and drug manufacturing credit. 
Sec. 8002. Qualifying advanced medical manufacturing equipment credit. 
Sec. 8003. New medical research expenditure component of credit for increas-
ing research activities. 
Sec. 8004. Refundable portion of research credit for small businesses engaging 
in specified medical research. 
Sec. 8005. Exception from passive loss rules for investments in specified med-
ical research small business pass-thru entities. 
Sec. 8006. Temporary carryover for health and dependent care flexible spend-
ing arrangements. 
Sec. 8007. Increase in exclusion for employer-provided dependent care assist-
ance. 
Sec. 8008. Temporary increase in contribution limits for health savings ac-
counts. 
Sec. 8009. Temporary allowance of payments for employment-related expenses 
under health savings accounts. 
Sec. 8010. Treatment of direct primary care service arrangements. 
19:08 Nov 24, 2020
H14
8 
•HR 14 IH
Sec. 8011. Allow both spouses to make catch-up contributions to the same HSA 
account. 
Sec. 8012. Repeal of ceiling on deductible and out-of-pocket expenses under a 
high deductible health plan. 
Sec. 8013. On-site employee clinics. 
Sec. 8014. Adjustment of medical expense deduction. 
Sec. 8015. Healthy workplace tax credit. 
TITLE IX—MEDICARE PROVISIONS 
Subtitle A—Telehealth 
Sec. 9001. Removing certain geographic and originating site restrictions on the 
furnishing of telehealth services under the Medicare program. 
Sec. 9002. Making permanent FQHC and RHC telehealth payments. 
Sec. 9003. Expanding the list of practitioners eligible to furnish telehealth serv-
ices. 
Sec. 9004. Allowing for the provision of telehealth services via audio-only tele-
communications systems. 
Sec. 9005. Making permanent the safe harbor for absence of deductible for tele-
health. 
Sec. 9006. Removing requirement for face-to-face visits between home dialysis 
patients and physicians. 
Sec. 9007. Report on telehealth payment integrity. 
Sec. 9008. Increasing funding for review of telehealth claims. 
Sec. 9009. Telehealth resources. 
Subtitle B—Protecting Access to Innovation During COVID–19 
Sec. 9011. Authorizing the extension of pass-through status under the Medicare 
program for certain drugs and devices impacted by COVID–19. 
Subtitle C—Reducing Unnecessary Senior Hospitalizations 
Sec. 9021. SNF-based provision of preventive acute care and hospitalization re-
duction program. 
TITLE X—APPROPRIATIONS 
Sec. 10001. Appropriations. 
Subtitle A—Health Programs 
Subtitle B—General Provisions–This Title 
19:08 Nov 24, 2020
H14
9 
•HR 14 IH
TITLE I—PANDEMIC 
1
PREPAREDNESS AND RESPONSE 
2
Subtitle A—Clarifying the Role of 
3
the Department of Health and 
4
Human Services During Public 
5
Health Emergencies 
6
SEC. 1001. LEAD AGENCY FOR FEDERAL PUBLIC HEALTH 
7
AND 
MEDICAL 
RESPONSE 
TO 
PUBLIC 
8
HEALTH EMERGENCIES. 
9
Section 2801 of the Public Health Service Act (42 
10
U.S.C. 300hh) is amended— 
11
(1) in subsection (a), by inserting after ‘‘shall 
12
lead all Federal public health and medical response 
13
to public health emergencies and incidents’’ the fol-
14
lowing: ‘‘(including emergencies and disasters de-
15
clared by the President pursuant to the National 
16
Emergencies Act or the Robert T. Stafford Disaster 
17
Relief and Emergency Assistance Act)’’; and 
18
(2) in subsection (b), by inserting after ‘‘shall 
19
assume operational control of emergency public 
20
health and medical response assets, as necessary, in 
21
the event of a public health emergency’’ the fol-
22
lowing: ‘‘or in the event of an emergency or disaster 
23
declared by the President under the National Emer-
24
19:08 Nov 24, 2020
H14
10 
•HR 14 IH
gencies Act or the Robert T. Stafford Disaster Re-
1
lief and Emergency Assistance Act’’. 
2
SEC. 1002. DEPLOYMENT BY THE SECRETARY OF HEALTH 
3
AND HUMAN SERVICES OF NATIONAL STRA-
4
TEGIC STOCKPILE. 
5
Section 319F–2(a)(3)(F) of the Public Health Serv-
6
ice Act (42 U.S.C. 247d–6b(a)(3)(F)) is amended by 
7
striking ‘‘as required by’’ and inserting ‘‘in consultation 
8
with’’. 
9
SEC. 1003. AUTHORITY AND RESPONSIBILITIES OF THE 
10
FEDERAL EMERGENCY MANAGEMENT AGEN-
11
CY REGARDING THE STRATEGIC NATIONAL 
12
STOCKPILE. 
13
The Homeland Security Act of 2002 is amended— 
14
(1) in subparagraph (A) of section 503(b)(2) (6 
15
U.S.C. 313(b)(2)), by inserting ‘‘, in coordination 
16
with relevant Federal agencies,’’ after ‘‘lead’’; and 
17
(2) in subparagraph (D) of section 504(a)(3) (6 
18
U.S.C. 314(a)(3)), by striking ‘‘requiring’’ and in-
19
serting ‘‘, at the direction of the Secretary of Health 
20
and Human Services, assisting in’’. 
21
19:08 Nov 24, 2020
H14
11 
•HR 14 IH
Subtitle B—Reagan-Udall Founda-
1
tion and Foundation for the Na-
2
tional Institutes of Health 
3
SEC. 1011. REAGAN-UDALL FOUNDATION AND FOUNDATION 
4
FOR THE NATIONAL INSTITUTES OF HEALTH. 
5
(a) REAGAN-UDALL FOUNDATION FOR THE FOOD 
6
AND DRUG ADMINISTRATION.—Section 770(n) of the 
7
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
8
379dd(n)) is amended by striking ‘‘$500,000 and not 
9
more than $1,250,000’’ and inserting ‘‘$1,250,000 and 
10
not more than $5,000,000’’. 
11
(b) FOUNDATION FOR THE NATIONAL INSTITUTES 
12
OF HEALTH.—Section 499(l) of the Public Health Service 
13
Act (42 U.S.C. 290b(l)) is amended by striking ‘‘$500,000 
14
and 
not 
more 
than 
$1,250,000’’ 
and 
inserting 
15
‘‘$1,250,000 and not more than $5,000,000’’. 
16
Subtitle C—Protections for Good 
17
Samaritan Health Professionals 
18
SEC. 1021. LIMITATION ON LIABILITY FOR VOLUNTEER 
19
HEALTH CARE PROFESSIONALS. 
20
(a) IN GENERAL.—Title II of the Public Health Serv-
21
ice Act (42 U.S.C. 202 et seq.) is amended by inserting 
22
after section 224 the following: 
23
19:08 Nov 24, 2020
H14
12 
•HR 14 IH
‘‘SEC. 224A. LIMITATION ON LIABILITY FOR VOLUNTEER 
1
HEALTH CARE PROFESSIONALS. 
2
‘‘(a) LIMITATION ON LIABILITY.—Except as provided 
3
in subsection (b), a health care professional shall not be 
4
liable under Federal or State law for any harm caused 
5
by an act or omission of the professional in the provision 
6
of health care services if— 
7
‘‘(1) the professional is serving, for purposes of 
8
responding to a disaster, as a volunteer; and 
9
‘‘(2) the act or omission occurs— 
10
‘‘(A) during the period of the disaster, as 
11
determined under the laws listed in subsection 
12
(d)(1); 
13
‘‘(B) in the State or States for which the 
14
disaster is declared; 
15
‘‘(C) in the health care professional’s ca-
16
pacity as a volunteer; 
17
‘‘(D) in the course of providing services 
18
that are within the scope of the license, reg-
19
istration, or certification of the volunteer, as de-
20
fined by the State of licensure, registration, or 
21
certification; and 
22
‘‘(E) in a good faith belief that the indi-
23
vidual being treated is in need of health care 
24
services. 
25
19:08 Nov 24, 2020
H14
13 
•HR 14 IH
‘‘(b) EXCEPTIONS.—Subsection (a) does not apply 
1
if— 
2
‘‘(1) the harm was caused by an act or omission 
3
constituting willful or criminal misconduct, gross 
4
negligence, reckless misconduct, or a conscious fla-
5
grant indifference to the rights or safety of the indi-
6
vidual harmed by the health care professional; or 
7
‘‘(2) the health care professional rendered the 
8
health care services under the influence (as deter-
9
mined pursuant to applicable State law) of alcohol 
10
or an intoxicating drug. 
11
‘‘(c) PREEMPTION.— 
12
‘‘(1) IN GENERAL.—This section preempts the 
13
laws of a State or any political subdivision of a State 
14
to the extent that such laws are inconsistent with 
15
this section, unless such laws provide greater protec-
16
tion from liability. 
17
‘‘(2) VOLUNTEER
PROTECTION
ACT.—Protec-
18
tions afforded by this section are in addition to those 
19
provided by the Volunteer Protection Act of 1997. 
20
‘‘(d) DEFINITIONS.—In this section: 
21
‘‘(1) The term ‘disaster’ means— 
22
‘‘(A) a national emergency declared by the 
23
President under the National Emergencies Act; 
24
19:08 Nov 24, 2020
H14
14 
•HR 14 IH
‘‘(B) an emergency or major disaster de-
1
clared by the President under the Robert T. 
2
Stafford Disaster Relief and Emergency Assist-
3
ance Act; or 
4
‘‘(C) a public health emergency that is de-
5
termined by the Secretary under section 319 of 
6
this Act with respect to one or more States 
7
specified in such determination— 
8
‘‘(i) during only the initial period cov-
9
ered by such determination; and 
10
‘‘(ii) excluding any period covered by 
11
a renewal of such determination. 
12
‘‘(2) The term ‘harm’ includes physical, non-
13
physical, economic, and noneconomic losses. 
14
‘‘(3) The term ‘health care professional’ means 
15
an individual who is licensed, registered, or certified 
16
under Federal or State law to provide health care 
17
services. 
18
‘‘(4) The term ‘health care services’ means any 
19
services provided by a health care professional, or by 
20
any individual working under the supervision of a 
21
health care professional, that relate to— 
22
‘‘(A) the diagnosis, prevention, or treat-
23
ment of any human disease or impairment; or 
24
19:08 Nov 24, 2020
H14
15 
•HR 14 IH
‘‘(B) the assessment or care of the health 
1
of a human being. 
2
‘‘(5) The term ‘State’ includes each of the sev-
3
eral States, the District of Columbia, the Common-
4
wealth of Puerto Rico, the Virgin Islands, Guam, 
5
American Samoa, the Northern Mariana Islands, 
6
and any other territory or possession of the United 
7
States. 
8
‘‘(6)(A) The term ‘volunteer’ means a health 
9
care professional who, with respect to the health 
10
care services rendered, does not receive— 
11
‘‘(i) compensation; or 
12
‘‘(ii) any other thing of value in lieu of 
13
compensation, in excess of $500 per year. 
14
‘‘(B) For purposes of subparagraph (A), the 
15
term ‘compensation’— 
16
‘‘(i) includes payment under any insurance 
17
policy or health plan, or under any Federal or 
18
State health benefits program; and 
19
‘‘(ii) excludes— 
20
‘‘(I) reasonable reimbursement or al-
21
lowance for expenses actually incurred; 
22
‘‘(II) receipt of paid leave; and 
23
‘‘(III) receipt of items to be used ex-
24
clusively for rendering the health services 
25
19:08 Nov 24, 2020
H14
16 
•HR 14 IH
in the health care professional’s capacity 
1
as a volunteer described in subsection 
2
(a)(1).’’. 
3
(b) EFFECTIVE DATE.— 
4
(1) IN GENERAL.—Section 224A of the Public 
5
Health Service Act, as added by subsection (a), shall 
6
take effect 90 days after the date of the enactment 
7
of this Act. 
8
(2) APPLICATION.—Section 224A of the Public 
9
Health Service Act, as added by subsection (a), ap-
10
plies to a claim for harm only if the act or omission 
11
that caused such harm occurred on or after the ef-
12
fective date described in paragraph (1). 
13
SEC. 1022. SENSE OF THE CONGRESS. 
14
It is the sense of Congress that— 
15
(1) health care professionals should be encour-
16
aged to register with the Emergency System for Ad-
17
vance Registration of Volunteer Health Professionals 
18
(ESAR–VHP), and States should employ online reg-
19
istration with the promptest processing possible of 
20
such registrations to foster the rapid deployment 
21
and utilization of volunteer health care professionals 
22
following a disaster; 
23
(2) Federal and State agencies and licensing 
24
boards should cooperate to facilitate the timely 
25
19:08 Nov 24, 2020
H14
17 
•HR 14 IH
movement of properly licensed volunteer health care 
1
professionals to areas affected by a disaster; and 
2
(3) the appropriate licensing entities should 
3
verify the licenses of volunteer health care profes-
4
sionals serving disaster victims as soon as is reason-
5
ably practical following a disaster. 
6
Subtitle D—Medical Sheltering 
7
SEC. 1031. REDUCING THE SPREAD OF COVID–19 THROUGH 
8
PAYMENTS TO STATES TO LEASE HOTELS TO 
9
TEMPORARILY 
HOUSE 
ELIGIBLE 
INDIVID-
10
UALS. 
11
(a) IN GENERAL.—The Secretary of Health and 
12
Human Services may make payments to States to lease 
13
hotels to temporarily house, on a voluntary basis, eligible 
14
individuals. 
15
(b) FORMULA.—The Secretary shall allocate the 
16
amount appropriated to carry out this section pursuant 
17
to a formula developed by the Secretary that— 
18
(1) distributes the amount among the States 
19
that— 
20
(A) submit applications in accordance with 
21
subsection (c); and 
22
(B) are determined by the Secretary to 
23
need such payments; and 
24
(2) takes into consideration— 
25
19:08 Nov 24, 2020
H14
18 
•HR 14 IH
(A) the number of active cases of individ-
1
uals infected with COVID–19 in the applying 
2
State relative to the overall population of the 
3
State; and 
4
(B) the average income of individuals in 
5
the applying State relative to the average in-
6
come of individuals in the United States. 
7
(c) APPLICATIONS.— 
8
(1) IN GENERAL.—To seek a payment under 
9
this section, a State shall submit an application to 
10
the Secretary at such time, in such manner, and 
11
containing such information and assurances as the 
12
Secretary may require. 
13
(2) PROCESS.—The Secretary shall— 
14
(A) not later than 15 days after the date 
15
of enactment of this Act, publish the process 
16
for States to apply for payments under this sec-
17
tion; and 
18
(B) not later than 15 days after the sub-
19
mission of an application in accordance with 
20
such process, approve or disapprove the applica-
21
tion. 
22
(3) CONTENTS.—The Secretary shall require 
23
the application of a State under this section to in-
24
clude— 
25
19:08 Nov 24, 2020
H14
19 
•HR 14 IH
(A) a plan for leasing hotels as described 
1
in subsection (a); 
2
(B) health guidelines which the State will 
3
require to be implemented to protect the staff 
4
of the hotels; 
5
(C) the rates to be paid to lease the hotels; 
6
(D) a plan to ensure that the hotels each 
7
have— 
8
(i) workplace safety standards for 
9
their staff; 
10
(ii) proper personal protective equip-
11
ment and sanitation supplies; 
12
(iii) a cleaning protocol for rooms and 
13
facilities; and 
14
(iv) at least one qualified health care 
15
professional onsite or on call to monitor 
16
the health of individuals being housed at 
17
the hotels; 
18
(E) a plan to feed and provide other nec-
19
essary materials to individuals described in sub-
20
section (a) at the hotels, including medications 
21
and hygiene products, without letting such indi-
22
viduals leave their rooms or accept visitors; 
23
19:08 Nov 24, 2020
H14
20 
•HR 14 IH
(F) a plan to assist the hotels in removing 
1
individuals who attempt to continue their stay 
2
after the allotted time; 
3
(G) a plan for hospital networks, local 
4
health departments, and the hotels to coordi-
5
nate on the exchange and protection of patient 
6
information in accordance with other applicable 
7
law; 
8
(H) a plan to effectively communicate the 
9
State’s program funded through this section to 
10
racial and ethnic minority groups and low-in-
11
come communities; and 
12
(I) each funding assurance listed in sub-
13
section (e). 
14
(d) NO RESPONSIBILITY FOR DIET OR ADMINISTRA-
15
TION
OF
MEDICINE.—Notwithstanding 
subsection 
16
(c)(3)(E), a contract between a State and a hotel pursuant 
17
to this section shall not make the hotel responsible for the 
18
diet of, or the administration of medications to, individuals 
19
described in subsection (a). 
20
(e) FUNDING ASSURANCES.—As a condition on re-
21
ceipt of a payment of this section, a State shall give such 
22
assurances as the Secretary may require that— 
23
(1) each contract between the State and a hotel 
24
pursuant to this section will be entered into on a vol-
25
19:08 Nov 24, 2020
H14
21 
•HR 14 IH
untary basis, and no hotel will be required by the 
1
State to participate in the program under this sec-
2
tion; 
3
(2) individuals described in subsection (a) will 
4
not be charged for their lodging at a hotel pursuant 
5
to this section, except that such individuals may be 
6
required to reimburse the costs of receiving food and 
7
beverages; 
8
(3) individuals described in subsection (a) will 
9
retain the option of self-isolating at home (including 
10
the option of checking out early and returning to 
11
their homes) rather than being required to stay at 
12
a hotel funded pursuant to this section; 
13
(4) before an individual is allowed to stay at a 
14
hotel pursuant to this section, the individual will be 
15
required to present, in such form and manner as 
16
may be required by the local department of health, 
17
documentation from a physician that the individual 
18
meets the criteria described in subsection (a); 
19
(5) any non-transient homeless population re-
20
siding at a hotel will not be displaced for purposes 
21
of entering into or carrying out a contract between 
22
the State and the hotel under this section; and 
23
19:08 Nov 24, 2020
H14
22 
•HR 14 IH
(6) the State will pay (from funds provided to 
1
the State under this section or from other State 
2
funds)— 
3
(A) at least 40 percent of the costs of the 
4
personal protective equipment and sanitation 
5
supplies needed by individuals staying at a hotel 
6
pursuant to this section and the staff of such 
7
hotel; and 
8
(B) all of the costs of having one or more 
9
qualified health care professionals described in 
10
subsection (c)(3)(D)(iii) for the provision of 
11
monitoring described in such subsection (wheth-
12
er by being onsite or on call). 
13
(f) REVIEW.—At the conclusion of the program under 
14
this section, the Inspector General of the Department of 
15
Health and Human Services shall— 
16
(1) review the program and activities of each 
17
State funded pursuant to this section; and 
18
(2) submit a report on the results of the review 
19
to— 
20
(A) the Committee on Energy and Com-
21
merce and the Committee on Ways and Means 
22
of the House of Representatives; and 
23
19:08 Nov 24, 2020
H14
23 
•HR 14 IH
(B) the Committee on Finance and the 
1
Committee on Health, Education, Labor, and 
2
Pensions of the Senate. 
3
(g) LIABILITY PROTECTION.— 
4
(1) IN GENERAL.—Except as provided under 
5
paragraph (2), a hotel or member of the staff shall 
6
not be liable under Federal or State law for— 
7
(A) any harm caused by an act or omission 
8
in the provision of hotel services pursuant to 
9
this section; or 
10
(B) failing to keep an individual who is 
11
staying at a hotel pursuant to this section iso-
12
lated from people other than the staff of the 
13
hotel and any qualified health care professional 
14
described in subsection (c)(3)(D)(iii). 
15
(2) EXCEPTION.—Paragraph (1) does not apply 
16
in the case that the harm was caused by an act or 
17
omission constituting willful or criminal misconduct, 
18
gross negligence, reckless misconduct, or a conscious 
19
flagrant indifference to the rights or safety of the in-
20
dividual harmed. 
21
(h) DEFINITIONS.—In this section: 
22
(1) The term ‘‘eligible individual’’ means an in-
23
dividual who is unable to self-isolate at home, does 
24
19:08 Nov 24, 2020
H14
24 
•HR 14 IH
not require inpatient or outpatient health care treat-
1
ment, and— 
2
(A) has a laboratory-confirmed case of 
3
COVID–19; 
4
(B) has a presumptive positive case of 
5
COVID–19; or 
6
(C) is a person under investigation who is 
7
displaying symptoms of COVID–19. 
8
(2) The terms ‘‘Indian tribe’’ and ‘‘tribal orga-
9
nization’’ have the meanings given to those terms in 
10
section 4 of the Indian Self-Determination and Edu-
11
cation Assistance Act (25 U.S.C. 5304). 
12
(3) The term ‘‘Secretary’’ means the Secretary 
13
of Health and Human Services. 
14
(4) The term ‘‘State’’ includes each of 50 
15
States, the District of Columbia, each Indian Tribe 
16
and tribal organization, Guam, American Samoa, the 
17
United States Virgin Islands, the Commonwealth of 
18
Puerto Rico, and the Commonwealth of the North-
19
ern Mariana Islands. 
20
(i) FUNDING.—To carry out this section, there is au-
21
thorized to be appropriated $1,000,000,000, to remain 
22
available through the earlier of— 
23
(1) the end of calendar year 2021; or 
24
19:08 Nov 24, 2020
H14
25 
•HR 14 IH
(2) the end of the emergency period (as defined 
1
in section 1135(g)(1)(B) of the Social Security Act 
2
(42 U.S.C. 1320b–5(g)(1)(B))). 
3
Subtitle E—CDC Campaign on 
4
COVID–19 Awareness 
5
SEC. 1041. COVID–19 PUBLIC AWARENESS CAMPAIGN. 
6
The Secretary of Health and Human Services, acting 
7
through the Director of the Centers for Disease Control 
8
and Prevention and in coordination with other offices and 
9
agencies, as appropriate, shall award competitive grants 
10
or contracts to one or more public or private entities to 
11
carry out a national campaign that is multilingual and cul-
12
turally competent and based on available scientific evi-
13
dence to increase awareness and knowledge of COVID– 
14
19, including reducing stigma associated with COVID–19 
15
and improving information on the availability of diagnostic 
16
testing and other related services at community health 
17
centers. 
18
Subtitle F—Protecting Children 
19
From COVID–19 
20
SEC. 1051. STUDY ON CHILDREN’S ROLE IN TRANSMITTING 
21
SARS–COV–2. 
22
(a) STUDY.— 
23
(1) IN GENERAL.—The Secretary of Health and 
24
Human Services (in this section referred to as the 
25
19:08 Nov 24, 2020
H14
26 
•HR 14 IH
‘‘Secretary’’), in coordination with the heads of 
1
agencies of the Department of Health and Human 
2
Services and experts from outside of the Depart-
3
ment, as appropriate, shall complete a study on chil-
4
dren’s role in transmitting SARS–CoV–2. 
5
(2) ISSUES TO BE STUDIED.—The study under 
6
paragraph (1) shall address— 
7
(A) the transmissibility of COVID–19 from 
8
child to child, child to adult, and adult to child; 
9
(B) the vulnerability of children, especially 
10
those with underlying health conditions, to se-
11
vere illness as such vulnerability relates to 
12
COVID–19; 
13
(C) the vulnerability of adults, especially 
14
those with underlying health conditions, who 
15
send their children back to school; and 
16
(D) the vulnerability of adults, especially 
17
those with underlying health conditions, who 
18
interact with children who may be asymp-
19
tomatic but infectious. 
20
(3) CONSIDERATIONS.—In carrying out the 
21
study under paragraph (1), the Secretary shall— 
22
(A) take into consideration the best avail-
23
able science, including as provided by the Na-
24
tional Academy of Sciences; and 
25
19:08 Nov 24, 2020
H14
27 
•HR 14 IH
(B) ensure that such study includes con-
1
sideration of children who are members of ra-
2
cial or ethnic minority groups. 
3
(b) REPORTING.—The Secretary shall submit a re-
4
port to the Congress on children’s role in transmitting 
5
SARS–CoV–2. The report shall include the results of the 
6
study under subsection (a). 
7
(c) DISSEMINATION OF BEST PRACTICES.—The Sec-
8
retary shall disseminate to stakeholders best practices for 
9
protecting children and adults in educational settings. The 
10
first best practices disseminated pursuant to the preceding 
11
sentence shall include any best practices for protecting 
12
children and adults in educational settings identified 
13
through the study under subsection (a). 
14
(d) DEFINITION.—In this section, the term ‘‘emer-
15
gency period’’ has the meaning given to such term in sec-
16
tion 1135(g)(1)(B) of the Social Security Act (42 U.S.C. 
17
1320b–5(g)(1)(B)). 
18
Subtitle G—Ensuring 
19
Understanding of COVID–19 
20
SEC. 1061. STUDY ON THE IMPACT OF COVID–19. 
21
Part A of title IV of the Public Health Service Act 
22
(42 U.S.C. 281 et seq.) is amended by adding at the end 
23
the following: 
24
19:08 Nov 24, 2020
H14
28 
•HR 14 IH
‘‘SEC. 404O. STUDY ON THE IMPACT OF COVID–19. 
1
‘‘(a) IN GENERAL.—The Secretary shall conduct a 
2
longitudinal study, over not less than 10 years, on the full 
3
impact of COVID–19 on infected individuals, including 
4
both short-term and long-term health impacts. 
5
‘‘(b) TIMING.—The Secretary shall begin enrolling 
6
patients in the study under this section not later than 6 
7
months after the date of enactment of this section. 
8
‘‘(c) REQUIREMENTS.—The study under this section 
9
shall— 
10
‘‘(1) be nationwide; 
11
‘‘(2) include diversity of enrollees to account for 
12
gender, 
age, 
race, 
ethnicity, 
geography, 
13
comorbidities, and underrepresented populations, in-
14
cluding pregnant and lactating women; 
15
‘‘(3) study individuals who were infected with 
16
COVID–19 who experienced mild symptoms, such 
17
individuals who experienced moderate symptoms, 
18
and such individuals who experienced severe symp-
19
toms; 
20
‘‘(4) monitor the health outcomes and symp-
21
toms of individuals who were infected with COVID– 
22
19, or had prenatal exposure to COVID–19, includ-
23
ing lung capacity and function, and immune re-
24
sponse, taking into account any pharmaceutical 
25
interventions such individuals may have received; 
26
19:08 Nov 24, 2020
H14
29 
•HR 14 IH
‘‘(5) monitor the mental health outcomes of in-
1
dividuals infected with COVID–19, taking into ac-
2
count any interventions that affected mental health; 
3
and 
4
‘‘(6) monitor individuals enrolled in the study 
5
not less frequently that twice per year after the first 
6
year of the individual’s infection with COVID–19. 
7
‘‘(d) PUBLIC-PRIVATE RESEARCH NETWORK.—For 
8
purposes of carrying out the study under this section, the 
9
Director of NIH may develop a network of public-private 
10
research partners, provided that all research, including the 
11
research carried out through any such partner, is available 
12
publicly. 
13
‘‘(e) SUMMARIES
OF FINDINGS.—The Director of 
14
NIH shall make public a summary of findings under this 
15
section not less frequently than once every 3 months for 
16
the first 2 years of the study, and not less frequently than 
17
every 6 months thereafter. Such summaries may include 
18
information about how the findings of the study under this 
19
section compare with findings from research conducted 
20
abroad. 
21
‘‘(f) AUTHORIZATION OF APPROPRIATIONS.—There 
22
are authorized to be appropriated such sums as may be 
23
necessary to carry out this section.’’. 
24
19:08 Nov 24, 2020
H14
30 
•HR 14 IH
Subtitle H—Safeguarding 
1
Therapeutics 
2
SEC. 1071. AUTHORITY TO DESTROY COUNTERFEIT DE-
3
VICES. 
4
(a) IN GENERAL.—Section 801(a) of the Federal 
5
Food, Drug, and Cosmetic Act (21 U.S.C. 381(a)) is 
6
amended— 
7
(1) in the fourth sentence, by inserting ‘‘or 
8
counterfeit device’’ after ‘‘counterfeit drug’’; and 
9
(2) by striking ‘‘The Secretary of the Treasury 
10
shall cause the destruction of’’ and all that follows 
11
through ‘‘liable for costs pursuant to subsection 
12
(c).’’ and inserting the following: ‘‘The Secretary of 
13
the Treasury shall cause the destruction of any such 
14
article refused admission unless such article is ex-
15
ported, under regulations prescribed by the Sec-
16
retary of the Treasury, within 90 days of the date 
17
of notice of such refusal or within such additional 
18
time as may be permitted pursuant to such regula-
19
tions, except that the Secretary of Health and 
20
Human Services may destroy, without the oppor-
21
tunity for export, any drug or device refused admis-
22
sion under this section, if such drug or device is val-
23
ued at an amount that is $2,500 or less (or such 
24
higher amount as the Secretary of the Treasury may 
25
19:08 Nov 24, 2020
H14
31 
•HR 14 IH
set by regulation pursuant to section 498(a)(1) of 
1
the Tariff Act of 1930 (19 U.S.C. 1498(a)(1))) and 
2
was not brought into compliance as described under 
3
subsection (b). The Secretary of Health and Human 
4
Services shall issue regulations providing for notice 
5
and an opportunity to appear before the Secretary 
6
of Health and Human Services and introduce testi-
7
mony, as described in the first sentence of this sub-
8
section, on destruction of a drug or device under the 
9
seventh sentence of this subsection. The regulations 
10
shall provide that prior to destruction, appropriate 
11
due process is available to the owner or consignee 
12
seeking to challenge the decision to destroy the drug 
13
or device. Where the Secretary of Health and 
14
Human Services provides notice and an opportunity 
15
to appear and introduce testimony on the destruc-
16
tion of a drug or device, the Secretary of Health and 
17
Human Services shall store and, as applicable, dis-
18
pose of the drug or device after the issuance of the 
19
notice, except that the owner and consignee shall re-
20
main liable for costs pursuant to subsection (c).’’. 
21
(b) DEFINITION.—Section 201(h) of the Federal 
22
Food, Drug, and Cosmetic Act (21 U.S.C. 321(h)) is 
23
amended— 
24
19:08 Nov 24, 2020
H14
32 
•HR 14 IH
(1) by redesignating subparagraphs (1), (2), 
1
and (3) as clauses (A), (B), and (C), respectively; 
2
and 
3
(2) after making such redesignations— 
4
(A) by striking ‘‘(h) The term’’ and insert-
5
ing ‘‘(h)(1) The term’’; and 
6
(B) by adding at the end the following: 
7
‘‘(2) The term ‘counterfeit device’ means a device 
8
which, or the container, packaging, or labeling of which, 
9
without authorization, bears a trademark, trade name, or 
10
other identifying mark, imprint, or symbol, or any likeness 
11
thereof, or is manufactured using a design, of a device 
12
manufacturer, packer, or distributor other than the person 
13
or persons who in fact manufactured, packed, or distrib-
14
uted such device and which thereby falsely purports or is 
15
represented to be the product of, or to have been packed 
16
or distributed by, such other device manufacturer, packer, 
17
or distributor. 
18
‘‘(3) For purposes of subparagraph (2)— 
19
‘‘(A) the term ‘manufactured’ refers to any of 
20
the following activities: manufacture, preparation, 
21
propagation, compounding, assembly, or processing; 
22
and 
23
19:08 Nov 24, 2020
H14
33 
•HR 14 IH
‘‘(B) the term ‘manufacturer’ means a person 
1
who is engaged in any of the activities listed in 
2
clause (A).’’. 
3
SEC. 1072. DETERMINATION OF BUDGETARY EFFECTS. 
4
The budgetary effects of this subtitle, for the purpose 
5
of complying with the Statutory Pay-As-You-Go Act of 
6
2010, shall be determined by reference to the latest state-
7
ment titled ‘‘Budgetary Effects of PAYGO Legislation’’ 
8
for this subtitle, submitted for printing in the Congres-
9
sional Record by the Chairman of the House Budget Com-
10
mittee, provided that such statement has been submitted 
11
prior to the vote on passage. 
12
Subtitle I—Advisory Committee on 
13
Immunization Practices 
14
SEC. 1081. EXPEDITED MEETING OF ACIP FOR COVID–19 
15
VACCINES. 
16
(a) IN GENERAL.—Notwithstanding section 3091 of 
17
the 21st Century Cures Act (21 U.S.C. 360bbb–4 note), 
18
the Advisory Committee on Immunization Practices shall 
19
meet and issue a recommendation with respect to a vac-
20
cine that is intended to prevent or treat COVID–19 not 
21
later than 15 business days after the date on which such 
22
vaccine is licensed under section 351 of the Public Health 
23
Service Act (42 U.S.C. 262) or authorized under section 
24
19:08 Nov 24, 2020
H14
34 
•HR 14 IH
564 of the Federal Food, Drug, and Cosmetic Act (21 
1
U.S.C. 360bbb–3). 
2
(b) DEFINITION.—In this section, the term ‘‘Advisory 
3
Committee on Immunization Practices’’ means the Advi-
4
sory Committee on Immunization Practices established by 
5
the Secretary of Health and Human Services pursuant to 
6
section 222 of the Public Health Service Act (42 U.S.C. 
7
217a), acting through the Director of the Centers for Dis-
8
ease Control and Prevention. 
9
Subtitle 
J—Improvements 
to 
10
Transparency of the Pricing of 
11
Diagnostic Testing for COVID– 
12
19 
13
SEC. 1091. IMPROVEMENTS TO TRANSPARENCY OF THE 
14
PRICING 
OF 
DIAGNOSTIC 
TESTING 
FOR 
15
COVID–19. 
16
(a) IN GENERAL.—Section 3202 of the CARES Act 
17
(Public Law 116–136) is amended— 
18
(1) in subsection (b)— 
19
(A) in the heading, by inserting ‘‘AND RE-
20
LATED ITEMS
AND SERVICES’’ after ‘‘DIAG-
21
NOSTIC TESTING FOR COVID–19’’; 
22
(B) in paragraph (1)— 
23
(i) by striking ‘‘a diagnostic test for 
24
COVID–19’’ and inserting ‘‘a test, item, or 
25
19:08 Nov 24, 2020
H14
35 
•HR 14 IH
service described in section 6001(a) of divi-
1
sion F of the Families First Coronavirus 
2
Response Act (Public Law 116–127)’’; and 
3
(ii) by striking ‘‘such test’’ and insert-
4
ing ‘‘such test, item, or service’’; and 
5
(C) in paragraph (2), by striking ‘‘a diag-
6
nostic test for COVID–19’’ and inserting ‘‘a 
7
test, item, or service described in section 
8
6001(a) of division F of the Families First 
9
Coronavirus Response Act (Public Law 116– 
10
127)’’; and 
11
(2) by adding at the end the following new sub-
12
sections: 
13
‘‘(c) IMPROVEMENTS TO TRANSPARENCY POLICY.— 
14
‘‘(1) IN
GENERAL.—Not later than 30 days 
15
after the date of the enactment of this subsection, 
16
the Secretary of Health and Human Services shall 
17
survey providers subject to the requirement under 
18
subsection (b) regarding the cash prices referred to 
19
in such subsection. 
20
‘‘(2) REPRESENTATIVE
SAMPLE.—In carrying 
21
out paragraph (1), the Secretary shall survey a sam-
22
ple of providers that is representative of the diver-
23
sity of sizes, geographic locations, and care settings 
24
(such as hospitals, laboratories, and independent 
25
19:08 Nov 24, 2020
H14
36 
•HR 14 IH
freestanding emergency departments) in which diag-
1
nostic testing for COVID–19 is performed. 
2
‘‘(3) CONSUMER COMPLAINTS.—The Secretary 
3
shall ensure that consumers have a method to sub-
4
mit complaints to the Department of Health and 
5
Human Services that identify providers that— 
6
‘‘(A) may be in violation of subsection (b); 
7
and 
8
‘‘(B) have not made public a cash price in 
9
accordance with such subsection. 
10
‘‘(d) PUBLIC REPORT.—Not later than 60 days after 
11
the date of the enactment of this subsection, the Secretary 
12
of Health and Human Services shall publish on the inter-
13
net website of the Department of Health and Human 
14
Services a report on cash prices for items and services 
15
published under subsection (b)(1) during the period begin-
16
ning on the date of the enactment of this Act and ending 
17
on the date of the enactment of this subsection, which 
18
shall include— 
19
‘‘(1) the percentage of providers that comply 
20
with the requirement under such subsection; 
21
‘‘(2) the average cash price for each such item 
22
and service published under such subsection; and 
23
19:08 Nov 24, 2020
H14
37 
•HR 14 IH
‘‘(3) any providers identified pursuant to para-
1
graph (2) or (3) of subsection (c) and found to be 
2
in violation of such requirement.’’. 
3
TITLE II—DOMESTIC MANUFAC-
4
TURING AND SUPPLY CHAIN 
5
Subtitle 
A—Sustained 
On-Shore 
6
Manufacturing 
Capacity 
for 
7
Public Health Emergencies 
8
SEC. 2001. SUSTAINED ON-SHORE MANUFACTURING CAPAC-
9
ITY FOR PUBLIC HEALTH EMERGENCIES. 
10
(a) IN GENERAL.—Section 319L of the Public 
11
Health Service Act (42 U.S.C. 247d–7e) is amended— 
12
(1) in subsection (a)(6)(B)— 
13
(A) by redesignating clauses (iv) and (v) as 
14
clauses (v) and (vi), respectively; 
15
(B) by inserting after clause (iii), the fol-
16
lowing: 
17
‘‘(iv) activities to support domestic 
18
manufacturing surge capacity of products 
19
or platform technologies, including manu-
20
facturing capacity and capabilities to uti-
21
lize platform technologies to provide for 
22
flexible manufacturing initiatives;’’; and 
23
(C) in clause (vi) (as so redesignated), by 
24
inserting ‘‘manufacture,’’ after ‘‘improvement,’’; 
25
19:08 Nov 24, 2020
H14
38 
•HR 14 IH
(2) in subsection (b)— 
1
(A) in the first sentence of paragraph (1), 
2
by inserting ‘‘support for domestic manufac-
3
turing surge capacity,’’ after ‘‘initiatives for in-
4
novation,’’; and 
5
(B) in paragraph (2)— 
6
(i) in subparagraph (B), by striking 
7
‘‘and’’ at the end; 
8
(ii) by redesignating subparagraph 
9
(C) as subparagraph (D); and 
10
(iii) by inserting after subparagraph 
11
(B), the following: 
12
‘‘(C) activities to support manufacturing 
13
surge capacities and capabilities to increase the 
14
availability of existing medical countermeasures 
15
and utilize existing novel platforms to manufac-
16
ture new medical countermeasures to meet 
17
manufacturing demands to address threats that 
18
pose a significant level of risk to national secu-
19
rity; and’’; 
20
(3) in subsection (c)— 
21
(A) in paragraph (2)— 
22
(i) in subparagraph (C), by striking 
23
‘‘and’’ at the end; 
24
19:08 Nov 24, 2020
H14
39 
•HR 14 IH
(ii) in subparagraph (D), by striking 
1
the period and inserting ‘‘; and’’; and 
2
(iii) by adding at the end the fol-
3
lowing: 
4
‘‘(E) promoting domestic manufacturing 
5
surge capacity and capabilities for counter-
6
measure advanced research and development, 
7
including facilitating contracts to support flexi-
8
ble or surge manufacturing.’’; 
9
(B) in paragraph (4)— 
10
(i) in subparagraph (B)— 
11
(I) in clause (iii), by striking 
12
‘‘and’’ at the end; 
13
(II) in clause (iv), by striking the 
14
period and inserting ‘‘; and’’; and 
15
(III) by adding at the end the 
16
following: 
17
‘‘(v) support and maintain domestic 
18
manufacturing surge capacity and capabili-
19
ties, including through contracts to sup-
20
port flexible or surge manufacturing, to en-
21
sure that additional production of counter-
22
measures is available in the event that the 
23
Secretary determines there is such a need 
24
for additional production.’’; 
25
19:08 Nov 24, 2020
H14
40 
•HR 14 IH
(ii) in subparagraph (D)— 
1
(I) in clause (ii), by striking 
2
‘‘and’’ at the end; 
3
(II) by redesignating clause (iii) 
4
as clause (iv); and 
5
(III) by inserting after clause (ii) 
6
the following: 
7
‘‘(iii) research to advance manufac-
8
turing capacities and capabilities for med-
9
ical countermeasures and platform tech-
10
nologies that may be utilized for medical 
11
countermeasures; and’’; and 
12
(iii) in subparagraph (E), by striking 
13
clause (ix); and 
14
(C) in paragraph (7)(C)(i), by striking ‘‘up 
15
to 100 highly qualified individuals, or up to 50 
16
percent of the total number of employees, 
17
whichever is less,’’ and inserting ‘‘75 percent of 
18
the total number of employees’’; 
19
(4) in subsection (e)(1)— 
20
(A) by redesignating subparagraphs (B) 
21
through (D) as subparagraphs (C) through (E), 
22
respectively; and 
23
(B) by inserting after subparagraph (A), 
24
the following: 
25
19:08 Nov 24, 2020
H14
41 
•HR 14 IH
‘‘(B) TEMPORARY FLEXIBILITY.—During a 
1
public health emergency under section 319, the 
2
Secretary shall be provided with an additional 
3
60 business days to comply with information re-
4
quests for the disclosure of information under 
5
section 552 of title 5, United States Code, re-
6
lated to the activities under this section (unless 
7
such activities are otherwise exempt under sub-
8
paragraph (A)).’’; and 
9
(5) in subsection (f)— 
10
(A) in paragraph (1), by striking ‘‘Not 
11
later than 180 days after the date of enactment 
12
of this subsection’’ and inserting ‘‘Not later 
13
than 180 days after the date of enactment of 
14
the Commitment to Defeat the Virus and Keep 
15
America Healthy Act’’; and 
16
(B) in paragraph (2), by striking ‘‘Not 
17
later than 1 year after the date of enactment of 
18
this subsection’’ and inserting ‘‘Not later than 
19
1 year after the date of enactment of the Com-
20
mitment to Defeat the Virus and Keep America 
21
Healthy Act’’. 
22
(b) MEDICAL COUNTERMEASURE INNOVATION PART-
23
NER.—The restrictions under section 202 of division A of 
24
the Further Consolidated Appropriations Act, 2020 (Pub-
25
19:08 Nov 24, 2020
H14
42 
•HR 14 IH
lic Law 116–94), or any other provision of law imposing 
1
a restriction on salaries of individuals related to a previous 
2
appropriation to the Department of Health and Human 
3
Services, shall not apply with respect to salaries paid pur-
4
suant to an agreement under the medical countermeasure 
5
innovation partner program under section 319L(c)(4)(E) 
6
of the Public Health Service Act (42 U.S.C. 247d– 
7
7e(c)(4)(E)). 
8
Subtitle B—Manufacturing API, 
9
Drugs, and Excipients in America 
10
SEC. 2011. REPORT TO CONGRESS ON BARRIERS TO DO-
11
MESTIC 
MANUFACTURING 
OF 
MEDICAL 
12
PRODUCTS AND SUPPLIES. 
13
(a) REPORT.—Not later than January 1, 2021, the 
14
Secretary of Health and Human Services (referred to in 
15
this section as the ‘‘Secretary’’) shall submit to the Com-
16
mittee on Energy and Commerce of the House of Rep-
17
resentatives and the Committee on Health, Education, 
18
Labor, and Pensions of the Senate a report on barriers 
19
to domestic manufacturing of active pharmaceutical ingre-
20
dients, drugs, and devices that are manufactured outside 
21
of the United States. 
22
(b) CONTENTS.—Such report shall— 
23
(1) identify factors that limit or otherwise dis-
24
courage the domestic manufacturing of active phar-
25
19:08 Nov 24, 2020
H14
43 
•HR 14 IH
maceutical ingredients, drugs, and devices that are 
1
currently manufactured outside of the United 
2
States, including any Federal, State, local, or Tribal 
3
laws and regulations that hinder domestic manufac-
4
turing opportunities; and 
5
(2) recommend specific strategies to overcome 
6
the challenges identified under paragraph (1), in-
7
cluding strategies— 
8
(A) to develop effective incentives for do-
9
mestic manufacturing; and 
10
(B) to make changes to laws or regulations 
11
that hinder domestic manufacturing opportuni-
12
ties. 
13
(c) CONSULTATION.—In carrying out the report 
14
under subsection (a), the Secretary shall consult with— 
15
(1) the Food and Drug Administration, the 
16
Centers for Medicare & Medicaid Services, the De-
17
partment of Defense, the Department of Commerce, 
18
the Department of State, the Department of Vet-
19
erans Affairs, the Department of Justice, and any 
20
other Federal agencies as appropriate; and 
21
(2) relevant stakeholders, including drug, de-
22
vice, and active pharmaceutical ingredient manufac-
23
turers, and other entities, as appropriate. 
24
19:08 Nov 24, 2020
H14
44 
•HR 14 IH
(d) DEFINITION.—In this section, the term ‘‘active 
1
pharmaceutical ingredient’’ has the meaning given to such 
2
term in section 207.1 of title 21, Code of Federal Regula-
3
tions (and any successor regulations). 
4
(e) PUBLICATION.—The Secretary shall make the re-
5
port under subsection (a) available on the public website 
6
of the Department of Health and Human Services. 
7
SEC. 2012. ENHANCING INTRA-AGENCY COORDINATION 
8
AND PUBLIC HEALTH ASSESSMENT WITH RE-
9
GARD TO COMPLIANCE ACTIVITIES. 
10
(a) BENEFIT/RISK FRAMEWORK.— 
11
(1) IN
GENERAL.—Paragraph (2) of section 
12
704(b) of the Federal Food, Drug, and Cosmetic Act 
13
(21 U.S.C. 374(b)) is amended by adding at the end 
14
the following: ‘‘The Secretary shall ensure timely 
15
and effective coordination among such offices re-
16
garding the reviews of such report and the align-
17
ment of any feedback regarding such report, and 
18
any corrective or preventive actions in response to 
19
such report, after consideration of the benefits and 
20
risks to the public health, patient safety, the drug 
21
supply and drug supply chain, and timely patient ac-
22
cess to drugs.’’. 
23
(2) ANNUAL
REPORTING.—Subsection (b) of 
24
section 704 of the Federal Food, Drug, and Cos-
25
19:08 Nov 24, 2020
H14
45 
•HR 14 IH
metic Act (21 U.S.C. 374) is amended by adding at 
1
the end the following new paragraph: 
2
‘‘(3) On an annual basis, the Secretary shall prepare 
3
a report on the utilization of the framework described in 
4
paragraph (2) and post such report on the public website 
5
of the Food and Drug Administration.’’. 
6
(3) APPLICABILITY.—The amendments made 
7
by paragraphs (1) and (2) shall take effect on the 
8
effective date described in section 3112 of the 
9
CARES Act (Public Law 116–136), after executing 
10
the amendments made by such section 3112, and 
11
shall apply beginning on the date that is 1 year after 
12
the date of enactment of this Act. 
13
(b) PUBLIC MEETING.—The Secretary of Health and 
14
Human Services shall publish in the Federal Register a 
15
notice of a public meeting to be held no later than six 
16
months after the date of enactment of this Act to discuss 
17
and obtain input and recommendations from public stake-
18
holders, including patient advocates, consumers, regulated 
19
industry, and health care providers, regarding the con-
20
tents of a benefit/risk framework described in section 
21
704(b)(2) of the Federal Food, Drug, and Cosmetic Act, 
22
as amended by subsection (a), that supports a safe, stable, 
23
redundant drug supply chain. 
24
19:08 Nov 24, 2020
H14
46 
•HR 14 IH
(c) GUIDANCE.—The Secretary of Health and 
1
Human Services shall— 
2
(1) not later than one year after the date on 
3
which the public meeting described in subsection (b) 
4
is held, issue draft guidance regarding the goals and 
5
implementation of a benefit/risk framework de-
6
scribed in subsection (b); and 
7
(2) not later than two years after such date of 
8
enactment, issue final guidance with respect to the 
9
implementation of such a framework. 
10
SEC. 
2013. 
ENCOURAGING 
INTERNATIONAL 
HARMONI-
11
ZATION. 
12
(a) GAO STUDY.—Not later than one year after the 
13
date of enactment of this Act, the Comptroller General 
14
of the United States shall issue a report evaluating— 
15
(1) the consistency with which the International 
16
Conference on Harmonisation (in this section re-
17
ferred to as ‘‘ICH’’) guidelines on good manufac-
18
turing practices, including ICH Guidelines Q8–11, 
19
are being implemented by drug regulatory authori-
20
ties across countries and international regions; 
21
(2) whether domestic active pharmaceutical in-
22
gredient manufacturers (including any such contract 
23
manufacturers) are provided sufficient opportunity 
24
19:08 Nov 24, 2020
H14
47 
•HR 14 IH
to participate with regulatory authorities in the de-
1
velopment of guidelines prior to implementation; 
2
(3) whether divergence from ICH guidelines or 
3
differing regulatory standards or requirements by 
4
drug regulatory authorities across countries and 
5
international regions creates— 
6
(A) inefficiencies in drug manufacturing; 
7
(B) incompatible requirements that can 
8
contribute to or exacerbate drug shortages; and 
9
(C) the most common areas of divergence 
10
between ICH guidelines and regulatory stand-
11
ards and requirements by drug regulatory au-
12
thorities across countries and international re-
13
gions that, if rectified, may reduce the ineffi-
14
ciencies and incompatibilities identified pursu-
15
ant to subparagraphs (A) and (B). 
16
(b) INTERNATIONAL TRAINING PROGRAM.—Not later 
17
than two years after the date of enactment of this Act, 
18
informed by the needs identified in the report issued pur-
19
suant to subsection (a), the Secretary of Health and 
20
Human Services, in conjunction with drug regulatory au-
21
thorities across countries and international regions and 
22
the ICH, shall develop and implement a training program 
23
for drug regulatory authorities across countries and inter-
24
national regions to promote consistent application of and 
25
19:08 Nov 24, 2020
H14
48 
•HR 14 IH
reduce divergence from ICH guidelines on good manufac-
1
turing practices. 
2
SEC. 2014. MUTUAL RECOGNITION AGREEMENTS FOR IN-
3
SPECTIONS AND REVIEW ACTIVITIES. 
4
(a) MUTUAL RECOGNITION OF INSPECTIONS.—Pur-
5
suant to section 809 of the Federal Food, Drug, and Cos-
6
metic Act (21 U.S.C. 384e), the Secretary of Health and 
7
Human Services (in this section referred to as the ‘‘Sec-
8
retary’’) shall establish or expand initiatives for mutual 
9
sharing of review and inspection findings between drug 
10
regulatory authorities across countries and international 
11
regions, such as through the Pharmaceutical Cooperation 
12
Inspection Scheme, the Mutual Recognition Agreement 
13
with the European Union, and the Australia-Canada- 
14
Singapore-Switzerland Consortium, to— 
15
(1) reduce the potential for duplicative regu-
16
latory evaluation of medical products regulated by 
17
the Food and Drug Administration; and 
18
(2) more constructively allocate appropriations 
19
to the Food and Drug Administration, including 
20
those attributable to user fees, to harmonized regu-
21
latory processes. 
22
(b) ADDITIONAL COUNTRIES, REGIONS, AND EVAL-
23
UATION.—In carrying out subsection (a), the Secretary 
24
may expand the initiatives to include— 
25
19:08 Nov 24, 2020
H14
49 
•HR 14 IH
(1) additional countries and geographic regions 
1
with established and competent regulatory frame-
2
works; and 
3
(2) additional types of regulatory evaluation, in-
4
cluding with respect to— 
5
(A) good manufacturing practice inspec-
6
tions; and 
7
(B) approval of changes to the manufac-
8
turing of drugs for which an approval or licen-
9
sure is in effect under section 505 of the Fed-
10
eral Food, Drug, and Cosmetic Act (21 U.S.C. 
11
355) or section 351 of the Public Health Serv-
12
ice Act (42 U.S.C. 262). 
13
(c) IMPLEMENTATION FRAMEWORK.— 
14
(1) PUBLICATION.—Not later than one year 
15
after the date of enactment of this Act, the Sec-
16
retary shall publish an implementation framework 
17
for the agreements to share review and inspection 
18
findings under subsection (a) on the public website 
19
of the Food and Drug Administration. 
20
(2) CONTENTS.—The implementation frame-
21
work under this subsection shall— 
22
(A) include the timeline for establishing or 
23
expanding initiatives described in subsection 
24
(a); 
25
19:08 Nov 24, 2020
H14
50 
•HR 14 IH
(B) describe additional types of regulatory 
1
processes that will become subject to such ini-
2
tiatives; 
3
(C) specify the countries and geographic 
4
regions where such initiatives will be established 
5
or expanded; and 
6
(D) identify additional opportunities and 
7
challenges for expanding mutual recognition 
8
agreements in drug and biologic regulation. 
9
(d) ANNUAL REPORTING.— 
10
(1) IN GENERAL.—Not later than the end of 
11
calendar year 2020 and annually thereafter, the Sec-
12
retary shall publish a report on the public website of 
13
the Food and Drug Administration on the utilization 
14
of agreements described in subsection (c)(1) in the 
15
previous fiscal year. 
16
(2) CONTENTS.—The report under paragraph 
17
(1) shall include each of the following: 
18
(A) The total number of establishments 
19
that are registered under section 510(i) of the 
20
Federal Food, Drug, and Cosmetic Act (21 
21
U.S.C. 360) and located outside of the United 
22
States, and of these establishments, the number 
23
in each region of interest. 
24
19:08 Nov 24, 2020
H14
51 
•HR 14 IH
(B) The total number of inspections con-
1
ducted at establishments described in subpara-
2
graph (A). 
3
(C) Of the inspections described in sub-
4
paragraph (B), the total number of inspections 
5
in each of region of interest. 
6
(D) Of the inspections in each region of in-
7
terest reported pursuant to subparagraph (C), 
8
the number of inspections in each FDA inspec-
9
tion category. 
10
(E) Of the number of inspections reported 
11
under each of subparagraphs (B), (C), and 
12
(D)— 
13
(i) the number of inspections which 
14
have been conducted pursuant to an agree-
15
ment described in subsection (c)(1); and 
16
(ii) the number of inspections which 
17
have been conducted by employees or other 
18
agents of the Food and Drug Administra-
19
tion. 
20
(3) DEFINITIONS.—In this subsection: 
21
(A) The term ‘‘region of interest’’ refers to 
22
China, India, the European Union, and any 
23
other geographic region as determined appro-
24
priate by the Secretary. 
25
19:08 Nov 24, 2020
H14
52 
•HR 14 IH
(B) The term ‘‘FDA inspection category’’ 
1
means refers to the following inspection cat-
2
egories: 
3
(i) Inspections to support an approval 
4
of a drug under section 505 of the Federal 
5
Food, Drug, and Cosmetic Act (21 U.S.C. 
6
355) or section 351 of the Public Health 
7
Service Act (42 U.S.C. 262). 
8
(ii) Good manufacturing practice in-
9
spections. 
10
(iii) For-cause inspections. 
11
SEC. 2015. ENHANCING TRANSPARENCY OF DRUG FACILITY 
12
INSPECTION TIMELINES. 
13
Section 902 of the FDA Reauthorization Act of 2017 
14
(21 U.S.C. 355 note) is amended to read as follows: 
15
‘‘SEC. 902. ANNUAL REPORT ON INSPECTIONS. 
16
‘‘Not later than March 1 of each year, the Secretary 
17
of Health and Human Services shall post on the public 
18
website of the Food and Drug Administration information 
19
related to inspections of facilities necessary for approval 
20
of a drug under subsection (c) or (j) of section 505 of 
21
the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
22
355), approval of a device under section 515 of such Act 
23
(21 U.S.C. 360e), or clearance of a device under section 
24
510(k) of such Act (21 U.S.C. 360(k)) that were con-
25
19:08 Nov 24, 2020
H14
53 
•HR 14 IH
ducted during the previous calendar year. Such informa-
1
tion shall include the following: 
2
‘‘(1) The median time following a request from 
3
staff of the Food and Drug Administration review-
4
ing an application or report to the beginning of the 
5
inspection, and the median time from the beginning 
6
of an inspection to the issuance of a report pursuant 
7
to section 704(b) of the Federal Food, Drug, and 
8
Cosmetic Act (21 U.S.C. 374(b)), including— 
9
‘‘(A) the median time for drugs described 
10
in 505(j)(11)(A)(i) of the Federal Food, Drug, 
11
and Cosmetic Act (21 U.S.C. 355(j)(11)(A)(i)); 
12
‘‘(B) the median time for drugs described 
13
in section 506C(a) of such Act (21 U.S.C. 
14
356c(a)) only; and 
15
‘‘(C) the median time for drugs on the 
16
drug shortage list in effect under section 506E 
17
of such Act (21 U.S.C. 356f). 
18
‘‘(2) The median time from the issuance of a 
19
report pursuant to such section 704(b) to the send-
20
ing of a warning letter, issuance of an import alert, 
21
or holding of a regulatory meeting for inspections 
22
for which the Secretary concluded that regulatory or 
23
enforcement action was indicated, including the me-
24
19:08 Nov 24, 2020
H14
54 
•HR 14 IH
dian time for each category of drugs listed in sub-
1
paragraphs (A) through (C) of paragraph (1). 
2
‘‘(3) The median time from the sending of a 
3
warning letter, issuance of an import alert, or hold-
4
ing of a regulatory meeting to resolution of the regu-
5
latory or enforcement action indicated for inspec-
6
tions for which the Secretary concluded that such 
7
action was indicated. 
8
‘‘(4) The number of times that a facility was 
9
issued a report pursuant to such section 704(b) and 
10
approval of an application was delayed due to the 
11
issuance of a withhold recommendation, including 
12
the number of such times for each category of drugs 
13
listed in subparagraphs (A) through (C) of para-
14
graph (1).’’. 
15
SEC. 2016. ADVANCED MANUFACTURING TECHNOLOGIES 
16
PROGRAM. 
17
Subchapter A of chapter V of the Federal Food, 
18
Drug, and Cosmetic Act (21 U.S.C. 351 et seq.) is amend-
19
ed by adding at the end the following: 
20
‘‘SEC. 524B. ADVANCED MANUFACTURING TECHNOLOGIES 
21
PROGRAM. 
22
‘‘(a) IN GENERAL.—Not later than 1 year after the 
23
date of enactment of the Commitment to Defeat the Virus 
24
and Keep America Healthy Act, the Secretary shall con-
25
19:08 Nov 24, 2020
H14
55 
•HR 14 IH
tinue in effect the program to evaluate new drug manufac-
1
turing technologies that are included in an application, or 
2
supplement to an application, for a drug under subsection 
3
(b) or (j) of section 505 of this Act or for a biological 
4
product submitted under subsection (a) or (k) of section 
5
351 of the Public Health Service Act. 
6
‘‘(b) DESIGNATION.—The Secretary shall designate a 
7
method of manufacturing a drug as an advanced manufac-
8
turing technology under this section if the drug manufac-
9
turer demonstrates that such technology is likely to— 
10
‘‘(1) prevent or resolve a drug shortage; 
11
‘‘(2) maintain an adequate supply of critical 
12
medications for national emergencies; or 
13
‘‘(3) promote the adoption of innovative ap-
14
proaches to drug product design and manufacturing. 
15
‘‘(c) CONSULTATION.—If the Secretary designates a 
16
method of manufacturing as an advanced manufacturing 
17
technology under this section, the Secretary shall take ac-
18
tions to expedite the development and implementation of 
19
such method of manufacture for purposes of approval of 
20
the application under subsection (c) or (j) of section 505 
21
of this Act or subsection (a) or (k) of section 351 of the 
22
Public Health Service Act, which may include, as appro-
23
priate— 
24
19:08 Nov 24, 2020
H14
56 
•HR 14 IH
‘‘(1) holding meetings between the sponsor of 
1
the application and appropriate Food and Drug Ad-
2
ministration staff throughout the development of the 
3
technology; 
4
‘‘(2) providing timely advice to, and interactive 
5
communication with, the sponsor regarding the de-
6
velopment of the technology; and 
7
‘‘(3) involving senior managers and experienced 
8
staff of the Food and Drug Administration, as ap-
9
propriate, in a collaborative, cross-disciplinary review 
10
of the method of manufacturing. 
11
‘‘(d) EVALUATION
OF
AN ADVANCED MANUFAC-
12
TURING TECHNOLOGY.— 
13
‘‘(1) PACKAGE.—A sponsor who receives des-
14
ignation of an advanced manufacturing technology 
15
under this section shall provide the Secretary with a 
16
package of scientific evidence supporting the imple-
17
mentation of the advanced manufacturing technology 
18
in a particular context-of-use. 
19
‘‘(2) EVALUATION.—Within 90 days of receiv-
20
ing the package, the Secretary shall determine 
21
whether a designated advanced manufacturing tech-
22
nology is validated for the proposed context of use 
23
based on the scientific merit the supporting evidence 
24
provided by the sponsor. 
25
19:08 Nov 24, 2020
H14
57 
•HR 14 IH
‘‘(3) EFFECT OF APPROVAL.—Upon approval, 
1
the same sponsor may rely upon the advanced man-
2
ufacturing technology for use across multiple manu-
3
facturing product lines within the same context-of- 
4
use without having to re-submit data to the Sec-
5
retary validating the underlying technology. 
6
‘‘(e) IMPLEMENTATION AND REPORTING.— 
7
‘‘(1) PUBLIC
MEETING.—The Secretary shall 
8
publish in the Federal Register a notice of a public 
9
meeting to be held no later than 1 year after the 
10
date of enactment of the Commitment to Defeat the 
11
Virus and Keep America Healthy Act to discuss and 
12
obtain input and recommendations from stake-
13
holders regarding the goals and scope of, and a suit-
14
able framework and procedures and requirements 
15
for, the program under this section. 
16
‘‘(2) 
PROGRAM
GUIDANCE.—The 
Secretary 
17
shall— 
18
‘‘(A) not later than 1 year after the date 
19
of enactment of the Commitment to Defeat the 
20
Virus and Keep America Healthy Act, issue 
21
draft guidance regarding the goals and imple-
22
mentation of the program under this section; 
23
and 
24
19:08 Nov 24, 2020
H14
58 
•HR 14 IH
‘‘(B) not later than 2 years after the date 
1
of enactment of the Commitment to Defeat the 
2
Virus and Keep America Healthy Act, issue 
3
final guidance with respect to the implementa-
4
tion of such program. 
5
‘‘(3) REPORT.—The Secretary shall make avail-
6
able on the public website of the Food and Drug Ad-
7
ministration an annual report on the progress of the 
8
program under this section.’’. 
9
Subtitle C—Improving the 
10
American Drug Supply Chain 
11
SEC. 2021. STUDY AND REPORTING ON DOMESTIC AND FOR-
12
EIGN PRODUCTION. 
13
(a) IN GENERAL.—The Secretary of Health and 
14
Human Services shall enter into an agreement with the 
15
National Academies of Sciences, Engineering, and Medi-
16
cine (referred to in this section as the ‘‘National Acad-
17
emies’’) under which, not later than 24 months after the 
18
date of enactment of this Act, the National Academies 
19
will— 
20
(1) study the current and historical production 
21
of drugs and key ingredients thereof (including ac-
22
tive pharmaceutical ingredients) in the United 
23
States and in foreign countries; 
24
19:08 Nov 24, 2020
H14
59 
•HR 14 IH
(2) formulate recommendations for promoting 
1
increased production of drugs and key ingredients 
2
thereof (including active pharmaceutical ingredients) 
3
in the United States; and 
4
(3) in a manner that does not compromise na-
5
tional security or disclose trade secrets or other con-
6
fidential commercial information that is subject to 
7
section 552(b)(4) of title 5, United States Code, or 
8
section 1905 of title 18, United States Code, submit 
9
a report to the Congress on— 
10
(A) the findings and conclusions of the 
11
study under paragraph (1); and 
12
(B) the recommendations under paragraph 
13
(2). 
14
(b) STUDY TOPICS.—The study pursuant to sub-
15
section (a)(1) shall include— 
16
(1) evaluation of— 
17
(A) the extent to which production of 
18
drugs for use in the United States and key in-
19
gredients thereof (including active pharma-
20
ceutical ingredients) takes place in the United 
21
States; and 
22
(B) the extent to which such production 
23
takes place in foreign countries; 
24
19:08 Nov 24, 2020
H14
60 
•HR 14 IH
(2) identification of the foreign countries in 
1
which such production takes place; 
2
(3) evaluation of historical changes in the coun-
3
tries in which such production takes place; 
4
(4) determination of the reasons why such pro-
5
duction takes place in foreign countries, including 
6
why such production takes place in particular for-
7
eign countries, including consideration of— 
8
(A) the reasons for historical migration of 
9
such production to foreign countries, or from 
10
foreign countries to other foreign countries or 
11
the United States; 
12
(B) economic factors, including economic 
13
impediments to domestic production and incen-
14
tives for foreign production; and 
15
(C) regulatory, intellectual property, inter-
16
national trade, and other legal and policy fac-
17
tors; and 
18
(5) evaluation of the benefits of redundancies in 
19
the supply chain of drugs in the United States in 
20
the event of a public health emergency. 
21
(c) RECOMMENDATIONS.—The agreement under sub-
22
section (a) shall— 
23
(1) provide for inclusion in the recommenda-
24
tions under subsection (a)(2) of measures (which 
25
19:08 Nov 24, 2020
H14
61 
•HR 14 IH
may include statutory, regulatory, and other policy 
1
changes) that should be taken— 
2
(A) to encourage the domestic production 
3
of drugs for use in the United States and key 
4
ingredients thereof (including active pharma-
5
ceutical ingredients); or 
6
(B) to otherwise reduce the risks to the 
7
availability of drugs in the United States in the 
8
event of a public health emergency; and 
9
(2) require consideration, in developing such 
10
recommendations, of— 
11
(A) factors affecting the production of 
12
drugs, including— 
13
(i) access to skilled labor; 
14
(ii) the cost of raw materials, the cost 
15
of energy, and related costs; 
16
(iii) taxes and other incentives; and 
17
(iv) the effects of regulations; and 
18
(B) the costs and consequences of imple-
19
menting, or failing to implement, each such rec-
20
ommendation. 
21
(d) INPUT.—The agreement under subsection (a) 
22
shall require— 
23
(1) consideration of input from the Department 
24
of Health and Human Services, the Department of 
25
19:08 Nov 24, 2020
H14
62 
•HR 14 IH
Commerce, and, as appropriate, other Federal agen-
1
cies; and 
2
(2) consultation with relevant stakeholders, 
3
which— 
4
(A) may include conducting public meet-
5
ings and other forms of engagement, as appro-
6
priate; 
7
(B) shall include consultation with experts 
8
in— 
9
(i) the manufacturing of drugs; 
10
(ii) pharmaceutical industry business 
11
and economics; 
12
(iii) drug purchasing, pricing, and re-
13
imbursement; 
14
(iv) regulatory and intellectual prop-
15
erty issues affecting drug manufacturing; 
16
(v) economics; 
17
(vi) international trade policy; and 
18
(vii) emergency planning; and 
19
(C) may include consultation with other 
20
entities with experience in drug manufacturing 
21
and pricing, as appropriate. 
22
(e) DEFINITIONS.—In this section, the term ‘‘drug’’ 
23
has the meaning given such term in section 201 of the 
24
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321). 
25
19:08 Nov 24, 2020
H14
63 
•HR 14 IH
Subtitle D—Essential Medicines 
1
Strategic Stockpile 
2
SEC. 2031. PILOT PROGRAM ON ENSURING MEDICATION 
3
SUPPLY STABILITY. 
4
Part D of title III of the Public Health Service Act 
5
(42 U.S.C. 254b et seq.) is amended by adding at the end 
6
the following new subpart: 
7
‘‘Subpart XIII—Ensuring Medication Supply Stability 
8
‘‘SEC. 340J. ENSURING MEDICATION SUPPLY STABILITY. 
9
‘‘(a) AWARD OF CONTRACTS.—Beginning not later 
10
than January 1, 2021, the Secretary shall award contracts 
11
to eligible entities to each implement and test the effective-
12
ness of acquiring, maintaining, managing, and distrib-
13
uting a stockpile that— 
14
‘‘(1) consists of generic drugs at risk of short-
15
age; and 
16
‘‘(2) is of sufficient quantity to ensure that cus-
17
tomers in the United States of the respective eligible 
18
entity have access to such drugs for at least 6 
19
months (as specified by the Secretary based on the 
20
historic demand for those drugs). 
21
‘‘(b) SELECTION OF DRUGS.— 
22
‘‘(1) IN GENERAL.—The Secretary shall— 
23
‘‘(A) select not more than 50 types of 
24
drugs that may be included by eligible entities 
25
19:08 Nov 24, 2020
H14
64 
•HR 14 IH
in a stockpile pursuant to a contract under this 
1
section; 
2
‘‘(B) maintain an up-to-date list of such 
3
drugs; and 
4
‘‘(C) make such list publicly available. 
5
‘‘(2) CHOICE OF ELIGIBLE ENTITIES.—A con-
6
tract awarded to an eligible entity under this section 
7
need not require the stockpile of the eligible entity 
8
to include all 50 types of drugs listed pursuant to 
9
paragraph (1). 
10
‘‘(c) SUFFICIENT QUANTITY.—For each generic drug 
11
in a stockpile maintained pursuant to subsection (a), the 
12
Secretary shall specify the quantity of such drug that is 
13
sufficient for purposes of such subsection to ensure that 
14
consumers in the United States of the respective eligible 
15
entity have access to such drug for at least 6 months. 
16
‘‘(d) DURATION; LIQUIDATION OF INVENTORY.— 
17
‘‘(1) DURATION.—A contract awarded under 
18
this section shall be for a term of no more than 3 
19
years. 
20
‘‘(2) LIQUIDATION
OF
INVENTORY.—A drug 
21
held in a stockpile pursuant to a contract under this 
22
section may be liquidated by the eligible entity at the 
23
end of the period of the contract. 
24
‘‘(e) STOCKPILE REQUIREMENTS.— 
25
19:08 Nov 24, 2020
H14
65 
•HR 14 IH
‘‘(1) ENSURING AVAILABILITY OF UNEXPIRED 
1
PRODUCTS.—Each eligible entity with a contract 
2
under this section for a stockpile of generic drugs at 
3
risk of shortage shall— 
4
‘‘(A) ensure that each drug maintained in 
5
the stockpile has an expiration date at least 1 
6
year beyond the current date; and 
7
‘‘(B) to comply with subparagraph (A)— 
8
‘‘(i) sell drugs in the stockpile through 
9
normal commercial channels and replace 
10
those drugs; or 
11
‘‘(ii) if there is no commercial market 
12
for a drug in the stockpile, dispose of the 
13
drug, report such disposal to the Secretary, 
14
and replace the drug. 
15
‘‘(2) MANAGEMENT OF STOCKPILE.— 
16
‘‘(A) IN
GENERAL.—Each eligible entity 
17
with a contract under this section for a stock-
18
pile of generic drugs at risk of shortage shall— 
19
‘‘(i) acquire not later than 6 months 
20
following the date the contract is awarded, 
21
and maintain thereafter, a 6-month supply 
22
of each type of drug the eligible entity has 
23
contracted to stockpile, which 6-month 
24
supply shall be in addition to the average 
25
19:08 Nov 24, 2020
H14
66 
•HR 14 IH
levels of inventory held by such eligible en-
1
tity over the previous year for such drug; 
2
and 
3
‘‘(ii) if it is not possible to comply 
4
with clause (i), notify the Secretary, citing 
5
the reason why it is not possible and the 
6
expected time of acquisition of the drug. 
7
‘‘(B) INVENTORY MANAGEMENT.—Each el-
8
igible entity with a contract under this section 
9
for a stockpile of generic drugs at risk of short-
10
age shall manage inventory to ensure that 
11
drugs in the stockpile are efficiently cycled to 
12
the commercial market and— 
13
‘‘(i) may stockpile inventory at the eli-
14
gible entity’s distribution center with speci-
15
fied inventory amounts virtually reserved 
16
for the Federal Government with constant 
17
cycling to reduce product expiration; or 
18
‘‘(ii) may store stockpiled inventory 
19
separately in a different location and re-
20
place drugs in the stockpile inventory with 
21
the same drug with newer dating. 
22
‘‘(C) INSUFFICIENT
FUNDS.—If amounts 
23
available to an eligible entity through contracts 
24
under this section are not sufficient to acquire 
25
19:08 Nov 24, 2020
H14
67 
•HR 14 IH
or maintain a 6-month supply of any drug in 
1
the stockpile of the eligible entity funded under 
2
this section, the eligible entity— 
3
‘‘(i) may acquire and maintain less 
4
than a 6-month supply, but in no case less 
5
than a 3-month supply; and 
6
‘‘(ii) shall submit a report to the Sec-
7
retary identifying— 
8
‘‘(I) each such drug; and 
9
‘‘(II) the reasons why such 
10
amounts are not sufficient to acquire 
11
or maintain a 6-month supply. 
12
‘‘(D) ANNUAL
AUDITS.—Not more than 
13
annually, the Secretary may request a physical 
14
audit count of the inventories of all eligible enti-
15
ties with a contract under this section to vali-
16
date that each such entity is maintaining the 
17
appropriate amount of stockpiled inventory. 
18
‘‘(3) PERIODIC PRODUCT REVIEW.— 
19
‘‘(A) USE OF PROCEEDS.—An eligible enti-
20
ty with a contract under this section for a 
21
stockpile of generic drugs at risk of shortage 
22
shall use the proceeds of the sale of any drugs 
23
in the stockpile to purchase drugs for the stock-
24
pile in accordance with this section. 
25
19:08 Nov 24, 2020
H14
68 
•HR 14 IH
‘‘(B) MARKET
INFLATION
OR
DEFLA-
1
TION.—In the case of market inflation or defla-
2
tion affecting the price of a drug in the stock-
3
pile of an eligible entity maintained pursuant to 
4
a contract under this section, the contract shall 
5
ensure that the Federal Government does not 
6
profit or suffer loss on items of such drug as 
7
a result of such inflation or deflation. 
8
‘‘(4) REPORTING.—Each eligible entity with a 
9
contract under this section shall submit reports at 
10
such time and in such manner as the Secretary may 
11
require regarding— 
12
‘‘(A) current inventory levels of stockpiled 
13
drugs at a drug level; 
14
‘‘(B) indicators of current inventory levels 
15
of stockpiled drugs relative to acceptable mini-
16
mums; and 
17
‘‘(C) such other matters as the Secretary 
18
determines appropriate. 
19
‘‘(f) CONTRACT TERMS.— 
20
‘‘(1) PAYMENT OF MONTHLY FEES FOR MAN-
21
AGEMENT.—Subject to paragraph (2), the Secretary 
22
shall pay to each eligible entity with a contract 
23
under this section for a stockpile of generic drugs at 
24
19:08 Nov 24, 2020
H14
69 
•HR 14 IH
risk of shortage appropriate monthly fees for the 
1
management of the stockpile. 
2
‘‘(2) PAYMENT
CONDITIONED
ON
STOCKPILE 
3
ADEQUACY.— 
4
‘‘(A) IN GENERAL.—Except as provided in 
5
subparagraph (B), each contract with an eligi-
6
ble entity under this section shall provide that 
7
no payment under the contract may be made 
8
until the entity demonstrates to the Secretary 
9
that the entity has stockpiled such portion of 
10
the total quantity of drugs to be stockpiled 
11
under the contract as the Secretary determines 
12
to be acceptable for payment. 
13
‘‘(B) EXCEPTIONS
FOR
ADVANCE
PAY-
14
MENTS.— 
15
‘‘(i) IN GENERAL.—A contract under 
16
this section may provide that, if the Sec-
17
retary determines (in the Secretary’s dis-
18
cretion) that an advance payment, partial 
19
payment for significant milestones, or pay-
20
ment to increase capacity is necessary to 
21
ensure success of the terms of the con-
22
tract, the Secretary shall pay, in advance 
23
of delivery, an amount not to exceed 10 
24
percent of the total contract amount to be 
25
19:08 Nov 24, 2020
H14
70 
•HR 14 IH
paid to the eligible entity by the Secretary 
1
pursuant to the contract over the full pe-
2
riod of the contract. 
3
‘‘(ii) COST OF CAPITAL.—A contract 
4
under this section may provide for pay-
5
ments to compensate the contracting eligi-
6
ble entity for additional capital require-
7
ments related to the additional inventory 
8
to be maintained. 
9
‘‘(iii) TIMING.—The Secretary shall, 
10
to the extent practicable, make any deter-
11
mination under clause (i) to make an ad-
12
vance payment at the same time as the 
13
issuance of a solicitation. 
14
‘‘(iv) REPAYMENT.—If the Secretary 
15
makes an advance payment pursuant to 
16
clause (i), the Secretary shall require the 
17
eligible entity receiving such advance pay-
18
ment to repay it if there is a failure to per-
19
form by the eligible entity. 
20
‘‘(3) TERMINATION.— 
21
‘‘(A) IN
GENERAL.—Subject to subpara-
22
graph (B), nothing in this section shall be con-
23
strued as affecting the rights of eligible entities 
24
under provisions of statute or regulation (in-
25
19:08 Nov 24, 2020
H14
71 
•HR 14 IH
cluding the Federal Acquisition Regulation) re-
1
lating to the termination of contracts for the 
2
convenience of the Government. 
3
‘‘(B) LIQUIDATION OF STOCKPILE.—If a 
4
contract under this section is terminated, the 
5
eligible entity with the contract shall liquidate 
6
the drugs comprising the stockpile funded 
7
through the contract and return to the Govern-
8
ment any amounts owed in relation to such 
9
drugs, but shall collect the management fees as-
10
sociated with such liquidation. 
11
‘‘(g) CONGRESSIONAL OVERSIGHT.— 
12
‘‘(1) INDEPENDENT
EVALUATION
AND
RE-
13
14
actment of this section and annually thereafter, the 
15
Comptroller General of the United States shall con-
16
duct an independent evaluation, and submit to the 
17
appropriate congressional committees a report, con-
18
cerning the program under this section. 
19
‘‘(2) CONTENTS OF REPORT.—The report under 
20
paragraph (1) shall review, assess, and provide rec-
21
ommendations, as appropriate, on the following: 
22
‘‘(A) Details on likely costs and resultant 
23
savings as compared to a stockpiling method 
24
19:08 Nov 24, 2020
H14
72 
•HR 14 IH
that does not incorporate perpetual inventory 
1
cycling. 
2
‘‘(B) Identification of drawdowns from the 
3
stockpile, as evidence of market shortage avoid-
4
ance. 
5
‘‘(C) The allocation of drugs included in 
6
the stockpiles funded pursuant to this section to 
7
the customers of the eligible entities with con-
8
tracts under this section. 
9
‘‘(D) The degree to which eligible entities 
10
with contracts under this section fulfilled their 
11
obligations under such contracts. 
12
‘‘(h) DEFINITIONS.—In this section: 
13
‘‘(1) The term ‘eligible entity’ means an entity 
14
that meets each of the following criteria: 
15
‘‘(A) The entity is licensed or registered in 
16
accordance with applicable Federal and State 
17
law and in good standing with respect to such 
18
licensure or registration. 
19
‘‘(B) The entity agrees— 
20
‘‘(i) to purchase all drugs to be main-
21
tained in its stockpile funded under this 
22
section directly from the manufacturers of 
23
the drugs or the exclusive distributors of 
24
such manufacturers; or 
25
19:08 Nov 24, 2020
H14
73 
•HR 14 IH
‘‘(ii) in the case of an entity that is a 
1
co-op or chain pharmacy warehouse— 
2
‘‘(I) to purchase drugs to be 
3
maintained in its stockpile funded 
4
under this section from an authorized 
5
distributor; and 
6
‘‘(II) distribute those drugs only 
7
to its member pharmacies. 
8
‘‘(C) The entity holds a verified authorized 
9
wholesale distributor certification issued by the 
10
National Association of Boards of Pharmacy. 
11
‘‘(D) The entity sells more than 90 percent 
12
of its drugs to dispensers. 
13
‘‘(E) The entity agrees to distribute inven-
14
tory from its stockpile funded under this section 
15
only to dispensers that are customers of the en-
16
tity. 
17
‘‘(2) The term ‘generic drug at risk of shortage’ 
18
means a drug (as defined in section 201 of the Fed-
19
eral Food, Drug, and Cosmetic Act) that— 
20
‘‘(A) is approved pursuant to section 
21
505(j) of such Act; 
22
‘‘(B) is included in the World Health Or-
23
ganization’s most recent Model List of Essen-
24
tial Medicines; 
25
19:08 Nov 24, 2020
H14
74 
•HR 14 IH
‘‘(C) is included, at any point during the 
1
preceding 36 months, on the drug shortage list 
2
in effect under section 506E of the Federal 
3
Food, Drug, and Cosmetic Act; and 
4
‘‘(D) is manufactured by 3 or fewer per-
5
sons that are registered under section 510 of 
6
the Federal Food, Drug, and Cosmetic Act for 
7
purposes of such manufacture. 
8
‘‘(i) AUTHORIZATION
OF
APPROPRIATIONS.—To 
9
carry out this section, there is authorized to be appro-
10
priated $120,000,000 for fiscal years 2021 through 2023, 
11
to remain available until expended.’’. 
12
Subtitle E—National Centers of Ex-
13
cellence in Continuous Pharma-
14
ceutical Manufacturing 
15
SEC. 2041. NATIONAL CENTERS OF EXCELLENCE IN CON-
16
TINUOUS 
PHARMACEUTICAL 
MANUFAC-
17
TURING. 
18
(a) IN GENERAL.—Section 3016 of the 21st Century 
19
Cures Act (21 U.S.C. 399h) is amended to read as follows: 
20
19:08 Nov 24, 2020
H14
75 
•HR 14 IH
‘‘SEC. 3016. NATIONAL CENTERS OF EXCELLENCE IN CON-
1
TINUOUS 
PHARMACEUTICAL 
MANUFAC-
2
TURING. 
3
‘‘(a) IN GENERAL.—The Secretary of Health and 
4
Human Services, acting through the Commissioner of 
5
Food and Drugs— 
6
‘‘(1) shall solicit and, beginning not later than 
7
one year after the date of enactment of the Commit-
8
ment to Defeat the Virus and Keep America Healthy 
9
Act, receive requests from institutions of higher edu-
10
cation to be designated as a National Center of Ex-
11
cellence in Continuous Pharmaceutical Manufac-
12
turing (in this section referred to as a ‘National 
13
Center of Excellence’) to support the advancement 
14
and development of continuous manufacturing; and 
15
‘‘(2) shall so designate any institution of higher 
16
education that— 
17
‘‘(A) requests such designation; and 
18
‘‘(B) meets the criteria specified in sub-
19
section (c). 
20
‘‘(b) REQUEST FOR DESIGNATION.—A request for 
21
designation under subsection (a) shall be made to the Sec-
22
retary at such time, in such manner, and containing such 
23
information as the Secretary may require. Any such re-
24
quest shall include a description of how the institution of 
25
19:08 Nov 24, 2020
H14
76 
•HR 14 IH
higher education meets or plans to meet each of the cri-
1
teria specified in subsection (c). 
2
‘‘(c) CRITERIA FOR DESIGNATION DESCRIBED.—The 
3
criteria specified in this subsection with respect to an in-
4
stitution of higher education are that the institution has, 
5
as of the date of the submission of a request under sub-
6
section (a) by such institution— 
7
‘‘(1) physical and technical capacity for re-
8
search and development of continuous manufac-
9
turing; 
10
‘‘(2) manufacturing knowledge-sharing net-
11
works with other institutions of higher education, 
12
large and small pharmaceutical manufacturers, ge-
13
neric and nonprescription manufacturers, contract 
14
manufacturers, and other entities; 
15
‘‘(3) proven capacity to design and demonstrate 
16
new, highly effective technology for use in contin-
17
uous manufacturing; 
18
‘‘(4) a track record for creating and transfer-
19
ring knowledge with respect to continuous manufac-
20
turing; 
21
‘‘(5) the potential to train a future workforce 
22
for research on and implementation of advanced 
23
manufacturing and continuous manufacturing; and 
24
19:08 Nov 24, 2020
H14
77 
•HR 14 IH
‘‘(6) experience in participating in and leading 
1
a continuous manufacturing technology partnership 
2
with other institutions of higher education, large and 
3
small pharmaceutical manufacturers, generic and 
4
nonprescription manufacturers, contract manufac-
5
turers, and other entities— 
6
‘‘(A) to support companies with continuous 
7
manufacturing in the United States; 
8
‘‘(B) to support Federal agencies with 
9
technical assistance, which may include regu-
10
latory and quality metric guidance as applica-
11
ble, for advanced manufacturing and continuous 
12
manufacturing; 
13
‘‘(C) with respect to continuous manufac-
14
turing, to organize and conduct research and 
15
development activities needed to create new and 
16
more effective technology, capture and dissemi-
17
nate expertise, create intellectual property, and 
18
maintain technological leadership; 
19
‘‘(D) to develop best practices for design-
20
ing continuous manufacturing; and 
21
‘‘(E) to assess and respond to the work-
22
force needs for continuous manufacturing, in-
23
cluding the development of training programs if 
24
needed. 
25
19:08 Nov 24, 2020
H14
78 
•HR 14 IH
‘‘(d) TERMINATION
OF DESIGNATION.—The Sec-
1
retary may terminate the designation of any National Cen-
2
ter of Excellence designated under this section if the Sec-
3
retary determines such National Center of Excellence no 
4
longer meets the criteria specified in subsection (c). Not 
5
later than 60 days before the effective date of such a ter-
6
mination, the Secretary shall provide written notice to the 
7
National Center of Excellence, including the rationale for 
8
such termination. 
9
‘‘(e) CONDITIONS FOR DESIGNATION.—As a condi-
10
tion of designation as a National Center of Excellence 
11
under this section, the Secretary shall require that an in-
12
stitution of higher education enter into an agreement with 
13
the Secretary under which the institution agrees— 
14
‘‘(1) to collaborate directly with the Food and 
15
Drug Administration to publish the reports required 
16
by subsection (g); 
17
‘‘(2) to share data with the Food and Drug Ad-
18
ministration regarding best practices and research 
19
generated through the funding under subsection (f); 
20
‘‘(3) to develop, along with industry partners 
21
(which may include large and small biopharma-
22
ceutical manufacturers, generic and nonprescription 
23
manufacturers, and contract manufacturers) and an-
24
other institution or institutions designated under 
25
19:08 Nov 24, 2020
H14
79 
•HR 14 IH
this section, if any, a roadmap for developing a con-
1
tinuous manufacturing workforce; 
2
‘‘(4) to develop, along with industry partners 
3
and other institutions designated under this section, 
4
a roadmap for strengthening existing, and devel-
5
oping new, relationships with other institutions; and 
6
‘‘(5) to provide an annual report to the Food 
7
and Drug Administration regarding the institution’s 
8
activities under this section, including a description 
9
of how the institution continues to meet and make 
10
progress on the criteria listed in subsection (c). 
11
‘‘(f) FUNDING.— 
12
‘‘(1) IN GENERAL.—The Secretary shall award 
13
funding, through grants, contracts, or cooperative 
14
agreements, to the National Centers of Excellence 
15
designated under this section for the purpose of 
16
studying and recommending improvements to contin-
17
uous manufacturing, including such improvements 
18
as may enable the Centers— 
19
‘‘(A) to continue to meet the conditions 
20
specified in subsection (e); and 
21
‘‘(B) to expand capacity for research on, 
22
and development of, continuing manufacturing. 
23
‘‘(2) CONSISTENCY WITH FDA MISSION.—As a 
24
condition on receipt of funding under this sub-
25
19:08 Nov 24, 2020
H14
80 
•HR 14 IH
section, a National Center of Excellence shall agree 
1
to consider any input from the Secretary regarding 
2
the use of funding that would— 
3
‘‘(A) help to further the advancement of 
4
continuous manufacturing through the National 
5
Center of Excellence; and 
6
‘‘(B) be relevant to the mission of the 
7
Food and Drug Administration. 
8
‘‘(3) AUTHORIZATION
OF
APPROPRIATIONS.— 
9
There is authorized to be appropriated to carry out 
10
this subsection $80,000,000 for the period of fiscal 
11
years 2021 through 2025. 
12
‘‘(4) RULE
OF
CONSTRUCTION.—Nothing in 
13
this section shall be construed as precluding a Na-
14
tional Center for Excellence designated under this 
15
section from receiving funds under any other provi-
16
sion of this Act or any other Federal law. 
17
‘‘(g) ANNUAL REVIEW AND REPORTS.— 
18
‘‘(1) ANNUAL
REPORT.—Beginning not later 
19
than one year after the date on which the first des-
20
ignation is made under subsection (a), and annually 
21
thereafter, the Secretary shall— 
22
‘‘(A) submit to Congress a report describ-
23
ing the activities, partnerships and collabora-
24
tions, Federal policy recommendations, previous 
25
19:08 Nov 24, 2020
H14
81 
•HR 14 IH
and continuing funding, and findings of, and 
1
any other applicable information from, the Na-
2
tional Centers of Excellence designated under 
3
this section; and 
4
‘‘(B) make such report available to the 
5
public in an easily accessible electronic format 
6
on the website of the Food and Drug Adminis-
7
tration. 
8
‘‘(2) REVIEW OF NATIONAL CENTERS OF EX-
9
CELLENCE AND POTENTIAL DESIGNEES.—The Sec-
10
retary shall periodically review the National Centers 
11
of Excellence designated under this section to ensure 
12
that such National Centers of Excellence continue to 
13
meet the criteria for designation under this section. 
14
‘‘(3) REPORT ON LONG-TERM VISION OF FDA 
15
ROLE.—Not later than 2 years after the date on 
16
which the first designation is made under subsection 
17
(a), the Secretary, in consultation with the National 
18
Centers of Excellence designated under this section, 
19
shall submit a report to the Congress on the long- 
20
term vision of the Department of Health and 
21
Human Services on the role of the Food and Drug 
22
Administration in supporting continuous manufac-
23
turing, including— 
24
19:08 Nov 24, 2020
H14
82 
•HR 14 IH
‘‘(A) a national framework of principles re-
1
lated to the implementation and regulation of 
2
continuous manufacturing; 
3
‘‘(B) a plan for the development of Federal 
4
regulations and guidance for how advanced 
5
manufacturing and continuous manufacturing 
6
can be incorporated into the development of 
7
pharmaceuticals and regulatory responsibilities 
8
of the Food and Drug Administration; and 
9
‘‘(C) appropriate feedback solicited from 
10
the public, which may include other institutions, 
11
large and small biopharmaceutical manufactur-
12
ers, generic and nonprescription manufacturers, 
13
and contract manufacturers. 
14
‘‘(h) DEFINITIONS.—In this section: 
15
‘‘(1) ADVANCED MANUFACTURING.—The term 
16
‘advanced manufacturing’ means an approach for 
17
the manufacturing of pharmaceuticals that incor-
18
porates novel technology, or uses an established 
19
technique or technology in a new or innovative way 
20
(such as continuous manufacturing where the input 
21
materials are continuously transformed within the 
22
process by two or more unit operations) that en-
23
hances drug quality or improves the manufacturing 
24
process. 
25
19:08 Nov 24, 2020
H14
83 
•HR 14 IH
‘‘(2) 
CONTINUOUS
MANUFACTURING.—The 
1
term ‘continuous manufacturing’— 
2
‘‘(A) means a process where the input ma-
3
terials are continuously fed into and trans-
4
formed within the process, and the processed 
5
output materials are continuously removed from 
6
the system; and 
7
‘‘(B) consists of an integrated process that 
8
consists of a series of two or more unit oper-
9
ations. 
10
‘‘(3) INSTITUTION OF HIGHER EDUCATION.— 
11
The term ‘institution of higher education’ has the 
12
meaning given such term in section 101(a) of the 
13
Higher Education Act of 1965 (20 U.S.C. 1001(a)). 
14
‘‘(4) SECRETARY.—The term ‘Secretary’ means 
15
the Secretary of Health and Human Services, acting 
16
through the Commissioner of Food and Drugs.’’. 
17
(b) TRANSITION RULE.—Section 3016 of the 21st 
18
Century Cures Act (21 U.S.C. 399h), as in effect on the 
19
day before the date of the enactment of this section, shall 
20
apply with respect to grants awarded under such section 
21
before such date of enactment. 
22
19:08 Nov 24, 2020
H14
84 
•HR 14 IH
TITLE 
III—STRATEGIC 
NA-
1
TIONAL 
STOCKPILE 
IM-
2
PROVEMENTS 
3
Subtitle A—Stockpiling for 
4
America’s Future Endeavors 
5
SEC. 3001. STRATEGIC NATIONAL STOCKPILE. 
6
Section 319F–2(a) of the Public Health Service Act 
7
(42 U.S.C. 247d–6b(a)) is amended by adding at the end 
8
the following: 
9
‘‘(6) ACCEPTANCE OF GIFTS.— 
10
‘‘(A) IN
GENERAL.—The Secretary may, 
11
without further appropriation and without fiscal 
12
year limitation, accept, use, and dispose of 
13
gifts, bequests, or devises of money, services, or 
14
property, both real and personal, for the pur-
15
pose of carrying out this subsection. Any such 
16
gift, bequest, or devise of money and proceeds 
17
from sales of other property received as a gift, 
18
bequest, or devise shall be deposited in the 
19
Treasury and shall be available for obligation 
20
and expenditure upon order of the Secretary. 
21
‘‘(B) LIMITATIONS.— 
22
‘‘(i) COMPROMISING INTEGRITY.—The 
23
Secretary may not accept a gift, bequest, 
24
or devise under this paragraph if the Sec-
25
19:08 Nov 24, 2020
H14
85 
•HR 14 IH
retary determines that the use of the prop-
1
erty or services would compromise the in-
2
tegrity or appearance of integrity of— 
3
‘‘(I) a program of the Depart-
4
ment of Health and Human Services; 
5
or 
6
‘‘(II) an individual involved in a 
7
program of the Department. 
8
‘‘(ii) UNAPPROVED
PRODUCTS.—The 
9
Secretary may accept a drug or device (as 
10
those terms are defined in section 201 of 
11
the Federal Food, Drug, and Cosmetic 
12
Act) as part of a gift, bequest, or devise 
13
under this paragraph only if such drug or 
14
device is— 
15
‘‘(I) a drug that is approved 
16
under section 505 of such Act, that 
17
meets the requirements for marketing 
18
under section 505G of such Act, or 
19
that is licensed under section 351 of 
20
this Act; 
21
‘‘(II) a device that is approved 
22
under section 515 of the Federal 
23
Food, Drug, and Cosmetic Act, that is 
24
classified under section 513(f)(2) of 
25
19:08 Nov 24, 2020
H14
86 
•HR 14 IH
such Act, that is licensed under sec-
1
tion 351 of this Act, that is cleared 
2
under section 510(k) of the Federal 
3
Food, Drug, and Cosmetic Act, or for 
4
which a report is not required under 
5
such section 510(k); 
6
‘‘(III) authorized for emergency 
7
use in accordance with section 564 or 
8
564A of the Federal Food, Drug, and 
9
Cosmetic Act or prepositioned for use 
10
in accordance with section 564B of 
11
such Act; 
12
‘‘(IV) authorized for investiga-
13
tional use under section 505, 512, or 
14
520 of the Federal Food, Drug, and 
15
Cosmetic Act or section 351 of this 
16
Act; 
17
‘‘(V) determined by the Commis-
18
sioner of Food and Drugs to be ap-
19
propriate for use, without approval, li-
20
censure, authorization, or clearance, 
21
to respond to a shortage or potential 
22
shortage situation; or 
23
‘‘(VI) a respiratory protective de-
24
vice approved and determined to be a 
25
19:08 Nov 24, 2020
H14
87 
•HR 14 IH
priority, as described in section 319F– 
1
3(i)(1)(D) of this Act. 
2
‘‘(C) REPORT.— 
3
‘‘(i) IN
GENERAL.—The Secretary 
4
shall submit to the Committee on Energy 
5
and Commerce of the House of Represent-
6
atives and the Committee on Health, Edu-
7
cation, Labor, and Pensions of the Senate 
8
an annual report disclosing— 
9
‘‘(I) any gift, bequest, or devise 
10
that was accepted under this para-
11
graph during the year covered by the 
12
report; 
13
‘‘(II) how the gifts, bequests, and 
14
devises contribute to the mission of 
15
the stockpile; and 
16
‘‘(III) the amount of Federal sav-
17
ings that were generated from the ac-
18
ceptance of the gifts, bequests, and 
19
devises. 
20
‘‘(ii) PUBLICATION.—Each report re-
21
quired under clause (i) shall be made pub-
22
licly available.’’. 
23
19:08 Nov 24, 2020
H14
88 
•HR 14 IH
Subtitle B—Stockpile Inventory 
1
Modernization 
2
SEC. 3011. REIMBURSABLE TRANSFERS. 
3
Section 319F–2(a) of the Public Health Service Act 
4
(42 U.S.C. 247d–6b(a)), as amended by section 3001, is 
5
further amended by adding at the end the following: 
6
‘‘(7) TRANSFERS AND REIMBURSEMENTS.— 
7
‘‘(A) IN
GENERAL.—Without regard to 
8
chapter 5 of title 40, United States Code, the 
9
Secretary may transfer to any Federal depart-
10
ment or agency, on a reimbursable basis, any 
11
drugs, vaccines and other biological products, 
12
medical devices, and other supplies in the stock-
13
pile if— 
14
‘‘(i) the transferred supplies are less 
15
than one year from expiry; 
16
‘‘(ii) the stockpile is able to replenish 
17
the supplies, as appropriate; and 
18
‘‘(iii) the Secretary decides the trans-
19
fer is in the best interest of the United 
20
States Government. 
21
‘‘(B) USE
OF
REIMBURSEMENT.—Reim-
22
bursement derived from the transfer of supplies 
23
pursuant to subparagraph (A) may, to the ex-
24
tent and in the amounts made available in ad-
25
19:08 Nov 24, 2020
H14
89 
•HR 14 IH
vance in appropriations Acts, be used by the 
1
Secretary to carry out this section. Funds made 
2
available pursuant to the preceding sentence are 
3
in addition to any other funds that may be 
4
made available for such purpose. 
5
‘‘(C) 
RULE
OF
CONSTRUCTION.—This 
6
paragraph shall not be construed to preclude 
7
transfers of products in the stockpile under 
8
other authorities. 
9
‘‘(D) REPORT.—Not later than September 
10
30, 2022, the Secretary shall submit to the 
11
Committee on Energy and Commerce of the 
12
House of Representatives and the Committee 
13
on Health, Education, Labor, and Pensions of 
14
the Senate a report on each transfer made 
15
under this paragraph and the amount received 
16
by the Secretary in exchange for that transfer. 
17
‘‘(E) SUNSET.—The authority to make 
18
transfers under this paragraph shall cease to be 
19
effective on September 30, 2023.’’. 
20
Subtitle C—Equipment 
21
Maintenance 
22
SEC. 3021. EQUIPMENT MAINTENANCE. 
23
Section 319F–2 of the Public Health Service Act (42 
24
U.S.C. 247d–6b) is amended— 
25
19:08 Nov 24, 2020
H14
90 
•HR 14 IH
(1) in subsection (a)(3)— 
1
(A) in subparagraph (I), by striking ‘‘; 
2
and’’ and inserting a semicolon; 
3
(B) in subparagraph (J), by striking the 
4
period at the end and inserting a semicolon; 
5
and 
6
(C) by inserting the following new subpara-
7
graph at the end: 
8
‘‘(K) ensure contents of the stockpile re-
9
main in good working order and, as appro-
10
priate, conduct maintenance services on con-
11
tents of the stockpile; and’’; and 
12
(2) in subsection (c)(7)(B), by adding at the 
13
end the following new clause: 
14
‘‘(ix) 
EQUIPMENT
MAINTENANCE 
15
SERVICE.—In carrying out this section, the 
16
Secretary may enter into contracts for the 
17
procurement of equipment maintenance 
18
services.’’. 
19
Subtitle D—Medical Supplies for 
20
Pandemics 
21
SEC. 3031. SUPPLY CHAIN FLEXIBILITY MANUFACTURING 
22
PILOT. 
23
(a) IN GENERAL.—Section 319F–2(a)(3) of the Pub-
24
lic Health Service Act (42 U.S.C. 247d–6b(a)(3)), as 
25
19:08 Nov 24, 2020
H14
91 
•HR 14 IH
amended by section 3012, is further amended by adding 
1
at the end the following new subparagraph: 
2
‘‘(L) enhance medical supply chain elas-
3
ticity and establish and maintain domestic re-
4
serves of critical medical supplies (including 
5
personal protective equipment, ancillary medical 
6
supplies, and other applicable supplies required 
7
for the administration of drugs, vaccines and 
8
other biological products, and other medical de-
9
vices (including diagnostic tests)) by— 
10
‘‘(i) increasing emergency stock of 
11
critical medical supplies; 
12
‘‘(ii) geographically diversifying do-
13
mestic production of such medical supplies, 
14
as appropriate; 
15
‘‘(iii) entering into cooperative agree-
16
ments or partnerships with respect to man-
17
ufacturing lines, facilities, and equipment 
18
for the domestic production of such med-
19
ical supplies; and 
20
‘‘(iv) managing, either directly or 
21
through cooperative agreements with man-
22
ufacturers and distributors, domestic re-
23
serves established under this subparagraph 
24
19:08 Nov 24, 2020
H14
92 
•HR 14 IH
by refreshing and replenishing stock of 
1
such medical supplies.’’. 
2
(b) REPORTING; SUNSET.—Section 319F–2(a) of the 
3
Public Health Service Act (42 U.S.C. 247d–6b(a)), as 
4
amended by section 3011, is further amended by adding 
5
at the end the following: 
6
‘‘(8) REPORTING.—Not later than September 
7
30, 2022, the Secretary shall submit to the Com-
8
mittee on Energy and Commerce of the House of 
9
Representatives and the Committee on Health, Edu-
10
cation, Labor, and Pensions of the Senate a report 
11
on the details of each cooperative agreement or part-
12
nership entered into under paragraph (3)(L), includ-
13
ing the amount expended by the Secretary on each 
14
such cooperative agreement or partnership. 
15
‘‘(9) SUNSET.—The authority to enter into co-
16
operative agreements or partnerships pursuant to 
17
paragraph (3)(L) shall cease to be effective on Sep-
18
tember 30, 2023.’’. 
19
(c) FUNDING.—Section 319F–2(f) of the Public 
20
Health Service Act (42 U.S.C. 247d–6b(f)) is amended by 
21
adding at the end the following: 
22
‘‘(3) SUPPLY CHAIN ELASTICITY.— 
23
‘‘(A) IN
GENERAL.—For the purpose of 
24
carrying out subsection (a)(3)(L), there is au-
25
19:08 Nov 24, 2020
H14
93 
•HR 14 IH
thorized to be appropriated $500,000,000 for 
1
each of fiscal years 2021 through 2023, to re-
2
main available until expended. 
3
‘‘(B) RELATION
TO
OTHER
AMOUNTS.— 
4
The amount authorized to be appropriated by 
5
subparagraph (A) for the purpose of carrying 
6
out subsection (a)(3)(L) is in addition to any 
7
other amounts available for such purpose.’’. 
8
Subtitle E—State Stockpile 
9
Readiness 
10
SEC. 3041. GRANTS FOR STATE STRATEGIC STOCKPILES. 
11
Title III of the Public Health Service Act is amended 
12
by inserting after section 319F–4 of such Act (42 U.S.C. 
13
247d–6e) the following new section: 
14
‘‘SEC. 319F–5. GRANTS FOR STATE STRATEGIC STOCKPILES. 
15
‘‘(a) IN GENERAL.—The Secretary may establish a 
16
pilot program consisting of awarding grants to States to 
17
expand or maintain a strategic stockpile of commercially 
18
available drugs, devices, personal protective equipment, 
19
and other products deemed by the State to be essential 
20
in the event of a public health emergency. 
21
‘‘(b) ALLOWABLE USE OF FUNDS.— 
22
‘‘(1) USES.—A State receiving a grant under 
23
this section may use the grant funds to— 
24
19:08 Nov 24, 2020
H14
94 
•HR 14 IH
‘‘(A) acquire commercially available prod-
1
ucts listed pursuant to paragraph (2) for inclu-
2
sion in the State’s strategic stockpile; 
3
‘‘(B) store, maintain, and distribute prod-
4
ucts in such stockpile; and 
5
‘‘(C) conduct planning in connection with 
6
such activities. 
7
‘‘(2) LIST.—The Secretary shall develop and 
8
publish a list of the products that are eligible, as de-
9
scribed in subsection (a), for inclusion in a State’s 
10
strategic stockpile using funds received under this 
11
section. 
12
‘‘(3) CONSULTATION.—In developing the list 
13
under paragraph (2) and otherwise determining the 
14
allowable uses of grant funds under this section, the 
15
Secretary shall consult with States and relevant 
16
stakeholders, including public health organizations. 
17
‘‘(c) FUNDING REQUIREMENT.—The Secretary may 
18
not obligate or expend any funds to award grants or fund 
19
any previously awarded grants under this section for a fis-
20
cal year unless the total amount made available to carry 
21
out section 319F–2 for such fiscal year is equal to or 
22
greater than the total amount of funds made available to 
23
carry out section 319F–2 for fiscal year 2020. 
24
‘‘(d) MATCHING FUNDS.— 
25
19:08 Nov 24, 2020
H14
95 
•HR 14 IH
‘‘(1) IN GENERAL.—With respect to the costs of 
1
expanding and maintaining a strategic stockpile 
2
through a grant under this section, as a condition on 
3
receipt of the grant, a State shall make available (di-
4
rectly) non-Federal contributions in cash toward 
5
such costs in an amount that is equal to not less 
6
than the amount of Federal funds provided through 
7
the grant. 
8
‘‘(2) WAIVER.—The Secretary may waive the 
9
requirement of paragraph (1) with respect to a State 
10
for the first two years of the State receiving a grant 
11
under this section if the Secretary determines that 
12
such waiver is needed for the State to establish a 
13
strategic stockpile described in subsection (a). 
14
‘‘(e) TECHNICAL ASSISTANCE.—The Secretary shall 
15
provide technical assistance to States in establishing, ex-
16
panding, and maintaining a stockpile described in sub-
17
section (a). 
18
‘‘(f) DEFINITION.—In this section, the term ‘drug’ 
19
has the meaning given to that term in section 201 of the 
20
Federal Food, Drug, and Cosmetic Act. 
21
‘‘(g) AUTHORIZATION
OF
APPROPRIATIONS.—To 
22
carry out this section, there is authorized to be appro-
23
priated $3,500,000,000 for each of fiscal years 2021 
24
through 2023, to remain available until expended. 
25
19:08 Nov 24, 2020
H14
96 
•HR 14 IH
‘‘(h) SUNSET.—The authority vested by this section 
1
terminates at the end of fiscal year 2023.’’. 
2
Subtitle F—Process Improvements 
3
and Reports 
4
SEC. 3051. GAO STUDY ON THE FEASIBILITY AND BENEFITS 
5
OF USER FEE AGREEMENTS. 
6
(a) IN GENERAL.—The Comptroller General of the 
7
United States shall conduct a study to investigate the fea-
8
sibility of establishing user fees to offset certain Federal 
9
costs attributable to the procurement of single-source ma-
10
terials for the Strategic National Stockpile under section 
11
319F–2 of the Public Health Service Act (42 U.S.C. 
12
247d–6b) and distributions of such materials from the 
13
Stockpile. In conducting this study, the Comptroller Gen-
14
eral shall consider, to the extent information is available— 
15
(1) whether entities receiving such distributions 
16
generate profits from those distributions; 
17
(2) any Federal costs attributable to such dis-
18
tributions; 
19
(3) whether such user fees would provide the 
20
Secretary with funding to potentially offset procure-
21
ment costs of such materials for the Strategic Na-
22
tional Stockpile; and 
23
(4) any other issues the Comptroller General 
24
identifies as relevant. 
25
19:08 Nov 24, 2020
H14
97 
•HR 14 IH
(b) REPORT.—Not later than February 1, 2023, the 
1
Comptroller General of the United States shall submit to 
2
the Congress a report on the findings and conclusions of 
3
the study under subsection (a). 
4
SEC. 3052. ACTION REPORTING. 
5
(a) IN GENERAL.—The Secretary of Health and 
6
Human Services or the Assistant Secretary for Prepared-
7
ness and Response, in consultation with the Administrator 
8
of the Federal Emergency Management Agency, shall— 
9
(1) not later than 30 days after the date of en-
10
actment of this Act, issue a report to the Committee 
11
on Energy and Commerce of the House of Rep-
12
resentatives and the Committee on Health, Edu-
13
cation, Labor, and Pensions of the Senate regarding 
14
all State, local, Tribal, and territorial requests for 
15
supplies from the Strategic National Stockpile re-
16
lated to COVID–19; and 
17
(2) not less than every 30 days thereafter 
18
through the end of the emergency period (as such 
19
term is defined in section 1135(g)(1)(B) of the So-
20
cial Security Act (42 U.S.C. 1320b–5(g)(1)(B))), 
21
submit to such committees an updated version of 
22
such report. 
23
(b) REPORTING PERIOD.— 
24
19:08 Nov 24, 2020
H14
98 
•HR 14 IH
(1) INITIAL REPORT.—The initial report under 
1
subsection (a) shall address all requests described in 
2
such subsection made during the period— 
3
(A) beginning on January 31, 2020; and 
4
(B) ending on the date that is 30 days be-
5
fore the date of submission of the report. 
6
(2) UPDATES.—Each update to the report 
7
under subsection (a) shall address all requests de-
8
scribed in such subsection made during the period— 
9
(A) beginning at the end of the previous 
10
reporting period under this section; and 
11
(B) ending on the date that is 30 days be-
12
fore the date of submission of the updated re-
13
port. 
14
(c) CONTENTS OF REPORT.—The report under sub-
15
section (a) (and updates thereto) shall include— 
16
(1) the details of each request described in such 
17
subsection, including— 
18
(A) the specific medical countermeasures, 
19
devices, personal protective equipment, and 
20
other materials requested; and 
21
(B) the amount of such materials re-
22
quested; and 
23
(2) the outcomes of each request described in 
24
subsection (a), including— 
25
19:08 Nov 24, 2020
H14
99 
•HR 14 IH
(A) whether the request was wholly ful-
1
filled, partially fulfilled, or denied; 
2
(B) if the request was wholly or partially 
3
fulfilled, the fulfillment amount; and 
4
(C) if the request was partially fulfilled or 
5
denied, a rationale for such outcome. 
6
SEC. 3053. IMPROVED, TRANSPARENT PROCESSES. 
7
(a) IN GENERAL.—Not later than January 1, 2021, 
8
the Secretary of Health and Human Services shall develop 
9
and implement improved, transparent processes for the 
10
use and distribution of drugs, vaccines and other biological 
11
products, medical devices, and other supplies (including 
12
personal protective equipment, ancillary medical supplies, 
13
and other applicable supplies required for the administra-
14
tion of drugs, vaccines and other biological products, med-
15
ical devices, and diagnostic tests) in the Strategic National 
16
Stockpile under section 319F–2 of the Public Health Serv-
17
ice Act (42 U.S.C. 247d–6b) (in this section referred to 
18
as the ‘‘Stockpile’’). 
19
(b) PROCESSES.—The processes developed under 
20
subsection (a) shall include— 
21
(1) the form and manner in which States, local-
22
ities, Tribes, and territories are required to submit 
23
requests for supplies from the Stockpile; 
24
19:08 Nov 24, 2020
H14
100 
•HR 14 IH
(2) the criteria used by the Secretary of Health 
1
and Human Services in responding to such requests, 
2
including the reasons for fulfilling or denying such 
3
requests; 
4
(3) what circumstances result in prioritization 
5
of distribution of supplies from the Stockpile to 
6
States, localities, Tribes, or territories; 
7
(4) clear plans for future, urgent communica-
8
tion between the Secretary and States, localities, 
9
Tribes, and territories regarding the outcome of 
10
such requests; and 
11
(5) any differences in the processes developed 
12
under subsection (a) for geographically related emer-
13
gencies, such as weather events, and national emer-
14
gencies, such as pandemics. 
15
(c) CLASSIFICATION.—The processes developed under 
16
subsection (a) shall be unclassified to the greatest extent 
17
possible consistent with national security. The Secretary 
18
of Health and Human Services may classify portions of 
19
such processes as necessary to protect national security. 
20
(d) REPORT TO CONGRESS.—Not later than January 
21
1, 2021, the Secretary of Health and Human Services 
22
shall— 
23
(1) submit a report to the Committee on En-
24
ergy and Commerce of the House of Representatives 
25
19:08 Nov 24, 2020
H14
101 
•HR 14 IH
and the Committee on Health, Education, Labor, 
1
and Pensions of the Senate regarding the improved, 
2
transparent processes developed under this section; 
3
(2) include in such report recommendations for 
4
opportunities for communication (by telebriefing, 
5
phone calls, or in-person meetings) between the Sec-
6
retary and States, localities, Tribes, and territories 
7
regarding such improved, transparent processes; and 
8
(3) submit such report in unclassified form to 
9
the greatest extent possible, except that the Sec-
10
retary may include a classified appendix if necessary 
11
to protect national security. 
12
Subtitle G—Strategic National 
13
Stockpile Funding 
14
SEC. 3061. AUTHORIZATION OF APPROPRIATIONS. 
15
Section 319F–2(f)(1) of the Public Health Service 
16
Act (42 U.S.C. 247d–6b(f)(1)) is amended by striking 
17
‘‘$610,000,000 for each of fiscal years 2019 through 
18
2023’’ and inserting ‘‘$705,000,000 for each of fiscal 
19
years 2021 through 2023’’. 
20
19:08 Nov 24, 2020
H14
102 
•HR 14 IH
TITLE IV—PUBLIC HEALTH IN-
1
FRASTRUCTURE 
IMPROVE-
2
MENTS 
3
Subtitle A—Public Health 
4
Infrastructure Modernization 
5
SEC. 
4001. 
PUBLIC 
HEALTH 
DATA 
SYSTEM 
TRANS-
6
FORMATION. 
7
Subtitle C of title XXVIII of the Public Health Serv-
8
ice Act (42 U.S.C. 300hh–31 et seq.) is amended by add-
9
ing at the end the following: 
10
‘‘SEC. 
2822. 
PUBLIC 
HEALTH 
DATA 
SYSTEM 
TRANS-
11
FORMATION. 
12
‘‘(a) EXPANDING CDC AND PUBLIC HEALTH DE-
13
PARTMENT CAPABILITIES.— 
14
‘‘(1) IN
GENERAL.—The Secretary, acting 
15
through the Director of the Centers for Disease 
16
Control and Prevention, shall— 
17
‘‘(A) conduct activities to expand, enhance, 
18
and improve public health data systems used by 
19
the Centers for Disease Control and Prevention, 
20
related to the interoperability and improvement 
21
of such systems (including with respect to pre-
22
paredness for, prevention and detection of, and 
23
response to public health emergencies); and 
24
19:08 Nov 24, 2020
H14
103 
•HR 14 IH
‘‘(B) award grants or cooperative agree-
1
ments to State, local, Tribal, or territorial pub-
2
lic health departments for the expansion and 
3
modernization of public health data systems, to 
4
assist public health departments in— 
5
‘‘(i) assessing current data infrastruc-
6
ture capabilities and gaps to improve con-
7
sistency in data collection, storage, and 
8
analysis, and as appropriate to improve 
9
dissemination of public health-related in-
10
formation; 
11
‘‘(ii) improving secure public health 
12
data collection, transmission, exchange, 
13
maintenance, and analysis; 
14
‘‘(iii) improving the secure exchange 
15
of data between the Centers for Disease 
16
Control and Prevention, State, local, Trib-
17
al, and territorial public health depart-
18
ments, public health organizations, and 
19
health care providers, including— 
20
‘‘(I) between public health offi-
21
cials in multiple jurisdictions within a 
22
State; and 
23
‘‘(II) by simplifying and sup-
24
porting reporting by health care pro-
25
19:08 Nov 24, 2020
H14
104 
•HR 14 IH
viders pursuant to State law, includ-
1
ing through the use of health informa-
2
tion technology; 
3
‘‘(iv) enhancing the interoperability of 
4
public health data systems (including sys-
5
tems created or accessed by public health 
6
departments) with health information tech-
7
nology, including with health information 
8
technology 
certified 
under 
section 
9
3001(c)(5); 
10
‘‘(v) supporting and training public 
11
health data systems, data science, and 
12
informatics personnel; 
13
‘‘(vi) supporting earlier disease and 
14
health condition detection, such as through 
15
near real-time data monitoring, to support 
16
rapid public health responses; 
17
‘‘(vii) supporting activities within the 
18
applicable jurisdiction related to the expan-
19
sion and modernization of electronic case 
20
reporting; and 
21
‘‘(viii) developing and disseminating 
22
information related to the use and impor-
23
tance of public health data. 
24
19:08 Nov 24, 2020
H14
105 
•HR 14 IH
‘‘(2) DATA STANDARDS.—In carrying out para-
1
graph (1), the Secretary, acting through the Direc-
2
tor of the Centers for Disease Control and Preven-
3
tion, shall, as appropriate and in coordination with 
4
the Office of the National Coordinator for Health 
5
Information Technology, designate data and tech-
6
nology standards (including standards for interoper-
7
ability) for public health data systems, with def-
8
erence given to standards published by consensus- 
9
based standards development organizations with 
10
public input and voluntary consensus-based stand-
11
ards bodies. 
12
‘‘(3) 
PUBLIC-PRIVATE
PARTNERSHIPS.—The 
13
Secretary may develop and utilize public-private 
14
partnerships for technical assistance, training, and 
15
related implementation support for State, local, 
16
Tribal, and territorial public health departments, 
17
and the Centers for Disease Control and Prevention, 
18
on the expansion and modernization of electronic 
19
case reporting and public health data systems, as 
20
applicable. 
21
‘‘(b) REQUIREMENTS.— 
22
‘‘(1) 
HEALTH
INFORMATION
TECHNOLOGY 
23
STANDARDS.—The Secretary may not award a grant 
24
or cooperative agreement under subsection (a)(1)(B) 
25
19:08 Nov 24, 2020
H14
106 
•HR 14 IH
unless the applicant uses or agrees to use standards 
1
endorsed by the National Coordinator for Health In-
2
formation 
Technology 
pursuant 
to 
section 
3
3001(c)(1) or adopted by the Secretary under sec-
4
tion 3004. 
5
‘‘(2) WAIVER.—The Secretary may waive the 
6
requirement under paragraph (1) with respect to an 
7
applicant if the Secretary determines that the activi-
8
ties under subsection (a)(1)(B) cannot otherwise be 
9
carried out within the applicable jurisdiction. 
10
‘‘(3) APPLICATION.—A State, local, Tribal, or 
11
territorial health department applying for a grant or 
12
cooperative agreement under this section shall sub-
13
mit an application to the Secretary at such time and 
14
in such manner as the Secretary may require. Such 
15
application shall include information describing— 
16
‘‘(A) the activities that will be supported 
17
by the grant or cooperative agreement; and 
18
‘‘(B) how the modernization of the public 
19
health data systems involved will support or im-
20
pact the public health infrastructure of the 
21
health department, including a description of 
22
remaining gaps, if any, and the actions needed 
23
to address such gaps. 
24
19:08 Nov 24, 2020
H14
107 
•HR 14 IH
‘‘(c) STRATEGY AND IMPLEMENTATION PLAN.—Not 
1
later than 180 days after the date of enactment of this 
2
section, the Secretary, acting through the Director of the 
3
Centers for Disease Control and Prevention, shall submit 
4
to the Committee on Health, Education, Labor, and Pen-
5
sions of the Senate and the Committee on Energy and 
6
Commerce of the House of Representatives a coordinated 
7
strategy and an accompanying implementation plan that 
8
identifies and describes the measures the Secretary will 
9
utilize to— 
10
‘‘(1) update and improve public health data sys-
11
tems used by the Centers for Disease Control and 
12
Prevention; and 
13
‘‘(2) carry out the activities described in this 
14
section to support the improvement of State, local, 
15
Tribal, and territorial public health data systems. 
16
‘‘(d) CONSULTATION.—In carrying out this section, 
17
the Secretary, acting through the Director of the Centers 
18
for Disease Control and Prevention, shall consult with 
19
State, local, Tribal, and territorial public health depart-
20
ments, professional medical and public health associations, 
21
associations representing hospitals or other health care en-
22
tities, health information technology experts, and other ap-
23
propriate public or private entities. 
24
19:08 Nov 24, 2020
H14
108 
•HR 14 IH
‘‘(e) REPORT TO CONGRESS.—Not later than 1 year 
1
after the date of enactment of this section, the Secretary 
2
shall submit a report to the Committee on Health, Edu-
3
cation, Labor, and Pensions of the Senate and the Com-
4
mittee on Energy and Commerce of the House of Rep-
5
resentatives that includes— 
6
‘‘(1) a description of any barriers to— 
7
‘‘(A) public health authorities imple-
8
menting interoperable public health data sys-
9
tems and electronic case reporting; 
10
‘‘(B) the exchange of information pursuant 
11
to electronic case reporting; or 
12
‘‘(C) reporting by health care providers 
13
using such public health data systems, as ap-
14
propriate, and pursuant to State law; 
15
‘‘(2) an assessment of the potential public 
16
health impact of implementing electronic case re-
17
porting and interoperable public health data sys-
18
tems; and 
19
‘‘(3) a description of the activities carried out 
20
pursuant to this section. 
21
‘‘(f) ELECTRONIC CASE REPORTING.—In this sec-
22
tion, the term ‘electronic case reporting’ means the auto-
23
mated identification, generation, and bilateral exchange of 
24
reports of health events among electronic health record or 
25
19:08 Nov 24, 2020
H14
109 
•HR 14 IH
health information technology systems and public health 
1
authorities. 
2
‘‘(g) AUTHORIZATION
OF
APPROPRIATIONS.—To 
3
carry out this section, there is authorized to be appro-
4
priated $100,000,000 for each of fiscal years 2021 
5
through 2025.’’. 
6
Subtitle B—Modernizing Infectious 
7
Disease Data Collection 
8
SEC. 4011. MODERNIZING INFECTIOUS DISEASE DATA COL-
9
LECTION. 
10
(a) IMPROVING INFECTIOUS DISEASE DATA COLLEC-
11
TION.—Section 319D of the Public Health Service Act (42 
12
U.S.C. 247d–4) is amended— 
13
(1) in subsection (c)— 
14
(A) in paragraph (3)(A)(iv), by inserting 
15
‘‘(such as commercial, academic, and other hos-
16
pital laboratories)’’ after ‘‘clinical laboratories’’; 
17
(B) in paragraph (5)— 
18
(i) in subparagraph (A)— 
19
(I) in the matter preceding clause 
20
(i), by striking ‘‘and operating’’ and 
21
inserting ‘‘, operating, and updating’’; 
22
(II) in clause (iv), by striking 
23
‘‘and’’ at the end; 
24
19:08 Nov 24, 2020
H14
110 
•HR 14 IH
(III) in clause (v), by striking the 
1
period and inserting ‘‘; and’’; and 
2
(IV) by adding at the end the fol-
3
lowing: 
4
‘‘(vi) integrate and update applicable 
5
existing Centers for Disease Control and 
6
Prevention data systems and networks in 
7
collaboration with State, local, tribal, and 
8
territorial public health officials, including 
9
public health surveillance and disease de-
10
tection systems.’’; and 
11
(ii) in subparagraph (B)— 
12
(I) in clause (i), by inserting 
13
‘‘and 60 days after the date of enact-
14
ment of the Commitment to Defeat 
15
the Virus and Keep America Healthy 
16
Act’’ after ‘‘Innovation Act of 2019’’; 
17
(II) in clause (ii), by inserting 
18
‘‘epidemiologists, clinical microbiolo-
19
gists, pathologists and laboratory ex-
20
perts, experts in health information 
21
technology, privacy, and data secu-
22
rity’’ after ‘‘forecasting);’’; and 
23
(III) in clause (iii)— 
24
19:08 Nov 24, 2020
H14
111 
•HR 14 IH
(aa) in subclause (V), by 
1
striking ‘‘and’’ at the end; 
2
(bb) in subclause (VI), by 
3
striking the period; and 
4
(cc) by adding at the end 
5
the following: 
6
‘‘(VII) strategies to integrate lab-
7
oratory and epidemiology systems and 
8
capabilities to conduct rapid and accu-
9
rate laboratory tests; 
10
‘‘(VIII) strategies to improve the 
11
collection and reporting of appro-
12
priate, aggregated, deidentified demo-
13
graphic data to inform responses to 
14
public health emergencies, including 
15
identification of at-risk populations 
16
and to address health disparities; and 
17
‘‘(IX) strategies to improve the 
18
electronic exchange of health informa-
19
tion between State and local health 
20
departments and health care providers 
21
and facilities to improve public health 
22
surveillance.’’; and 
23
(C) in paragraph (6)— 
24
(i) in subparagraph (A)— 
25
19:08 Nov 24, 2020
H14
112 
•HR 14 IH
(I) in clause (iii)— 
1
(aa) in subclause (III), by 
2
striking ‘‘and’’ at the end; 
3
(bb) in subclause (IV), by 
4
inserting ‘‘, including the ability 
5
to conduct and report on rapid 
6
and accurate laboratory testing 
7
during a public health emer-
8
gency’’ before the semicolon; and 
9
(cc) by adding at the end 
10
the following: 
11
‘‘(V) improve coordination and 
12
collaboration, as appropriate, with 
13
other Federal departments; and 
14
‘‘(VI) implement applicable les-
15
sons learned from recent public health 
16
emergencies to address gaps in situa-
17
tional awareness and biosurveillance 
18
capabilities, including an evaluation of 
19
ways to improve the collection and re-
20
porting of aggregated, deidentified de-
21
mographic data to inform public 
22
health preparedness and response’’; 
23
(II) in clause (iv), by striking 
24
‘‘and’’ at the end; 
25
19:08 Nov 24, 2020
H14
113 
•HR 14 IH
(III) in clause (v), by striking the 
1
period and inserting ‘‘including a de-
2
scription of how such steps will fur-
3
ther the goal of improving awareness 
4
of and timely responses to emerging 
5
infectious disease threats; and’’; and 
6
(IV) by adding at the end the fol-
7
lowing: 
8
‘‘(vi) 
identifies 
and 
demonstrates 
9
measurable steps the Secretary will take to 
10
further develop and integrate infectious 
11
disease detection, including expanding ca-
12
pabilities to conduct rapid and accurate di-
13
agnostic laboratory testing during a public 
14
health emergency, and improve coordina-
15
tion and collaboration with State, local, 
16
Tribal, and territorial public health offi-
17
cials, clinical laboratories (including com-
18
mercial, hospital and academic labora-
19
tories), and other entities with expertise in 
20
public health surveillance.’’; and 
21
(ii) by redesignating subparagraph 
22
(B) as subparagraph (C); and 
23
(iii) by inserting after subparagraph 
24
(A), the following: 
25
19:08 Nov 24, 2020
H14
114 
•HR 14 IH
‘‘(B) REPORTS.— 
1
‘‘(i) IN GENERAL.—Not later than 1 
2
month after date of enactment of the Com-
3
mitment to Defeat the Virus and Keep 
4
America Healthy Act, and as provided for 
5
in clause (ii), the Secretary shall submit to 
6
the Committee on Health, Education, 
7
Labor, and Pensions of the Senate and the 
8
Committee on Energy and Commerce of 
9
the House of Representatives, a report on 
10
the status of the Department of Health 
11
and Human Services’ biosurveillance mod-
12
ernization and assessment progress with 
13
respect to emerging infectious disease 
14
threats. 
15
‘‘(ii) ADDITIONAL REPORTS.—During 
16
the 2-year period beginning on the date of 
17
enactment of the Commitment to Defeat 
18
the Virus and Keep America Healthy Act, 
19
the Secretary shall provide additional re-
20
ports under clause (i) every 90 days after 
21
the submission of the initial report under 
22
such clause. The Secretary shall provide 
23
such reports annually thereafter. The Sec-
24
retary may provide such additional reports 
25
19:08 Nov 24, 2020
H14
115 
•HR 14 IH
less frequently, but not less frequently 
1
than every 180 days, during an ongoing 
2
public health emergency or another signifi-
3
cant infectious disease outbreak.’’; 
4
(2) in subsection (d)— 
5
(A) in paragraph (2)(C), by inserting ‘‘, in-
6
cluding any public-private partnerships entered 
7
into to improve such capacity’’ before the semi-
8
colon; and 
9
(B) in paragraph (3)— 
10
(i) in subparagraph (B), by striking 
11
‘‘and’’ at the end; 
12
(ii) in subparagraph (C), by striking 
13
the period and inserting ‘‘; and’’; and 
14
(iii) by adding at the end the fol-
15
lowing: 
16
‘‘(D) may establish, enhance, or maintain 
17
a system or network for the collection of data 
18
to provide for early detection of infectious dis-
19
ease outbreaks, near real-time access to rel-
20
evant electronic data and integration of elec-
21
tronic data and information from public health 
22
and other appropriate sources, such as labora-
23
tories, hospitals, and epidemiology systems, to 
24
enhance the capability to conduct rapid and ac-
25
19:08 Nov 24, 2020
H14
116 
•HR 14 IH
curate diagnostic laboratory tests to provide for 
1
disease detection.’’; 
2
(3) in subsection (f)(1)(A), by inserting ‘‘pa-
3
thologists, clinical microbiologists, laboratory profes-
4
sionals, epidemiologists,’’ after ‘‘forecasting),’’; and 
5
(4) in subsection (h), by adding at the end the 
6
following: ‘‘Such evaluation shall include identifica-
7
tion of any gaps in biosurveillance and situational 
8
awareness capabilities identified related to recent 
9
public health emergencies, any immediate steps 
10
taken to address such gaps, and any long-term plans 
11
to address such gaps, including steps related to ac-
12
tivities authorized under this section.’’. 
13
(b) NATIONAL HEALTH SECURITY STRATEGY.—Sec-
14
tion 2802(b)(2) of the Public Health Service Act (42 
15
U.S.C. 300hh–1(b)(2)) is amended— 
16
(1) in subparagraph (A), by inserting ‘‘such as 
17
by integrating laboratory and epidemiology systems 
18
and capability to conduct rapid and accurate labora-
19
tory tests,’’ after ‘‘detection, identification,’’; and 
20
(2) in subparagraph (B), by inserting ‘‘labora-
21
tory testing,’’ after ‘‘services and supplies,’’. 
22
(c) 
EPIDEMIOLOGY-LABORATORY
CAPACITY 
23
GRANTS.—Section 2821(a) of the Public Health Service 
24
Act (42 U.S.C. 300hh–31(a)) is amended— 
25
19:08 Nov 24, 2020
H14
117 
•HR 14 IH
(1) in paragraph (3), by striking ‘‘and’’; 
1
(2) in paragraph (4), by striking the period and 
2
inserting ‘‘; and’’; and 
3
(3) by adding at the end the following: 
4
‘‘(5) supporting activities of State and local 
5
public health departments related to biosurveillance 
6
and disease detection, which may include activities 
7
related to section 319D, as appropriate.’’. 
8
Subtitle C—Diagnostic Testing for 
9
Public Health Labs 
10
SEC. 4021. GRANTS FOR PUBLIC HEALTH LABORATORIES 
11
TO 
ACQUIRE 
HIGH-THROUGHPUT 
DIAG-
12
NOSTIC EQUIPMENT. 
13
Section 2821 of the Public Health Service Act (42 
14
U.S.C. 300hh–31) is amended— 
15
(1) by redesignating subsection (b) as sub-
16
section (c); 
17
(2) by inserting after subsection (a) the fol-
18
lowing new subsection: 
19
‘‘(b) GRANTS FOR PUBLIC HEALTH LABORATORIES 
20
TO ACQUIRE HIGH-THROUGHPUT DIAGNOSTIC EQUIP-
21
MENT.— 
22
‘‘(1) GRANTS.—The Secretary shall award 
23
grants to eligible entities to assist such entities in 
24
purchasing high-throughput diagnostic equipment 
25
19:08 Nov 24, 2020
H14
118 
•HR 14 IH
and related supplies and in hiring and training staff 
1
to use such equipment. 
2
‘‘(2) ELIGIBILITY.—To be eligible for a grant 
3
under paragraph (1), an entity shall— 
4
‘‘(A) be— 
5
‘‘(i) a State, local, or Tribal public 
6
health laboratory; 
7
‘‘(ii) a laboratory within a public 
8
health laboratory network coordinated or 
9
managed by the Centers for Disease Con-
10
trol and Prevention; 
11
‘‘(iii) a laboratory not described in 
12
clause (i) or (ii) that the Secretary deter-
13
mines (at the Secretary’s discretion) pro-
14
vides population-based testing for the pre-
15
vention and control of infectious, commu-
16
nicable, genetic, or chronic diseases; or 
17
‘‘(iv) a consortium of 2 or more enti-
18
ties described in any of clauses (i) through 
19
(iii); and 
20
‘‘(B) submit to the Secretary an applica-
21
tion at such time, in such manner, and con-
22
taining such information as the Secretary may 
23
reasonably require. 
24
19:08 Nov 24, 2020
H14
119 
•HR 14 IH
‘‘(3) 
USE
OF
FUNDS.—Amounts 
received 
1
through a grant under this subsection shall be 
2
used— 
3
‘‘(A) to purchase high-throughput diag-
4
nostic equipment and such materials as are nec-
5
essary to administer, store, and process applica-
6
ble tests, including diagnostic and serological 
7
tests; and 
8
‘‘(B) to hire and train staff to use such 
9
equipment. 
10
‘‘(4) AMOUNT OF GRANT.—The amount of a 
11
grant under paragraph (1) may not exceed 
12
$2,000,000, except in the case of eligible entity de-
13
scribed in paragraph (2)(A)(iv). 
14
‘‘(5) HIGH-THROUGHPUT
DIAGNOSTIC
EQUIP-
15
MENT DEFINED.—In this subsection, the term ‘high- 
16
throughput diagnostic equipment’ means legally 
17
marketed equipment and supplies capable of per-
18
forming multichannel analysis for use in clinical lab-
19
oratory diagnostic testing.’’; and 
20
(3) in subsection (c), as so redesignated— 
21
(A) by redesignating paragraphs (1), (2), 
22
and (3) as subparagraphs (A), (B), and (C), re-
23
spectively, and moving the margin of each such 
24
redesignated subparagraph 2 ems to the right; 
25
19:08 Nov 24, 2020
H14
120 
•HR 14 IH
(B) by striking ‘‘There are authorized to 
1
be appropriated to carry out this section’’ and 
2
inserting the following: 
3
‘‘(1) IN GENERAL.—There are authorized to be 
4
appropriated to carry out subsection (a)’’; and 
5
(C) by adding at the end the following new 
6
paragraph: 
7
‘‘(2) AUTHORIZATION OF APPROPRIATIONS.— 
8
‘‘(A) IN
GENERAL.—For the purpose of 
9
carrying out subsection (b), there is authorized 
10
to be appropriated $250,000,000 for fiscal year 
11
2021, to remain available until expended. 
12
‘‘(B) ADMINISTRATIVE EXPENSES.—Of the 
13
amount made available to carry out subsection 
14
(b) for any fiscal year, the Secretary may not 
15
use more than 5 percent of such amount for the 
16
expenses of administering subsection (b).’’. 
17
Subtitle D—Rapid Testing for 
18
Communities 
19
SEC. 4031. GRANTS FOR SAME-DAY POINT-OF-CARE CLIN-
20
ICAL LABORATORY DIAGNOSTIC TESTING IN 
21
COMMUNITIES. 
22
Section 2821 of the Public Health Service Act (42 
23
U.S.C. 300hh–31) is amended— 
24
19:08 Nov 24, 2020
H14
121 
•HR 14 IH
(1) by redesignating subsection (c), as redesig-
1
nated by section 4021, as subsection (d); 
2
(2) by inserting after subsection (b), as added 
3
by section 4021, the following new subsection: 
4
‘‘(c) GRANTS FOR SAME-DAY POINT-OF-CARE CLIN-
5
ICAL LABORATORY DIAGNOSTIC TESTING
IN COMMU-
6
NITIES.— 
7
‘‘(1) GRANTS.—The Secretary shall award 
8
grants to eligible entities to assist such entities in 
9
acquiring legally marketed equipment and supplies 
10
capable of performing same-day clinical laboratory 
11
diagnostic testing in a point-of-care setting. 
12
‘‘(2) ELIGIBILITY.—To be eligible for a grant 
13
under paragraph (1), an entity shall— 
14
‘‘(A) be— 
15
‘‘(i) a hospital; 
16
‘‘(ii) a primary care facility; 
17
‘‘(iii) a clinic; 
18
‘‘(iv) a physician; or 
19
‘‘(v) another type of health care pro-
20
vider as the Secretary may define; and 
21
‘‘(B) submit to the Secretary an applica-
22
tion at such time, in such manner, and con-
23
taining such information as the Secretary may 
24
reasonably require. 
25
19:08 Nov 24, 2020
H14
122 
•HR 14 IH
‘‘(3) 
USE
OF
FUNDS.—Amounts 
received 
1
through a grant under this subsection shall be used 
2
to purchase legally marketed rapid diagnostic equip-
3
ment and such materials as are necessary to admin-
4
ister, store, and process same-day clinical laboratory 
5
diagnostic testing in a point-of-care setting, includ-
6
ing diagnostic and serological tests. 
7
‘‘(4) AMOUNT OF GRANT.—The amount of a 
8
grant under paragraph (1) may not exceed $20,000. 
9
‘‘(5) PRIORITY IN MAKING AWARDS.—In award-
10
ing grants under paragraph (1), the Secretary shall 
11
give priority to eligible entities providing services 
12
to— 
13
‘‘(A) medically underserved populations (as 
14
defined in section 330(b)(3)) in rural areas; and 
15
‘‘(B) all other areas.’’; and 
16
(3) by adding at the end of subsection (d), as 
17
redesignated, the following new paragraph: 
18
‘‘(3) AUTHORIZATION OF APPROPRIATIONS.— 
19
‘‘(A) IN
GENERAL.—For the purpose of 
20
carrying out subsection (c), there is authorized 
21
to be appropriated $500,000,000 for fiscal year 
22
2021, to remain available until expended. 
23
‘‘(B) ADMINISTRATIVE EXPENSES.—Of the 
24
amount made available to carry out subsection 
25
19:08 Nov 24, 2020
H14
123 
•HR 14 IH
(c) for any fiscal year, the Secretary may not 
1
use more than 5 percent of such amount for the 
2
expenses of administering this section.’’. 
3
Subtitle E—Public Health 
4
Workforce Loan Repayment 
5
SEC. 4041. PUBLIC HEALTH WORKFORCE LOAN REPAY-
6
MENT PROGRAM. 
7
Part D of title III of the Public Health Service Act 
8
(42 U.S.C. 254b et seq.), as amended by section 2031, 
9
is further amended by adding at the end the following new 
10
subpart: 
11
‘‘Subpart XIV—Public Health Workforce 
12
‘‘SEC. 340K. LOAN REPAYMENT PROGRAM. 
13
‘‘(a) ESTABLISHMENT.—The Secretary of Health 
14
and Human Services shall establish a program to be 
15
known as the Public Health Workforce Loan Repayment 
16
Program (referred to in this section as the ‘Program’) to 
17
assure an adequate supply of and encourage recruitment 
18
of public health professionals to eliminate critical public 
19
health workforce shortages in local, State, and Tribal pub-
20
lic health agencies. 
21
‘‘(b) ELIGIBILITY.—To be eligible to participate in 
22
the Program, an individual shall— 
23
‘‘(1)(A) be accepted for enrollment, or be en-
24
rolled, as a student in an accredited academic edu-
25
19:08 Nov 24, 2020
H14
124 
•HR 14 IH
cational institution in a State or territory in the 
1
final year of a course of study or program leading 
2
to a public health or health professions degree or 
3
certificate and have accepted employment with a 
4
local, State, or Tribal public health agency, or a re-
5
lated training fellowship, as recognized by the Sec-
6
retary, to commence upon graduation; or 
7
‘‘(B)(i) have graduated, during the preceding 
8
10-year period, from an accredited educational insti-
9
tution in a State or territory and received a public 
10
health or health professions degree or certificate; 
11
and 
12
‘‘(ii) be employed by, or have accepted employ-
13
ment with, a local, State, or Tribal public health 
14
agency or a related training fellowship, as recognized 
15
by the Secretary; 
16
‘‘(2) be a United States citizen; 
17
‘‘(3)(A) submit an application to the Secretary 
18
to participate in the Program; and 
19
‘‘(B) execute a written contract as required in 
20
subsection (c); and 
21
‘‘(4) not have received, for the same service, a 
22
reduction of loan obligations under section 428J, 
23
428K, 428L, 455(m), or 460 of the Higher Edu-
24
19:08 Nov 24, 2020
H14
125 
•HR 14 IH
cation Act of 1965 (20 U.S.C. 1078–10, 1078–11, 
1
1078–12, 1087e(m), and 1087j). 
2
‘‘(c) CONTRACT.—The written contract referred to in 
3
subsection (b)(3)(B) between the Secretary and an indi-
4
vidual shall contain— 
5
‘‘(1) an agreement on the part of the Secretary 
6
that the Secretary will repay, on behalf of the indi-
7
vidual, loans incurred by the individual in the pur-
8
suit of the relevant degree or certificate in accord-
9
ance with the terms of the contract; 
10
‘‘(2) an agreement on the part of the individual 
11
that the individual will serve in the full-time employ-
12
ment of a local, State, or Tribal public health agency 
13
or a related fellowship program in a position related 
14
to the course of study or program for which the con-
15
tract was awarded for a period of time equal to the 
16
greater of— 
17
‘‘(A) 3 years; or 
18
‘‘(B) such longer period of time as deter-
19
mined appropriate by the Secretary and the in-
20
dividual; 
21
‘‘(3) an agreement, as appropriate, on the part 
22
of the individual to relocate to a priority service area 
23
(as determined by the Secretary) in exchange for an 
24
19:08 Nov 24, 2020
H14
126 
•HR 14 IH
additional loan repayment incentive amount to be 
1
determined by the Secretary; 
2
‘‘(4) a provision that any financial obligation of 
3
the United States arising out of a contract entered 
4
into under this section and any obligation of the in-
5
dividual that is conditioned thereon, is contingent on 
6
funds being appropriated for loan repayments under 
7
this section; 
8
‘‘(5) a statement of the damages to which the 
9
United States is entitled, under this section for the 
10
individual’s breach of the contract; and 
11
‘‘(6) such other statements of the rights and li-
12
abilities of the Secretary and of the individual as the 
13
Secretary determines appropriate, not inconsistent 
14
with this section. 
15
‘‘(d) PAYMENTS.— 
16
‘‘(1) IN GENERAL.—A loan repayment provided 
17
for an individual under a written contract referred 
18
to in subsection (b)(3)(B) shall consist of payment, 
19
in accordance with paragraph (2), on behalf of the 
20
individual of the principal, interest, and related ex-
21
penses on government and commercial loans received 
22
by the individual regarding the undergraduate or 
23
graduate education of the individual (or both), which 
24
19:08 Nov 24, 2020
H14
127 
•HR 14 IH
loans were made for tuition expenses incurred by the 
1
individual. 
2
‘‘(2) PAYMENTS
FOR
YEARS
SERVED.—For 
3
each year of service that an individual contracts to 
4
serve pursuant to subsection (c)(2), the Secretary 
5
may pay not more than $35,000 on behalf of the in-
6
dividual for loans described in paragraph (1). With 
7
respect to participants under the Program whose 
8
total eligible loans are less than $105,000, the Sec-
9
retary shall pay an amount that does not exceed 1⁄3 
10
of the eligible loan balance for each year of such 
11
service of such individual. 
12
‘‘(3) TAX LIABILITY.—For the purpose of pro-
13
viding reimbursements for tax liability resulting 
14
from payments under paragraph (2) on behalf of an 
15
individual, the Secretary shall, in addition to such 
16
payments, make payments to the individual in an 
17
amount not to exceed 39 percent of the total amount 
18
of loan repayments made for the taxable year in-
19
volved. 
20
‘‘(e) POSTPONING OBLIGATED SERVICE.—With re-
21
spect to an individual receiving a degree or certificate from 
22
a health professions or other related school, the date of 
23
the initiation of the period of obligated service may be 
24
postponed as approved by the Secretary. 
25
19:08 Nov 24, 2020
H14
128 
•HR 14 IH
‘‘(f) BREACH OF CONTRACT.—An individual who fails 
1
to comply with the contract entered into under subsection 
2
(c) shall be subject to the same financial penalties as pro-
3
vided for under section 338E of the Public Health Service 
4
Act (42 U.S.C. 254o) for breaches of loan repayment con-
5
tracts under section 338B of such Act (42 U.S.C. section 
6
254l–1). 
7
‘‘(g) AUTHORIZATION OF APPROPRIATIONS.—There 
8
is authorized to be appropriated to carry out this section— 
9
‘‘(1) $100,000,000 for fiscal year 2021; and 
10
‘‘(2) $75,000,000 for each of fiscal years 2022 
11
through 2026.’’. 
12
Subtitle F—Vaccine Awareness and 
13
Disease Prevention 
14
SEC. 4051. IMPROVING AWARENESS OF DISEASE PREVEN-
15
TION. 
16
(a) IN GENERAL.—The Public Health Service Act is 
17
amended by striking section 313 of such Act (42 U.S.C. 
18
245) and inserting the following: 
19
‘‘SEC. 313. PUBLIC AWARENESS CAMPAIGN ON THE IMPOR-
20
TANCE OF VACCINATIONS. 
21
‘‘(a) IN GENERAL.—The Secretary, acting through 
22
the Director of the Centers for Disease Control and Pre-
23
vention and in coordination with other offices and agen-
24
cies, as appropriate, shall award competitive grants or 
25
19:08 Nov 24, 2020
H14
129 
•HR 14 IH
contracts to one or more public or private entities to carry 
1
out a national, evidence-based campaign to increase 
2
awareness and knowledge of the safety and effectiveness 
3
of vaccines for the prevention and control of diseases, com-
4
bat misinformation about vaccines, and disseminate sci-
5
entific and evidence-based vaccine-related information, 
6
with the goal of increasing rates of vaccination across all 
7
ages, as applicable, particularly in communities with low 
8
rates of vaccination, to reduce and eliminate vaccine-pre-
9
ventable diseases. 
10
‘‘(b) CONSULTATION.—In carrying out the campaign 
11
under this section, the Secretary shall consult with appro-
12
priate public health and medical experts, including the Na-
13
tional Academy of Medicine and medical and public health 
14
associations and nonprofit organizations, in the develop-
15
ment, implementation, and evaluation of the evidence- 
16
based public awareness campaign. 
17
‘‘(c) REQUIREMENTS.—The campaign under this sec-
18
tion shall— 
19
‘‘(1) be a nationwide, evidence-based media and 
20
public engagement initiative; 
21
‘‘(2) include the development of resources for 
22
communities with low rates of vaccination, including 
23
culturally and linguistically appropriate resources, as 
24
applicable; 
25
19:08 Nov 24, 2020
H14
130 
•HR 14 IH
‘‘(3) include the dissemination of vaccine infor-
1
mation and communication resources to public 
2
health departments, health care providers, and 
3
health care facilities, including such providers and 
4
facilities that provide prenatal and pediatric care; 
5
‘‘(4) be complementary to, and coordinated 
6
with, any other Federal, State, local, or Tribal ef-
7
forts, as appropriate; and 
8
‘‘(5) assess the effectiveness of communication 
9
strategies to increase rates of vaccination. 
10
‘‘(d) ADDITIONAL ACTIVITIES.—The campaign under 
11
this section may— 
12
‘‘(1) include the use of television, radio, the 
13
internet, and other media and telecommunications 
14
technologies; 
15
‘‘(2) include the use of in-person activities; 
16
‘‘(3) be focused to address specific needs of 
17
communities and populations with low rates of vac-
18
cination; and 
19
‘‘(4) include the dissemination of scientific and 
20
evidence-based vaccine-related information, such 
21
as— 
22
‘‘(A) advancements in evidence-based re-
23
search related to diseases that may be pre-
24
vented by vaccines and vaccine development; 
25
19:08 Nov 24, 2020
H14
131 
•HR 14 IH
‘‘(B) information on vaccinations for indi-
1
viduals and communities, including individuals 
2
for whom vaccines are not recommended by the 
3
Advisory Committee for Immunization Prac-
4
tices, and the effects of low vaccination rates 
5
within a community on such individuals; 
6
‘‘(C) information on diseases that may be 
7
prevented by vaccines; and 
8
‘‘(D) information on vaccine safety and the 
9
systems in place to monitor vaccine safety. 
10
‘‘(e) EVALUATION.—The Secretary shall— 
11
‘‘(1) establish benchmarks and metrics to quan-
12
titatively measure and evaluate the awareness cam-
13
paign under this section; 
14
‘‘(2) conduct qualitative assessments regarding 
15
the awareness campaign under this section; and 
16
‘‘(3) prepare and submit to the Committee on 
17
Health, Education, Labor, and Pensions of the Sen-
18
ate and Committee on Energy and Commerce of the 
19
House of Representatives an evaluation of the 
20
awareness campaign under this section. 
21
‘‘(f) SUPPLEMENT NOT SUPPLANT.—Funds appro-
22
priated under this section shall be used to supplement and 
23
not supplant other Federal, State, and local public funds 
24
provided for activities described in this section. 
25
19:08 Nov 24, 2020
H14
132 
•HR 14 IH
‘‘(g) AUTHORIZATION OF APPROPRIATIONS.—There 
1
are authorized to be appropriated to carry out this section 
2
and subsections (k) and (n) of section 317 $10,000,000 
3
for each of fiscal years 2021 through 2025.’’. 
4
(b) GRANTS TO ADDRESS VACCINE-PREVENTABLE 
5
DISEASES.—Section 317 of the Public Health Service Act 
6
(42 U.S.C. 247b) is amended— 
7
(1) in subsection (k)(1)— 
8
(A) in subparagraph (C), by striking ‘‘; 
9
and’’ and inserting a semicolon; 
10
(B) in subparagraph (D), by striking the 
11
period and inserting a semicolon; and 
12
(C) by adding at the end the following: 
13
‘‘(E) planning, implementation, and eval-
14
uation of activities to address vaccine-prevent-
15
able diseases, including activities to— 
16
‘‘(i) identify communities at high risk 
17
of outbreaks related to vaccine-preventable 
18
diseases, including through improved data 
19
collection and analysis; 
20
‘‘(ii) pilot innovative approaches to 
21
improve vaccination rates in communities 
22
and among populations with low rates of 
23
vaccination; 
24
19:08 Nov 24, 2020
H14
133 
•HR 14 IH
‘‘(iii) reduce barriers to accessing vac-
1
cines and evidence-based information about 
2
the health effects of vaccines; 
3
‘‘(iv) partner with community organi-
4
zations and health care providers to de-
5
velop and deliver evidence-based interven-
6
tions, including culturally and linguistically 
7
appropriate interventions, to increase vac-
8
cination rates; 
9
‘‘(v) improve delivery of evidence- 
10
based, vaccine-related information to par-
11
ents and others; and 
12
‘‘(vi) improve the ability of State, 
13
local, Tribal, and territorial public health 
14
departments to engage communities at 
15
high risk for outbreaks related to vaccine- 
16
preventable diseases, in coordination, as 
17
appropriate, with local educational agen-
18
cies, as defined in section 8101 of the Ele-
19
mentary and Secondary Education Act of 
20
1965; and 
21
‘‘(F) research related to strategies for im-
22
proving awareness of scientific and evidence- 
23
based, vaccine-related information, including for 
24
communities with low rates of vaccination, in 
25
19:08 Nov 24, 2020
H14
134 
•HR 14 IH
order to understand barriers to vaccination, im-
1
prove vaccination rates, and assess the public 
2
health outcomes of such strategies.’’; and 
3
(2) by adding at the end the following: 
4
‘‘(n) VACCINATION DATA.—The Secretary, acting 
5
through the Director of the Centers for Disease Control 
6
and Prevention, shall expand and enhance, and, as appro-
7
priate, establish and improve, programs and conduct ac-
8
tivities to collect, monitor, and analyze vaccination cov-
9
erage data to assess levels of protection from vaccine-pre-
10
ventable diseases, including by assessing factors contrib-
11
uting to underutilization of vaccines and variations of such 
12
factors, and identifying communities at high risk of out-
13
breaks associated with vaccine-preventable diseases.’’. 
14
(c) 
SUPPLEMENTAL
GRANT
FUNDS.—Section 
15
330(d)(1) of the Public Health Service Act (42 U.S.C. 
16
254b) is amended— 
17
(1) in subparagraph (F), by striking ‘‘and’’ at 
18
the end; 
19
(2) in subparagraph (G), by striking the period 
20
and inserting ‘‘; and’’; and 
21
(3) by adding at the end the following: 
22
‘‘(H) improving access to recommended 
23
immunizations.’’. 
24
19:08 Nov 24, 2020
H14
135 
•HR 14 IH
(d) UPDATE OF 2015 NVAC REPORT.—The National 
1
Vaccine Advisory Committee established under section 
2
2105 of the Public Health Service Act (42 U.S.C. 300aa– 
3
5) shall, as appropriate, update the report entitled, ‘‘As-
4
sessing the State of Vaccine Confidence in the United 
5
States: Recommendations from the National Vaccine Advi-
6
sory Committee’’, approved by the National Vaccine Advi-
7
sory Committee on June 10, 2015, with respect to factors 
8
affecting childhood vaccination. 
9
Subtitle G—Protecting the Health 
10
of America’s Older Adults Dur-
11
ing COVID–19 & Beyond 
12
SEC. 4061. NATIONAL COVID–19 RESOURCE CENTER FOR 
13
OLDER ADULTS. 
14
(a) IN GENERAL.—The Secretary of Health and 
15
Human Services (in this subtitle referred to as the ‘‘Sec-
16
retary’’) shall establish within the Office of the Assistant 
17
Secretary for Health a National COVID–19 Resource 
18
Center for Older Adults (in this section referred to as the 
19
‘‘Center’’) to identify, curate, and disseminate, promising 
20
and proven practices and tools for the care of older adults 
21
in their homes, community-based care settings, hospitals, 
22
and nursing and acute care facilities. 
23
(b) INVOLVEMENT BY FEDERAL DEPARTMENTS AND 
24
ALL LEVELS OF GOVERNMENT.—The Center shall— 
25
19:08 Nov 24, 2020
H14
136 
•HR 14 IH
(1) be advised by a team of senior officials 
1
from— 
2
(A) agencies across the Department of 
3
Health and Human Services, including the Ad-
4
ministration for Community Living (including 
5
the Administration on Aging), the Centers for 
6
Disease Control and Prevention, the Centers for 
7
Medicare & Medicaid Services, the Health Re-
8
sources and Services Administration, the Indian 
9
Health Service, and the Office of Minority 
10
Health in the Office of the Secretary; and 
11
(B) other Federal departments, including 
12
the Department of Housing and Urban Devel-
13
opment and the Department of Veterans Af-
14
fairs; and 
15
(2) collaborate with State and local govern-
16
ments, Indian tribes and Tribal organizations, and 
17
nonprofit organizations. 
18
(c) ACTIVITIES.—The Center shall perform the fol-
19
lowing activities: 
20
(1) Develop a set of best practices for older 
21
adult health and well-being during and beyond the 
22
period of the COVID–19 pandemic, including such 
23
best practices with respect to the following focus 
24
areas: 
25
19:08 Nov 24, 2020
H14
137 
•HR 14 IH
(A) Providing specialized services to over-
1
come the risks associated with social isolation, 
2
such as additional resources for home-delivered 
3
meals and other nutrition programs to provide 
4
not only food but also face-to-face interactions. 
5
(B) Streamlining and improving access to 
6
screening, testing, and health care services and 
7
resources, and prioritizing venues older adults 
8
can reach. 
9
(C) Expanding the use of telemedicine, in-
10
cluding the provision of technology to execute 
11
televisits that safely and comprehensively ad-
12
dress older adults’ health care needs. 
13
(D) Supporting family caregivers, includ-
14
ing those with additional responsibilities for 
15
homebound individuals. 
16
(E) Reducing disparities among under-
17
served populations. 
18
(F) Developing cross-sector collaborative 
19
efforts. 
20
(2) Create and disseminate tools, technical as-
21
sistance, training, and funding to State, local, Trib-
22
al, and territorial governments to adopt best prac-
23
tices developed under subparagraphs (E) and (F) of 
24
paragraph (1). 
25
19:08 Nov 24, 2020
H14
138 
•HR 14 IH
(3) Establish mechanisms for providing training 
1
and technical assistance to State, local, Tribal, and 
2
territorial governments to ensure that complemen-
3
tary cross-sector activities are replicated at the 
4
State, local, Tribal, and territorial levels. 
5
(4) Facilitate the development of learning net-
6
works of practitioners at the hospital, nursing facil-
7
ity, and community levels to disseminate the best 
8
practices developed under paragraph (1) and ensure 
9
implementation of such best practices to reduce mor-
10
bidity and mortality of older adults affected by 
11
COVID–19. 
12
(5) Identify and disseminate approaches that 
13
strengthen public health and health care system ca-
14
pacity to serve older Americans with regard to 
15
health issues during and beyond the COVID–19 
16
pandemic. 
17
SEC. 4062. HEALTHY AGING PROGRAM. 
18
(a) IN GENERAL.—The Secretary, acting through the 
19
Director of the Centers for Disease Control and Preven-
20
tion, shall establish a Healthy Aging Program for the pur-
21
pose of promoting the health and well-being of older adults 
22
by— 
23
19:08 Nov 24, 2020
H14
139 
•HR 14 IH
(1) improving the coordination of public health 
1
interventions that promote the health and well-being 
2
of older adults; 
3
(2) disseminating and implementing evidence- 
4
based best practices and programs with respect to 
5
promoting the health and well-being of older adults; 
6
and 
7
(3) coordinating multisectoral efforts to pro-
8
mote the health and well-being of older adults across 
9
governmental and nongovernmental health and re-
10
lated agencies. 
11
(b) ACTIVITIES.—For the purpose described in sub-
12
section (a), the Secretary shall design the Healthy Aging 
13
Program to carry out the following activities: 
14
(1) Regularly assess the health-related needs of 
15
older adults and promote policies addressing those 
16
needs through evidence-based public health interven-
17
tions to promote overall health and well-being among 
18
older adults and reduce health care costs. 
19
(2) Identify disparities in health among vulner-
20
able populations of older adults. 
21
(3) Identify gaps in existing public health pro-
22
grams and policies that focus on older adults. 
23
(4) Promote public health partnerships with 
24
aging and other sector stakeholders to ensure non-
25
19:08 Nov 24, 2020
H14
140 
•HR 14 IH
duplication of efforts and increase efficiency by 
1
working collaboratively across sectors. 
2
(5) Work with multisectoral agencies to improve 
3
emergency preparedness plans and activities for vul-
4
nerable older adult populations. 
5
(6) Coordinate efforts to promote the health of 
6
older adults with the Administration for Community 
7
Living, other Federal departments and agencies, and 
8
nonprofit organizations. 
9
(7) Identify resources and evidence-based pro-
10
grams available to local and State health depart-
11
ments, including resources and programs that could 
12
be coordinated across sectors, to address the health 
13
and well-being of older adults. 
14
(c) GRANTS TO HEALTH DEPARTMENTS.—The Sec-
15
retary, acting through the Director of the Centers for Dis-
16
ease Control and Prevention, shall award grants or cooper-
17
ative agreements to eligible health departments to carry 
18
out any of the following activities: 
19
(1) Improving availability of data on the older 
20
adult population, including through data-sharing 
21
with elder affairs agencies. 
22
(2) Linking the health care sector with the 
23
community services sector (including aging services 
24
19:08 Nov 24, 2020
H14
141 
•HR 14 IH
and supports) to coordinate and promote commu-
1
nity-based prevention services. 
2
(3) Ensuring that State and local emergency 
3
preparedness plans and activities address the special 
4
needs of older adults, particularly the most vulner-
5
able populations. 
6
(4) Training State and local public health per-
7
sonnel to implement or adapt evidence-based and in-
8
novative health promotion and disease prevention 
9
programs and policies. 
10
(5) Improving community conditions and ad-
11
dressing social determinants to promote health and 
12
well-being and foster independence among older 
13
adults, such as efforts to advance age-friendly com-
14
munities and dementia-friendly communities. 
15
(d) TECHNICAL ASSISTANCE.—The Secretary shall 
16
(directly or through grants, cooperative agreements, or 
17
contracts) provide technical assistance to eligible health 
18
departments in carrying out activities described in sub-
19
section (c). 
20
(e) EVALUATIONS.—The Secretary shall (directly or 
21
through grants, cooperative agreements, or contracts) pro-
22
vide for the evaluation of activities carried out under sub-
23
sections (a), (b), and (c) in order to determine the extent 
24
to which such activities have been effective in carrying out 
25
19:08 Nov 24, 2020
H14
142 
•HR 14 IH
the purpose described in subsection (a), including the ef-
1
fects of such activities on addressing health disparities. 
2
(f) DEFINITION.—In this section, the term ‘‘eligible 
3
health department’’ means a health department of a State, 
4
the District of Columbia, the Commonwealth of Puerto 
5
Rico, the United States Virgin Islands, Guam, American 
6
Samoa, the Commonwealth of the Northern Mariana Is-
7
lands, a Tribe (as defined in section 4 of the Indian Self- 
8
Determination and Education Assistance Act (25 U.S.C. 
9
5304)), or a large city (as defined by the Director of the 
10
Centers for Disease Control and Prevention for purposes 
11
of this section). 
12
SEC. 4063. AUTHORIZATION OF APPROPRIATIONS. 
13
There is authorized to be appropriated— 
14
(1) $10,000,000 for the period of fiscal years 
15
2021 through 2025 to carry out section 4061, to re-
16
main available until September 30, 2025; and 
17
(2) $20,000,000 for each of fiscal years 2021 
18
through 2025 to carry out section 4062, including 
19
for grants under section 4062(c), to remain available 
20
until September 30, 2025. 
21
19:08 Nov 24, 2020
H14
143 
•HR 14 IH
Subtitle H—Expanding Capacity 
1
for Health Outcomes 
2
SEC. 4071. EXPANDING CAPACITY FOR HEALTH OUTCOMES. 
3
Title III of the Public Health Service Act is amended 
4
by inserting after section 330M (42 U.S.C. 254c–19) the 
5
following: 
6
‘‘SEC. 330N. EXPANDING CAPACITY FOR HEALTH OUT-
7
COMES. 
8
‘‘(a) DEFINITIONS.—In this section: 
9
‘‘(1) ELIGIBLE ENTITY.—The term ‘eligible en-
10
tity’— 
11
‘‘(A) means an entity that provides, or 
12
supports the provision of, health care services— 
13
‘‘(i) in rural areas, frontier areas, 
14
health professional shortage areas, or 
15
medically underserved areas; or 
16
‘‘(ii) to medically underserved popu-
17
lations or Native Americans, including In-
18
dian Tribes, Tribal organizations, or urban 
19
Indian organizations; and 
20
‘‘(B) may include entities leading, or capa-
21
ble of leading, a technology-enabled collabo-
22
rative learning and capacity building model or 
23
engaging in technology-enabled collaborative 
24
training of participants in such model. 
25
19:08 Nov 24, 2020
H14
144 
•HR 14 IH
‘‘(2) 
HEALTH
PROFESSIONAL
SHORTAGE 
1
AREA.—The term ‘health professional shortage area’ 
2
means a health professional shortage area des-
3
ignated under section 332. 
4
‘‘(3) INDIAN TRIBE.—The terms ‘Indian Tribe’ 
5
and ‘Tribal organization’ have the meanings given 
6
the terms ‘Indian tribe’ and ‘tribal organization’ in 
7
section 4 of the Indian Self-Determination and Edu-
8
cation Assistance Act. 
9
‘‘(4) 
MEDICALLY
UNDERSERVED
10
LATION.—The term ‘medically underserved popu-
11
lation’ has the meaning given the term in section 
12
330(b)(3). 
13
‘‘(5) NATIVE
AMERICANS.—The term ‘Native 
14
Americans’ has the meaning given such term in sec-
15
tion 736 and includes Indian Tribes and Tribal or-
16
ganizations. 
17
‘‘(6) TECHNOLOGY-ENABLED
COLLABORATIVE 
18
LEARNING AND CAPACITY BUILDING MODEL.—The 
19
term ‘technology-enabled collaborative learning and 
20
capacity building model’ means a distance health 
21
education model that connects health care profes-
22
sionals, and particularly specialists, with multiple 
23
other health care professionals through simultaneous 
24
interactive videoconferencing for the purpose of fa-
25
19:08 Nov 24, 2020
H14
145 
•HR 14 IH
cilitating case-based learning, disseminating best 
1
practices, and evaluating outcomes. 
2
‘‘(7) 
URBAN
INDIAN
ORGANIZATION.—The 
3
‘urban Indian organization’ has the meaning given 
4
the term ‘Urban Indian organization’ in section 4 of 
5
the Indian Health Care Improvement Act. 
6
‘‘(b) PROGRAM ESTABLISHED.—The Secretary shall, 
7
as appropriate, award grants to evaluate, develop, and, as 
8
appropriate, expand the use of technology-enabled collabo-
9
rative learning and capacity building models, to improve 
10
retention of health care providers and increase access to 
11
health care services, such as those to address chronic dis-
12
eases and conditions, infectious diseases, mental health, 
13
substance use disorders, prenatal and maternal health, pe-
14
diatric care, pain management, palliative care, and other 
15
specialty care in rural areas, frontier areas, health profes-
16
sional shortage areas, or medically underserved areas and 
17
for medically underserved populations or Native Ameri-
18
cans, including Indian Tribes and Tribal organizations. 
19
‘‘(c) USE OF FUNDS.— 
20
‘‘(1) IN GENERAL.—Grants awarded under sub-
21
section (b) shall be used for— 
22
‘‘(A) the development and acquisition of 
23
instructional programming, and the training of 
24
health care providers and other professionals 
25
19:08 Nov 24, 2020
H14
146 
•HR 14 IH
that provide or assist in the provision of serv-
1
ices through models described in subsection (b), 
2
such as training on best practices for data col-
3
lection and leading or participating in such 
4
technology-enabled activities consistent with 
5
technology-enabled collaborative learning and 
6
capacity building models; 
7
‘‘(B) information collection and evaluation 
8
activities to study the impact of such models on 
9
patient outcomes and health care providers, and 
10
to identify best practices for the expansion and 
11
use of such models; or 
12
‘‘(C) other activities consistent with achiev-
13
ing the objectives of the grants awarded under 
14
this section, as determined by the Secretary. 
15
‘‘(2) OTHER USES.—In addition to any of the 
16
uses under paragraph (1), grants awarded under 
17
subsection (b) may be used for— 
18
‘‘(A) equipment to support the use and ex-
19
pansion 
of 
technology-enabled 
collaborative 
20
learning and capacity building models, including 
21
for hardware and software that enables distance 
22
learning, health care provider support, and the 
23
secure exchange of electronic health informa-
24
tion; or 
25
19:08 Nov 24, 2020
H14
147 
•HR 14 IH
‘‘(B) support for health care providers and 
1
other professionals that provide or assist in the 
2
provision of services through such models. 
3
‘‘(d) LENGTH OF GRANTS.—Grants awarded under 
4
subsection (b) shall be for a period of up to 5 years. 
5
‘‘(e) GRANT REQUIREMENTS.—The Secretary may 
6
require entities awarded a grant under this section to col-
7
lect information on the effect of the use of technology- 
8
enabled collaborative learning and capacity building mod-
9
els, such as on health outcomes, access to health care serv-
10
ices, quality of care, and provider retention in areas and 
11
populations described in subsection (b). The Secretary 
12
may award a grant or contract to assist in the coordina-
13
tion of such models, including to assess outcomes associ-
14
ated with the use of such models in grants awarded under 
15
subsection (b), including for the purpose described in sub-
16
section (c)(1)(B). 
17
‘‘(f) APPLICATION.—An eligible entity that seeks to 
18
receive a grant under subsection (b) shall submit to the 
19
Secretary an application, at such time, in such manner, 
20
and containing such information as the Secretary may re-
21
quire. Such application shall include plans to assess the 
22
effect of technology-enabled collaborative learning and ca-
23
pacity building models on patient outcomes and health 
24
care providers. 
25
19:08 Nov 24, 2020
H14
148 
•HR 14 IH
‘‘(g) ACCESS
TO BROADBAND.—In administering 
1
grants under this section, the Secretary may coordinate 
2
with other agencies to ensure that funding opportunities 
3
are available to support access to reliable, high-speed 
4
internet for grantees. 
5
‘‘(h) TECHNICAL ASSISTANCE.—The Secretary shall 
6
provide (either directly through the Department of Health 
7
and Human Services or by contract) technical assistance 
8
to eligible entities, including recipients of grants under 
9
subsection (b), on the development, use, and evaluation 
10
of technology-enabled collaborative learning and capacity 
11
building models in order to expand access to health care 
12
services provided by such entities, including for medically 
13
underserved areas and to medically underserved popu-
14
lations or Native Americans, including Indian Tribes and 
15
Tribal organizations. 
16
‘‘(i) RESEARCH AND EVALUATION.—The Secretary, 
17
in consultation with stakeholders with appropriate exper-
18
tise in such models, shall develop a strategic plan to re-
19
search and evaluate the evidence for such models. The 
20
Secretary shall use such plan to inform the activities car-
21
ried out under this section. 
22
‘‘(j) REPORT
BY SECRETARY.—Not later than 4 
23
years after the date of enactment of this section, the Sec-
24
retary shall prepare and submit to the Committee on 
25
19:08 Nov 24, 2020
H14
149 
•HR 14 IH
Health, Education, Labor, and Pensions of the Senate and 
1
the Committee on Energy and Commerce of the House 
2
of Representatives, and post on the internet website of the 
3
Department of Health and Human Services, a report in-
4
cluding, at minimum— 
5
‘‘(1) a description of any new and continuing 
6
grants awarded to entities under subsection (b) and 
7
the specific purpose and amounts of such grants; 
8
‘‘(2) an overview of— 
9
‘‘(A) the evaluations conducted under sub-
10
section (b); 
11
‘‘(B) technical assistance provided under 
12
subsection (h); and 
13
‘‘(C) activities conducted by entities award-
14
ed grants under subsection (b); and 
15
‘‘(3) a description of any significant findings or 
16
developments related to patient outcomes or health 
17
care providers and best practices for eligible entities 
18
expanding, using, or evaluating technology-enabled 
19
collaborative learning and capacity building models, 
20
including through the activities described in sub-
21
section (h). 
22
‘‘(k) AUTHORIZATION OF APPROPRIATIONS.—There 
23
is authorized to be appropriated to carry out this section, 
24
$20,000,000 for each of fiscal years 2021 through 2025.’’. 
25
19:08 Nov 24, 2020
H14
150 
•HR 14 IH
Subtitle I—Community Readiness 
1
SEC. 4081. GRANTS FOR RESEARCH ON, OR ESTABLISHING, 
2
WASTEWATER SURVEILLANCE AND OTHER 
3
EARLY WARNING SYSTEMS. 
4
Subtitle C of title XXVIII of the Public Health Serv-
5
ice Act (42 U.S.C. 300hh–31 et seq.) is amended by add-
6
ing at the end the following: 
7
‘‘SEC. 2823. GRANTS FOR RESEARCH ON, OR ESTABLISHING, 
8
WASTEWATER SURVEILLANCE AND OTHER 
9
EARLY WARNING SYSTEMS. 
10
‘‘(a) IN GENERAL.—The Secretary, in consultation 
11
with the Administrator of the Environmental Protection 
12
Agency, may award grants to eligible entities to conduct 
13
research on, or to establish, a wastewater surveillance or 
14
other early warning system through— 
15
‘‘(1) wastewater testing; 
16
‘‘(2) temperature tracking to monitor axillary 
17
body temperature; and 
18
‘‘(3) other methods deemed permissible by the 
19
Secretary and Administrator. 
20
‘‘(b) PERMISSIBLE USES OF FUNDS.—A grant recipi-
21
ent under this section may use grant funds to support the 
22
activities described in subsection (a), including by— 
23
19:08 Nov 24, 2020
H14
151 
•HR 14 IH
‘‘(1) paying for data-centric services that can 
1
detect infectious diseases before positive cases or 
2
hospitalizations; 
3
‘‘(2) entering into contracts with private compa-
4
nies to implement early warning detection methods; 
5
or 
6
‘‘(3) funding research to study early warning 
7
detection methods. 
8
‘‘(c) PRIORITY.—In selecting grant recipients under 
9
this section, the Secretary shall give priority to eligible en-
10
tities proposing to conduct research on, or to establish, 
11
wastewater surveillance or other early warning system in 
12
one or more areas that— 
13
‘‘(1) are (or include one or more areas that are) 
14
a hot spot; or 
15
‘‘(2) a higher percentage of vulnerable popu-
16
lations than the national average. 
17
‘‘(d) FEDERAL PRIVACY REQUIREMENTS.—Nothing 
18
in this section shall be construed to supersede any Federal 
19
privacy or confidentiality requirement, including the regu-
20
lations promulgated under section 264(c) of the Health 
21
Insurance Portability and Accountability Act of 1996 and 
22
section 543 of this Act. 
23
‘‘(e) DEFINITIONS.—In this section: 
24
19:08 Nov 24, 2020
H14
152 
•HR 14 IH
‘‘(1) The term ‘Administrator’ means the Ad-
1
ministrator of the Environmental Protection Agency. 
2
‘‘(2) The term ‘eligible entity’ means— 
3
‘‘(A) a State government; 
4
‘‘(B) a local government; 
5
‘‘(C) a Tribal government; 
6
‘‘(D) an entity that conducts health re-
7
search; and 
8
‘‘(E) an academic institution. 
9
‘‘(3) The term ‘emergency period’ has the 
10
meaning given to that term in section 1135(g)(1)(B) 
11
of the Social Security Act. 
12
‘‘(4) The term ‘hot spot’ means a geographic 
13
area where the rate of infection with a particular 
14
pathogen exceeds the national average. 
15
‘‘(5) The term ‘local government’ means a 
16
county, municipality, town, township, village, parish, 
17
borough, or other unit of general local government. 
18
‘‘(6) The term ‘Secretary’ means the Secretary 
19
of Health and Human Services. 
20
‘‘(7) The term ‘State’ means each of the several 
21
States, the District of Columbia, the Commonwealth 
22
of Puerto Rico, American Samoa, Guam, the Com-
23
monwealth of the Northern Mariana Islands, the 
24
19:08 Nov 24, 2020
H14
153 
•HR 14 IH
Virgin Islands, and the Trust Territory of the Pa-
1
cific Islands. 
2
‘‘(8) The term ‘vulnerable population’ means 
3
people at increased risk of severe illness. 
4
‘‘(f) AUTHORIZATION
OF
APPROPRIATIONS.—To 
5
carry out this section, there are authorized to be appro-
6
priated $18,000,000 for each of fiscal years 2021 through 
7
2025.’’. 
8
TITLE V—ADDRESSING COVID–19 
9
HEALTH DISPARITIES 
10
Subtitle A—Tribal Health Data 
11
Improvement 
12
SEC. 5001. COLLECTION AND AVAILABILITY OF HEALTH 
13
DATA WITH RESPECT TO INDIAN TRIBES. 
14
(a) DATA COLLECTION.—Section 3101(a)(1) of the 
15
Public Health Service Act (42 U.S.C. 300kk(a)(1)) is 
16
amended— 
17
(1) by striking ‘‘, by not later than 2 years 
18
after the date of enactment of this title,’’; and 
19
(2) in subparagraph (B), by inserting ‘‘Tribal,’’ 
20
after ‘‘State,’’. 
21
(b) DATA REPORTING AND DISSEMINATION.—Sec-
22
tion 3101(c) of the Public Health Service Act (42 U.S.C. 
23
300kk(c)) is amended— 
24
19:08 Nov 24, 2020
H14
154 
•HR 14 IH
(1) by amending subparagraph (F) of para-
1
graph (1) to read as follows: 
2
‘‘(F) the Indian Health Service, Indian 
3
Tribes, Tribal organizations, and epidemiology 
4
centers authorized under the Indian Health 
5
Care Improvement Act;’’; and 
6
(2) in paragraph (3), by inserting ‘‘Indian 
7
Tribes, Tribal organizations, and epidemiology cen-
8
ters,’’ after ‘‘Federal agencies,’’. 
9
(c) PROTECTION AND SHARING OF DATA.—Section 
10
3101(e) of the Public Health Service Act (42 U.S.C. 
11
300kk(e)) is amended by adding at the end the following 
12
new paragraphs: 
13
‘‘(3) DATA SHARING STRATEGY.—With respect 
14
to data access for Tribal epidemiology centers and 
15
Tribes, the Secretary shall create a data sharing 
16
strategy that takes into consideration recommenda-
17
tions by the Secretary’s Tribal Advisory Committee 
18
for— 
19
‘‘(A) ensuring that Tribal epidemiology 
20
centers and Indian Tribes have access to the 
21
data sources necessary to accomplish their pub-
22
lic health responsibilities; and 
23
‘‘(B) protecting the privacy and security of 
24
such data. 
25
19:08 Nov 24, 2020
H14
155 
•HR 14 IH
‘‘(4) TRIBAL PUBLIC HEALTH AUTHORITY.— 
1
‘‘(A) AVAILABILITY.—Beginning not later 
2
than 180 days after the date of the enactment 
3
of the Commitment to Defeat the Virus and 
4
Keep America Healthy Act, the Secretary shall 
5
make available to the entities listed in subpara-
6
graph (B) all data that is collected pursuant to 
7
this title with respect to health care and public 
8
health surveillance programs and activities, in-
9
cluding such programs and activities that are 
10
federally supported or conducted, so long as— 
11
‘‘(i) such entities request the data 
12
pursuant to statute; and 
13
‘‘(ii) the data is requested for use— 
14
‘‘(I) consistent with Federal law 
15
and obligations; and 
16
‘‘(II) to satisfy a particular pur-
17
pose or carry out a specific function 
18
consistent with the purpose for which 
19
the data was collected. 
20
‘‘(B) ENTITIES.—The entities listed in this 
21
subparagraph are— 
22
‘‘(i) the Indian Health Service; 
23
‘‘(ii) Indian Tribes and Tribal organi-
24
zations; and 
25
19:08 Nov 24, 2020
H14
156 
•HR 14 IH
‘‘(iii) epidemiology centers.’’. 
1
(d) TECHNICAL UPDATES.—Section 3101 of the 
2
Public Health Service Act (42 U.S.C. 300kk) is amend-
3
ed— 
4
(1) by striking subsections (g) and (h); and 
5
(2) by redesignating subsection (i) as subsection 
6
(h). 
7
(e) DEFINITIONS.—After executing the amendments 
8
made by subsection (d), section 3101 of the Public Health 
9
Service Act (42 U.S.C. 300kk) is amended by inserting 
10
after subsection (f) the following new subsection: 
11
‘‘(g) DEFINITIONS.—In this section: 
12
‘‘(1) The term ‘epidemiology center’ means an 
13
epidemiology center established under section 214 of 
14
the Indian Health Care Improvement Act, including 
15
such Tribal epidemiology centers serving Indian 
16
Tribes regionally and any Tribal epidemiology center 
17
serving Urban Indian organizations nationally. 
18
‘‘(2) The term ‘Indian Tribe’ has the meaning 
19
given to the term ‘Indian tribe’ in section 4 of the 
20
Indian Self-Determination and Education Assistance 
21
Act. 
22
‘‘(3) The term ‘Tribal organization’ has the 
23
meaning given to the term ‘tribal organization’ in 
24
19:08 Nov 24, 2020
H14
157 
•HR 14 IH
section 4 of the of the Indian Self-Determination 
1
and Education Assistance Act. 
2
‘‘(4) The term ‘Urban Indian organization’ has 
3
the meaning given to that term in section 4 of the 
4
Indian Health Care Improvement Act.’’. 
5
(f) TECHNICAL CORRECTION.—Section 3101(b) of 
6
the Public Health Service Act (42 U.S.C. 300kk(b)) is 
7
amended by striking ‘‘DATA ANALYSIS.—’’ and all that 
8
follows through ‘‘For each federally’’ and inserting ‘‘DATA 
9
ANALYSIS.—For each federally’’. 
10
SEC. 5002. IMPROVING HEALTH STATISTICS REPORTING 
11
WITH RESPECT TO INDIAN TRIBES. 
12
(a) TECHNICAL AID TO STATES AND LOCALITIES.— 
13
Section 306(d) of the Public Health Service Act (42 
14
U.S.C. 242k(d)) is amended by inserting ‘‘, Indian Tribes, 
15
Tribal organizations, and epidemiology centers’’ after ‘‘ju-
16
risdictions’’. 
17
(b) COOPERATIVE HEALTH STATISTICS SYSTEM.— 
18
Section 306(e)(3) of the Public Health Service Act (42 
19
U.S.C. 242k(e)(3)) is amended by inserting ‘‘, Indian 
20
Tribes, Tribal organizations, and epidemiology centers’’ 
21
after ‘‘health agencies’’. 
22
(c) FEDERAL-STATE-TRIBAL COOPERATION.—Sec-
23
tion 306(f) of the Public Health Service Act (42 U.S.C. 
24
242k(f)) is amended— 
25
19:08 Nov 24, 2020
H14
158 
•HR 14 IH
(1) by inserting ‘‘the Indian Health Service,’’ 
1
before ‘‘the Departments of Commerce’’; 
2
(2) by inserting a comma after ‘‘the Depart-
3
ments of Commerce and Labor’’; 
4
(3) by inserting ‘‘, Indian Tribes, Tribal organi-
5
zations, and epidemiology centers’’ after ‘‘State and 
6
local health departments and agencies’’; and 
7
(4) by striking ‘‘he shall’’ and inserting ‘‘the 
8
Secretary shall’’. 
9
(d) 
REGISTRATION
AREA
RECORDS.—Section 
10
306(h)(1) of the Public Health Service Act (42 U.S.C. 
11
242k(h)(1)) is amended— 
12
(1) by striking ‘‘in his discretion’’ and inserting 
13
‘‘in the discretion of the Secretary’’; and 
14
(2) by striking ‘‘Hispanics, Asian Americans, 
15
and Pacific Islanders’’ and inserting ‘‘American In-
16
dians and Alaska Natives, Hispanics, Asian Ameri-
17
cans, and Native Hawaiian and other Pacific Island-
18
ers’’. 
19
(e) NATIONAL COMMITTEE ON VITAL AND HEALTH 
20
STATISTICS.—Section 306(k) of the Public Health Service 
21
Act (42 U.S.C. 242k(k)) is amended— 
22
(1) in paragraph (3), by striking ‘‘, not later 
23
than 60 days after the date of the enactment of the 
24
19:08 Nov 24, 2020
H14
159 
•HR 14 IH
Health Insurance Portability and Accountability Act 
1
of 1996,’’ each place it appears; and 
2
(2) in paragraph (7), by striking ‘‘Not later 
3
than 1 year after the date of the enactment of the 
4
Health Insurance Portability and Accountability Act 
5
of 1996, and annually thereafter, the Committee 
6
shall’’ and inserting ‘‘The Committee shall, on an bi-
7
ennial basis,’’. 
8
(f) GRANTS FOR ASSEMBLY AND ANALYSIS OF DATA 
9
ON
ETHNIC
AND
RACIAL
10
306(m)(4) of the Public Health Service Act (42 U.S.C. 
11
242k(m)(4)) is amended— 
12
(1) in subparagraph (A)— 
13
(A) by striking ‘‘Subject to subparagraph 
14
(B), the’’ and inserting ‘‘The’’; and 
15
(B) by striking ‘‘and major Hispanic sub-
16
population groups and American Indians’’ and 
17
inserting ‘‘, major Hispanic subgroups, and 
18
American Indians and Alaska Natives’’; and 
19
(2) by amending subparagraph (B) to read as 
20
follows: 
21
‘‘(B) In carrying out subparagraph (A), with respect 
22
to American Indians and Alaska Natives, the Secretary 
23
shall— 
24
19:08 Nov 24, 2020
H14
160 
•HR 14 IH
‘‘(i) consult with Indian Tribes, Tribal organi-
1
zations, the Tribal Technical Advisory Group of the 
2
Centers for Medicare & Medicaid Services main-
3
tained under section 5006(e) of the American Recov-
4
ery and Reinvestment Act of 2009, and the Tribal 
5
Advisory Committee established by the Centers for 
6
Disease Control and Prevention, in coordination with 
7
epidemiology centers, to develop guidelines for State 
8
and local health agencies to improve the quality and 
9
accuracy of data with respect to the birth and death 
10
records of American Indians and Alaska Natives; 
11
‘‘(ii) confer with Urban Indian organizations to 
12
develop guidelines for State and local health agencies 
13
to improve the quality and accuracy of data with re-
14
spect to the birth and death records of American In-
15
dians and Alaska Natives; 
16
‘‘(iii) enter into cooperative agreements with In-
17
dian Tribes, Tribal organizations, Urban Indian or-
18
ganizations, and epidemiology centers to address 
19
misclassification and undersampling of American In-
20
dians and Alaska Natives with respect to— 
21
‘‘(I) birth and death records; and 
22
‘‘(II) health care and public health surveil-
23
lance systems, including, but not limited to, 
24
data with respect to chronic and infectious dis-
25
19:08 Nov 24, 2020
H14
161 
•HR 14 IH
eases, unintentional injuries, environmental 
1
health, child and adolescent health, maternal 
2
health and mortality, foodborne and waterborne 
3
illness, reproductive health, and any other 
4
notifiable disease or condition; 
5
‘‘(iv) encourage States to enter into data shar-
6
ing agreements with Indian Tribes, Tribal organiza-
7
tions, and epidemiology centers to improve the qual-
8
ity and accuracy of public health data; and 
9
‘‘(v) not later than 180 days after the date of 
10
enactment of the Commitment to Defeat the Virus 
11
and Keep America Healthy Act, and biennially 
12
thereafter, issue a report on the following: 
13
‘‘(I) Which States have data sharing agree-
14
ments with Indian Tribes, Tribal organizations, 
15
Urban Indian organizations, and Tribal epide-
16
miology centers to improve the quality and ac-
17
curacy of health data. 
18
‘‘(II) What the Centers for Disease Control 
19
and Prevention is doing to encourage States to 
20
enter into data sharing agreements with Indian 
21
Tribes, Tribal organizations, Urban Indian or-
22
ganizations, and Tribal epidemiology centers to 
23
improve the quality and accuracy of health 
24
data. 
25
19:08 Nov 24, 2020
H14
162 
•HR 14 IH
‘‘(III) Best practices and guidance for 
1
States, Indian Tribes, Tribal organizations, 
2
Urban Indian organizations, and Tribal epide-
3
miology centers that wish to enter into data 
4
sharing agreements. 
5
‘‘(IV) Best practices and guidance for 
6
local, State, Tribal, and Federal uniform stand-
7
ards for the collection of data on race and eth-
8
nicity.’’. 
9
(g) DEFINITIONS.—Section 306 of the Public Health 
10
Service Act (42 U.S.C. 242k) is amended— 
11
(1) by redesignating subsection (n) as sub-
12
section (o); and 
13
(2) by inserting after subsection (m) the fol-
14
lowing: 
15
‘‘(n) In this section: 
16
‘‘(1) The term ‘epidemiology center’ means an 
17
epidemiology center established under section 214 of 
18
the Indian Health Care Improvement Act, including 
19
such Tribal epidemiology centers serving Indian 
20
Tribes regionally and any Tribal epidemiology center 
21
serving Urban Indian organizations nationally. 
22
‘‘(2) The term ‘Indian Tribe’ has the meaning 
23
given to the term ‘Indian tribe’ in section 4 of the 
24
19:08 Nov 24, 2020
H14
163 
•HR 14 IH
Indian Self-Determination and Education Assistance 
1
Act. 
2
‘‘(3) The term ‘Tribal organization’ has the 
3
meaning given to the term ‘tribal organization’ in 
4
section 4 of the Indian Self-Determination and Edu-
5
cation Assistance Act. 
6
‘‘(4) The term ‘Urban Indian organization’ has 
7
the meaning given to that term in section 4 of the 
8
Indian Health Care Improvement Act.’’. 
9
(h) AUTHORIZATION OF APPROPRIATIONS.—Section 
10
306(o) of the Public Health Service Act, as redesignated 
11
by subsection (g), is amended to read as follows: 
12
‘‘(o)(1) To carry out this section, there is authorized 
13
to be appropriated $185,000,000 for each of the fiscal 
14
years 2021 through 2025. 
15
‘‘(2) Of the amount authorized to be appropriated to 
16
carry out this section for a fiscal year, the Secretary shall 
17
not use more than 10 percent for the combined costs of— 
18
‘‘(A) administration of this section; and 
19
‘‘(B) carrying out subsection (m)(2).’’. 
20
19:08 Nov 24, 2020
H14
164 
•HR 14 IH
Subtitle B—Tribal Medical 
1
Supplies Stockpile Access 
2
SEC. 5011. PROVISION OF ITEMS TO INDIAN PROGRAMS 
3
AND FACILITIES. 
4
(a) STRATEGIC
NATIONAL
STOCKPILE.—Section 
5
319F–2(a)(3)(G) of the Public Health Service Act (42 
6
U.S.C. 247d–6b(a)(3)(G)) is amended by inserting ‘‘, and, 
7
in the case that the Secretary deploys the stockpile under 
8
this subparagraph, ensure that appropriate drugs, vac-
9
cines and other biological products, medical devices, and 
10
other supplies are deployed by the Secretary directly to 
11
health programs or facilities operated by the Indian 
12
Health Service, an Indian tribe, a tribal organization (as 
13
those terms are defined in section 4 of the Indian Self- 
14
Determination and Education Assistance Act (25 U.S.C. 
15
5304)), or an inter-tribal consortium (as defined in section 
16
501 of the Indian Self-Determination and Education As-
17
sistance Act (25 U.S.C. 5381)) or through an urban In-
18
dian organization (as defined in section 4 of the Indian 
19
Health Care Improvement Act), while avoiding duplicative 
20
distributions to such programs or facilities’’ before the 
21
semicolon. 
22
(b) DISTRIBUTION OF QUALIFIED PANDEMIC OR EPI-
23
DEMIC PRODUCTS TO IHS FACILITIES.—Title III of the 
24
Public Health Service Act (42 U.S.C. 241 et seq.), as 
25
19:08 Nov 24, 2020
H14
165 
•HR 14 IH
amended by section 3015, is further amended by inserting 
1
after section 319F–5 the following: 
2
‘‘SEC. 319F–6. DISTRIBUTION OF QUALIFIED PANDEMIC OR 
3
EPIDEMIC PRODUCTS TO INDIAN PROGRAMS 
4
AND FACILITIES. 
5
‘‘In the case that the Secretary distributes qualified 
6
pandemic or epidemic products (as defined in section 
7
319F–3(i)(7)) to States or other entities, the Secretary 
8
shall ensure that, as appropriate, such products are dis-
9
tributed directly to health programs or facilities operated 
10
by the Indian Health Service, an Indian tribe, a tribal or-
11
ganization (as those terms are defined in section 4 of the 
12
Indian Self-Determination and Education Assistance Act 
13
(25 U.S.C. 5304)), or an inter-tribal consortium (as de-
14
fined in section 501 of the Indian Self-Determination and 
15
Education Assistance Act (25 U.S.C. 5381)) or through 
16
an urban Indian organization (as defined in section 4 of 
17
the Indian Health Care Improvement Act), while avoiding 
18
duplicative distributions to such programs or facilities.’’. 
19
Subtitle C—Native American 
20
Suicide Prevention 
21
SEC. 5021. NATIVE AMERICAN SUICIDE PREVENTION. 
22
Section 520E(b) of the Public Health Service Act (42 
23
U.S.C. 290bb–36(b)) is amended by inserting after para-
24
graph (3) the following: 
25
19:08 Nov 24, 2020
H14
166 
•HR 14 IH
‘‘(4) CONSULTATION.—A State applying for a 
1
grant or cooperative agreement under this section 
2
shall, in the development and implementation of a 
3
statewide early intervention strategy, consult or con-
4
fer with entities described in paragraph (1)(C) in 
5
such State.’’. 
6
Subtitle D—Pursuing Equity in 
7
Mental Health 
8
PART 1—HEALTH EQUITY AND ACCOUNTABILITY 
9
SEC. 5031. INTEGRATED HEALTH CARE DEMONSTRATION 
10
PROGRAM. 
11
Part D of title V of the Public Health Service Act 
12
(42 U.S.C. 290dd et seq.) is amended by adding at the 
13
end the following: 
14
‘‘SEC. 554. INTERPROFESSIONAL HEALTH CARE TEAMS FOR 
15
PROVISION OF BEHAVIORAL HEALTH CARE 
16
IN PRIMARY CARE SETTINGS. 
17
‘‘(a) GRANTS.—The Secretary shall award grants to 
18
eligible entities for the purpose of establishing interprofes-
19
sional health care teams that provide behavioral health 
20
care. 
21
‘‘(b) ELIGIBLE ENTITIES.—To be eligible to receive 
22
a grant under this section, an entity shall be a federally 
23
qualified health center (as defined in section 1861(aa) of 
24
the Social Security Act), rural health clinic, or behavioral 
25
19:08 Nov 24, 2020
H14
167 
•HR 14 IH
health program, serving a high proportion of individuals 
1
from racial and ethnic minority groups (as defined in sec-
2
tion 1707(g)). 
3
‘‘(c) SCIENTIFICALLY
BASED.—Integrated health 
4
care funded through this section shall be scientifically 
5
based, taking into consideration the results of the most 
6
recent peer-reviewed research available. 
7
‘‘(d) AUTHORIZATION
OF
APPROPRIATIONS.—To 
8
carry out this section, there is authorized to be appro-
9
priated $20,000,000 for each of the first 5 fiscal years 
10
following the date of enactment of the Commitment to De-
11
feat the Virus and Keep America Healthy Act.’’. 
12
SEC. 5032. ADDRESSING RACIAL AND ETHNIC MINORITY 
13
MENTAL HEALTH DISPARITIES RESEARCH 
14
GAPS. 
15
Not later than 6 months after the date of the enact-
16
ment of this Act, the Director of the National Institutes 
17
of Health shall enter into an arrangement with the Na-
18
tional Academies of Sciences, Engineering, and Medicine 
19
(or, if the National Academies of Sciences, Engineering, 
20
and Medicine decline to enter into such an arrangement, 
21
the Patient-Centered Outcomes Research Institute, the 
22
Agency for Healthcare Research and Quality, or another 
23
appropriate entity)— 
24
19:08 Nov 24, 2020
H14
168 
•HR 14 IH
(1) to conduct a study with respect to mental 
1
health disparities in racial and ethnic minority 
2
groups (as defined in section 1707(g) of the Public 
3
Health Service Act (42 U.S.C. 300u–6(g))); and 
4
(2) to submit to the Congress a report on the 
5
results of such study, including— 
6
(A) a compilation of information on the dy-
7
namics of mental disorders in such racial and 
8
ethnic minority groups; and 
9
(B) a compilation of information on the 
10
impact of exposure to community violence, ad-
11
verse childhood experiences, structural racism, 
12
and other psychological traumas on mental dis-
13
orders in such racial and minority groups. 
14
SEC. 5033. HEALTH PROFESSIONS COMPETENCIES TO AD-
15
DRESS RACIAL AND ETHNIC MINORITY MEN-
16
TAL HEALTH DISPARITIES. 
17
(a) IN GENERAL.—The Secretary of Health and 
18
Human Services shall award grants to qualified national 
19
organizations for the purposes of— 
20
(1) developing, and disseminating to health pro-
21
fessional educational programs best practices or core 
22
competencies addressing mental health disparities 
23
among racial and ethnic minority groups for use in 
24
the training of students in the professions of social 
25
19:08 Nov 24, 2020
H14
169 
•HR 14 IH
work, psychology, psychiatry, marriage and family 
1
therapy, mental health counseling, and substance 
2
misuse counseling; and 
3
(2) certifying community health workers and 
4
peer wellness specialists with respect to such best 
5
practices and core competencies and integrating and 
6
expanding the use of such workers and specialists 
7
into health care to address mental health disparities 
8
among racial and ethnic minority groups. 
9
(b) BEST PRACTICES; CORE COMPETENCIES.—Orga-
10
nizations receiving funds under subsection (a) may use the 
11
funds to engage in the following activities related to the 
12
development and dissemination of best practices or core 
13
competencies described in subsection (a)(1): 
14
(1) Formation of committees or working groups 
15
comprised of experts from accredited health profes-
16
sions schools to identify best practices and core com-
17
petencies relating to mental health disparities among 
18
racial and ethnic minority groups. 
19
(2) Planning of workshops in national fora to 
20
allow for public input into the educational needs as-
21
sociated with mental health disparities among racial 
22
and ethnic minority groups. 
23
(3) Dissemination and promotion of the use of 
24
best practices or core competencies in undergraduate 
25
19:08 Nov 24, 2020
H14
170 
•HR 14 IH
and graduate health professions training programs 
1
nationwide. 
2
(4) Establishing external stakeholder advisory 
3
boards to provide meaningful input into policy and 
4
program development and best practices to reduce 
5
mental health disparities among racial and ethnic 
6
minority groups. 
7
(c) DEFINITIONS.—In this section: 
8
(1) QUALIFIED NATIONAL ORGANIZATION.—The 
9
term ‘‘qualified national organization’’ means a na-
10
tional organization that focuses on the education of 
11
students in one or more of the professions of social 
12
work, psychology, psychiatry, marriage and family 
13
therapy, mental health counseling, and substance 
14
misuse counseling. 
15
(2) RACIAL AND ETHNIC MINORITY GROUP.— 
16
The term ‘‘racial and ethnic minority group’’ has the 
17
meaning given to such term in section 1707(g) of 
18
the Public Health Service Act (42 U.S.C. 300u– 
19
6(g)). 
20
SEC. 5034. RACIAL AND ETHNIC MINORITY BEHAVIORAL 
21
AND MENTAL HEALTH OUTREACH AND EDU-
22
CATION STRATEGY. 
23
Part D of title V of the Public Health Service Act 
24
(42 U.S.C. 290dd et seq.), as amended by section 5031, 
25
19:08 Nov 24, 2020
H14
171 
•HR 14 IH
is further amended by adding at the end the following new 
1
section: 
2
‘‘SEC. 555. BEHAVIORAL AND MENTAL HEALTH OUTREACH 
3
AND EDUCATION STRATEGY. 
4
‘‘(a) IN GENERAL.—The Secretary shall, in consulta-
5
tion with advocacy and behavioral and mental health orga-
6
nizations serving racial and ethnic minority groups, de-
7
velop and implement an outreach and education strategy 
8
to promote behavioral and mental health and reduce stig-
9
ma associated with mental health conditions and sub-
10
stance abuse among racial and ethnic minority groups. 
11
Such strategy shall— 
12
‘‘(1) be designed to— 
13
‘‘(A) meet the diverse cultural and lan-
14
guage needs of the various racial and ethnic mi-
15
nority groups; and 
16
‘‘(B) be developmentally and age-appro-
17
priate; 
18
‘‘(2) increase awareness of symptoms of mental 
19
illnesses common among such groups, taking into 
20
account differences within at-risk subgroups; 
21
‘‘(3) provide information on evidence-based, cul-
22
turally and linguistically appropriate and adapted 
23
interventions and treatments; 
24
19:08 Nov 24, 2020
H14
172 
•HR 14 IH
‘‘(4) ensure full participation of, and engage, 
1
both consumers and community members in the de-
2
velopment and implementation of materials; and 
3
‘‘(5) seek to broaden the perspective among 
4
both individuals in these groups and stakeholders 
5
serving these groups to use a comprehensive public 
6
health approach to promoting behavioral health that 
7
addresses a holistic view of health by focusing on the 
8
intersection between behavioral and physical health. 
9
‘‘(b) REPORTS.—Beginning not later than 1 year 
10
after the date of the enactment of this section and annu-
11
ally thereafter, the Secretary shall submit to Congress, 
12
and make publicly available, a report on the extent to 
13
which the strategy developed and implemented under sub-
14
section (a) increased behavioral and mental health out-
15
comes associated with mental health conditions and sub-
16
stance abuse among racial and ethnic minority groups. 
17
‘‘(c) DEFINITION.—In this section, the term ‘racial 
18
and ethnic minority group’ has the meaning given to that 
19
term in section 1707(g). 
20
‘‘(d) AUTHORIZATION OF APPROPRIATIONS.—There 
21
is authorized to be appropriated to carry out this section 
22
$10,000,000 for each of fiscal years 2021 through 2025.’’. 
23
19:08 Nov 24, 2020
H14
173 
•HR 14 IH
SEC. 5035. ADDITIONAL FUNDS FOR NATIONAL INSTITUTES 
1
OF HEALTH. 
2
(a) IN GENERAL.—In addition to amounts otherwise 
3
authorized to be appropriated to the National Institutes 
4
of Health, there is authorized to be appropriated to such 
5
Institutes $100,000,000 for each of fiscal years 2021 
6
through 2025 to build relations with communities and con-
7
duct or support clinical research, including clinical re-
8
search on racial or ethnic disparities in physical and men-
9
tal health. 
10
(b) DEFINITION.—In this section, the term ‘‘clinical 
11
research’’ has the meaning given to such term in section 
12
409 of the Public Health Service Act (42 U.S.C. 284d). 
13
SEC. 5036. ADDITIONAL FUNDS FOR NATIONAL INSTITUTE 
14
ON MINORITY HEALTH AND HEALTH DISPARI-
15
TIES. 
16
In addition to amounts otherwise authorized to be ap-
17
propriated to the National Institute on Minority Health 
18
and Health Disparities, there is authorized to be appro-
19
priated to such Institute $650,000,000 for each of fiscal 
20
years 2021 through 2025. 
21
PART 2—OTHER PROVISIONS 
22
SEC. 5037. REAUTHORIZATION OF MINORITY FELLOWSHIP 
23
PROGRAM. 
24
Section 597(c) of the Public Health Service Act (42 
25
U.S.C. 297ll(c)) is amended by striking ‘‘$12,669,000 for 
26
19:08 Nov 24, 2020
H14
174 
•HR 14 IH
each of fiscal years 2018 through 2022’’ and inserting 
1
‘‘$25,000,000 for each of fiscal years 2021 through 
2
2025’’. 
3
SEC. 5038. STUDY ON THE EFFECTS OF SMARTPHONE AND 
4
SOCIAL MEDIA USE ON ADOLESCENTS. 
5
(a) IN GENERAL.—Not later than 1 year after the 
6
date of enactment of this Act, the Secretary of Health and 
7
Human Services shall conduct or support research on— 
8
(1) smartphone and social media use by adoles-
9
cents; and 
10
(2) the effects of such use on— 
11
(A) emotional, behavioral, and physical 
12
health and development; and 
13
(B) disparities in minority and under-
14
served populations. 
15
(b) REPORT.—Not later than 5 years after the date 
16
of the enactment of this Act, the Secretary shall submit 
17
to the Congress, and make publicly available, a report on 
18
the findings of research described in this section. 
19
SEC. 5039. TECHNICAL CORRECTION. 
20
Title V of the Public Health Service Act (42 U.S.C. 
21
290aa et seq.) is amended— 
22
(1) by redesignating the second section 550 of 
23
such Act (42 U.S.C. 290ee–10) (relating to Sobriety 
24
19:08 Nov 24, 2020
H14
175 
•HR 14 IH
Treatment And Recovery Teams) as section 553; 
1
and 
2
(2) by moving such section 553, as so redesig-
3
nated, so as to appear after section 552 of such Act 
4
(42 U.S.C. 290ee–7). 
5
Subtitle E—Maternal Health 
6
Quality Improvement 
7
SEC. 5041. INNOVATION FOR MATERNAL HEALTH. 
8
Part D of title III of the Public Health Service Act 
9
(42 U.S.C. 254b et seq.), as amended by section 4071, 
10
is further amended— 
11
(1) in the section designation of section 330M 
12
of such Act (42 U.S.C. 254c–19) by inserting a pe-
13
riod after ‘‘330M’’; and 
14
(2) by inserting after section 330N of such Act, 
15
as inserted by section 4071, the following: 
16
‘‘SEC. 330O. INNOVATION FOR MATERNAL HEALTH. 
17
‘‘(a) IN GENERAL.—The Secretary, in consultation 
18
with experts representing a variety of clinical specialties, 
19
State, Tribal, or local public health officials, researchers, 
20
epidemiologists, statisticians, and community organiza-
21
tions, shall establish or continue a program to award com-
22
petitive grants to eligible entities for the purposes of— 
23
‘‘(1) identifying, developing, or disseminating 
24
best practices to improve maternal health care qual-
25
19:08 Nov 24, 2020
H14
176 
•HR 14 IH
ity and outcomes, eliminate preventable maternal 
1
mortality and severe maternal morbidity, and im-
2
prove infant health outcomes, which may include— 
3
‘‘(A) information on evidence-based prac-
4
tices to improve the quality and safety of ma-
5
ternal health care in hospitals and other health 
6
care settings of a State or health care system, 
7
including by addressing topics commonly associ-
8
ated with health complications or risks related 
9
to prenatal care, labor care, birthing, and 
10
postpartum care; 
11
‘‘(B) best practices for improving maternal 
12
health care based on data findings and reviews 
13
conducted by a State maternal mortality review 
14
committee that address topics of relevance to 
15
common complications or health risks related to 
16
prenatal 
care, 
labor 
care, 
birthing, 
and 
17
postpartum care; and 
18
‘‘(C) information on addressing deter-
19
minants of health that impact maternal health 
20
outcomes for women before, during, and after 
21
pregnancy; 
22
‘‘(2) collaborating with State maternal mor-
23
tality review committees to identify issues for the de-
24
velopment and implementation of evidence-based 
25
19:08 Nov 24, 2020
H14
177 
•HR 14 IH
practices to improve maternal health outcomes and 
1
reduce preventable maternal mortality and severe 
2
maternal morbidity; 
3
‘‘(3) providing technical assistance and sup-
4
porting the implementation of best practices identi-
5
fied pursuant to paragraph (1) to entities providing 
6
health care services to pregnant and postpartum 
7
women; and 
8
‘‘(4) identifying, developing, and evaluating new 
9
models of care that improve maternal and infant 
10
health outcomes, which may include the integration 
11
of community-based services and clinical care. 
12
‘‘(b) ELIGIBLE ENTITIES.—To be eligible for a grant 
13
under subsection (a), an entity shall— 
14
‘‘(1) submit to the Secretary an application at 
15
such time, in such manner, and containing such in-
16
formation as the Secretary may require; and 
17
‘‘(2) demonstrate in such application that the 
18
entity is capable of carrying out data-driven mater-
19
nal safety and quality improvement initiatives in the 
20
areas of obstetrics and gynecology or maternal 
21
health. 
22
‘‘(c) AUTHORIZATION
OF
APPROPRIATIONS.—To 
23
carry out this section, there are authorized to be appro-
24
19:08 Nov 24, 2020
H14
178 
•HR 14 IH
priated $5,000,000 for each of fiscal years 2021 through 
1
2025.’’. 
2
SEC. 5042. TRAINING FOR HEALTH CARE PROVIDERS. 
3
Title VII of the Public Health Service Act is amended 
4
by striking section 763 (42 U.S.C. 294p) and inserting 
5
the following: 
6
‘‘SEC. 763. TRAINING FOR HEALTH CARE PROVIDERS. 
7
‘‘(a) GRANT PROGRAM.—The Secretary shall estab-
8
lish a program to award grants to accredited schools of 
9
allopathic medicine, osteopathic medicine, and nursing, 
10
and other health professional training programs for the 
11
training of health care professionals to reduce and prevent 
12
discrimination (including training related to implicit and 
13
explicit biases) in the provision of health care services re-
14
lated to prenatal care, labor care, birthing, and 
15
postpartum care. 
16
‘‘(b) ELIGIBILITY.—To be eligible for a grant under 
17
subsection (a), an entity described in such subsection shall 
18
submit to the Secretary an application at such time, in 
19
such manner, and containing such information as the Sec-
20
retary may require. 
21
‘‘(c) 
REPORTING
REQUIREMENT.—Each 
entity 
22
awarded a grant under this section shall periodically sub-
23
mit to the Secretary a report on the status of activities 
24
19:08 Nov 24, 2020
H14
179 
•HR 14 IH
conducted using the grant, including a description of the 
1
impact of such training on patient outcomes, as applicable. 
2
‘‘(d) BEST PRACTICES.—The Secretary may identify 
3
and disseminate best practices for the training of health 
4
care professionals to reduce and prevent discrimination 
5
(including training related to implicit and explicit biases) 
6
in the provision of health care services related to prenatal 
7
care, labor care, birthing, and postpartum care. 
8
‘‘(e) AUTHORIZATION
OF
APPROPRIATIONS.—To 
9
carry out this section, there are authorized to be appro-
10
priated $5,000,000 for each of fiscal years 2021 through 
11
2025.’’. 
12
SEC. 5043. STUDY ON TRAINING TO REDUCE AND PREVENT 
13
DISCRIMINATION. 
14
Not later than 2 years after date of enactment of this 
15
Act, the Secretary of Health and Human Services shall, 
16
through a contract with an independent research organiza-
17
tion, conduct a study and make recommendations for ac-
18
credited schools of allopathic medicine, osteopathic medi-
19
cine, and nursing, and other health professional training 
20
programs, on best practices related to training to reduce 
21
and prevent discrimination, including training related to 
22
implicit and explicit biases, in the provision of health care 
23
services related to prenatal care, labor care, birthing, and 
24
postpartum care. 
25
19:08 Nov 24, 2020
H14
180 
•HR 14 IH
SEC. 5044. PERINATAL QUALITY COLLABORATIVES. 
1
Section 317K(a)(2) of the Public Health Service Act 
2
(42 U.S.C. 247b–12(a)(2)) is amended by adding at the 
3
end the following: 
4
‘‘(E)(i) The Secretary, acting through the 
5
Director of the Centers for Disease Control and 
6
Prevention and in coordination with other of-
7
fices and agencies, as appropriate, shall estab-
8
lish or continue a competitive grant program 
9
for the establishment or support of perinatal 
10
quality collaboratives to improve perinatal care 
11
and perinatal health outcomes for pregnant and 
12
postpartum women and their infants. A State, 
13
Indian Tribe, or Tribal organization may use 
14
funds received through such grant to— 
15
‘‘(I) support the use of evidence-based 
16
or evidence-informed practices to improve 
17
outcomes for maternal and infant health; 
18
‘‘(II) work with clinical teams; ex-
19
perts; State, local, and, as appropriate, 
20
Tribal public health officials; and stake-
21
holders, including patients and families, to 
22
identify, develop, or disseminate best prac-
23
tices to improve perinatal care and out-
24
comes; and 
25
19:08 Nov 24, 2020
H14
181 
•HR 14 IH
‘‘(III) employ strategies that provide 
1
opportunities for health care professionals 
2
and clinical teams to collaborate across 
3
health care settings and disciplines, includ-
4
ing primary care and mental health, as ap-
5
propriate, to improve maternal and infant 
6
health outcomes, which may include the 
7
use of data to provide timely feedback 
8
across hospital and clinical teams to in-
9
form responses, and to provide support 
10
and training to hospital and clinical teams 
11
for quality improvement, as appropriate. 
12
‘‘(ii) To be eligible for a grant under 
13
clause (i), an entity shall submit to the Sec-
14
retary an application in such form and manner 
15
and containing such information as the Sec-
16
retary may require.’’. 
17
SEC. 5045. INTEGRATED SERVICES FOR PREGNANT AND 
18
19
(a) GRANTS.—Title III of the Public Health Service 
20
Act is amended by inserting after section 330O of such 
21
Act, as added by section 5041, the following: 
22
19:08 Nov 24, 2020
H14
182 
•HR 14 IH
‘‘SEC. 330P. INTEGRATED SERVICES FOR PREGNANT AND 
1
2
‘‘(a) IN GENERAL.—The Secretary may award grants 
3
to States, Indian Tribes, and Tribal organizations for the 
4
purpose of establishing or operating evidence-based or in-
5
novative, evidence-informed programs to deliver integrated 
6
health care services to pregnant and postpartum women 
7
to optimize the health of women and their infants, includ-
8
ing to reduce adverse maternal health outcomes, preg-
9
nancy-related deaths, and related health disparities (in-
10
cluding such disparities associated with racial and ethnic 
11
minority populations), and, as appropriate, by addressing 
12
issues researched under subsection (b)(2) of section 317K. 
13
‘‘(b) INTEGRATED SERVICES FOR PREGNANT AND 
14
15
‘‘(1) ELIGIBILITY.—To be eligible to receive a 
16
grant under subsection (a), a State, Indian Tribe, or 
17
Tribal organization shall work with relevant stake-
18
holders that coordinate care (including coordinating 
19
resources and referrals for health care and social 
20
services) to develop and carry out the program, in-
21
cluding— 
22
‘‘(A) State, Tribal, and local agencies re-
23
sponsible for Medicaid, public health, social 
24
services, mental health, and substance use dis-
25
order treatment and services; 
26
19:08 Nov 24, 2020
H14
183 
•HR 14 IH
‘‘(B) health care providers who serve preg-
1
nant and postpartum women; and 
2
‘‘(C) community-based health organiza-
3
tions and health workers, including providers of 
4
home visiting services and individuals rep-
5
resenting communities with disproportionately 
6
high rates of maternal mortality and severe ma-
7
ternal morbidity, and including individuals rep-
8
resenting racial and ethnic minority popu-
9
lations. 
10
‘‘(2) TERMS.— 
11
‘‘(A) PERIOD.—A grant awarded under 
12
subsection (a) shall be made for a period of 5 
13
years. Any supplemental award made to a 
14
grantee under subsection (a) may be made for 
15
a period of less than 5 years. 
16
‘‘(B) PREFERENCE.—In awarding grants 
17
under subsection (a), the Secretary shall— 
18
‘‘(i) give preference to States, Indian 
19
Tribes, and Tribal organizations that have 
20
the highest rates of maternal mortality and 
21
severe maternal morbidity relative to other 
22
such States, Indian Tribes, or Tribal orga-
23
nizations, respectively; and 
24
19:08 Nov 24, 2020
H14
184 
•HR 14 IH
‘‘(ii) shall consider health disparities 
1
related to maternal mortality and severe 
2
maternal morbidity, including such dispari-
3
ties associated with racial and ethnic mi-
4
nority populations. 
5
‘‘(C) 
PRIORITY.—In 
awarding 
grants 
6
under subsection (a), the Secretary shall give 
7
priority to applications from up to 15 entities 
8
described in subparagraph (B)(i). 
9
‘‘(D) EVALUATION.—The Secretary shall 
10
require grantees to evaluate the outcomes of the 
11
programs supported under the grant. 
12
‘‘(c) DEFINITIONS.—In this section, the terms ‘In-
13
dian Tribe’ and ‘Tribal organization’ have the meanings 
14
given the terms ‘Indian tribe’ and ‘tribal organization’, re-
15
spectively, in section 4 of the Indian Self-Determination 
16
and Education Assistance Act. 
17
‘‘(d) AUTHORIZATION OF APPROPRIATIONS.—There 
18
are authorized to be appropriated to carry out this section 
19
$10,000,000 for each of fiscal years 2021 through 2025.’’. 
20
(b) REPORT ON GRANT OUTCOMES AND DISSEMINA-
21
TION OF BEST PRACTICES.— 
22
(1) REPORT.—Not later than February 1, 
23
2026, the Secretary of Health and Human Services 
24
shall submit to the Committee on Health, Edu-
25
19:08 Nov 24, 2020
H14
185 
•HR 14 IH
cation, Labor, and Pensions of the Senate and the 
1
Committee on Energy and Commerce of the House 
2
of Representatives a report that describes— 
3
(A) the outcomes of the activities sup-
4
ported by the grants awarded under the amend-
5
ment made by this section on maternal and 
6
child health; 
7
(B) best practices and models of care used 
8
by recipients of grants under such amendment; 
9
and 
10
(C) obstacles identified by recipients of 
11
grants under such amendment, and strategies 
12
used by such recipients to deliver care, improve 
13
maternal and child health, and reduce health 
14
disparities. 
15
(2) DISSEMINATION OF BEST PRACTICES.—Not 
16
later than August 1, 2026, the Secretary of Health 
17
and Human Services shall disseminate information 
18
on best practices and models of care used by recipi-
19
ents of grants under the amendment made by this 
20
section (including best practices and models of care 
21
relating to the reduction of health disparities, includ-
22
ing such disparities associated with racial and ethnic 
23
minority populations, in rates of maternal mortality 
24
and severe maternal morbidity) to relevant stake-
25
19:08 Nov 24, 2020
H14
186 
•HR 14 IH
holders, which may include health providers, medical 
1
schools, nursing schools, relevant State, Tribal, and 
2
local agencies, and the general public. 
3
SEC. 5046. IMPROVING RURAL MATERNAL AND OBSTETRIC 
4
CARE DATA. 
5
(a) MATERNAL MORTALITY AND MORBIDITY ACTIVI-
6
TIES.—Section 301(e) of the Public Health Service Act 
7
(42 U.S.C. 241(e)) is amended by inserting ‘‘, preventable 
8
maternal mortality and severe maternal morbidity,’’ after 
9
‘‘delivery’’. 
10
(b) 
OFFICE
OF
WOMEN’S
HEALTH.—Section 
11
310A(b)(1) of the Public Health Service Act (42 U.S.C. 
12
242s(b)(1)) is amended by striking ‘‘and sociocultural con-
13
texts,’’ and inserting ‘‘sociocultural (including among 
14
American Indians, Native Hawaiians, and Alaska Na-
15
tives), and geographical contexts’’. 
16
(c) SAFE MOTHERHOOD.—Section 317K of the Pub-
17
lic Health Service Act (42 U.S.C. 247b–12) is amended— 
18
(1) in subsection (a)(2)(A), by inserting ‘‘, in-
19
cluding improving collection of data on race, eth-
20
nicity, and other demographic information’’ before 
21
the period; and 
22
(2) in subsection (b)(2)— 
23
(A) in subparagraph (L), by striking 
24
‘‘and’’ at the end; 
25
19:08 Nov 24, 2020
H14
187 
•HR 14 IH
(B) by redesignating subparagraph (M) as 
1
subparagraph (N); and 
2
(C) by inserting after subparagraph (L) 
3
the following: 
4
‘‘(M) an examination of the relationship 
5
between maternal health and obstetric services 
6
in rural areas and outcomes in delivery and 
7
postpartum care; and’’. 
8
(d) OFFICE OF RESEARCH ON WOMEN’S HEALTH.— 
9
Section 486 of the Public Health Service Act (42 U.S.C. 
10
287d) is amended— 
11
(1) in subsection (b), by amending paragraph 
12
(3) to read as follows: 
13
‘‘(3) carry out paragraphs (1) and (2) with re-
14
spect to— 
15
‘‘(A) the aging process in women, with pri-
16
ority given to menopause; and 
17
‘‘(B) pregnancy, with priority given to 
18
deaths related to preventable maternal mor-
19
tality and severe maternal morbidity;’’; and 
20
(2) in subsection (d)(4)(A)(iv), by inserting ‘‘, 
21
including preventable maternal morbidity and severe 
22
maternal morbidity’’ before the semicolon. 
23
19:08 Nov 24, 2020
H14
188 
•HR 14 IH
SEC. 5047. RURAL OBSTETRIC NETWORK GRANTS. 
1
The Public Health Service Act is amended by insert-
2
ing after section 330A–1 (42 U.S.C. 254c–1a) the fol-
3
lowing: 
4
‘‘SEC. 330A–2. RURAL OBSTETRIC NETWORK GRANTS. 
5
‘‘(a) PROGRAM ESTABLISHED.—The Secretary shall 
6
award grants or cooperative agreements to eligible entities 
7
to establish collaborative improvement and innovation net-
8
works (referred to in this section as ‘rural obstetric net-
9
works’) to improve maternal and infant health outcomes 
10
and reduce preventable maternal mortality and severe ma-
11
ternal morbidity by improving maternity care and access 
12
to care in rural areas, frontier areas, maternity care health 
13
professional target areas, or jurisdictions of Indian Tribes 
14
and Tribal organizations. 
15
‘‘(b) USE OF FUNDS.—Grants or cooperative agree-
16
ments awarded pursuant to this section shall be used for 
17
the establishment or continuation of collaborative improve-
18
ment and innovation networks to improve maternal health 
19
in rural areas by improving infant health and maternal 
20
outcomes and reducing preventable maternal mortality 
21
and severe maternal morbidity. Rural obstetric networks 
22
established in accordance with this section may— 
23
‘‘(1) develop a network to improve coordination 
24
and increase access to maternal health care and as-
25
sist pregnant women in the areas described in sub-
26
19:08 Nov 24, 2020
H14
189 
•HR 14 IH
section (a) with accessing and utilizing maternal and 
1
obstetric care, including health care services related 
2
to 
prenatal 
care, 
labor 
care, 
birthing, 
and 
3
postpartum care to improve outcomes in birth and 
4
maternal mortality and morbidity; 
5
‘‘(2) identify and implement evidence-based and 
6
sustainable delivery models for maternal and obstet-
7
ric care (including health care services related to 
8
prenatal care, labor care, birthing, and postpartum 
9
care for women in the areas described in subsection 
10
(a)), including home visiting programs and culturally 
11
appropriate care models that reduce health dispari-
12
ties; 
13
‘‘(3) develop a model for maternal health care 
14
collaboration between health care settings to improve 
15
access to care in areas described in subsection (a), 
16
which may include the use of telehealth; 
17
‘‘(4) provide training for professionals in health 
18
care settings that do not have specialty maternity 
19
care; 
20
‘‘(5) collaborate with academic institutions that 
21
can provide regional expertise and help identify bar-
22
riers to providing maternal health care, including 
23
strategies for addressing such barriers; and 
24
19:08 Nov 24, 2020
H14
190 
•HR 14 IH
‘‘(6) assess and address disparities in infant 
1
and maternal health outcomes, including among ra-
2
cial and ethnic minority populations and underserved 
3
populations in areas described in subsection (a). 
4
‘‘(c) DEFINITIONS.—In this section: 
5
‘‘(1) ELIGIBLE ENTITIES.—The term ‘eligible 
6
entities’ means entities providing maternal health 
7
care services in rural areas, frontier areas, or medi-
8
cally underserved areas, or to medically underserved 
9
populations or Indian Tribes or Tribal organizations. 
10
‘‘(2) FRONTIER
AREA.—The term ‘frontier 
11
area’ means a frontier county, as defined in section 
12
1886(d)(3)(E)(iii)(III) of the Social Security Act. 
13
‘‘(3) INDIAN TRIBES; TRIBAL ORGANIZATION.— 
14
The terms ‘Indian Tribe’ and ‘Tribal organization’ 
15
have the meanings given the terms ‘Indian tribe’ and 
16
‘tribal organization’, respectively, in section 4 of the 
17
Indian Self-Determination and Education Assistance 
18
Act. 
19
‘‘(4) MATERNITY CARE HEALTH PROFESSIONAL 
20
TARGET
AREA.—The term ‘maternity care health 
21
professional target area’ has the meaning described 
22
in section 332(k)(2). 
23
19:08 Nov 24, 2020
H14
191 
•HR 14 IH
‘‘(d) AUTHORIZATION OF APPROPRIATIONS.—There 
1
are authorized to be appropriated to carry out this section 
2
$3,000,000 for each of fiscal years 2021 through 2025.’’. 
3
SEC. 5048. TELEHEALTH NETWORK AND TELEHEALTH RE-
4
SOURCE CENTERS GRANT PROGRAMS. 
5
Section 330I of the Public Health Service Act (42 
6
U.S.C. 254c–14) is amended— 
7
(1) in subsection (f)(3), by adding at the end 
8
the following: 
9
‘‘(M) Providers of maternal care, including 
10
prenatal, labor care, birthing, and postpartum 
11
care services and entities operating obstetric 
12
care units.’’; and 
13
(2) in subsection (h)(1)(B), by inserting ‘‘labor 
14
care, birthing care, postpartum care,’’ before ‘‘or 
15
prenatal’’. 
16
SEC. 5049. RURAL MATERNAL AND OBSTETRIC CARE 
17
TRAINING DEMONSTRATION. 
18
Subpart 1 of part E of title VII of the Public Health 
19
Service Act (42 U.S.C. 294n et seq.) is amended by adding 
20
at the end the following: 
21
‘‘SEC. 764. RURAL MATERNAL AND OBSTETRIC CARE TRAIN-
22
ING DEMONSTRATION. 
23
‘‘(a) IN
GENERAL.—The Secretary shall award 
24
grants to accredited schools of allopathic medicine, osteo-
25
19:08 Nov 24, 2020
H14
192 
•HR 14 IH
pathic medicine, and nursing, and other appropriate 
1
health professional training programs, to establish a train-
2
ing demonstration program to support— 
3
‘‘(1) training for physicians, medical residents, 
4
fellows, nurse practitioners, physician assistants, 
5
nurses, certified nurse midwives, relevant home vis-
6
iting workforce professionals and paraprofessionals, 
7
or other professionals who meet relevant State train-
8
ing and licensing requirements, as applicable, to pro-
9
vide maternal health care services in rural commu-
10
nity-based settings; and 
11
‘‘(2) developing recommendations for such 
12
training programs. 
13
‘‘(b) APPLICATION.—To be eligible to receive a grant 
14
under subsection (a), an entity shall submit to the Sec-
15
retary an application at such time, in such manner, and 
16
containing such information as the Secretary may require. 
17
‘‘(c) ACTIVITIES.— 
18
‘‘(1) TRAINING
FOR
HEALTH
CARE
PROFES-
19
SIONALS.—A recipient of a grant under subsection 
20
(a)— 
21
‘‘(A) shall use the grant funds to plan, de-
22
velop, and operate a training program to pro-
23
vide maternal health care in rural areas; and 
24
19:08 Nov 24, 2020
H14
193 
•HR 14 IH
‘‘(B) may use the grant funds to provide 
1
additional support for the administration of the 
2
program or to meet the costs of projects to es-
3
tablish, maintain, or improve faculty develop-
4
ment, or departments, divisions, or other units 
5
necessary to implement such training. 
6
‘‘(2) TRAINING
PROGRAM
REQUIREMENTS.— 
7
The recipient of a grant under subsection (a) shall 
8
ensure that training programs carried out under the 
9
grant are evidence-based and address improving ma-
10
ternal health care in rural areas, and such programs 
11
may include training on topics such as— 
12
‘‘(A) maternal mental health, including 
13
perinatal depression and anxiety; 
14
‘‘(B) substance use disorders; 
15
‘‘(C) social determinants of health that af-
16
fect individuals living in rural areas; and 
17
‘‘(D) implicit and explicit bias. 
18
‘‘(d) EVALUATION AND REPORT.— 
19
‘‘(1) EVALUATION.— 
20
‘‘(A) IN
GENERAL.—The Secretary shall 
21
evaluate the outcomes of the demonstration 
22
program under this section. 
23
‘‘(B) DATA SUBMISSION.—Recipients of a 
24
grant under subsection (a) shall submit to the 
25
19:08 Nov 24, 2020
H14
194 
•HR 14 IH
Secretary performance metrics and other re-
1
lated data in order to evaluate the program for 
2
the report described in paragraph (2). 
3
‘‘(2) REPORT TO CONGRESS.—Not later than 
4
January 1, 2025, the Secretary shall submit to the 
5
Committee on Health, Education, Labor, and Pen-
6
sions of the Senate and the Committee on Energy 
7
and Commerce of the House of Representatives a re-
8
port that includes— 
9
‘‘(A) an analysis of the effects of the dem-
10
onstration program under this section on the 
11
quality, quantity, and distribution of maternal 
12
health care services, including health care serv-
13
ices related to prenatal care, labor care, birth-
14
ing, and postpartum care, and the demo-
15
graphics of the recipients of those services; 
16
‘‘(B) an analysis of maternal and infant 
17
health outcomes (including quality of care, mor-
18
bidity, and mortality) before and after imple-
19
mentation of the program in the communities 
20
served by entities participating in the dem-
21
onstration program; and 
22
‘‘(C) recommendations on whether the 
23
demonstration program should be continued. 
24
19:08 Nov 24, 2020
H14
195 
•HR 14 IH
‘‘(e) AUTHORIZATION OF APPROPRIATIONS.—There 
1
are authorized to be appropriated to carry out this section 
2
$5,000,000 for each of fiscal years 2021 through 2025.’’. 
3
TITLE VI—ADDRESSING THE IM-
4
PACTS OF COVID–19 ON MEN-
5
TAL HEALTH 
6
Subtitle A—Creating Resources To 
7
Improve Situations of Inherent 
8
Severity 
9
SEC. 6001. SET-ASIDE FOR EVIDENCE-BASED CRISIS CARE 
10
SERVICES. 
11
Section 1920 of the Public Health Service Act (42 
12
U.S.C. 300x–9) is amended— 
13
(1) 
in 
subsection 
(a), 
by 
striking 
14
‘‘$532,571,000 for each of fiscal years 2018 through 
15
2022’’ and inserting ‘‘$532,571,000 for each of fis-
16
cal years 2018 through 2020, and $758,000,000 for 
17
each of fiscal years 2021 through 2022’’; and 
18
(2) by adding at the end the following: 
19
‘‘(d) CRISIS CARE.— 
20
‘‘(1) IN GENERAL.—Except as provided in para-
21
graph (3), a State shall expend at least 5 percent of 
22
the amount the State receives pursuant to section 
23
1911 for each fiscal year to support evidenced-based 
24
programs that address the crisis care needs of indi-
25
19:08 Nov 24, 2020
H14
196 
•HR 14 IH
viduals with serious mental disorders, and children 
1
with serious mental and emotional disturbances. 
2
‘‘(2) CORE
ELEMENTS.—At the discretion of 
3
the single State agency responsible for the adminis-
4
tration of the program of the State under a grant 
5
under section 1911, funds expended pursuant to 
6
paragraph (1) may be used to fund some or all of 
7
the core crisis care service components, delivered ac-
8
cording to evidence-based principles, including the 
9
following: 
10
‘‘(A) Crisis call centers. 
11
‘‘(B) 24/7 mobile crisis services. 
12
‘‘(C) Crisis stabilization programs offering 
13
acute care or subacute care in a hospital or ap-
14
propriately licensed facility, as determined by 
15
the Substance Abuse and Mental Health Serv-
16
ices Administration, with referrals to inpatient 
17
or outpatient care. 
18
‘‘(3) STATE FLEXIBILITY.—In lieu of expending 
19
5 percent of the amount the State receives pursuant 
20
to section 1911 for a fiscal year to support evidence- 
21
based programs as required by paragraph (1), a 
22
State may elect to expend not less than 10 percent 
23
of such amount to support such programs by the 
24
end of two consecutive fiscal years.’’. 
25
19:08 Nov 24, 2020
H14
197 
•HR 14 IH
Subtitle 
B—Emergency 
Mental 
1
Health 
and 
Substance 
Use 
2
Training and Technical Assist-
3
ance Center 
4
SEC. 6011. EMERGENCY MENTAL HEALTH AND SUBSTANCE 
5
USE TRAINING AND TECHNICAL ASSISTANCE 
6
CENTER. 
7
Subpart 3 of part B of title V of the Public Health 
8
Service Act (42 U.S.C. 290bb–31 et seq.) is amended by 
9
inserting after section 520A (42 U.S.C. 290bb–32) the fol-
10
lowing: 
11
‘‘SEC. 520B. EMERGENCY MENTAL HEALTH AND SUB-
12
STANCE USE TRAINING AND TECHNICAL AS-
13
SISTANCE CENTER. 
14
‘‘(a) 
ESTABLISHMENT.—The 
Secretary, 
acting 
15
through the Assistant Secretary, shall establish or operate 
16
a center to be known as the Emergency Mental Health 
17
and Substance Use Training and Technical Assistance 
18
Center (referred to in this section as the ‘Center’) to pro-
19
vide technical assistance and support— 
20
‘‘(1) to public or nonprofit entities seeking to 
21
establish or expand access to mental health and sub-
22
stance use prevention, treatment, and recovery sup-
23
port services, and increase awareness of such serv-
24
ices; and 
25
19:08 Nov 24, 2020
H14
198 
•HR 14 IH
‘‘(2) to public health professionals, health care 
1
professionals and support staff, essential workers (as 
2
defined by a State, Tribe, locality, or territory), and 
3
members of the public to address the trauma, stress, 
4
and mental health needs associated with an emer-
5
gency period. 
6
‘‘(b) ASSISTANCE
AND SUPPORT.—The assistance 
7
and support provided under subsection (a) shall include 
8
assistance and support with respect to— 
9
‘‘(1) training on identifying signs of trauma, 
10
stress, and mental health needs; 
11
‘‘(2) providing accessible resources to assist in-
12
dividuals and families experiencing trauma, stress, 
13
or other mental health needs during and after an 
14
emergency period; 
15
‘‘(3) providing resources for substance use dis-
16
order prevention, treatment, and recovery designed 
17
to assist individuals and families during and after an 
18
emergency period; 
19
‘‘(4) the provision of language access services, 
20
including translation services, interpretation, or 
21
other such services for individuals with limited 
22
English speaking proficiency or individuals with dis-
23
abilities; and 
24
19:08 Nov 24, 2020
H14
199 
•HR 14 IH
‘‘(5) evaluation and improvement, as necessary, 
1
of the effectiveness of such services provided by pub-
2
lic or nonprofit entities. 
3
‘‘(c) BEST PRACTICES.—The Center shall periodi-
4
cally issue best practices for use by organizations seeking 
5
to provide mental health services or substance use disorder 
6
prevention, treatment, or recovery services, including best 
7
practices for the following special populations: 
8
‘‘(1) Incarcerated individuals. 
9
‘‘(2) Children. 
10
‘‘(3) Pregnant women. 
11
‘‘(4) Underserved populations. 
12
‘‘(5) Communities of color. 
13
‘‘(6) Health care providers and essential work-
14
ers. 
15
‘‘(d) EMERGENCY PERIOD.—In this section, the term 
16
‘emergency period’ has the meaning given such term in 
17
section 1135(g)(1)(A) of the Social Security Act. 
18
‘‘(e) AUTHORIZATION OF APPROPRIATIONS.—There 
19
is authorized to be appropriated to carry out this section 
20
$20,000,000 for each of fiscal years 2021 and 2022.’’. 
21
19:08 Nov 24, 2020
H14
200 
•HR 14 IH
Subtitle C—Suicide Prevention 
1
Grants 
2
SEC. 6021. SYNDROMIC SURVEILLANCE OF SELF-HARM BE-
3
HAVIORS PROGRAM. 
4
Title III of the Public Health Service Act is amended 
5
by inserting after section 317U of such Act (42 U.S.C. 
6
247b–23) the following: 
7
‘‘SEC. 317V. SYNDROMIC SURVEILLANCE OF SELF-HARM BE-
8
HAVIORS PROGRAM. 
9
‘‘(a) IN
GENERAL.—The Secretary shall award 
10
grants to State, local, Tribal, and territorial public health 
11
departments for the expansion of surveillance of self-harm. 
12
‘‘(b) DATA SHARING BY GRANTEES.—As a condition 
13
of receipt of such grant under subsection (a), each grantee 
14
shall agree to share with the Centers for Disease Control 
15
and Prevention in real time, to the extent feasible and as 
16
specified in the grant agreement, data on suicides and self- 
17
harm for purposes of— 
18
‘‘(1) tracking and monitoring self-harm to in-
19
form response activities to suicide clusters; 
20
‘‘(2) informing prevention programming for 
21
identified at-risk populations; and 
22
‘‘(3) conducting or supporting research. 
23
‘‘(c) DISAGGREGATION
OF DATA.—The Secretary 
24
shall provide for the data collected through surveillance 
25
19:08 Nov 24, 2020
H14
201 
•HR 14 IH
of self-harm under subsection (b) to be disaggregated by 
1
the following categories: 
2
‘‘(1) Nonfatal self-harm data of any intent. 
3
‘‘(2) Data on suicidal ideation. 
4
‘‘(3) Data on self-harm where there is no evi-
5
dence, whether implicit or explicit, of suicidal intent. 
6
‘‘(4) Data on self-harm where there is evidence, 
7
whether implicit or explicit, of suicidal intent. 
8
‘‘(5) Data on self-harm where suicidal intent is 
9
unclear based on the available evidence. 
10
‘‘(d) PRIORITY.—In making awards under subsection 
11
(a), the Secretary shall give priority to eligible entities that 
12
are— 
13
‘‘(1) located in a State with an age-adjusted 
14
rate of nonfatal suicidal behavior that is above the 
15
national rate of nonfatal suicidal behavior, as deter-
16
mined by the Director of the Centers for Disease 
17
Control and Prevention; 
18
‘‘(2) serving an Indian Tribe (as defined in sec-
19
tion 4 of the Indian Self-Determination and Edu-
20
cation Assistance Act) with an age-adjusted rate of 
21
nonfatal suicidal behavior that is above the national 
22
rate of nonfatal suicidal behavior, as determined 
23
through appropriate mechanisms determined by the 
24
Secretary in consultation with Indian Tribes; or 
25
19:08 Nov 24, 2020
H14
202 
•HR 14 IH
‘‘(3) located in a State with a high rate of cov-
1
erage of statewide (or Tribal) emergency department 
2
visits, as determined by the Director of the Centers 
3
for Disease Control and Prevention. 
4
‘‘(e) 
GEOGRAPHIC
DISTRIBUTION.—In 
making 
5
grants under this section, the Secretary shall make an ef-
6
fort to ensure geographic distribution, taking into account 
7
the unique needs of rural communities, including— 
8
‘‘(1) communities with an incidence of individ-
9
uals with serious mental illness, demonstrated suici-
10
dal ideation or behavior, or suicide rates that are 
11
above the national average, as determined by the As-
12
sistant Secretary for Mental Health and Substance 
13
Use; 
14
‘‘(2) communities with a shortage of prevention 
15
and treatment services, as determined by the Assist-
16
ant Secretary for Mental Health and Substance Use 
17
and the Administrator of the Health Resources and 
18
Services Administration; and 
19
‘‘(3) other appropriate community-level factors 
20
and social determinants of health such as income, 
21
employment, and education. 
22
‘‘(f) PERIOD OF PARTICIPATION.—To be selected as 
23
a grant recipient under this section, a State, local, Tribal, 
24
or territorial public health department shall agree to par-
25
19:08 Nov 24, 2020
H14
203 
•HR 14 IH
ticipate in the program for a period of not less than 4 
1
years. 
2
‘‘(g) TECHNICAL ASSISTANCE.—The Secretary shall 
3
provide technical assistance and training to grantees for 
4
collecting and sharing the data under subsection (b). 
5
‘‘(h) DATA SHARING
BY HHS.—Subject to sub-
6
section (b), the Secretary shall, with respect to data on 
7
self-harm that is collected pursuant to this section, share 
8
and integrate such data through— 
9
‘‘(1) the National Syndromic Surveillance Pro-
10
gram’s Early Notification of Community Epidemics 
11
(ESSENCE) platform (or any successor platform); 
12
‘‘(2) the National Violent Death Reporting Sys-
13
tem, as appropriate; or 
14
‘‘(3) another appropriate surveillance program, 
15
including such a program that collects data on sui-
16
cides and self-harm among special populations, such 
17
as members of the military and veterans. 
18
‘‘(i) RULE OF CONSTRUCTION REGARDING APPLICA-
19
BILITY OF PRIVACY PROTECTIONS.—Nothing in this sec-
20
tion shall be construed to limit or alter the application 
21
of Federal or State law relating to the privacy of informa-
22
tion to data or information that is collected or created 
23
under this section. 
24
‘‘(j) REPORT.— 
25
19:08 Nov 24, 2020
H14
204 
•HR 14 IH
‘‘(1) SUBMISSION.—Not later than 3 years 
1
after the date of enactment of this Act, the Sec-
2
retary shall evaluate the suicide and self-harm 
3
syndromic surveillance systems at the Federal, 
4
State, and local levels and submit a report to Con-
5
gress on the data collected under subsections (b) and 
6
(c) in a manner that prevents the disclosure of indi-
7
vidually identifiable information, at a minimum, con-
8
sistent with all applicable privacy laws and regula-
9
tions. 
10
‘‘(2) CONTENTS.—In addition to the data col-
11
lected under subsections (b) and (c), the report 
12
under paragraph (1) shall include— 
13
‘‘(A) challenges and gaps in data collection 
14
and reporting; 
15
‘‘(B) recommendations to address such 
16
gaps and challenges; and 
17
‘‘(C) a description of any public health re-
18
sponses initiated at the Federal, State, or local 
19
level in response to the data collected. 
20
‘‘(k) AUTHORIZATION
OF
APPROPRIATIONS.—To 
21
carry out this section, there are authorized to be appro-
22
priated $20,000,000 for each of fiscal years 2021 through 
23
2025.’’. 
24
19:08 Nov 24, 2020
H14
205 
•HR 14 IH
SEC. 6022. GRANTS TO PROVIDE SELF-HARM AND SUICIDE 
1
PREVENTION SERVICES. 
2
Part B of title V of the Public Health Service Act 
3
(42 U.S.C. 290aa et seq.) is amended by adding at the 
4
end the following: 
5
‘‘SEC. 520N. GRANTS TO PROVIDE SELF-HARM AND SUICIDE 
6
PREVENTION SERVICES. 
7
‘‘(a) IN GENERAL.—The Secretary of Health and 
8
Human Services shall award grants to hospital emergency 
9
departments to provide self-harm and suicide prevention 
10
services. 
11
‘‘(b) ACTIVITIES SUPPORTED.— 
12
‘‘(1) IN GENERAL.—A hospital emergency de-
13
partment awarded a grant under subsection (a) shall 
14
use amounts under the grant to implement a pro-
15
gram or protocol to better prevent suicide attempts 
16
among hospital patients after discharge, which may 
17
include— 
18
‘‘(A) screening patients for self-harm and 
19
suicide in accordance with the standards of 
20
practice described in subsection (e)(1) and 
21
standards of care established by appropriate 
22
medical and advocacy organizations; 
23
‘‘(B) providing patients short-term self- 
24
harm and suicide prevention services in accord-
25
19:08 Nov 24, 2020
H14
206 
•HR 14 IH
ance with the results of the screenings de-
1
scribed in subparagraph (A); and 
2
‘‘(C) referring patients, as appropriate, to 
3
a health care facility or provider for purposes of 
4
receiving long-term self-harm and suicide pre-
5
vention services, and providing any additional 
6
follow up services and care identified as appro-
7
priate as a result of the screenings and short- 
8
term self-harm and suicide prevention services 
9
described in subparagraphs (A) and (B). 
10
‘‘(2) USE
OF
FUNDS
TO
HIRE
AND
TRAIN 
11
STAFF.—Amounts awarded under subsection (a) 
12
may be used to hire clinical social workers, mental 
13
and behavioral health care professionals, and sup-
14
port staff as appropriate, and to train existing staff 
15
and newly hired staff to carry out the activities de-
16
scribed in paragraph (1). 
17
‘‘(c) GRANT TERMS.—A grant awarded under sub-
18
section (a)— 
19
‘‘(1) shall be for a period of 3 years; and 
20
‘‘(2) may be renewed subject to the require-
21
ments of this section. 
22
‘‘(d) APPLICATIONS.—A hospital emergency depart-
23
ment seeking a grant under subsection (a) shall submit 
24
an application to the Secretary at such time, in such man-
25
19:08 Nov 24, 2020
H14
207 
•HR 14 IH
ner, and accompanied by such information as the Sec-
1
retary may require. 
2
‘‘(e) STANDARDS OF PRACTICE.— 
3
‘‘(1) IN GENERAL.—Not later than 180 days 
4
after the date of the enactment of this section, the 
5
Secretary shall develop standards of practice for 
6
screening patients for self-harm and suicide for pur-
7
poses of carrying out subsection (b)(1)(C). 
8
‘‘(2) CONSULTATION.—The Secretary shall de-
9
velop the standards of practice described in para-
10
graph (1) in consultation with individuals and enti-
11
ties with expertise in self-harm and suicide preven-
12
tion, including public, private, and non-profit enti-
13
ties. 
14
‘‘(f) REPORTING.— 
15
‘‘(1) REPORTS TO THE SECRETARY.— 
16
‘‘(A) IN GENERAL.—A hospital emergency 
17
department awarded a grant under subsection 
18
(a) shall, at least quarterly for the duration of 
19
the grant, submit to the Secretary a report 
20
evaluating the activities supported by the grant. 
21
‘‘(B) MATTERS
TO
BE
INCLUDED.—The 
22
report required under subparagraph (A) shall 
23
include— 
24
19:08 Nov 24, 2020
H14
208 
•HR 14 IH
‘‘(i) the number of patients receiv-
1
ing— 
2
‘‘(I) screenings carried out at the 
3
hospital emergency department; 
4
‘‘(II) short-term self-harm and 
5
suicide prevention services at the hos-
6
pital emergency department; and 
7
‘‘(III) referrals to health care fa-
8
cilities for the purposes of receiving 
9
long-term self-harm and suicide pre-
10
vention; 
11
‘‘(ii) information on the adherence of 
12
the hospital emergency department to the 
13
standards of practice described in sub-
14
section (f)(1); and 
15
‘‘(iii) other information as the Sec-
16
retary determines appropriate to evaluate 
17
the use of grant funds. 
18
‘‘(2) REPORTS TO CONGRESS.—Not later than 
19
2 years after the date of the enactment of the Com-
20
mitment to Defeat the Virus and Keep America 
21
Healthy Act, and biennially thereafter, the Secretary 
22
shall submit to the Committee on Health, Edu-
23
cation, Labor, and Pensions of the Senate and the 
24
Committee on Energy and Commerce of the House 
25
19:08 Nov 24, 2020
H14
209 
•HR 14 IH
of Representatives a report on the grant program 
1
under this section, including— 
2
‘‘(A) a summary of reports received by the 
3
Secretary under paragraph (1); and 
4
‘‘(B) an evaluation of the program by the 
5
Secretary. 
6
‘‘(g) AUTHORIZATION
OF
APPROPRIATIONS.—To 
7
carry out this section, there are authorized to be appro-
8
priated $30,000,000 for each of fiscal years 2021 through 
9
2025.’’. 
10
Subtitle 
D—Effective 
Suicide 
11
Screening in the Emergency De-
12
partment 
13
SEC. 6031. PROGRAM TO IMPROVE THE CARE PROVIDED TO 
14
PATIENTS IN THE EMERGENCY DEPARTMENT 
15
WHO ARE AT RISK OF SUICIDE. 
16
Part P of title III of the Public Health Service Act 
17
(42 U.S.C. 280g et seq.) is amended by adding at the end 
18
the following new section: 
19
‘‘SEC. 399V–7. PROGRAM TO IMPROVE THE CARE PROVIDED 
20
TO PATIENTS IN THE EMERGENCY DEPART-
21
MENT WHO ARE AT RISK OF SUICIDE. 
22
‘‘(a) IN GENERAL.—The Secretary shall establish a 
23
program (in this section referred to as the ‘Program’) to 
24
improve the identification, assessment, and treatment of 
25
19:08 Nov 24, 2020
H14
210 
•HR 14 IH
patients in emergency departments who are at risk for sui-
1
cide, including by— 
2
‘‘(1) developing policies and procedures for 
3
identifying and assessing individuals who are at risk 
4
of suicide; and 
5
‘‘(2) enhancing the coordination of care for 
6
such individuals after discharge. 
7
‘‘(b) GRANT
ESTABLISHMENT
AND
PARTICIPA-
8
TION.— 
9
‘‘(1) IN GENERAL.—In carrying out the Pro-
10
gram, the Secretary shall award grants on a com-
11
petitive basis to not more than 40 eligible health 
12
care sites described in paragraph (2). 
13
‘‘(2) ELIGIBILITY.—To be eligible for a grant 
14
under this section, a health care site shall— 
15
‘‘(A) submit an application to the Sec-
16
retary at such time, in such manner, and con-
17
taining such information as the Secretary may 
18
specify; 
19
‘‘(B) be a hospital (as defined in section 
20
1861(e) of the Social Security Act); 
21
‘‘(C) have an emergency department; and 
22
‘‘(D) deploy onsite health care or social 
23
service professionals to help connect and inte-
24
19:08 Nov 24, 2020
H14
211 
•HR 14 IH
grate patients who are at risk of suicide with 
1
treatment and mental health support services. 
2
‘‘(3) PREFERENCE.—In awarding grants under 
3
this section, the Secretary may give preference to eli-
4
gible health care sites described in paragraph (2) 
5
that meet at least one of the following criteria: 
6
‘‘(A) The eligible health care site is a crit-
7
ical access hospital (as defined in section 
8
1861(mm)(1) of the Social Security Act). 
9
‘‘(B) The eligible health care site is a sole 
10
community hospital (as defined in section 
11
1886(d)(5)(D)(iii) of the Social Security Act). 
12
‘‘(C) The eligible health care site is oper-
13
ated by the Indian Health Service, by an Indian 
14
tribe or tribal organization (as such terms are 
15
defined in section 4 of the Indian Self-Deter-
16
mination and Education Assistance Act), or by 
17
an urban Indian organization (as defined in 
18
section 4 of the Indian Health Care Improve-
19
ment Act). 
20
‘‘(D) The eligible health care site is located 
21
in a geographic area with a suicide rate that is 
22
higher than the national rate, as determined by 
23
the Secretary based on the most recent data 
24
19:08 Nov 24, 2020
H14
212 
•HR 14 IH
from the Centers for Disease Control and Pre-
1
vention. 
2
‘‘(c) PERIOD OF GRANT.—A grant awarded to an eli-
3
gible health care site under this section shall be for a pe-
4
riod of at least 2 years. 
5
‘‘(d) GRANT USES.— 
6
‘‘(1) REQUIRED USES.—A grant awarded under 
7
this section to an eligible health care site shall be 
8
used for the following purposes: 
9
‘‘(A) To train emergency department 
10
health care professionals to identify, assess, and 
11
treat patients who are at risk of suicide. 
12
‘‘(B) To establish and implement policies 
13
and procedures for emergency departments to 
14
improve the identification, assessment and 
15
treatment of individuals who are at risk of sui-
16
cide. 
17
‘‘(C) To establish and implement policies 
18
and procedures with respect to care coordina-
19
tion, integrated care models, or referral to evi-
20
dence-based treatment to be used upon the dis-
21
charge from the emergency department of pa-
22
tients who are at risk of suicide. 
23
‘‘(2) ADDITIONAL PERMISSIBLE USES.—In ad-
24
dition to the required uses listed in paragraph (1), 
25
19:08 Nov 24, 2020
H14
213 
•HR 14 IH
a grant awarded under this section to an eligible 
1
health care site may be used for any of the following 
2
purposes: 
3
‘‘(A) To hire emergency department psy-
4
chiatrists, psychologists, nurse practitioners, 
5
counselors, therapists, or other licensed health 
6
care and behavioral health professionals special-
7
izing in the treatment of individuals at risk of 
8
suicide. 
9
‘‘(B) To develop and implement best prac-
10
tices for the follow-up care and long-term treat-
11
ment of individuals who are at risk of suicide. 
12
‘‘(C) To increase the availability of and ac-
13
cess to evidence-based treatment for individuals 
14
who are at risk of suicide, including through 
15
telehealth services and strategies to reduce the 
16
boarding of these patients in emergency depart-
17
ments. 
18
‘‘(D) To offer consultation with and refer-
19
ral to other supportive services that provide evi-
20
dence-based treatment and recovery for individ-
21
uals who are at risk of suicide. 
22
‘‘(e) REPORTING REQUIREMENTS.— 
23
‘‘(1) REPORTS
BY
GRANTEES.—Each eligible 
24
health care site receiving a grant under this section 
25
19:08 Nov 24, 2020
H14
214 
•HR 14 IH
shall submit to the Secretary an annual report for 
1
each year for which the grant is received on the 
2
progress of the program funded through the grant. 
3
Each such report shall include information on— 
4
‘‘(A) the number of individuals screened in 
5
the site’s emergency department for being at 
6
risk of suicide; 
7
‘‘(B) the number of individuals identified 
8
in the site’s emergency department as being— 
9
‘‘(i) survivors of an attempted suicide; 
10
or 
11
‘‘(ii) are at risk of suicide; 
12
‘‘(C) the number of individuals who are 
13
identified in the site’s emergency department as 
14
being at risk of suicide by a health care or be-
15
havioral health professional hired pursuant to 
16
subsection (d)(2)(A); 
17
‘‘(D) the number of individuals referred by 
18
the site’s emergency department to other treat-
19
ment facilities, the types of such other facilities, 
20
and the number of such individuals admitted to 
21
such other facilities pursuant to such referrals; 
22
‘‘(E) the effectiveness of programs and ac-
23
tivities funded through the grant in preventing 
24
suicides and suicide attempts; and 
25
19:08 Nov 24, 2020
H14
215 
•HR 14 IH
‘‘(F) any other relevant additional data re-
1
garding the programs and activities funded 
2
through the grant. 
3
‘‘(2) REPORT BY SECRETARY.—Not later than 
4
one year after the end of fiscal year 2025, the Sec-
5
retary shall submit to Congress a report that in-
6
cludes— 
7
‘‘(A) findings on the Program; 
8
‘‘(B) overall patient outcomes achieved 
9
through the Program; 
10
‘‘(C) an evaluation of the effectiveness of 
11
having a trained health care or behavioral 
12
health professional onsite to identify, assess, 
13
and treat patients who are at risk of suicide; 
14
and 
15
‘‘(D) a compilation of policies, procedures, 
16
and best practices established, developed, or im-
17
plemented by grantees under this section. 
18
‘‘(f) AUTHORIZATION OF APPROPRIATIONS.—There 
19
is authorized to be appropriated to carry out this section 
20
$20,000,000 for the period of fiscal years 2021 through 
21
2025.’’. 
22
19:08 Nov 24, 2020
H14
216 
•HR 14 IH
Subtitle E—Suicide
Prevention 
1
Lifeline
Improvement 
2
SEC. 6041. SUICIDE PREVENTION LIFELINE. 
3
(a) PLAN.—Section 520E–3 of the Public Health 
4
Service Act (42 U.S.C. 290bb–36c) is amended— 
5
(1) by redesignating subsection (c) as sub-
6
section (e); and 
7
(2) by inserting after subsection (b) the fol-
8
lowing: 
9
‘‘(c) PLAN.— 
10
‘‘(1) IN GENERAL.—For purposes of maintain-
11
ing the suicide prevention hotline under subsection 
12
(b)(2), the Secretary shall develop and implement a 
13
plan to ensure the provision of high-quality service. 
14
‘‘(2) CONTENTS.—The plan required by para-
15
graph (1) shall include the following: 
16
‘‘(A) Quality assurance provisions, includ-
17
ing— 
18
‘‘(i) clearly defined and measurable 
19
performance indicators and objectives to 
20
improve the responsiveness and perform-
21
ance of the hotline, including at backup 
22
call centers; and 
23
19:08 Nov 24, 2020
H14
217 
•HR 14 IH
‘‘(ii) quantifiable timeframes to track 
1
the progress of the hotline in meeting such 
2
performance indicators and objectives. 
3
‘‘(B) Standards that crisis centers and 
4
backup centers must meet— 
5
‘‘(i) to participate in the network 
6
under subsection (b)(1); and 
7
‘‘(ii) to ensure that each telephone 
8
call, online chat message, and other com-
9
munication received by the hotline, includ-
10
ing at backup call centers, is answered in 
11
a timely manner by a person, consistent 
12
with the guidance established by the Amer-
13
ican Association of Suicidology or other 
14
guidance determined by the Secretary to be 
15
appropriate. 
16
‘‘(C) Guidelines for crisis centers and 
17
backup centers to implement evidence-based 
18
practices including with respect to followup and 
19
referral to other health and social services re-
20
sources. 
21
‘‘(D) Guidelines to ensure that resources 
22
are available and distributed to individuals 
23
using the hotline who are not personally in a 
24
time of crisis but know of someone who is. 
25
19:08 Nov 24, 2020
H14
218 
•HR 14 IH
‘‘(E) Guidelines to carry out periodic test-
1
ing of the hotline, including at crisis centers 
2
and backup centers, during each fiscal year to 
3
identify and correct any problems in a timely 
4
manner. 
5
‘‘(F) Guidelines to operate in consultation 
6
with the State department of health, local gov-
7
ernments, Indian tribes, and tribal organiza-
8
tions. 
9
‘‘(3) INITIAL PLAN; UPDATES.—The Secretary 
10
shall— 
11
‘‘(A) not later than 6 months after the 
12
date of enactment of the Commitment to Defeat 
13
the Virus and Keep America Healthy Act, com-
14
plete development of the initial version of the 
15
plan required by paragraph (1), begin imple-
16
mentation of such plan, and make such plan 
17
publicly available; and 
18
‘‘(B) periodically thereafter, update such 
19
plan and make the updated plan publicly avail-
20
able.’’. 
21
(b) TRANSMISSION
OF DATA
TO CDC.—Section 
22
520E–3 of the Public Health Service Act (42 U.S.C. 
23
290bb–36c) is amended by inserting after subsection (c) 
24
19:08 Nov 24, 2020
H14
219 
•HR 14 IH
of such section, as added by subsection (a) of this section, 
1
the following: 
2
‘‘(d) TRANSMISSION OF DATA TO CDC.—The Sec-
3
retary shall formalize and strengthen agreements between 
4
the National Suicide Prevention Lifeline program and the 
5
Centers for Disease Control and Prevention to transmit 
6
any necessary epidemiological data from the program to 
7
the Centers, including local call center data, to assist the 
8
Centers in suicide prevention efforts.’’. 
9
(c) AUTHORIZATION
OF
APPROPRIATIONS.—Sub-
10
section (e) of section 520E–3 of the Public Health Service 
11
Act (42 U.S.C. 290bb–36c) is amended to read as follows: 
12
‘‘(e) AUTHORIZATION OF APPROPRIATIONS.— 
13
‘‘(1) IN GENERAL.—To carry out this section, 
14
there are authorized to be appropriated $50,000,000 
15
for each of fiscal years 2021 through 2023. 
16
‘‘(2) ALLOCATION.—Of the amount authorized 
17
to be appropriated by paragraph (1) for each of fis-
18
cal years 2021 through 2023, at least 80 percent 
19
shall be made available to crisis centers.’’. 
20
SEC. 
6042. 
PILOT 
PROGRAM 
ON 
INNOVATIVE 
TECH-
21
NOLOGIES. 
22
(a) PILOT PROGRAM.— 
23
(1) IN GENERAL.—The Secretary of Health and 
24
Human Services, acting through the Assistant Sec-
25
19:08 Nov 24, 2020
H14
220 
•HR 14 IH
retary for Mental Health and Substance Use, shall 
1
carry out a pilot program to research, analyze, and 
2
employ various technologies and platforms of com-
3
munication 
(including 
social 
media 
platforms, 
4
texting platforms, and email platforms) for suicide 
5
prevention in addition to the telephone and online 
6
chat service provided by the Suicide Prevention Life-
7
line. 
8
(2) AUTHORIZATION OF APPROPRIATIONS.—To 
9
carry out paragraph (1), there is authorized to be 
10
appropriated $5,000,000 for the period of fiscal 
11
years 2021 and 2022. 
12
(b) REPORT.—Not later than 24 months after the 
13
date on which the pilot program under subsection (a) com-
14
mences, the Secretary of Health and Human Services, act-
15
ing through the Assistant Secretary for Mental Health 
16
and Substance Use, shall submit to the Congress a report 
17
on the pilot program. With respect to each platform of 
18
communication employed pursuant to the pilot program, 
19
the report shall include— 
20
(1) a full description of the program; 
21
(2) the number of individuals served by the pro-
22
gram; 
23
(3) the average wait time for each individual to 
24
receive a response; 
25
19:08 Nov 24, 2020
H14
221 
•HR 14 IH
(4) the cost of the program, including the cost 
1
per individual served; and 
2
(5) any other information the Secretary deter-
3
mines appropriate. 
4
SEC. 6043. HHS STUDY AND REPORT. 
5
Not later than 24 months after the Secretary of 
6
Health and Human Services begins implementation of the 
7
plan required by section 520E–3(c) of the Public Health 
8
Service Act, as added by section 6041(a)(2) of this sub-
9
title, the Secretary shall— 
10
(1) complete a study on— 
11
(A) the implementation of such plan, in-
12
cluding the progress towards meeting the objec-
13
tives identified pursuant to paragraph (2)(A)(i) 
14
of such section 520E–3(c) by the timeframes 
15
identified pursuant to paragraph (2)(A)(ii) of 
16
such section 520E–3(c); and 
17
(B) in consultation with the Director of 
18
the Centers for Disease Control and Prevention, 
19
options to expand data gathering from calls to 
20
the Suicide Prevention Lifeline in order to bet-
21
ter track aspects of usage such as repeat calls, 
22
consistent with applicable Federal and State 
23
privacy laws; and 
24
19:08 Nov 24, 2020
H14
222 
•HR 14 IH
(2) submit a report to the Congress on the re-
1
sults of such study, including recommendations on 
2
whether additional legislation or appropriations are 
3
needed. 
4
SEC. 6044. GAO STUDY AND REPORT. 
5
(a) IN GENERAL.—Not later than 24 months after 
6
the Secretary of Health and Human Services begins imple-
7
mentation of the plan required by section 520E–3(c) of 
8
the Public Health Service Act, as added by section 
9
6041(a)(2) of this subtitle, the Comptroller General of the 
10
United States shall— 
11
(1) complete a study on the Suicide Prevention 
12
Lifeline; and 
13
(2) submit a report to the Congress on the re-
14
sults of such study. 
15
(b) ISSUES TO BE STUDIED.—The study required by 
16
subsection (a) shall address— 
17
(1) the feasibility of geolocating callers to direct 
18
calls to the nearest crisis center; 
19
(2) operation shortcomings of the Suicide Pre-
20
vention Lifeline; 
21
(3) geographic coverage of each crisis call cen-
22
ter; 
23
(4) the call answer rate of each crisis call cen-
24
ter; 
25
19:08 Nov 24, 2020
H14
223 
•HR 14 IH
(5) the call wait time of each crisis call center; 
1
(6) the hours of operation of each crisis call 
2
center; 
3
(7) funding avenues of each crisis call center; 
4
(8) the implementation of the plan under sec-
5
tion 520E–3(c) of the Public Health Service Act, as 
6
added by section 6041(a) of this subtitle, including 
7
the progress towards meeting the objectives identi-
8
fied pursuant to paragraph (2)(A)(i) of such section 
9
520E–3(c) by the timeframes identified pursuant to 
10
paragraph (2)(A)(ii) of such section 520E–3(c); and 
11
(9) service to individuals requesting a foreign 
12
language speaker, including— 
13
(A) the number of calls or chats the Life-
14
line receives from individuals speaking a foreign 
15
language; 
16
(B) the capacity of the Lifeline to handle 
17
these calls or chats; and 
18
(C) the number of crisis centers with the 
19
capacity to serve foreign language speakers, in 
20
house. 
21
(c) RECOMMENDATIONS.—The report required by 
22
subsection (a) shall include recommendations for improv-
23
ing the Suicide Prevention Lifeline, including rec-
24
ommendations for legislative and administrative actions. 
25
19:08 Nov 24, 2020
H14
224 
•HR 14 IH
SEC. 6045. DEFINITION. 
1
In this subtitle, the term ‘‘Suicide Prevention Life-
2
line’’ means the suicide prevention hotline maintained pur-
3
suant to section 520E–3 of the Public Health Service Act 
4
(42 U.S.C. 290bb–36c). 
5
Subtitle F—Campaign To Prevent 
6
Suicide 
7
SEC. 6051. NATIONAL SUICIDE PREVENTION LIFELINE. 
8
Section 520E–3(b)(2) of the Public Health Service 
9
Act (42 U.S.C. 290bb–36c(b)(2)) is amended by inserting 
10
after ‘‘suicide prevention hotline’’ the following: ‘‘, which, 
11
beginning not later than one year after the date of the 
12
enactment of the Commitment to Defeat the Virus and 
13
Keep America Healthy Act, shall be a 3-digit nationwide 
14
toll-free telephone number,’’. 
15
SEC. 6052. NATIONAL SUICIDE PREVENTION MEDIA CAM-
16
PAIGN. 
17
(a) NATIONAL SUICIDE PREVENTION MEDIA CAM-
18
PAIGN.— 
19
(1) IN GENERAL.—Not later than the date that 
20
is three years after the date of the enactment of this 
21
Act, the Secretary of Health and Human Services 
22
(referred to in this section as the ‘‘Secretary’’), in 
23
coordination with the Assistant Secretary for Mental 
24
Health and Substance Use (referred to in this sec-
25
tion as the ‘‘Assistant Secretary’’) and the Director 
26
19:08 Nov 24, 2020
H14
225 
•HR 14 IH
of the Centers for Disease Control and Prevention 
1
(referred to in this section as the ‘‘Director’’), shall 
2
conduct a national suicide prevention media cam-
3
paign (referred to in this section as the ‘‘national 
4
media campaign’’), in accordance with the require-
5
ments of this section, for purposes of— 
6
(A) preventing suicide in the United 
7
States; 
8
(B) educating families, friends, and com-
9
munities on how to address suicide and suicidal 
10
thoughts, including when to encourage individ-
11
uals with suicidal risk to seek help; and 
12
(C) increasing awareness of suicide preven-
13
tion resources of the Centers for Disease Con-
14
trol and Prevention and the Substance Abuse 
15
and Mental Health Services Administration (in-
16
cluding the suicide prevention hotline main-
17
tained under section 520E–3 of the Public 
18
Health Service Act (42 U.S.C. 290bb–36c)), 
19
any suicide prevention mobile application of the 
20
Centers for Disease Control and Prevention or 
21
the Substance Abuse Mental Health Services 
22
Administration, and other support resources de-
23
termined appropriate by the Secretary. 
24
19:08 Nov 24, 2020
H14
226 
•HR 14 IH
(2) ADDITIONAL CONSULTATION.—In addition 
1
to coordinating with the Assistant Secretary and the 
2
Director under this section, the Secretary shall con-
3
sult with, as appropriate, State, local, Tribal, and 
4
territorial health departments, primary health care 
5
providers, hospitals with emergency departments, 
6
mental and behavioral health services providers, cri-
7
sis response services providers, first responders, sui-
8
cide prevention and mental health professionals, pa-
9
tient advocacy groups, survivors of suicide attempts, 
10
and representatives of television and social media 
11
platforms in planning the national media campaign 
12
to be conducted under paragraph (1). 
13
(b) TARGET AUDIENCES.— 
14
(1) TAILORING ADVERTISEMENTS AND OTHER 
15
COMMUNICATIONS.—In 
conducting 
the 
national 
16
media campaign under subsection (a)(1), the Sec-
17
retary may tailor culturally competent advertise-
18
ments and other communications of the campaign 
19
across all available media for a target audience 
20
(such as a particular geographic location or demo-
21
graphic) across the lifespan. 
22
(2) TARGETING CERTAIN LOCAL AREAS.—The 
23
Secretary shall, to the maximum extent practicable, 
24
use amounts made available under subsection (f) for 
25
19:08 Nov 24, 2020
H14
227 
•HR 14 IH
media that targets individuals in local areas with 
1
higher suicide rates. 
2
(c) USE OF FUNDS.— 
3
(1) REQUIRED USES.— 
4
(A) IN GENERAL.—The Secretary shall, to 
5
the extent reasonably feasible with the funds 
6
made available under subsection (f), carry out 
7
the following, with respect to the national media 
8
campaign: 
9
(i) The purchase of advertising time 
10
and space, including the strategic planning 
11
for, and accounting of, any such purchase. 
12
(ii) Creative services and talent costs. 
13
(iii) Advertising production costs. 
14
(iv) Testing and evaluation of adver-
15
tising. 
16
(v) Evaluation of the effectiveness of 
17
the national media campaign. 
18
(vi) Operational and management ex-
19
penses. 
20
(vii) The creation of an educational 
21
toolkit for television and social media plat-
22
forms to use in discussing suicide and rais-
23
ing awareness about how to prevent sui-
24
cide. 
25
19:08 Nov 24, 2020
H14
228 
•HR 14 IH
(B) SPECIFIC REQUIREMENTS.— 
1
(i) TESTING AND EVALUATION OF AD-
2
VERTISING.—In testing and evaluating ad-
3
vertising under subparagraph (A)(iv), the 
4
Secretary shall test all advertisements 
5
after use in the national media campaign 
6
to evaluate the extent to which such adver-
7
tisements have been effective in carrying 
8
out the purposes of the national media 
9
campaign. 
10
(ii) EVALUATION OF EFFECTIVENESS 
11
OF NATIONAL MEDIA CAMPAIGN.—In eval-
12
uating the effectiveness of the national 
13
media 
campaign 
under 
subparagraph 
14
(A)(v), the Secretary shall take into ac-
15
count— 
16
(I) the number of unique calls 
17
that are made to the suicide preven-
18
tion hotline maintained under section 
19
520E–3 of the Public Health Service 
20
Act (42 U.S.C. 290bb–36c) and as-
21
sess whether there are any State and 
22
regional variations with respect to the 
23
capacity to answer such calls; 
24
19:08 Nov 24, 2020
H14
229 
•HR 14 IH
(II) the number of unique en-
1
counters with suicide prevention and 
2
support resources of the Centers for 
3
Disease Control and Prevention and 
4
the Substance Abuse and Mental 
5
Health Services Administration and 
6
assess engagement with such suicide 
7
prevention and support resources; 
8
(III) whether the national media 
9
campaign has contributed to increased 
10
awareness that suicidal individuals 
11
should be engaged, rather than ig-
12
nored; and 
13
(IV) such other measures of eval-
14
uation as the Secretary determines 
15
are appropriate. 
16
(2) OPTIONAL USES.—The Secretary may use 
17
amounts made available under subsection (f) for the 
18
following, with respect to the national media cam-
19
paign: 
20
(A) Partnerships with professional and 
21
civic groups, community-based organizations, 
22
including faith-based organizations, and Gov-
23
ernment or Tribal organizations that the Sec-
24
retary determines have experience in suicide 
25
19:08 Nov 24, 2020
H14
230 
•HR 14 IH
prevention, including the Substance Abuse and 
1
Mental Health Services Administration and the 
2
Centers for Disease Control and Prevention. 
3
(B) 
Entertainment 
industry 
outreach, 
4
interactive outreach, media projects and activi-
5
ties, public information, news media outreach, 
6
outreach through television programs, and cor-
7
porate sponsorship and participation. 
8
(d) PROHIBITIONS.—None of the amounts made 
9
available under subsection (f) may be obligated or ex-
10
pended for any of the following: 
11
(1) To supplant current suicide prevention cam-
12
paigns. 
13
(2) For partisan political purposes, or to ex-
14
press advocacy in support of or to defeat any clearly 
15
identified candidate, clearly identified ballot initia-
16
tive, or clearly identified legislative or regulatory 
17
proposal. 
18
(e) REPORT
TO CONGRESS.—Not later than 18 
19
months after implementation of the national media cam-
20
paign has begun, the Secretary, in coordination with the 
21
Assistant Secretary and the Director, shall, with respect 
22
to the first year of the national media campaign, submit 
23
to Congress a report that describes— 
24
19:08 Nov 24, 2020
H14
231 
•HR 14 IH
(1) the strategy of the national media campaign 
1
and whether specific objectives of such campaign 
2
were accomplished, including whether such campaign 
3
impacted the number of calls made to lifeline crisis 
4
centers and the capacity of such centers to manage 
5
such calls; 
6
(2) steps taken to ensure that the national 
7
media campaign operates in an effective and effi-
8
cient manner consistent with the overall strategy 
9
and focus of the national media campaign; 
10
(3) plans to purchase advertising time and 
11
space; 
12
(4) policies and practices implemented to ensure 
13
that Federal funds are used responsibly to purchase 
14
advertising time and space and eliminate the poten-
15
tial for waste, fraud, and abuse; and 
16
(5) all contracts entered into with a corpora-
17
tion, a partnership, or an individual working on be-
18
half of the national media campaign. 
19
(f) AUTHORIZATION OF APPROPRIATIONS.—For pur-
20
poses of carrying out this section, there is authorized to 
21
be appropriated $10,000,000 for each of fiscal years 2021 
22
through 2025. 
23
19:08 Nov 24, 2020
H14
232 
•HR 14 IH
Subtitle G—Helping Emergency 
1
Responders Overcome 
2
SEC. 6061. DATA SYSTEM TO CAPTURE NATIONAL PUBLIC 
3
SAFETY OFFICER SUICIDE INCIDENCE. 
4
The Public Health Service Act is amended by insert-
5
ing before section 318 of such Act (42 U.S.C. 247c) the 
6
following: 
7
‘‘SEC. 317W. DATA SYSTEM TO CAPTURE NATIONAL PUBLIC 
8
SAFETY OFFICER SUICIDE INCIDENCE. 
9
‘‘(a) IN GENERAL.—The Secretary, in coordination 
10
with the Director of the Centers for Disease Control and 
11
Prevention and other agencies as the Secretary determines 
12
appropriate, shall— 
13
‘‘(1) develop and maintain a data system, to be 
14
known as the Public Safety Officer Suicide Report-
15
ing System, for the purposes of— 
16
‘‘(A) collecting data on the suicide inci-
17
dence among public safety officers; and 
18
‘‘(B) facilitating the study of successful 
19
interventions to reduce suicide among public 
20
safety officers; and 
21
‘‘(2) integrate such system into the National 
22
Violent Death Reporting System, so long as the Sec-
23
retary determines such integration to be consistent 
24
with the purposes described in paragraph (1). 
25
19:08 Nov 24, 2020
H14
233 
•HR 14 IH
‘‘(b) DATA COLLECTION.—In collecting data for the 
1
Public Safety Officer Suicide Reporting System, the Sec-
2
retary shall, at a minimum, collect the following informa-
3
tion: 
4
‘‘(1) The total number of suicides in the United 
5
States among all public safety officers in a given cal-
6
endar year. 
7
‘‘(2) Suicide rates for public safety officers in 
8
a given calendar year, disaggregated by— 
9
‘‘(A) age and gender of the public safety 
10
officer; 
11
‘‘(B) State; 
12
‘‘(C) occupation; including both the indi-
13
vidual’s role in their public safety agency and 
14
their primary occupation in the case of volun-
15
teer public safety officers; 
16
‘‘(D) where available, the status of the 
17
public safety officer as volunteer, paid-on-call, 
18
or career; and 
19
‘‘(E) status of the public safety officer as 
20
active or retired. 
21
‘‘(c) CONSULTATION DURING DEVELOPMENT.—In 
22
developing the Public Safety Officer Suicide Reporting 
23
System, the Secretary shall consult with non-Federal ex-
24
perts to determine the best means to collect data regard-
25
19:08 Nov 24, 2020
H14
234 
•HR 14 IH
ing suicide incidence in a safe, sensitive, anonymous, and 
1
effective manner. Such non-Federal experts shall include, 
2
as appropriate, the following: 
3
‘‘(1) Public health experts with experience in 
4
developing and maintaining suicide registries. 
5
‘‘(2) Organizations that track suicide among 
6
public safety officers. 
7
‘‘(3) Mental health experts with experience in 
8
studying suicide and other profession-related trau-
9
matic stress. 
10
‘‘(4) Clinicians with experience in diagnosing 
11
and treating mental health issues. 
12
‘‘(5) Active and retired volunteer, paid-on-call, 
13
and career public safety officers. 
14
‘‘(6) Relevant national police, and fire and 
15
emergency medical services, organizations. 
16
‘‘(d) DATA PRIVACY AND SECURITY.—In developing 
17
and maintaining the Public Safety Officer Suicide Report-
18
ing System, the Secretary shall ensure that all applicable 
19
Federal privacy and security protections are followed to 
20
ensure that— 
21
‘‘(1) the confidentiality and anonymity of sui-
22
cide victims and their families are protected, includ-
23
ing so as to ensure that data cannot be used to deny 
24
benefits; and 
25
19:08 Nov 24, 2020
H14
235 
•HR 14 IH
‘‘(2) data is sufficiently secure to prevent unau-
1
thorized access. 
2
‘‘(e) REPORTING.— 
3
‘‘(1) ANNUAL REPORT.—Not later than 2 years 
4
after the date of enactment of the Commitment to 
5
Defeat the Virus and Keep America Healthy Act, 
6
and biannually thereafter, the Secretary shall submit 
7
a report to the Congress on the suicide incidence 
8
among public safety officers. Each such report 
9
shall— 
10
‘‘(A) include the number and rate of such 
11
suicide incidence, disaggregated by age, gender, 
12
and State of employment; 
13
‘‘(B) identify characteristics and contrib-
14
uting circumstances for suicide among public 
15
safety officers; 
16
‘‘(C) disaggregate rates of suicide by— 
17
‘‘(i) occupation; 
18
‘‘(ii) status as volunteer, paid-on-call, 
19
or career; and 
20
‘‘(iii) status as active or retired; 
21
‘‘(D) include recommendations for further 
22
study regarding the suicide incidence among 
23
public safety officers; 
24
19:08 Nov 24, 2020
H14
236 
•HR 14 IH
‘‘(E) specify in detail, if found, any obsta-
1
cles in collecting suicide rates for volunteers 
2
and include recommended improvements to 
3
overcome such obstacles; 
4
‘‘(F) identify options for interventions to 
5
reduce suicide among public safety officers; and 
6
‘‘(G) describe procedures to ensure the 
7
confidentiality and anonymity of suicide victims 
8
and their families, as described in subsection 
9
(d)(1). 
10
‘‘(2) PUBLIC AVAILABILITY.—Upon the submis-
11
sion of each report to the Congress under paragraph 
12
(1), the Secretary shall make the full report publicly 
13
available on the website of the Centers for Disease 
14
Control and Prevention. 
15
‘‘(f) DEFINITION.—In this section, the term ‘public 
16
safety officer’ means— 
17
‘‘(1) a public safety officer as defined in section 
18
1204 of the Omnibus Crime Control and Safe 
19
Streets Act of 1968; or 
20
‘‘(2) a public safety telecommunicator as de-
21
scribed in detailed occupation 43–5031 in the Stand-
22
ard Occupational Classification Manual of the Office 
23
of Management and Budget (2018). 
24
19:08 Nov 24, 2020
H14
237 
•HR 14 IH
‘‘(g) PROHIBITED USE OF INFORMATION.—Notwith-
1
standing any other provision of law, if an individual is 
2
identified as deceased based on information contained in 
3
the Public Safety Officer Suicide Reporting System, such 
4
information may not be used to deny or rescind life insur-
5
ance payments or other benefits to a survivor of the de-
6
ceased individual.’’. 
7
SEC. 6062. PEER-SUPPORT BEHAVIORAL HEALTH AND 
8
WELLNESS PROGRAMS WITHIN FIRE DEPART-
9
MENTS AND EMERGENCY MEDICAL SERVICE 
10
AGENCIES. 
11
(a) IN GENERAL.—Part B of title III of the Public 
12
Health Service Act (42 U.S.C. 243 et seq.) is amended 
13
by adding at the end the following: 
14
‘‘SEC. 320B. PEER-SUPPORT BEHAVIORAL HEALTH AND 
15
WELLNESS PROGRAMS WITHIN FIRE DEPART-
16
MENTS AND EMERGENCY MEDICAL SERVICE 
17
AGENCIES. 
18
‘‘(a) IN
GENERAL.—The Secretary shall award 
19
grants to eligible entities for the purpose of establishing 
20
or enhancing peer-support behavioral health and wellness 
21
programs within fire departments and emergency medical 
22
services agencies. 
23
19:08 Nov 24, 2020
H14
238 
•HR 14 IH
‘‘(b) PROGRAM DESCRIPTION.—A peer-support be-
1
havioral health and wellness program funded under this 
2
section shall— 
3
‘‘(1) use career and volunteer members of fire 
4
departments or emergency medical services agencies 
5
to serve as peer counselors; 
6
‘‘(2) provide training to members of career, vol-
7
unteer, and combination fire departments or emer-
8
gency medical service agencies to serve as such peer 
9
counselors; 
10
‘‘(3) purchase materials to be used exclusively 
11
to provide such training; and 
12
‘‘(4) disseminate such information and mate-
13
rials as are necessary to conduct the program. 
14
‘‘(c) DEFINITION.—In this section: 
15
‘‘(1) The term ‘eligible entity’ means a non-
16
profit organization with expertise and experience 
17
with respect to the health and life safety of members 
18
of fire and emergency medical services agencies. 
19
‘‘(2) The term ‘member’— 
20
‘‘(A) with respect to an emergency medical 
21
services agency, means an employee, regardless 
22
of rank or whether the employee receives com-
23
pensation (as defined in section 1204(7) of the 
24
19:08 Nov 24, 2020
H14
239 
•HR 14 IH
Omnibus Crime Control and Safe Streets Act of 
1
1968); and 
2
‘‘(B) with respect to a fire department, 
3
means any employee, regardless of rank or 
4
whether the employee receives compensation, of 
5
a Federal, State, Tribal, or local fire depart-
6
ment who is responsible for responding to calls 
7
for emergency service.’’. 
8
(b) TECHNICAL CORRECTION.—Effective as if in-
9
cluded in the enactment of the Children’s Health Act of 
10
2000 (Public Law 106–310), the amendment instruction 
11
in section 1603 of such Act is amended by striking ‘‘Part 
12
B of the Public Health Service Act’’ and inserting ‘‘Part 
13
B of title III of the Public Health Service Act’’. 
14
SEC. 6063. HEALTH CARE PROVIDER BEHAVIORAL HEALTH 
15
AND WELLNESS PROGRAMS. 
16
Part B of title III of the Public Health Service Act 
17
(42 U.S.C. 243 et seq.), as amended by section 6062, is 
18
further amended by adding at the end the following: 
19
‘‘SEC. 
320C. 
HEALTH 
CARE 
PROVIDER 
BEHAVIORAL 
20
HEALTH AND WELLNESS PROGRAMS. 
21
‘‘(a) IN
GENERAL.—The Secretary shall award 
22
grants to eligible entities for the purpose of establishing 
23
or enhancing behavioral health and wellness programs for 
24
health care providers. 
25
19:08 Nov 24, 2020
H14
240 
•HR 14 IH
‘‘(b) PROGRAM DESCRIPTION.—A behavioral health 
1
and wellness program funded under this section shall— 
2
‘‘(1) provide confidential support services for 
3
health care providers to help handle stressful or 
4
traumatic patient-related events, including coun-
5
seling services and wellness seminars; 
6
‘‘(2) provide training to health care providers to 
7
serve as peer counselors to other health care pro-
8
viders; 
9
‘‘(3) purchase materials to be used exclusively 
10
to provide such training; and 
11
‘‘(4) disseminate such information and mate-
12
rials as are necessary to conduct such training and 
13
provide such peer counseling. 
14
‘‘(c) DEFINITIONS.—In this section, the term ‘eligible 
15
entity’ means a hospital, including a critical access hos-
16
pital (as defined in section 1861(mm)(1) of the Social Se-
17
curity Act) or a disproportionate share hospital (as defined 
18
under section 1923(a)(1)(A) of such Act), a federally 
19
qualified 
health 
center 
(as 
defined 
in 
section 
20
1905(1)(2)(B) of such Act), or any other health care facil-
21
ity.’’. 
22
19:08 Nov 24, 2020
H14
241 
•HR 14 IH
SEC. 6064. DEVELOPMENT OF RESOURCES FOR EDUCATING 
1
MENTAL HEALTH PROFESSIONALS ABOUT 
2
TREATING FIRE FIGHTERS AND EMERGENCY 
3
MEDICAL SERVICES PERSONNEL. 
4
(a) IN GENERAL.—The Administrator of the United 
5
States Fire Administration, in consultation with the Sec-
6
retary of Health and Human Services, shall develop and 
7
make publicly available resources that may be used by the 
8
Federal Government and other entities to educate mental 
9
health professionals about— 
10
(1) the culture of Federal, State, Tribal, and 
11
local career, volunteer, and combination fire depart-
12
ments and emergency medical services agencies; 
13
(2) the different stressors experienced by fire-
14
fighters and emergency medical services personnel, 
15
supervisory firefighters and emergency medical serv-
16
ices personnel, and chief officers of fire departments 
17
and emergency medical services agencies; 
18
(3) challenges encountered by retired fire-
19
fighters and emergency medical services personnel; 
20
and 
21
(4) evidence-based therapies for mental health 
22
issues common to firefighters and emergency med-
23
ical services personnel within such departments and 
24
agencies. 
25
19:08 Nov 24, 2020
H14
242 
•HR 14 IH
(b) CONSULTATION.—In developing resources under 
1
subsection (a), the Administrator of the United States 
2
Fire Administration and the Secretary of Health and 
3
Human Services shall consult with national fire and emer-
4
gency medical services organizations. 
5
(c) DEFINITIONS.—In this section: 
6
(1) The term ‘‘firefighter’’ means any employee, 
7
regardless of rank or whether the employee receives 
8
compensation, of a Federal, State, Tribal, or local 
9
fire department who is responsible for responding to 
10
calls for emergency service. 
11
(2) The term ‘‘emergency medical services per-
12
sonnel’’ means any employee, regardless of rank or 
13
whether the employee receives compensation, as de-
14
fined in section 1204(7) of the Omnibus Crime Con-
15
trol and Safe Streets Act of 1968 (34 U.S.C. 
16
10284(7)). 
17
(3) The term ‘‘chief officer’’ means any indi-
18
vidual who is responsible for the overall operation of 
19
a fire department or an emergency medical services 
20
agency, irrespective of whether such individual also 
21
serves as a firefighter or emergency medical services 
22
personnel. 
23
19:08 Nov 24, 2020
H14
243 
•HR 14 IH
SEC. 6065. BEST PRACTICES AND OTHER RESOURCES FOR 
1
ADDRESSING POSTTRAUMATIC STRESS DIS-
2
ORDER IN PUBLIC SAFETY OFFICERS. 
3
(a) DEVELOPMENT; UPDATES.—The Secretary of 
4
Health and Human Services shall— 
5
(1) develop and assemble evidence-based best 
6
practices and other resources to identify, prevent, 
7
and treat posttraumatic stress disorder and co-oc-
8
curring disorders in public safety officers; and 
9
(2) reassess and update, as the Secretary deter-
10
mines necessary, such best practices and resources, 
11
including based upon the options for interventions to 
12
reduce suicide among public safety officers identified 
13
in 
the 
annual 
reports 
required 
by 
section 
14
317W(e)(1)(F) of the Public Health Service Act, as 
15
added by section 6061 of this subtitle. 
16
(b) CONSULTATION.—In developing, assembling, and 
17
updating the best practices and resources under sub-
18
section (a), the Secretary of Health and Human Services 
19
shall consult with, at a minimum, the following: 
20
(1) Public health experts. 
21
(2) Mental health experts with experience in 
22
studying suicide and other profession-related trau-
23
matic stress. 
24
(3) Clinicians with experience in diagnosing and 
25
treating mental health issues. 
26
19:08 Nov 24, 2020
H14
244 
•HR 14 IH
(4) Relevant national police, fire, and emer-
1
gency medical services organizations. 
2
(c) AVAILABILITY.—The Secretary of Health and 
3
Human Services shall make the best practices and re-
4
sources under subsection (a) available to Federal, State, 
5
and local fire, law enforcement, and emergency medical 
6
services agencies. 
7
(d) FEDERAL TRAINING AND DEVELOPMENT PRO-
8
GRAMS.—The Secretary of Health and Human Services 
9
shall work with Federal departments and agencies, includ-
10
ing the United States Fire Administration, to incorporate 
11
education and training on the best practices and resources 
12
under subsection (a) into Federal training and develop-
13
ment programs for public safety officers. 
14
(e) DEFINITION.—In this section, the term ‘‘public 
15
safety officer’’ means— 
16
(1) a public safety officer as defined in section 
17
1204 of the Omnibus Crime Control and Safe 
18
Streets Act of 1968 (34 U.S.C. 10284); or 
19
(2) a public safety telecommunicator as de-
20
scribed in detailed occupation 43–5031 in the Stand-
21
ard Occupational Classification Manual of the Office 
22
of Management and Budget (2018). 
23
19:08 Nov 24, 2020
H14
245 
•HR 14 IH
Subtitle H—Behavioral Health 
1
Intervention Guidelines 
2
SEC. 6071. BEST PRACTICES FOR BEHAVIORAL INTERVEN-
3
TION TEAMS. 
4
The Public Health Service Act is amended by insert-
5
ing after section 520G of such Act (42 U.S.C. 290bb–38) 
6
the following new section: 
7
‘‘SEC. 520H. BEST PRACTICES FOR BEHAVIORAL INTERVEN-
8
TION TEAMS. 
9
‘‘(a) IN GENERAL.—The Secretary, acting through 
10
the Assistant Secretary, shall develop and periodically up-
11
date— 
12
‘‘(1) best practices to assist elementary schools, 
13
secondary schools, and institutions of higher edu-
14
cation in establishing and using behavioral interven-
15
tion teams; and 
16
‘‘(2) a list of evidence-based threat assessment 
17
training providers to assist personnel in elementary 
18
schools, secondary schools, and institutions of higher 
19
education in implementing such best practices, in-
20
cluding with respect to training behavioral interven-
21
tion teams. 
22
‘‘(b) ELEMENTS.—The best practices under sub-
23
section (a)(1) shall include guidance on the following: 
24
19:08 Nov 24, 2020
H14
246 
•HR 14 IH
‘‘(1) How behavioral intervention teams can op-
1
erate effectively from an evidence-based, objective 
2
perspective while protecting the constitutional and 
3
civil rights of individuals, including any individual of 
4
concern. 
5
‘‘(2) The use of behavioral intervention teams 
6
to identify individuals of concern, implement inter-
7
ventions, and manage risk through the framework of 
8
the school’s or institution’s rules or code of conduct, 
9
as applicable. 
10
‘‘(3) How behavioral intervention teams can, 
11
when assessing an individual of concern— 
12
‘‘(A) seek training on evidence-based, 
13
threat-assessment rubrics; 
14
‘‘(B) ensure that such teams— 
15
‘‘(i) have adequately trained, diverse 
16
stakeholders with varied expertise; and 
17
‘‘(ii) use cross validation by a wide- 
18
range of individual perspectives on the 
19
team; and 
20
‘‘(C) use violence risk assessment. 
21
‘‘(4) How behavioral intervention teams can 
22
avoid— 
23
‘‘(A) attempting to predict future behavior 
24
by the concept of pre-crime; 
25
19:08 Nov 24, 2020
H14
247 
•HR 14 IH
‘‘(B) inappropriately using a mental health 
1
assessment; 
2
‘‘(C) inappropriately limiting or restricting 
3
law enforcement’s jurisdiction over criminal 
4
matters; 
5
‘‘(D) attempting to substitute the behav-
6
ioral intervention process in place of a criminal 
7
process, or impede a criminal process, when an 
8
individual of concern’s behavior has potential 
9
criminal implications; 
10
‘‘(E) endangering an individual’s privacy 
11
by failing to ensure that all applicable Federal 
12
and State privacy laws are fully complied with; 
13
or 
14
‘‘(F) creating school-to-prison pipelines. 
15
‘‘(c) CONSULTATION.—In carrying out subsection 
16
(a)(1), the Secretary shall consult with— 
17
‘‘(1) the Secretary of Education; 
18
‘‘(2) the Director of the National Threat As-
19
sessment Center of the Department of Homeland 
20
Security; 
21
‘‘(3) the Attorney General of the United States; 
22
and 
23
‘‘(4) as appropriate, relevant stakeholders in-
24
cluding— 
25
19:08 Nov 24, 2020
H14
248 
•HR 14 IH
‘‘(A) teachers and other educators, prin-
1
cipals, school administrators, school board 
2
members, school psychologists, mental health 
3
professionals, and parents of elementary school 
4
and secondary school students; 
5
‘‘(B) local law enforcement agencies and 
6
campus law enforcement administrators; 
7
‘‘(C) mental health mobile crisis providers; 
8
‘‘(D) child and adolescent psychiatrists; 
9
and 
10
‘‘(E) other education and mental health 
11
professionals. 
12
‘‘(d) PUBLICATION.—Not later than 2 years after the 
13
date of enactment of this section, the Secretary shall pub-
14
lish the best practices under subsection (a)(1) and the list 
15
under subsection (a)(2) on a publicly accessible website 
16
of the Department of Health and Human Services. 
17
‘‘(e) TECHNICAL ASSISTANCE.—The Secretary shall 
18
provide technical assistance to institutions of higher edu-
19
cation, elementary schools, and secondary schools to assist 
20
such institutions and schools in implementing the best 
21
practices under subsection (a). 
22
‘‘(f) DEFINITIONS.—In this section: 
23
‘‘(1) The term ‘behavioral intervention team’ 
24
means a team of qualified individuals who— 
25
19:08 Nov 24, 2020
H14
249 
•HR 14 IH
‘‘(A) are responsible for identifying and as-
1
sessing individuals of concern; and 
2
‘‘(B) develop and facilitate implementation 
3
of evidence-based interventions to mitigate the 
4
threat of harm to self or others posed by indi-
5
viduals of concern and address the mental and 
6
behavioral health needs of individuals of con-
7
cern to reduce such threat. 
8
‘‘(2) The terms ‘elementary school’, ‘parent’, 
9
and ‘secondary school’ have the meanings given to 
10
such terms in section 8101 of the Elementary and 
11
Secondary Education Act of 1965 (20 U.S.C. 7801). 
12
‘‘(3) The term ‘individual of concern’ means an 
13
individual whose behavior indicates a potential 
14
threat to self or others. 
15
‘‘(4) The term ‘institution of higher education’ 
16
has the meaning given to such term in section 102 
17
of the Higher Education Act of 1965 (20 U.S.C. 
18
1002). 
19
‘‘(5) The term ‘mental health assessment’ 
20
means an evaluation, primarily focused on diagnosis, 
21
determining the need for involuntary commitment, 
22
medication management, and on-going treatment 
23
recommendations. 
24
19:08 Nov 24, 2020
H14
250 
•HR 14 IH
‘‘(6) The term ‘pre-crime’ means law-enforce-
1
ment efforts and strategies to deter crime by pre-
2
dicting when and where criminal activity will occur. 
3
‘‘(7) The term ‘violence risk assessment’ refers 
4
to a broad determination of the potential risk of vio-
5
lence based on evidence-based literature.’’. 
6
Subtitle I—Suicide Training and 
7
Awareness Nationally Delivered 
8
for Universal Prevention 
9
SEC. 6081. STUDENT SUICIDE AWARENESS AND PREVEN-
10
TION TRAINING. 
11
(a) IN GENERAL.—Title V of the Public Health Serv-
12
ice Act is amended by inserting after section 520A of such 
13
Act (42 U.S.C. 290bb–32) the following: 
14
‘‘SEC. 520B. STUDENT SUICIDE AWARENESS AND PREVEN-
15
TION TRAINING POLICIES. 
16
‘‘(a) IN GENERAL.—As a condition on receipt of 
17
funds under section 520A, each State educational agency, 
18
local educational agency, and Tribal educational agency 
19
that receives such funds, directly or through a State or 
20
Indian Tribe, for activities to be performed within sec-
21
ondary schools, including the Project AWARE State Edu-
22
cation Agency Grant Program, shall— 
23
19:08 Nov 24, 2020
H14
251 
•HR 14 IH
‘‘(1) establish and implement a school-based 
1
student suicide awareness and prevention training 
2
policy; 
3
‘‘(2) consult with stakeholders (including prin-
4
cipals, teachers, parents, local Tribal officials, and 
5
other school leaders) in the development of the pol-
6
icy under subsection (a)(1); and 
7
‘‘(3) collect and report information in accord-
8
ance with subsection (c). 
9
‘‘(b) SCHOOL-BASED STUDENT SUICIDE AWARENESS 
10
AND PREVENTION TRAINING POLICY.—A school-based 
11
student suicide awareness and prevention training policy 
12
implemented pursuant to subsection (a)— 
13
‘‘(1) shall be evidence-based; 
14
‘‘(2) shall be culturally and linguistically appro-
15
priate; 
16
‘‘(3) shall provide evidence-based training to 
17
students in grades 6 through 12, in coordination 
18
with school-based mental health service providers as 
19
defined in section 4102(6) of the Elementary and 
20
Secondary Education Act of 1965, if applicable, re-
21
garding— 
22
‘‘(A) suicide education and awareness, in-
23
cluding warning signs of self-harm or suicidal 
24
ideation; 
25
19:08 Nov 24, 2020
H14
252 
•HR 14 IH
‘‘(B) methods that students can use to 
1
seek help for themselves and others; and 
2
‘‘(C) student resources for suicide aware-
3
ness and prevention; 
4
‘‘(4) shall provide for retraining of such stu-
5
dents every school year; 
6
‘‘(5) may last for such period as the State edu-
7
cational agency, local educational agency, or Tribal 
8
educational agency involved determines to be appro-
9
priate; 
10
‘‘(6) may be implemented through any delivery 
11
method, 
including 
in-person 
trainings, 
digital 
12
trainings, or train-the-trainer models; and 
13
‘‘(7) may include discussion of comorbidities or 
14
risk factors for suicidal ideation or self-harm, includ-
15
ing substance misuse, sexual or physical abuse, men-
16
tal illness, or other evidence-based comorbidities and 
17
risk factors. 
18
‘‘(c) COLLECTION OF INFORMATION AND REPORT-
19
ING.—Each State educational agency, local educational 
20
agency, and Tribal educational agency that receives funds 
21
under section 520A shall, with respect to each school 
22
served by the agency, collect and report to the Secretary 
23
the following information: 
24
19:08 Nov 24, 2020
H14
253 
•HR 14 IH
‘‘(1) The number of student trainings con-
1
ducted. 
2
‘‘(2) 
The 
number 
of 
students 
trained, 
3
disaggregated by age and grade level. 
4
‘‘(3) The number of help-seeking reports made 
5
by students after implementation of such policy. 
6
‘‘(d) EVIDENCE-BASED
PROGRAM
LISTING.—The 
7
Secretary of Health and Human Services shall coordinate 
8
with the Secretary of Education to make publicly available 
9
the policies established by State educational agencies, local 
10
educational agencies, and Tribal educational agencies pur-
11
suant to this section and the training that is available to 
12
students and teams pursuant to such policies, including 
13
identification of whether such training is available to 
14
trainees at no cost. 
15
‘‘(e) IMPLEMENTATION TIMELINE.—A State edu-
16
cational agency, local educational agency, or Tribal edu-
17
cational agency shall establish and begin implementation 
18
of the policies required by subsection (a)(1) not later than 
19
the beginning of the third fiscal year following the date 
20
of enactment of this section for which the agency receives 
21
funds under section 520A. 
22
‘‘(f) DEFINITIONS.—In this section and section 
23
520B–1: 
24
19:08 Nov 24, 2020
H14
254 
•HR 14 IH
‘‘(1) The term ‘evidence-based’ has the meaning 
1
given to such term in section 8101 of the Elemen-
2
tary and Secondary Education Act of 1965. 
3
‘‘(2) The term ‘local educational agency’ has 
4
the meaning given to such term in section 8101 of 
5
the Elementary and Secondary Education Act of 
6
1965. 
7
‘‘(3) The term ‘State educational agency’ has 
8
the meaning given to such term in section 8101 of 
9
the Elementary and Secondary Education Act of 
10
1965. 
11
‘‘(4) The term ‘Tribal educational agency’ has 
12
the meaning given to the term ‘tribal educational 
13
agency’ in section 6132 of the Elementary and Sec-
14
ondary Education Act of 1965. 
15
‘‘SEC. 520B–1. BEST PRACTICES FOR STUDENT SUICIDE 
16
AWARENESS AND PREVENTION TRAINING. 
17
‘‘The Secretary of Health and Human Services, in 
18
consultation with the Secretary of Education and the Bu-
19
reau of Indian Education, shall— 
20
‘‘(1) publish best practices for school-based stu-
21
dent suicide awareness and prevention training, pur-
22
suant to section 520B, that are based on— 
23
‘‘(A) evidence-based practices; and 
24
19:08 Nov 24, 2020
H14
255 
•HR 14 IH
‘‘(B) input from relevant Federal agencies, 
1
national organizations, Indian Tribes and Trib-
2
al organizations, and related stakeholders; 
3
‘‘(2) publish guidance, based on the best prac-
4
tices under paragraph (1), to provide State edu-
5
cational agencies, local educational agencies, and 
6
Tribal educational agencies with information on stu-
7
dent suicide awareness and prevention best prac-
8
tices; 
9
‘‘(3) disseminate such best practices to State 
10
educational agencies, local educational agencies, and 
11
Tribal educational agencies; and 
12
‘‘(4) provide technical assistance to State edu-
13
cational agencies, local educational agencies, and 
14
Tribal educational agencies.’’. 
15
SEC. 6082. EFFECTIVE DATE. 
16
The amendments made by this subtitle shall only 
17
apply with respect to applications for assistance under sec-
18
tion 520A of the Public Health Service Act (42 U.S.C. 
19
290bb–32) that are submitted after the date of enactment 
20
of this Act. 
21
19:08 Nov 24, 2020
H14
256 
•HR 14 IH
TITLE VII—ADDRESSING THE IM-
1
PACTS OF COVID–19 ON SUB-
2
STANCE USE DISORDERS 
3
Subtitle A—Easy Medication Ac-
4
cess and Treatment for Opioid 
5
Addiction 
6
SEC. 7001. DISPENSATION OF NARCOTIC DRUGS FOR THE 
7
PURPOSE 
OF 
RELIEVING 
ACUTE 
WITH-
8
DRAWAL SYMPTOMS FROM OPIOID USE DIS-
9
ORDER. 
10
Not later than 180 days after the date of enactment 
11
of this Act, the Attorney General shall revise section 
12
1306.07(b) of title 21, Code of Federal Regulations, so 
13
that practitioners, in accordance with applicable State, 
14
Federal, or local laws relating to controlled substances, are 
15
allowed to dispense not more than a three-day supply of 
16
narcotic drugs to one person or for one person’s use at 
17
one time for the purpose of initiating maintenance treat-
18
ment or detoxification treatment (or both). 
19
Subtitle B—Access to Remote 
20
Behavioral Health Treatment 
21
SEC. 7011. REGISTRATION OF QUALIFIED COMMUNITY 
22
MENTAL HEALTH CENTERS. 
23
(a) DEFINITIONS.—Section 102 of the Controlled 
24
Substances Act (21 U.S.C. 802) is amended— 
25
19:08 Nov 24, 2020
H14
257 
•HR 14 IH
(1) by striking paragraph (54)(A)(i) and insert-
1
ing the following: 
2
‘‘(i) while the patient is being treated by, 
3
and physically located in— 
4
‘‘(I) a hospital or clinic registered 
5
under section 303(f); or 
6
‘‘(II) a qualified community mental 
7
health center registered under section 
8
303(l); and’’; 
9
(2) by redesignating paragraph (58) as para-
10
graph (59); 
11
(3) by redesignating the second paragraph (57) 
12
(as added by section 401(a) of the First Step Act 
13
of 2018 (Public Law 115–391)) as paragraph (58); 
14
and 
15
(4) by adding at the end the following: 
16
‘‘(60) The term ‘qualified community mental health 
17
center’ means a facility that— 
18
‘‘(A)(i) meets the criteria specified in section 
19
1913(c) of the Public Health Service Act to be con-
20
sidered a community mental health center; or 
21
‘‘(ii) meets the criteria specified pursuant to 
22
section 223 of the Protecting Access to Medicare Act 
23
of 2014 to be considered a certified community be-
24
havioral health clinic; and 
25
19:08 Nov 24, 2020
H14
258 
•HR 14 IH
‘‘(B) is licensed, operated, authorized, certified, 
1
or otherwise recognized by a State government.’’. 
2
(b) REGISTRATION.—Section 303 of the Controlled 
3
Substances Act (21 U.S.C. 823) is amended by adding at 
4
the end the following: 
5
‘‘(l) QUALIFIED COMMUNITY MENTAL HEALTH CEN-
6
TERS.— 
7
‘‘(1) REGISTRATION.—The Attorney General 
8
shall register qualified community mental health 
9
centers to administer controlled substances through 
10
the practice of telemedicine. 
11
‘‘(2) DENIAL OF APPLICATIONS.—The Attorney 
12
General may deny an application for registration 
13
under paragraph (1) if the Attorney General deter-
14
mines that the registration would be inconsistent 
15
with the public interest after considering— 
16
‘‘(A) any recommendation by the licensing 
17
board or professional disciplinary authority of 
18
the State in which the applicant is located; 
19
‘‘(B) the experience of the applicant in 
20
treating patients; 
21
‘‘(C) any conviction of an employee of the 
22
applicant under Federal or State law relating to 
23
treatment of patients; 
24
19:08 Nov 24, 2020
H14
259 
•HR 14 IH
‘‘(D) the compliance of the applicant with 
1
applicable Federal, State, or local laws relating 
2
to treatment of patients; and 
3
‘‘(E) any other conduct by the applicant 
4
that may threaten the public’s health and safe-
5
ty.’’. 
6
(c) REPORT TO CONGRESS.—Not later than 60 days 
7
after the date of enactment of this Act, the Attorney Gen-
8
eral of the United States shall submit to the Congress a 
9
plan for implementation of the amendments made by sub-
10
sections (a) and (b). 
11
(d) DELAYED
APPLICABILITY.—The amendments 
12
made by subsections (a) and (b) apply beginning on the 
13
date that is 120 days after the date of enactment of this 
14
Act. 
15
Subtitle C—PDMP Pilot Program 
16
SEC. 7021. PILOT PROGRAM FOR INTEGRATING SUBSTANCE 
17
USE DISORDER AND BEHAVIORAL HEALTH 
18
TREATMENT LOCATOR TOOL INTO STATE 
19
PRESCRIPTION 
DRUG 
MONITORING 
PRO-
20
GRAMS. 
21
(a) IN GENERAL.—The Secretary of Health and 
22
Human Services, in consultation with the Assistant Sec-
23
retary for Mental Health and Substance Use, shall estab-
24
lish and implement a pilot program in which the Secretary 
25
19:08 Nov 24, 2020
H14
260 
•HR 14 IH
awards grants to, or enters into cooperative agreements 
1
with, not more than 5 eligible States to test the feasibility 
2
and outcomes of integrating a substance use disorder and 
3
behavioral health treatment locator tool into the State’s 
4
prescription drug monitoring program. 
5
(b) GRANT ESTABLISHMENT AND PARTICIPATION.— 
6
(1) IN
GENERAL.—In carrying out the pilot 
7
program under this section, the Secretary shall, on 
8
a competitive basis, award grants to, or enter into 
9
cooperative agreements with, not more than 5 eligi-
10
ble States. 
11
(2) ELIGIBILITY.—To be eligible for a grant 
12
under this section, a State shall demonstrate to the 
13
Secretary’s satisfaction that the State is making 
14
progress in integrating the State’s PDMP with elec-
15
tronic health records and health information tech-
16
nology infrastructure. 
17
(3) PREFERENCE.—In awarding grants under 
18
this section, the Secretary shall give preference to el-
19
igible States described in paragraph (2) whose rates 
20
of death due to drug overdose per population of 
21
100,000 are in the top quartile according to the 
22
most recent data of the Centers for Disease Control 
23
and Prevention. 
24
19:08 Nov 24, 2020
H14
261 
•HR 14 IH
(c) PERIOD OF GRANT.—A grant awarded to an eligi-
1
ble entity under this section shall be for a period of 2 
2
years. 
3
(d) GRANT USES.— 
4
(1) REQUIRED USES.—A grant awarded under 
5
this section to an eligible State shall be used for 
6
both of the following purposes: 
7
(A) To integrate a substance use disorder 
8
and behavioral health treatment locator tool 
9
into the PDMP. 
10
(B) To develop and disseminate guidance 
11
for health care providers on how to consult and 
12
share information obtained through the sub-
13
stance use disorder and behavioral health treat-
14
ment locator tool when a patient’s PDMP infor-
15
mation indicates possible misuse of a controlled 
16
substance. 
17
(2) ADDITIONAL PERMISSIBLE USES.—A grant 
18
awarded under this section to an eligible State may 
19
be used for any of the following additional purposes: 
20
(A) To integrate a substance use disorder 
21
and behavioral health treatment locator tool 
22
into the PDMP that incorporates direct referral 
23
capabilities that enable the health care pro-
24
vider— 
25
19:08 Nov 24, 2020
H14
262 
•HR 14 IH
(i) to refer a patient to treatment or 
1
for an assessment; and 
2
(ii) consistent with the protection of 
3
information by Federal and State privacy 
4
laws and security rules, receive feedback 
5
about the patient’s engagement with such 
6
treatment or assessment. 
7
(B) To integrate a substance use disorder 
8
and behavioral health treatment locator tool 
9
into the PDMP that provides information re-
10
garding the current capacity of inpatient or 
11
outpatient treatment resources of a health care 
12
provider. 
13
(e) REPORTING REQUIREMENTS.— 
14
(1) REPORTS BY STATES.—Each eligible State 
15
that participates in the pilot program under this sec-
16
tion shall submit to the Secretary an annual report 
17
for each year of the pilot program that includes in-
18
formation on— 
19
(A) the number of health care providers 
20
and health facilities with access to the sub-
21
stance use disorder and behavioral health treat-
22
ment locator tool; 
23
19:08 Nov 24, 2020
H14
263 
•HR 14 IH
(B) the number of individuals referred to 
1
treatment with the assistance of the locator 
2
tool; 
3
(C) aggregate, de-identified patient data 
4
related to the type of treatment located by the 
5
locator tool, how often patients followed 
6
through on seeking such treatment, and the av-
7
erage duration of such treatment, to the extent 
8
collected by the State; 
9
(D) feedback from providers with access to 
10
the locator tool on usability and any impact on 
11
outcomes; 
12
(E) recommendations to improve the 
13
usability and efficacy of a substance use dis-
14
order and behavioral health treatment locator 
15
tool within the PDMP; and 
16
(F) additional information and reporting 
17
metrics as determined by the Secretary. 
18
(2) REPORT
BY
SECRETARY.—Not less than 
19
180 days after the conclusion of the pilot program 
20
under this section, the Secretary shall submit to the 
21
Congress a report on the findings of the program, 
22
including— 
23
(A) outcomes reported by the participating 
24
States; 
25
19:08 Nov 24, 2020
H14
264 
•HR 14 IH
(B) findings on the suitability of including 
1
a substance use disorder and behavioral health 
2
treatment locator tool within State PDMPs; 
3
and 
4
(C) recommendations on best practices for 
5
integrating a substance use disorder and behav-
6
ioral health treatment locator tool within State 
7
PDMPs. 
8
(f) DEFINITIONS.—In this section: 
9
(1) The term ‘‘prescription drug monitoring 
10
program’’ or ‘‘PDMP’’ has the meaning given to the 
11
term ‘‘PDMP’’ in section 399O of the Public Health 
12
Service Act (42 U.S.C. 280g–3). 
13
(2) The term ‘‘Secretary’’ means the Secretary 
14
of Health and Human Services. 
15
(g) AUTHORIZATION OF APPROPRIATIONS.—To carry 
16
out this section, there are authorized to be appropriated 
17
$2,500,000 for each of fiscal years 2021 and 2022. 
18
19:08 Nov 24, 2020
H14
265 
•HR 14 IH
Subtitle D—Family Support 
1
Services for Addiction 
2
SEC. 7031. FAMILY SUPPORT SERVICES FOR INDIVIDUALS 
3
STRUGGLING WITH SUBSTANCE USE DIS-
4
ORDER. 
5
Part D of title V of the Public Health Service Act 
6
(42 U.S.C. 290dd et seq.) is amended by adding at the 
7
end the following: 
8
‘‘SEC. 553. FAMILY SUPPORT SERVICES FOR INDIVIDUALS 
9
STRUGGLING WITH SUBSTANCE USE DIS-
10
ORDER. 
11
‘‘(a) DEFINITIONS.—In this section— 
12
‘‘(1) the term ‘family community organization’ 
13
means an independent nonprofit organization that— 
14
‘‘(A) mobilizes resources within and out-
15
side of the community of families with individ-
16
uals living with addiction, to provide a support 
17
network, education, and evidence-informed tools 
18
for families and loved ones of individuals strug-
19
gling with substance use disorders; and 
20
‘‘(B) is governed by experts in the field of 
21
addiction, which may include— 
22
‘‘(i) 
experts 
in 
evidence-informed 
23
interventions for family members; 
24
19:08 Nov 24, 2020
H14
266 
•HR 14 IH
‘‘(ii) experts in the impact of addic-
1
tion on family systems; 
2
‘‘(iii) families who have experience 
3
with substance use disorders and addiction; 
4
and 
5
‘‘(iv) other experts in the field of ad-
6
diction; and 
7
‘‘(2) the term ‘family support services’ means 
8
resources or programs that support families that in-
9
clude an individual with substance use disorder. 
10
‘‘(b) GRANTS AUTHORIZED.—The Secretary shall 
11
award grants to family community organizations to enable 
12
such organizations to develop, expand, and enhance evi-
13
dence-informed family support services. 
14
‘‘(c) FEDERAL SHARE.—The Federal share of the 
15
costs of a program funded by a grant under this section 
16
may not exceed 85 percent. 
17
‘‘(d) USE OF FUNDS.—Grants awarded under sub-
18
section (b)— 
19
‘‘(1) shall be used to develop, expand, and en-
20
hance community and statewide evidence-informed 
21
family support services; and 
22
‘‘(2) may be used to— 
23
‘‘(A) build connections between family sup-
24
port networks, including providing technical as-
25
19:08 Nov 24, 2020
H14
267 
•HR 14 IH
sistance between family community organiza-
1
tions and peer support networks, and with 
2
other family support services, focused on en-
3
hancing knowledge of evidence-informed inter-
4
ventions for family members and loved ones of 
5
individuals living with substance use disorders 
6
and reducing harm by educating service pro-
7
viders on current evidence regarding addiction 
8
and the family, including— 
9
‘‘(i) behavioral health providers, in-
10
cluding such providers focused specifically 
11
on family and couples therapy in the con-
12
text of addiction; 
13
‘‘(ii) primary care providers; 
14
‘‘(iii) providers of foster care services 
15
or support services for grandparents, 
16
guardians, and other extended family im-
17
pacted by addiction; and 
18
‘‘(iv) other family support services 
19
that connect to community resources for 
20
individuals with substance use disorders, 
21
including non-clinical community services; 
22
‘‘(B) reduce stigma associated with the 
23
family of individuals with substance use dis-
24
orders by improving knowledge about addiction 
25
19:08 Nov 24, 2020
H14
268 
•HR 14 IH
and its treatment, providing compassionate sup-
1
port, and dispelling myths that perpetuate such 
2
stigma; 
3
‘‘(C) conduct outreach on issues relating to 
4
substance use disorders and family support, 
5
which may include education, training, and re-
6
sources with respect to— 
7
‘‘(i) 
building 
a 
resilience- 
and 
8
strengths-based approach to prevention of, 
9
and living with, addiction in the family; 
10
‘‘(ii) identifying the signs of substance 
11
use disorder; 
12
‘‘(iii) adopting an approach that mini-
13
mizes harm to all family members; and 
14
‘‘(iv) families of individuals with a 
15
substance use disorder, including with re-
16
spect to— 
17
‘‘(I) navigating the treatment 
18
and recovery systems; 
19
‘‘(II) paying for addiction treat-
20
ment; 
21
‘‘(III) education about substance 
22
use disorder; and 
23
‘‘(IV) avoiding predatory treat-
24
ment programs; and 
25
19:08 Nov 24, 2020
H14
269 
•HR 14 IH
‘‘(D) connect families to evidence-informed 
1
peer support programs. 
2
‘‘(e) DATA
REPORTING
AND
PROGRAM
OVER-
3
SIGHT.—With respect to a grant awarded under sub-
4
section (a), not later than 90 days after the end of the 
5
first year of the grant period, and annually thereafter for 
6
the duration of the grant period, the entity shall submit 
7
data, as appropriate and to the extent practicable, to the 
8
Secretary regarding— 
9
‘‘(1) the programs and activities funded by the 
10
grant; 
11
‘‘(2) health outcomes of the population of indi-
12
viduals with a substance use disorder who received 
13
services through programs supported by the grant, 
14
as evaluated by an independent program evaluator 
15
through the use of outcomes measures, as deter-
16
mined by the Secretary; and 
17
‘‘(3) any other information that the secretary 
18
may require for the purpose of ensuring that the 
19
grant recipient is complying with all the require-
20
ments of the grant. 
21
‘‘(f) AUTHORIZATION OF APPROPRIATIONS.—There 
22
is authorized to be appropriated to carry out this section 
23
$5,000,000 for each of fiscal years 2021 through 2025.’’. 
24
19:08 Nov 24, 2020
H14
270 
•HR 14 IH
Subtitle E—Block, Report, And 
1
Suspend Suspicious Shipments 
2
SEC. 7041. CLARIFICATION OF PROCESS FOR REGISTRANTS 
3
TO EXERCISE DUE DILIGENCE UPON DISCOV-
4
ERING A SUSPICIOUS ORDER. 
5
(a) IN GENERAL.—Paragraph (3) of section 312(a) 
6
of the Controlled Substances Act (21 U.S.C. 832(a)) is 
7
amended to read as follows: 
8
‘‘(3) upon discovering a suspicious order or se-
9
ries of orders— 
10
‘‘(A) exercise due diligence; 
11
‘‘(B) establish and maintain (for not less 
12
than a period to be determined by the Adminis-
13
trator of the Drug Enforcement Administra-
14
tion) a record of the due diligence that was per-
15
formed; 
16
‘‘(C) decline to fill the order or series of 
17
orders if the due diligence fails to resolve all of 
18
the indicators that gave rise to the suspicion 
19
that filling the order or series of orders would 
20
cause a violation of this title by the registrant 
21
or the prospective purchaser; and 
22
‘‘(D) notify the Administrator of the Drug 
23
Enforcement Administration and the Special 
24
Agent in Charge of the Division Office of the 
25
19:08 Nov 24, 2020
H14
271 
•HR 14 IH
Drug Enforcement Administration for the area 
1
in which the registrant is located or conducts 
2
business of— 
3
‘‘(i) each suspicious order or series of 
4
orders discovered by the registrant; and 
5
‘‘(ii) the indicators giving rise to the 
6
suspicion that filling the order or series of 
7
orders would cause a violation of this title 
8
by the registrant or the prospective pur-
9
chaser.’’. 
10
(b) APPLICABILITY.—Section 312(a)(3) of the Con-
11
trolled Substances Act, as amended by subsection (a), 
12
shall apply beginning on the day that is 6 months after 
13
the date of enactment of this Act. Until such day, section 
14
312(a)(3) of the Controlled Substances Act shall apply as 
15
such section 312(a)(3) was in effect on the day before the 
16
date of enactment of this Act. 
17
(c) REGULATIONS.—The Attorney General shall, 
18
issue regulations specifying, for purposes of paragraph (3) 
19
of section 312(a) of the Controlled Substances Act, as 
20
added by subsection (a), the indicators that give rise to 
21
a suspicion that filling an order or series of orders would 
22
cause a violation of title III of the Controlled Substances 
23
Act (21 U.S.C. 801 et seq.) by a registrant or a prospec-
24
tive purchaser. 
25
19:08 Nov 24, 2020
H14
272 
•HR 14 IH
Subtitle 
F—Debarment 
Enforce-
1
ment of Bad Actor Registrants 
2
SEC. 7051. DEBARMENT OF CERTAIN REGISTRANTS. 
3
Section 304 of the Controlled Substances Act (21 
4
U.S.C. 824) is amended by adding at the end the fol-
5
lowing: 
6
‘‘(h) The Attorney General may issue an order to pro-
7
hibit, conditionally or unconditionally, and permanently or 
8
for such period as the Attorney General may determine, 
9
any person from being registered under this title to manu-
10
facture, distribute, or dispense a controlled substance or 
11
a list I chemical, if the Attorney General finds that— 
12
‘‘(1) such person meets or has met any of the 
13
conditions for suspension or revocation of registra-
14
tion under subsection (a); and 
15
‘‘(2) such person has a history of prior suspen-
16
sions or revocations of registration.’’. 
17
19:08 Nov 24, 2020
H14
273 
•HR 14 IH
Subtitle G—Ensuring Compliance 
1
Against Opioid Diversion 
2
SEC. 7061. MODIFICATION, TRANSFER, AND TERMINATION 
3
OF REGISTRATION TO MANUFACTURE, DIS-
4
TRIBUTE, OR DISPENSE CONTROLLED SUB-
5
STANCES. 
6
Subsection (a) of section 302 of the Controlled Sub-
7
stances Act (21 U.S.C. 822) is amended by adding at the 
8
end the following new paragraph: 
9
‘‘(3)(A) Except as provided in subparagraph (C), the 
10
registration of any registrant under this title to manufac-
11
ture, distribute, or dispense controlled substances or list 
12
I chemicals terminates if and when such registrant— 
13
‘‘(i) dies; 
14
‘‘(ii) ceases legal existence; 
15
‘‘(iii) discontinues business or professional prac-
16
tice; or 
17
‘‘(iv) surrenders such registration. 
18
‘‘(B) In the case of such a registrant who ceases legal 
19
existence or discontinues business or professional practice, 
20
such registrant shall promptly notify the Attorney General 
21
in writing of such fact. 
22
‘‘(C) No registration under this title to manufacture, 
23
distribute, or dispense controlled substances or list I 
24
chemicals, and no authority conferred thereby, may be as-
25
19:08 Nov 24, 2020
H14
274 
•HR 14 IH
signed or otherwise transferred except upon such condi-
1
tions as the Attorney General may specify and then only 
2
pursuant to written consent. A registrant to whom a reg-
3
istration is assigned or transferred pursuant to the pre-
4
ceding sentence may not manufacture, distribute, or dis-
5
pense controlled substances or list I chemicals pursuant 
6
to such registration until the Attorney General receives 
7
such written consent. 
8
‘‘(D) In the case of a registrant under this title to 
9
manufacture, distribute, or dispense controlled substances 
10
or list I chemicals desiring to discontinue business or pro-
11
fessional practice altogether or with respect to controlled 
12
substances and list I chemicals (without assigning or 
13
transferring such business or professional practice to an-
14
other entity), such registrant shall return to the Attorney 
15
General for cancellation— 
16
‘‘(i) the registrant’s certificate of registration; 
17
‘‘(ii) any unexecuted order forms in the reg-
18
istrant’s possession; and 
19
‘‘(iii) any other documentation that the Attor-
20
ney General may require.’’. 
21
19:08 Nov 24, 2020
H14
275 
•HR 14 IH
Subtitle H—Opioid Prescription 
1
Verification 
2
SEC. 7071. MATERIALS FOR TRAINING PHARMACISTS ON 
3
CERTAIN CIRCUMSTANCES UNDER WHICH A 
4
PHARMACIST MAY DECLINE TO FILL A PRE-
5
SCRIPTION. 
6
(a) UPDATES TO MATERIALS.—Section 3212(a) of 
7
the SUPPORT for Patients and Communities Act (Public 
8
Law 115–271) is amended by striking ‘‘Not later than 1 
9
year after the date of enactment of this Act, the Secretary 
10
of Health and Human Services, in consultation with the 
11
Administrator of the Drug Enforcement Administration, 
12
Commissioner of Food and Drugs, Director of the Centers 
13
for Disease Control and Prevention, and Assistant Sec-
14
retary for Mental Health and Substance Use, shall develop 
15
and disseminate’’ and inserting ‘‘The Secretary of Health 
16
and Human Services, in consultation with the Adminis-
17
trator of the Drug Enforcement Administration, Commis-
18
sioner of Food and Drugs, Director of the Centers for Dis-
19
ease Control and Prevention, and Assistant Secretary for 
20
Mental Health and Substance Use, shall develop and dis-
21
seminate not later than 1 year after the date of enactment 
22
of this Act, and update periodically thereafter’’. 
23
19:08 Nov 24, 2020
H14
276 
•HR 14 IH
(b) MATERIALS INCLUDED.—Section 3212(b) of the 
1
SUPPORT for Patients and Communities Act (Public 
2
Law 115–271) is amended— 
3
(1) by redesignating paragraphs (1) and (2) as 
4
paragraphs (2) and (3), respectively; and 
5
(2) by inserting before paragraph (2), as so re-
6
designated, the following new paragraph: 
7
‘‘(1) pharmacists on how to verify the identity 
8
of individuals picking up prescriptions;’’. 
9
(c) MATERIALS FOR TRAINING ON VERIFICATION OF 
10
IDENTITY.—Section 3212 of the SUPPORT for Patients 
11
and Communities Act (Public Law 115–271) is amended 
12
by adding at the end the following new subsection: 
13
‘‘(d) MATERIALS FOR TRAINING ON VERIFICATION 
14
OF IDENTITY OF INDIVIDUALS PICKING UP PRESCRIBED 
15
MEDICATIONS.—Not later than 6 months after the date 
16
of enactment of this subsection, the Secretary of Health 
17
and Human Services, after seeking stakeholder input in 
18
accordance with subsection (c), shall— 
19
‘‘(1) update the materials developed under sub-
20
section (a) to include information for pharmacists on 
21
how to verify the identity of individuals picking up 
22
prescribed medications; and 
23
‘‘(2) disseminate, as appropriate, the updated 
24
materials.’’. 
25
19:08 Nov 24, 2020
H14
277 
•HR 14 IH
SEC. 7072. INCENTIVIZING STATES TO FACILITATE RESPON-
1
SIBLE, 
INFORMED 
DISPENSING 
OF 
CON-
2
TROLLED SUBSTANCES. 
3
(a) IN GENERAL.—Section 392A of the Public 
4
Health Service Act (42 U.S.C. 280b–1) is amended— 
5
(1) by redesignating subsections (c) and (d) as 
6
subsections (d) and (e), respectively; and 
7
(2) by inserting after subsection (b) the fol-
8
lowing new subsection: 
9
‘‘(c) PREFERENCE.—In determining the amounts of 
10
grants awarded to States under subsections (a) and (b), 
11
the Director of the Centers for Disease Control and Pre-
12
vention may give preference to States in accordance with 
13
such criteria as the Director may specify and may choose 
14
to give preference to States that— 
15
‘‘(1) maintain a prescription drug monitoring 
16
program; 
17
‘‘(2) require dispensers of controlled substances 
18
in schedule II, III, or IV to verify the identity of the 
19
person who picks up a prescribed medication by re-
20
quiring such person to present a photo identification 
21
card that is valid as determined by the respective 
22
State; and 
23
‘‘(3) require dispensers of such controlled sub-
24
stances to enter certain information about the pur-
25
chase of such controlled substances into the respec-
26
19:08 Nov 24, 2020
H14
278 
•HR 14 IH
tive State’s prescription drug monitoring program, 
1
including— 
2
‘‘(A) the National Drug Code or, in the 
3
case of compounded medications, compound 
4
identifier; 
5
‘‘(B) the quantity dispensed; 
6
‘‘(C) the name of the patient; 
7
‘‘(D) the name of the ultimate user; 
8
‘‘(E) the name of the person who picks up 
9
the controlled substance, if different from the 
10
patient and ultimate user; and 
11
‘‘(F) the date filled.’’. 
12
(b) DEFINITIONS.—Subsection (d) of section 392A of 
13
the Public Health Service Act (42 U.S.C. 280b–1), as re-
14
designated by subsection (a)(1), is amended to read as fol-
15
lows: 
16
‘‘(d) DEFINITIONS.—In this section: 
17
‘‘(1) CONTROLLED
SUBSTANCE.—The term 
18
‘controlled substance’ has the meaning given that 
19
term in section 102 of the Controlled Substances. 
20
‘‘(2) DISPENSER.—The term ‘dispenser’ means 
21
a physician, pharmacist, or other person that dis-
22
penses a controlled substance to an ultimate user. 
23
‘‘(3) INDIAN TRIBE.—The term ‘Indian tribe’ 
24
has the meaning given that term in section 4 of the 
25
19:08 Nov 24, 2020
H14
279 
•HR 14 IH
Indian Self-Determination and Education Assistance 
1
Act. 
2
‘‘(4) STATE.—The term ‘State’ means each of 
3
the 50 States, the District of Columbia, and any 
4
commonwealth or territory of the United States. 
5
‘‘(5) ULTIMATE
USER.—The term ‘ultimate 
6
user’ means a person who has obtained from a dis-
7
penser, and who possesses, a controlled substance 
8
for the person’s own use, for the use of a member 
9
of the person’s household, or for the use of an ani-
10
mal.’’. 
11
Subtitle I—Suspicious Order 
12
Identification 
13
SEC. 7081. STRENGTHENING ARCOS. 
14
Section 307(d) of the Controlled Substances Act (21 
15
U.S.C. 827(d)) is amended to read as follows: 
16
‘‘(1)(A) Every registrant under section 303 shall and 
17
in such form as the Attorney General may require, make 
18
reports in electronic format to the Attorney General of 
19
every sale, delivery, or other disposal (other than by dis-
20
pensing by a practitioner) by the registrant of any con-
21
trolled substance, identifying by the registration number 
22
assigned under this title the person or establishment (un-
23
less exempt from registration under section 302(d)) to 
24
whom such sale, delivery, or other disposal was made. 
25
19:08 Nov 24, 2020
H14
280 
•HR 14 IH
‘‘(B) Every registrant shall make each report re-
1
quired under subparagraph (A)— 
2
‘‘(i) not later than 30 days after the sale, deliv-
3
ery, or other disposal; or 
4
‘‘(ii) after the date on which the real-time re-
5
porting 
system 
is 
established 
under 
section 
6
7082(e)(3) of the Commitment to Defeat the Virus 
7
and Keep America Healthy Act is implemented, in 
8
real time.’’. 
9
SEC. 7082. SUSPICIOUS ORDERS TASK FORCE. 
10
(a) DEFINITIONS.—In this section: 
11
(1) ADMINISTRATOR.—The term ‘‘Adminis-
12
trator’’ means the Administrator of the Drug En-
13
forcement Administration. 
14
(2) CONTROLLED
SUBSTANCE; DISTRIBUTOR; 
15
MANUFACTURER.—The 
terms 
‘‘controlled 
sub-
16
stance’’, ‘‘distributor’’, and ‘‘manufacturer’’ have the 
17
meanings given those terms in section 102 of the 
18
Controlled Substances Act (21 U.S.C. 802). 
19
(3) REAL TIME.—The term ‘‘real time’’ means 
20
with as little delay as technically and economically 
21
feasible, as determined by the Attorney General fol-
22
lowing the program designed under subsection 
23
(e)(1), but not to exceed 24 hours. 
24
(4) REGISTRANT.—The term ‘‘registrant’’— 
25
19:08 Nov 24, 2020
H14
281 
•HR 14 IH
(A) means a person registered under sec-
1
tion 303 of the Controlled Substances Act (21 
2
U.S.C. 823); and 
3
(B) does not include practitioner. 
4
(b) ESTABLISHMENT.—The Attorney General, in 
5
consultation with the Director of the Office of National 
6
Drug Control Policy and the Secretary of Health and 
7
Human Services, shall establish a Suspicious Order Moni-
8
toring Task Force (referred to in this section as the ‘‘Task 
9
Force’’). 
10
(c) COMPOSITION.— 
11
(1) IN
GENERAL.—The Task Force shall be 
12
composed of appropriate personnel from— 
13
(A) the Department of Justice; 
14
(B) the Drug Enforcement Administration; 
15
(C) the Office of National Drug Control 
16
Policy; 
17
(D) the National Institute of Standards 
18
and Technology; and 
19
(E) other appropriate Federal, State, and 
20
local law enforcement and regulatory agencies 
21
with experience in investigating and prosecuting 
22
illegal transactions of controlled substances as 
23
determined by the Attorney General, in con-
24
19:08 Nov 24, 2020
H14
282 
•HR 14 IH
sultation with the Secretary of Health and 
1
Human Services. 
2
(2) CONSULTANTS.—The Task Force shall con-
3
sult with— 
4
(A) industry members, including— 
5
(i) data analytic professionals; 
6
(ii) community pharmacies that dis-
7
pense controlled substances; 
8
(iii) chain pharmacies that dispense 
9
controlled substances; 
10
(iv) distributors of controlled sub-
11
stances; 
12
(v) manufacturers of controlled sub-
13
stances; 
14
(vi) State and local public health offi-
15
cials; and 
16
(vii) other relevant industry profes-
17
sionals; and 
18
(B) relevant industry regulators and enti-
19
ties that utilize real-time reporting of trans-
20
actions, orders, or other activities with the goal 
21
of identifying suspicious activity, such as appro-
22
priate personnel from the Financial Crimes En-
23
forcement Network and money transfer indus-
24
try professionals. 
25
19:08 Nov 24, 2020
H14
283 
•HR 14 IH
(d) MEETINGS.— 
1
(1) IN GENERAL.—The Task Force shall meet 
2
not less frequently than 4 times per year and at 
3
such other times as may be determined necessary by 
4
the Task Force. 
5
(2) INITIAL MEETING.—Not later than 60 days 
6
after the date of enactment of this Act, the Task 
7
Force shall hold the initial meeting of the Task 
8
Force. 
9
(e) PRELIMINARY ORDER EVALUATION PROGRAM.— 
10
(1) IN GENERAL.— 
11
(A) DESIGN.—Not later than 60 days after 
12
the date on which the Task Force holds the ini-
13
tial meeting required under subsection (d)(2), 
14
the Task Force shall begin to design a program 
15
in accordance with paragraph (2). 
16
(B) PURPOSE.—The program described in 
17
subparagraph (A) shall be designed to share 
18
necessary data, in a limited capacity, with reg-
19
istrants in order to provide registrants with in-
20
formation to identify suspicious ordering in real 
21
time. 
22
(C) DEADLINE
FOR
COMPLETION.—Not 
23
later than 8 months after the date of enactment 
24
19:08 Nov 24, 2020
H14
284 
•HR 14 IH
of this Act, the Task Force shall complete the 
1
design required under subparagraph (A). 
2
(2) REQUIREMENTS.— 
3
(A) IN GENERAL.—The program required 
4
under paragraph (1) shall establish a process 
5
for— 
6
(i) transitioning to a requirement to 
7
report in real time to the Attorney General 
8
under section 307(d) of the Controlled 
9
Substances Act (21 U.S.C. 827(d)) every 
10
sale, delivery, or other disposal by a reg-
11
istrant of any controlled substance; 
12
(ii) limited sharing in real time of Au-
13
tomation of Reports and Consolidated Or-
14
ders 
System 
(commonly 
known 
as 
15
‘‘ARCOS’’) data with registrants to share 
16
necessary data, in a limited capacity, with 
17
registrants in order to provide registrants 
18
with information to identify suspicious or-
19
dering in real time; and 
20
(iii) ensuring data privacy, data de- 
21
identification, protection of trade secrets 
22
and purchasing history. 
23
19:08 Nov 24, 2020
H14
285 
•HR 14 IH
(B) OTHER CONSIDERATIONS.—In design-
1
ing the program under paragraph (1), the Task 
2
Force shall take into consideration— 
3
(i) the inclusion of a waiver process 
4
for pharmacies and other registrants un-
5
able to transmit orders electronically on 
6
the date of enactment of this Act; 
7
(ii) a mechanism to ensure that the 
8
costs of running the program are not 
9
passed through to customers of registrants, 
10
unless the registrants are customers of 
11
other registrants; 
12
(iii) technical requirements for ensur-
13
ing that registrants may access all relevant 
14
de-identified data, with output provided in 
15
a standard database file format; and 
16
(iv) a mechanism to ensure that the 
17
program required to be designed under 
18
subparagraph (A) is updated based on 
19
feedback from industry members and other 
20
relevant entities. 
21
(3) IMPLEMENTATION.—Not later than 1 year 
22
after the date of enactment of this Act, the Attorney 
23
General shall— 
24
19:08 Nov 24, 2020
H14
286 
•HR 14 IH
(A) implement the program designed under 
1
paragraph (1) to collect and share in real time 
2
data for registrants to evaluate the orders of 
3
controlled substances from distributors to man-
4
ufacturers and from pharmacies to distributors; 
5
or 
6
(B) otherwise implement a program to col-
7
lect and share in real time data for drug manu-
8
facturers and distributors, by providing access 
9
to anonymized information to help drug manu-
10
facturers and distributors identify, report, and 
11
stop suspicious orders of controlled substances 
12
and reduce diversion rates. 
13
(4) RECOMMENDED
STATUTORY
AND
REGU-
14
LATORY CHANGES.—In designing the program re-
15
quired under paragraph (1), the Task Force— 
16
(A) shall submit to the Attorney General 
17
any recommendations for necessary amend-
18
ments to regulations of the Department of Jus-
19
tice relating to the requirements for ordering 
20
schedule II controlled substances, so as to allow 
21
uniform electronic ordering of controlled sub-
22
stances in schedules II, III, IV, and V electroni-
23
cally through the program; and 
24
19:08 Nov 24, 2020
H14
287 
•HR 14 IH
(B) may submit to Congress any rec-
1
ommendations for necessary legislative changes 
2
so that a real-time data analytics solution can 
3
be used across the United States. 
4
(5) RESPONSIBILITY
OF
REGISTRANTS.—All 
5
registered drug manufacturers and distributors shall 
6
be responsible for reviewing any information made 
7
available by the Attorney General and complying 
8
with any regulations regarding the program designed 
9
under paragraph (1) and implemented under para-
10
graph (3). 
11
(f) FUNDING.— 
12
(1) IN GENERAL.—The Attorney General, act-
13
ing through the Administrator, shall use amounts 
14
collected as fees for distributors and registrants 
15
under section 303 of the Controlled Substances Act 
16
(21 U.S.C. 823) and section 1007 of the Controlled 
17
Substances Import and Export Act (21 U.S.C. 957) 
18
to carry out this section. 
19
(2) OFFSET.— 
20
(A) IN
GENERAL.—The Administrator 
21
may, on an equal basis and in accordance with 
22
subparagraph (B), increase the fees described 
23
in paragraph (1) for distributors and reg-
24
19:08 Nov 24, 2020
H14
288 
•HR 14 IH
istrants to the extent necessary to defray the 
1
costs of this section. 
2
(B) TIERED
FEE.—The Administrator 
3
shall establish a tiered user fee for distributors 
4
and registrants in proportion to the volume of 
5
sales and purchases. 
6
(g) APPLICABILITY OF FACA.— 
7
(1) IN GENERAL.—Except as provided in para-
8
graph (2), the Federal Advisory Committee Act (5 
9
U.S.C. App.) shall apply to the Task Force. 
10
(2) TERMINATION.—The Task Force shall ter-
11
minate on the date on which the program is fully 
12
implemented under subsection (e)(3). 
13
(h) RULES OF CONSTRUCTION.—Nothing in this sub-
14
title shall be construed as relieving any manufacturer, dis-
15
tributor, or other registrant from the responsibilities of 
16
the manufacturer, distributor, or other registrant, as the 
17
case may be, to— 
18
(1) identify, stop, and report suspicious orders; 
19
(2) maintain effective controls against diversion 
20
in accordance with section 303 of the Controlled 
21
Substances Act (21 U.S.C. 823); and 
22
(3) comply with the requirements established in 
23
section 1301.74(b) of title 21, Code of Federal Reg-
24
19:08 Nov 24, 2020
H14
289 
•HR 14 IH
ulations, or any successor regulation thereto, with 
1
respect to suspicious orders. 
2
Subtitle J—Stop the Importation 
3
and Manufacturing of Synthetic 
4
Analogues 
5
SEC. 7091. ESTABLISHMENT OF SCHEDULE A. 
6
Section 202 of the Controlled Substances Act (21 
7
U.S.C. 812) is amended— 
8
(1) in subsection (a), by striking ‘‘five schedules 
9
of controlled substances, to be known as schedules I, 
10
II, III, IV, and V’’ and inserting ‘‘six schedules of 
11
controlled substances, to be known as schedules I, 
12
II, III, IV, V, and A’’; 
13
(2) in subsection (b), by adding at the end the 
14
following: 
15
‘‘(6) SCHEDULE A.— 
16
‘‘(A) IN GENERAL.—The drug or substance— 
17
‘‘(i) is or has been imported, or is offered 
18
for import, into the United States; 
19
‘‘(ii) has— 
20
‘‘(I) a chemical structure that is sub-
21
stantially similar to the chemical structure 
22
of a controlled substance in schedule I, II, 
23
III, IV, or V; and 
24
19:08 Nov 24, 2020
H14
290 
•HR 14 IH
‘‘(II) an actual or predicted stimulant, 
1
depressant, or hallucinogenic effect on the 
2
central nervous system that is substantially 
3
similar to or greater than the stimulant, 
4
depressant, or hallucinogenic effect on the 
5
central nervous system of a controlled sub-
6
stance in schedule I, II, III, IV, or V; and 
7
‘‘(iii) is not— 
8
‘‘(I) listed or otherwise included in 
9
any other schedule in this section or by 
10
regulation of the Attorney General; and 
11
‘‘(II) with respect to a particular per-
12
son, subject to an exemption that is in ef-
13
fect for investigational use, for that person, 
14
under section 505 of the Federal Food, 
15
Drug, and Cosmetic Act (21 U.S.C. 355) 
16
to the extent conduct with respect to such 
17
substance is pursuant to such exemption. 
18
‘‘(B) PREDICTED STIMULANT, DEPRESSANT, OR 
19
HALLUCINOGENIC
EFFECT.—For purposes of this 
20
paragraph, a predicted stimulant, depressant, or hal-
21
lucinogenic effect on the central nervous system may 
22
be based on— 
23
‘‘(i)(I) the chemical structure; and 
24
19:08 Nov 24, 2020
H14
291 
•HR 14 IH
‘‘(II)(aa) the structure activity relation-
1
ships; or 
2
‘‘(bb) binding receptor assays and other 
3
relevant scientific information about the sub-
4
stance; 
5
‘‘(ii)(I) the current or relative potential for 
6
abuse of the substance; and 
7
‘‘(II) the clandestine importation, manu-
8
facture, or distribution, or diversion from legiti-
9
mate channels, of the substance; or 
10
‘‘(iii) the capacity of the substance to 
11
cause a state of dependence, including physical 
12
or psychological dependence that is similar to or 
13
greater than that of a controlled substance in 
14
schedule I, II, III, IV, or V.’’; and 
15
(3) in subsection (c)— 
16
(A) in the matter preceding schedule I, by 
17
striking ‘‘IV, and V’’ and inserting ‘‘IV, V, and 
18
A’’; and 
19
(B) by adding at the end the following: 
20
‘‘SCHEDULE A 
21
‘‘Any substance temporarily or permanently sched-
22
uled by the Attorney General in accordance with section 
23
201(k).’’. 
24
19:08 Nov 24, 2020
H14
292 
•HR 14 IH
SEC. 7092. TEMPORARY AND PERMANENT SCHEDULING OF 
1
SCHEDULE A SUBSTANCES. 
2
Section 201 of the Controlled Substances Act (21 
3
U.S.C. 811) is amended by adding at the end the fol-
4
lowing: 
5
‘‘(k) TEMPORARY AND PERMANENT SCHEDULING OF 
6
SCHEDULE A SUBSTANCES.— 
7
‘‘(1) IN GENERAL.—The Attorney General may 
8
issue a temporary order adding a drug or substance 
9
to schedule A if the Attorney General finds that— 
10
‘‘(A) the drug or other substance satisfies 
11
the criteria for being considered a schedule A 
12
substance; and 
13
‘‘(B) adding such drug or substance to 
14
schedule A will assist in preventing abuse of the 
15
drug or other substance. 
16
‘‘(2) DURATION OF TEMPORARY SCHEDULING 
17
ORDER.—A temporary scheduling order issued under 
18
paragraph (1) shall— 
19
‘‘(A) not take effect until 30 days after the 
20
date of the publication by the Attorney General 
21
of a notice in the Federal Register of the inten-
22
tion to issue such order and the grounds upon 
23
which such order is to be issued; and 
24
‘‘(B) expire not later than 5 years after 
25
the date on which the order becomes effective, 
26
19:08 Nov 24, 2020
H14
293 
•HR 14 IH
except that the Attorney General may, during 
1
the pendency of proceedings under paragraph 
2
(5), extend the temporary scheduling order for 
3
up to 180 days. 
4
‘‘(3) EFFECT
OF
ISSUANCE
OF
PERMANENT 
5
SCHEDULING
ORDER.—A 
temporary 
scheduling 
6
order issued under paragraph (1) shall be vacated 
7
upon the issuance of a permanent order issued 
8
under paragraph (5) with regard to the same sub-
9
stance, or upon the subsequent issuance of any 
10
scheduling order under this section. 
11
‘‘(4) LIMITATION
ON
JUDICIAL
REVIEW.—A 
12
temporary scheduling order issued under paragraph 
13
(1) shall not be subject to judicial review. 
14
‘‘(5) PERMANENT SCHEDULING ORDER.— 
15
‘‘(A) IN GENERAL.—Except as provided in 
16
subparagraph (B), not earlier than 3 years 
17
after the date on which the Attorney General 
18
issues an order temporarily scheduling a drug 
19
or substance under this subsection, the Attor-
20
ney General may, by rule, issue a permanent 
21
order adding the drug or other substance to 
22
schedule A if such drug or substance satisfies 
23
the criteria for being considered a schedule A 
24
substance. 
25
19:08 Nov 24, 2020
H14
294 
•HR 14 IH
‘‘(B) LIMITATION.—If the Secretary of 
1
Health and Human Services has determined, 
2
based on relevant scientific studies and nec-
3
essary data requested by the Secretary of 
4
Health and Human Services and gathered by 
5
the Attorney General, that a drug or other sub-
6
stance that has been temporarily placed in 
7
schedule A does not have sufficient potential for 
8
abuse to warrant control in any schedule, and 
9
provides written notice of such determination to 
10
the Attorney General, the Attorney General— 
11
‘‘(i) may not issue a permanent sched-
12
uling order under subparagraph (A); and 
13
‘‘(ii) not later than 30 days after the 
14
date on which the Attorney General re-
15
ceives such notice, shall issue an order im-
16
mediately 
terminating 
the 
temporary 
17
scheduling order for the drug or other sub-
18
stance. 
19
‘‘(6) NOTICE TO HHS.—Before initiating pro-
20
ceedings under paragraph (1), the Attorney General 
21
shall transmit notice of a temporary order proposed 
22
to be issued to the Secretary of Health and Human 
23
Services. In issuing an order under paragraph (1), 
24
the Attorney General shall take into consideration 
25
19:08 Nov 24, 2020
H14
295 
•HR 14 IH
any comments submitted by the Secretary of Health 
1
and Human Services in response to a notice trans-
2
mitted pursuant to this paragraph.’’. 
3
SEC. 7093. PENALTIES. 
4
Section 1010 of the Controlled Substances Import 
5
and Export Act (21 U.S.C. 960) is amended— 
6
(1) in subsection (a), by inserting ‘‘or a drug or 
7
substance in schedule A’’ after ‘‘controlled sub-
8
stance’’ each place it appears; and 
9
(2) in subsection (b), by adding at the end the 
10
following: 
11
‘‘(8) In the case of a violation under subsection (a) 
12
involving a controlled substance in schedule A, the person 
13
committing such violation shall be sentenced to a term of 
14
imprisonment of not more than 20 years and if death or 
15
serious bodily injury results from the use of such sub-
16
stance shall be sentenced to a term of imprisonment for 
17
any term of years or for life, a fine not to exceed the great-
18
er of that authorized in accordance with the provisions of 
19
title 18, United States Code, or $1,000,000 if the defend-
20
ant is an individual or $5,000,000 if the defendant is other 
21
than an individual, or both. If any person commits such 
22
a violation after a prior conviction for a felony drug of-
23
fense has become final, such person shall be sentenced to 
24
a term of imprisonment of not more than 30 years and 
25
19:08 Nov 24, 2020
H14
296 
•HR 14 IH
if death or serious bodily injury results from the use of 
1
such substance shall be sentenced to a term of imprison-
2
ment for any term of years or for life, a fine not to exceed 
3
the greater of twice that authorized in accordance with 
4
the provisions of title 18, United States Code, or 
5
$2,000,000 if the defendant is an individual or 
6
$10,000,000 if the defendant is other than an individual, 
7
or both. Notwithstanding section 3583 of title 18, United 
8
States Code, any sentence imposing a term of imprison-
9
ment under this paragraph shall, in the absence of such 
10
a prior conviction, impose a term of supervised release of 
11
not less than 3 years in addition to such term of imprison-
12
ment and shall, if there was such a prior conviction, im-
13
pose a term of supervised release of not less than 6 years 
14
in addition to such term of imprisonment. Notwith-
15
standing the prior sentence, and notwithstanding any 
16
other provision of law, the court shall not place on proba-
17
tion or suspend the sentence of any person sentenced 
18
under the provisions of this paragraph which provide for 
19
a mandatory term of imprisonment if death or serious 
20
bodily injury results.’’. 
21
19:08 Nov 24, 2020
H14
297 
•HR 14 IH
SEC. 7094. FALSE LABELING OF SCHEDULE A CONTROLLED 
1
SUBSTANCES. 
2
(a) IN GENERAL.—Section 305 of the Controlled 
3
Substances Act (21 U.S.C. 825) is amended by adding at 
4
the end the following: 
5
‘‘(f) FALSE
LABELING
OF
SCHEDULE
A CON-
6
TROLLED SUBSTANCES.— 
7
‘‘(1) It shall be unlawful to import or export, 
8
with intent to manufacture, distribute, or dispense, 
9
a schedule A substance or product containing a 
10
schedule A substance, unless the substance or prod-
11
uct bears a label clearly identifying a schedule A 
12
substance or product containing a schedule A sub-
13
stance by the nomenclature used by the Inter-
14
national Union of Pure and Applied Chemistry 
15
(IUPAC). 
16
‘‘(2)(A) A product described in subparagraph 
17
(B) is exempt from the International Union of Pure 
18
and Applied Chemistry nomenclature requirement of 
19
this subsection if such product is labeled in the man-
20
ner required under the Federal Food, Drug, and 
21
Cosmetic Act. 
22
‘‘(B) A product is described in this subpara-
23
graph if the product— 
24
19:08 Nov 24, 2020
H14
298 
•HR 14 IH
‘‘(i) is the subject of an approved applica-
1
tion as described in section 505(b) or (j) of the 
2
Federal Food, Drug, and Cosmetic Act; or 
3
‘‘(ii) is exempt from the provisions of sec-
4
tion 505 of such Act relating to new drugs be-
5
cause— 
6
‘‘(I) it is intended solely for investiga-
7
tional use as described in section 505(i) of 
8
such Act; and 
9
‘‘(II) such product is being used ex-
10
clusively for purposes of a clinical trial 
11
that is the subject of an effective investiga-
12
tional new drug application.’’. 
13
(b) PENALTIES.—Section 402 of the Controlled Sub-
14
stances Act (21 U.S.C. 842) is amended— 
15
(1) in subsection (a)— 
16
(A) in paragraph (16), by striking ‘‘or’’ at 
17
the end; 
18
(B) by redesignating paragraph (17) as 
19
paragraph (18); and 
20
(C) by inserting after paragraph (16) the 
21
following: 
22
‘‘(17) to violate section 305(f); or’’; and 
23
(2) in subsection (c)— 
24
(A) in paragraph (1)— 
25
19:08 Nov 24, 2020
H14
299 
•HR 14 IH
(i) in subparagraph (B)(i), by striking 
1
‘‘(17)’’ and inserting ‘‘(18)’’; and 
2
(ii) in subparagraph (C), by inserting 
3
‘‘or (17)’’ after ‘‘paragraph (16)’’ each 
4
place it appears; and 
5
(B) in paragraph (2)(D), by striking 
6
‘‘(17)’’ and inserting ‘‘(18)’’. 
7
SEC. 7095. REGISTRATION REQUIREMENTS FOR IMPORT-
8
ERS AND EXPORTERS OF SCHEDULE A SUB-
9
STANCES. 
10
Section 1008 of the Controlled Substances Import 
11
and Export Act (21 U.S.C. 958) is amended by adding 
12
at the end the following: 
13
‘‘(j)(1) The Attorney General shall register an appli-
14
cant to import or export a schedule A substance if— 
15
‘‘(A) the applicant demonstrates that the sched-
16
ule A substance will be used for research, analytical, 
17
or industrial purposes approved by the Attorney 
18
General; and 
19
‘‘(B) the Attorney General determines that such 
20
registration is consistent with the public interest and 
21
with the United States obligations under inter-
22
national treaties, conventions, or protocols in effect 
23
on the date of enactment of this subsection. 
24
19:08 Nov 24, 2020
H14
300 
•HR 14 IH
‘‘(2) In determining the public interest under para-
1
graph (1)(B), the Attorney General shall consider— 
2
‘‘(A) maintenance of effective controls against 
3
diversion of particular controlled substances and any 
4
controlled substance in schedule A compounded 
5
therefrom into other than legitimate medical, sci-
6
entific, research, or industrial channels, by limiting 
7
the importation and bulk manufacture of such con-
8
trolled substances to a number of establishments 
9
which can produce an adequate and uninterrupted 
10
supply of these substances under adequately com-
11
petitive conditions for legitimate medical, scientific, 
12
research, and industrial purposes; 
13
‘‘(B) compliance with applicable State and local 
14
law; 
15
‘‘(C) promotion of technical advances in the art 
16
of manufacturing substances described in subpara-
17
graph (A) and the development of new substances; 
18
‘‘(D) prior conviction record of applicant under 
19
Federal and State laws relating to the importation, 
20
manufacture, distribution, or dispensing of sub-
21
stances described in subparagraph (A); 
22
‘‘(E) past experience in the importation and 
23
manufacture of controlled substances, and the exist-
24
19:08 Nov 24, 2020
H14
301 
•HR 14 IH
ence in the establishment of effective control against 
1
diversion; and 
2
‘‘(F) such other factors as may be relevant to 
3
and consistent with the public health and safety. 
4
‘‘(3) If an applicant is registered to import or export 
5
a controlled substance in schedule I or II under subsection 
6
(a), the applicant shall not be required to apply for a sepa-
7
rate registration under this subsection.’’. 
8
SEC. 7096. ADDITIONAL CONFORMING AMENDMENTS. 
9
The Controlled Substances Import and Export Act 
10
(21 U.S.C. 951 et seq.) is amended— 
11
(1) in section 1002(a) (21 U.S.C. 952(a))— 
12
(A) in the matter preceding paragraph (1), 
13
by inserting ‘‘or drug or substance in schedule 
14
A’’ after ‘‘schedule I or II’’; and 
15
(B) in paragraph (2), by inserting ‘‘or 
16
drug or substances in schedule A’’ after ‘‘sched-
17
ule I or II’’; 
18
(2) in section 1003 (21 U.S.C. 953)— 
19
(A) in subsection (c), in the matter pre-
20
ceding paragraph (1), by inserting ‘‘or drug or 
21
substance in schedule A’’ after ‘‘schedule I or 
22
II’’; and 
23
19:08 Nov 24, 2020
H14
302 
•HR 14 IH
(B) in subsection (d), by inserting ‘‘or 
1
drug or substance in schedule A’’ after ‘‘sched-
2
ule I or II’’; 
3
(3) in section 1004(1) (21 U.S.C. 954(1)), in 
4
the matter preceding subparagraph (A), by inserting 
5
‘‘or drug or substance in schedule A’’ after ‘‘sched-
6
ule I’’; 
7
(4) in section 1005 (21 U.S.C. 955), by insert-
8
ing ‘‘or drug or substance in schedule A’’ after 
9
‘‘schedule I or II’’; and 
10
(5) in section 1009(a) (21 U.S.C. 959(a)), by 
11
inserting ‘‘or drug or substance in schedule A’’ after 
12
‘‘schedule I or II’’. 
13
SEC. 7097. SENTENCING REVIEW. 
14
(a) COVERED OFFENSE DEFINED.—In this section, 
15
the term ‘‘covered offense’’ means an offense involving a 
16
schedule A substance for which the penalty was estab-
17
lished under section 7093 or 7094 of this subtitle. 
18
(b) SENTENCING REVIEW.— 
19
(1) PETITION FOR REVIEW.—If a schedule A 
20
substance that is temporarily or permanently sched-
21
uled under section 201(k) of the Controlled Sub-
22
stances Act, as added by this subtitle, is subse-
23
quently descheduled or rescheduled on a schedule 
24
with lower penalties, any individual convicted of a 
25
19:08 Nov 24, 2020
H14
303 
•HR 14 IH
covered offense involving such schedule A substance 
1
who is awaiting sentencing or is still serving a term 
2
of imprisonment for such covered offense on the date 
3
of the descheduling or rescheduling may petition the 
4
court that imposed the sentence for a sentencing re-
5
duction hearing for such covered offense. 
6
(2) SENTENCING REVIEW.—Not later than 30 
7
days after the date on which a petition is filed under 
8
paragraph (1), the court shall conduct a sentencing 
9
reduction hearing and may modify the sentence of 
10
the petitioner as if the descheduling or rescheduling 
11
described in paragraph (1) had been in effect on the 
12
date the covered offense was committed. 
13
SEC. 7098. RULES OF CONSTRUCTION. 
14
Nothing in this subtitle, or the amendments made by 
15
this subtitle, may be construed to limit— 
16
(1) the prosecution of offenses involving con-
17
trolled substance analogues under the Controlled 
18
Substances Act (21 U.S.C. 801 et seq.); or 
19
(2) the authority of the Attorney General to 
20
temporarily or permanently schedule, reschedule, or 
21
decontrol controlled substances under provisions of 
22
section 201 of the Controlled Substances Act (21 
23
U.S.C. 811) that are in effect on the day before the 
24
date of enactment of this Act. 
25
19:08 Nov 24, 2020
H14
304 
•HR 14 IH
SEC. 7099. CLARIFICATION OF CERTAIN REGISTRATION RE-
1
QUIREMENTS RELATED TO RESEARCH. 
2
(a) EXCEPTION FOR AGENTS OR EMPLOYEES OF 
3
REGISTERED RESEARCHERS.—Section 302(c) of the Con-
4
trolled Substances Act (21 U.S.C. 822(c)) is amended in 
5
paragraph (1) by striking ‘‘or dispenser’’ and inserting 
6
‘‘dispenser, or researcher’’. 
7
(b) CONFORMING AMENDMENT.—Section 102(3) of 
8
the Controlled Substances Act (21 U.S.C. 802(3)) is 
9
amended by striking ‘‘or dispenser’’ and inserting ‘‘dis-
10
penser, or researcher’’. 
11
(c) SINGLE REGISTRATION FOR CONTIGUOUS RE-
12
SEARCH SITES.—Section 302(e) of the Controlled Sub-
13
stances Act (21 U.S.C. 822(e)) is amended by adding at 
14
the end the following new paragraph: 
15
‘‘(3) Notwithstanding paragraph (1), a person 
16
registered to conduct research with a controlled sub-
17
stance under section 303(f) may conduct such re-
18
search under a single registration if such research 
19
occurs exclusively on a single, contiguous campus 
20
and the registrant notifies the Attorney General in 
21
writing of all sites on the campus where the research 
22
will be conducted or where the controlled substance 
23
will be stored or administered. The registrant must 
24
so notify the Attorney General prior to conducting 
25
research at such additional sites.’’. 
26
19:08 Nov 24, 2020
H14
305 
•HR 14 IH
(d) NEW INSPECTION NOT REQUIRED IN CERTAIN 
1
SITUATIONS.—Section 303(f) of the Controlled Sub-
2
stances Act (21 U.S.C. 823(f)) is amended— 
3
(1) by redesignating paragraphs (1) through 
4
(5) as subparagraphs (A) through (E), respectively, 
5
and by moving the margins of such subparagraphs 
6
two ems to the right; 
7
(2) by striking ‘‘(f) The’’ and inserting ‘‘(f)(1) 
8
The’’; and 
9
(3) by adding at the end, after the matter fol-
10
lowing subparagraph (E), as so redesignated, the 
11
following new paragraph: 
12
‘‘(2)(A) If a person is registered to conduct research 
13
with a controlled substance and applies for a registration, 
14
or a modification of a registration to conduct research 
15
with a second controlled substance that is in the same 
16
schedule or in a schedule with a higher numerical designa-
17
tion, a new inspection by the Attorney General of the reg-
18
istered location is not required. 
19
‘‘(B) Nothing in this paragraph shall prohibit the At-
20
torney General from conducting any inspection if the At-
21
torney General deems it necessary.’’. 
22
(e) CONTINUATION OF RESEARCH ON SUBSTANCES 
23
NEWLY ADDED TO SCHEDULE I; AUTHORITY TO CON-
24
DUCT RESEARCH WITH OTHER SUBSTANCES IN SCHED-
25
19:08 Nov 24, 2020
H14
306 
•HR 14 IH
ULE I.—Section 302 of the Controlled Substances Act (21 
1
U.S.C. 822) is amended by adding at the end the following 
2
new subsection: 
3
‘‘(h) CONTINUATION OF RESEARCH ON SUBSTANCES 
4
NEWLY ADDED TO SCHEDULE I; AUTHORITY TO CON-
5
DUCT RESEARCH WITH OTHER SUBSTANCES IN SCHED-
6
ULE I.— 
7
‘‘(1) If a person is conducting research on a 
8
substance at the time the substance is added to 
9
schedule I, and such person is already registered to 
10
conduct research with a controlled substance in 
11
schedule I or II then— 
12
‘‘(A) the person shall, within 30 days of 
13
the scheduling of the newly scheduled sub-
14
stance, submit a completed application for reg-
15
istration or modification of existing registration, 
16
to conduct research on such substance, in ac-
17
cordance with the regulations issued by the At-
18
torney General; 
19
‘‘(B) the person may, notwithstanding sub-
20
sections (a) and (b), continue to conduct the re-
21
search on such substance until the application 
22
referred to in subparagraph (A) is withdrawn 
23
by the applicant or until the Attorney General 
24
serves on the applicant an order to show cause 
25
19:08 Nov 24, 2020
H14
307 
•HR 14 IH
proposing the denial of the application pursuant 
1
to section 304(c); and 
2
‘‘(C) if the Attorney General serves such 
3
an order to show cause and the applicant re-
4
quests a hearing, such hearing shall be held on 
5
an expedited basis and not later than 45 days 
6
after the request is made, except that the hear-
7
ing may be held at a later time if so requested 
8
by the applicant. 
9
‘‘(2)(A) A person who is registered to conduct 
10
research with a controlled substance in schedule I 
11
may, notwithstanding subsections (a) and (b), con-
12
duct research with another controlled substance in 
13
schedule I, provided the following conditions are 
14
met: 
15
‘‘(i) The person has applied for a modifica-
16
tion of the person’s registration to authorize re-
17
search with such other controlled substance in 
18
accordance with the regulations issued by the 
19
Attorney General. 
20
‘‘(ii) The Attorney General has obtained 
21
verification from the Secretary that the re-
22
search protocol submitted with the application 
23
is meritorious. 
24
19:08 Nov 24, 2020
H14
308 
•HR 14 IH
‘‘(iii) The Attorney General has deter-
1
mined that such activity is consistent with 
2
United States obligations under the Single Con-
3
vention on Narcotic Drugs, 1961. The Attorney 
4
General shall make such determination not 
5
later than 30 days after receiving the applica-
6
tion referred to in clause (i). 
7
‘‘(B) Nothing in this section shall be construed 
8
to alter the authority of the Attorney General to ini-
9
tiate proceedings to deny, suspend, or revoke any 
10
registration in accordance with sections 303 and 
11
304.’’. 
12
(f) TREATMENT OF CERTAIN ACTIVITIES AS COINCI-
13
DENT TO RESEARCH.—Section 302 of the Controlled Sub-
14
stances Act (21 U.S.C. 822), as amended by subsection 
15
(d), is further amended by adding at the end the following 
16
new subsection: 
17
‘‘(i) TREATMENT OF CERTAIN ACTIVITIES AS COIN-
18
CIDENT TO RESEARCH.— 
19
‘‘(1) IN
GENERAL.—Except as specified in 
20
paragraph (2), a person who is registered to perform 
21
research with a controlled substance may perform 
22
the following activities with small quantities of that 
23
substance, as set forth in the relevant statement or 
24
protocol filed with the application for registration 
25
19:08 Nov 24, 2020
H14
309 
•HR 14 IH
approved by the Attorney General without being re-
1
quired to obtain a manufacturing registration: 
2
‘‘(A) Processing the substance to create ex-
3
tracts, tinctures, oils, solutions, derivatives, or 
4
other forms of the substance consistent with the 
5
approved research protocol. 
6
‘‘(B) Dosage form development for the 
7
purpose of satisfying regulatory requirements 
8
implemented by the Food and Drug Adminis-
9
tration for submitting an investigational new 
10
drug application. 
11
‘‘(2) EXCEPTION
REGARDING
MARIHUANA.— 
12
The authority under paragraph (1) does not include 
13
authority to grow marihuana.’’. 
14
SEC. 7100. REVIEW OF RESEARCH REGISTRATION PROCESS. 
15
(a) REVIEW.—Not later than one year after the date 
16
of the enactment of this section, the Attorney General and 
17
the Secretary of Health and Human Services shall conduct 
18
a review of the processes used to obtain or modify Federal 
19
authorization to conduct research with controlled sub-
20
stances, including— 
21
(1) an evaluation of the impacts of the amend-
22
ments made by section 7099 on the risk of the diver-
23
sion of controlled substances used in research and 
24
related public safety considerations; and 
25
19:08 Nov 24, 2020
H14
310 
•HR 14 IH
(2) identification of opportunities to reduce any 
1
unnecessary burden on persons seeking registration, 
2
potential redundancies, and inefficiencies in the 
3
process to obtain or modify Federal authorization to 
4
conduct research with controlled substances, includ-
5
ing the process for obtaining a registration under 
6
section 303 of the Controlled Substances Act (21 
7
U.S.C. 823) and the process by which the Secretary 
8
of Health and Human Services reviews research pro-
9
tocols. 
10
(b) GUIDANCE.—Following the review described in 
11
subsection (a), the Attorney General and the Secretary of 
12
Health and Human Services shall, as appropriate, jointly 
13
issue guidance to registrants and potential registrants 
14
clarifying the process for registration under section 303 
15
of the Controlled Substances Act (21 U.S.C. 823). 
16
TITLE VIII—TAX INCENTIVES TO 
17
IMPROVE HEALTH CARE 
18
SEC. 8001. DOMESTIC MEDICAL AND DRUG MANUFAC-
19
TURING CREDIT. 
20
(a) IN GENERAL.—Subpart D of part IV of sub-
21
chapter A of chapter 1 of the Internal Revenue Code of 
22
1986 is amended by adding at the end the following new 
23
section: 
24
19:08 Nov 24, 2020
H14
311 
•HR 14 IH
‘‘SEC. 45U. DOMESTIC MEDICAL AND DRUG MANUFAC-
1
TURING CREDIT. 
2
‘‘(a) IN GENERAL.—For purposes of section 38, the 
3
domestic medical and drug manufacturing credit deter-
4
mined under this section for any taxable year is an amount 
5
equal to 10.5 percent of the lesser of— 
6
‘‘(1) the qualified medical and drug manufac-
7
turing income of the taxpayer for the taxable year, 
8
or 
9
‘‘(2) taxable income of the taxpayer for the tax-
10
able year. 
11
‘‘(b) CREDIT LIMITED TO WAGES PAID.— 
12
‘‘(1) IN GENERAL.—The amount of the credit 
13
allowable under subsection (a) for any taxable year 
14
shall not exceed 50 percent of the W–2 wages of the 
15
taxpayer for the taxable year. 
16
‘‘(2) W–2 WAGES.—For purposes of this sec-
17
tion— 
18
‘‘(A) 
IN
GENERAL.—The 
term 
‘W–2 
19
wages’ means, with respect to any person for 
20
any taxable year of such person, the sum of the 
21
amounts described in paragraphs (3) and (8) of 
22
section 6051(a) paid by such person with re-
23
spect to employment of employees by such per-
24
son during the calendar year ending during 
25
such taxable year. 
26
19:08 Nov 24, 2020
H14
312 
•HR 14 IH
‘‘(B) LIMITATION
TO
WAGES
ATTRIB-
1
UTABLE
TO
DOMESTIC
PRODUCTION.—Such 
2
term shall not include any amount which is not 
3
properly allocable to domestic medical and drug 
4
manufacturing gross receipts for purposes of 
5
subsection (c)(1). 
6
‘‘(C) RETURN REQUIREMENT.—Such term 
7
shall not include any amount which is not prop-
8
erly included in a return filed with the Social 
9
Security Administration on or before the 60th 
10
day after the due date (including extensions) 
11
for such return. 
12
‘‘(3) ACQUISITIONS, DISPOSITIONS, AND SHORT 
13
TAXABLE YEARS.—The Secretary shall provide for 
14
the application of this subsection in cases of a short 
15
taxable year or where the taxpayer acquires, or dis-
16
poses of, the major portion of a trade or business or 
17
the major portion of a separate unit of a trade or 
18
business during the taxable year. 
19
‘‘(c) QUALIFIED MEDICAL
AND DRUG MANUFAC-
20
TURING INCOME.—For purposes of this section— 
21
‘‘(1) IN GENERAL.—The term ‘qualified medical 
22
and drug manufacturing income’ for any taxable 
23
year means an amount equal to the excess (if any) 
24
of— 
25
19:08 Nov 24, 2020
H14
313 
•HR 14 IH
‘‘(A) the taxpayer’s domestic medical and 
1
drug manufacturing gross receipts for the tax-
2
able year, over 
3
‘‘(B) the sum of— 
4
‘‘(i) the cost of goods sold that are al-
5
locable to such receipts, and 
6
‘‘(ii) other expenses, losses, or deduc-
7
tions which are properly allocable to such 
8
receipts. 
9
‘‘(2) ALLOCATION
METHOD.—The Secretary 
10
shall prescribe rules for the proper allocation of 
11
items described in paragraph (1)(B) for purposes of 
12
determining qualified medical and drug manufac-
13
turing income. Such rules shall provide for the prop-
14
er allocation of items whether or not such items are 
15
directly allocable to domestic medical and drug man-
16
ufacturing gross receipts. 
17
‘‘(3) 
SPECIAL
RULES
FOR
DETERMINING 
18
COSTS.— 
19
‘‘(A) IN GENERAL.—For purposes of deter-
20
mining costs under clause (i) of paragraph 
21
(1)(B), any item or service brought into the 
22
United States shall be treated as acquired by 
23
purchase, and its cost shall be treated as not 
24
19:08 Nov 24, 2020
H14
314 
•HR 14 IH
less than its value immediately after it entered 
1
the United States. 
2
‘‘(B) EXPORTS FOR FURTHER MANUFAC-
3
TURE.—In the case of any property described 
4
in subparagraph (A) that had been exported by 
5
the taxpayer for further manufacture, the in-
6
crease in cost or adjusted basis under subpara-
7
graph (A) shall not exceed the difference be-
8
tween the value of the property when exported 
9
and the value of the property when brought 
10
back into the United States after the further 
11
manufacture. 
12
‘‘(4) DOMESTIC MEDICAL AND DRUG MANUFAC-
13
TURING GROSS RECEIPTS.— 
14
‘‘(A) IN
GENERAL.—The term ‘domestic 
15
medical and drug manufacturing gross receipts’ 
16
means the gross receipts of the taxpayer which 
17
are derived from any sale, exchange, or other 
18
disposition of— 
19
‘‘(i) any active pharmaceutical ingre-
20
dient, or 
21
‘‘(ii) any qualified countermeasure, 
22
which was manufactured or produced by the 
23
taxpayer in whole or in significant part within 
24
the United States. 
25
19:08 Nov 24, 2020
H14
315 
•HR 14 IH
‘‘(B) ACTIVE
PHARMACEUTICAL
INGRE-
1
DIENT.—The term ‘active pharmaceutical ingre-
2
dient’ means any substance or mixture of sub-
3
stances intended to be used in the manufacture 
4
of a drug product and (when so used) becomes 
5
an active ingredient in the drug product. 
6
‘‘(C) QUALIFIED COUNTERMEASURE.—The 
7
term ‘qualified countermeasure’ has the mean-
8
ing given such term in section 319F–1(a)(2) of 
9
the Public Health Service Act (42 U.S.C. 
10
247d–6a(a)(2)).’’ 
11
‘‘(D) PARTNERSHIPS
OWNED
BY
EX-
12
PANDED
AFFILIATED
GROUPS.—For purposes 
13
of this paragraph, if all of the interests in the 
14
capital and profits of a partnership are owned 
15
by members of a single expanded affiliated 
16
group at all times during the taxable year of 
17
such partnership, the partnership and all mem-
18
bers of such group shall be treated as a single 
19
taxpayer during such period. 
20
‘‘(d) DEFINITIONS AND SPECIAL RULES.—For pur-
21
poses of this section— 
22
‘‘(1) APPLICATION OF SECTION TO PASS-THRU 
23
ENTITIES.— 
24
19:08 Nov 24, 2020
H14
316 
•HR 14 IH
‘‘(A) PARTNERSHIPS
AND
S
CORPORA-
1
TIONS.—In the case of a partnership or S cor-
2
poration— 
3
‘‘(i) this section shall be applied at the 
4
partner or shareholder level, 
5
‘‘(ii) each partner or shareholder shall 
6
take into account such person’s allocable 
7
share of each item described in subpara-
8
graph (A) or (B) of subsection (c)(1) (de-
9
termined without regard to whether the 
10
items described in such subparagraph (A) 
11
exceed the items described in such sub-
12
paragraph (B)), and 
13
‘‘(iii) each partner or shareholder 
14
shall be treated for purposes of subsection 
15
(b) as having W–2 wages for the taxable 
16
year in an amount equal to such person’s 
17
allocable share of the W–2 wages of the 
18
partnership or S corporation for the tax-
19
able year (as determined under regulations 
20
prescribed by the Secretary). 
21
‘‘(B) TRUSTS AND ESTATES.—In the case 
22
of a trust or estate— 
23
‘‘(i) the items referred to in subpara-
24
graph (A)(ii) (as determined therein) and 
25
19:08 Nov 24, 2020
H14
317 
•HR 14 IH
the W–2 wages of the trust or estate for 
1
the taxable year, shall be apportioned be-
2
tween the beneficiaries and the fiduciary 
3
(and among the beneficiaries) under regu-
4
lations prescribed by the Secretary, and 
5
‘‘(ii) for purposes of paragraph (2), 
6
adjusted gross income of the trust or es-
7
tate shall be determined as provided in sec-
8
tion 67(e) with the adjustments described 
9
in such paragraph. 
10
‘‘(C) REGULATIONS.—The Secretary may 
11
prescribe rules requiring or restricting the allo-
12
cation of items and wages under this paragraph 
13
and may prescribe such reporting requirements 
14
as the Secretary determines appropriate. 
15
‘‘(2) APPLICATION
TO
INDIVIDUALS.—In the 
16
case of an individual, subsection (a)(2) shall be ap-
17
plied by substituting ‘adjusted gross income’ for 
18
‘taxable income’. For purposes of the preceding sen-
19
tence, adjusted gross income shall be determined 
20
after application of sections 86, 135, 137, 219, 221, 
21
222, and 469. 
22
‘‘(3) 
SPECIAL
RULE
FOR
AFFILIATED 
23
GROUPS.— 
24
19:08 Nov 24, 2020
H14
318 
•HR 14 IH
‘‘(A) IN GENERAL.—All members of an ex-
1
panded affiliated group shall be treated as a 
2
single corporation for purposes of this section. 
3
‘‘(B) EXPANDED
AFFILIATED
GROUP.— 
4
For purposes of this section, the term ‘ex-
5
panded affiliated group’ means an affiliated 
6
group as defined in section 1504(a), deter-
7
mined— 
8
‘‘(i) by substituting ‘more than 50 
9
percent’ for ‘at least 80 percent’ each place 
10
it appears, and 
11
‘‘(ii) without regard to paragraphs (2) 
12
and (4) of section 1504(b). 
13
‘‘(C) ALLOCATION OF CREDIT.—Except as 
14
provided in regulations, the credit under sub-
15
section (a) shall be allocated among the mem-
16
bers of the expanded affiliated group in propor-
17
tion to each member’s respective amount (if 
18
any) of qualified medical and drug manufac-
19
turing income. 
20
‘‘(4) TRADE
OR
BUSINESS
REQUIREMENT.— 
21
This section shall be applied by only taking into ac-
22
count items which are attributable to the actual con-
23
duct of a trade or business. 
24
19:08 Nov 24, 2020
H14
319 
•HR 14 IH
‘‘(5) COORDINATION WITH MINIMUM TAX.—For 
1
purposes of determining alternative minimum tax-
2
able income under section 55, qualified medical and 
3
drug manufacturing income shall be determined 
4
without regard to any adjustments under sections 56 
5
through 59. 
6
‘‘(6) UNRELATED
BUSINESS
TAXABLE
IN-
7
COME.—For purposes of determining the tax im-
8
posed by section 511, subsection (a)(1)(B) shall be 
9
applied by substituting ‘unrelated business taxable 
10
income’ for ‘taxable income’. 
11
‘‘(7) REGULATIONS.—The Secretary shall pre-
12
scribe such regulations as are necessary to carry out 
13
the purposes of this section, including regulations 
14
which prevent more than 1 taxpayer from being al-
15
lowed a credit under this section with respect to any 
16
activity described in subsection (c)(4)(A).’’. 
17
(b) TREATMENT UNDER BASE EROSION TAX.—Sec-
18
tion 59A(b)(1)(B)(ii) of such Code is amended by striking 
19
‘‘plus’’ at the end of subclause (I), by redesignating sub-
20
clause (II) as subclause (III), and by inserting after sub-
21
clause (I) the following new subclause: 
22
‘‘(II) the credit allowed under 
23
section 38 for the taxable year which 
24
is properly allocable to the domestic 
25
19:08 Nov 24, 2020
H14
320 
•HR 14 IH
medical and drug manufacturing cred-
1
it determined under section 45U(a), 
2
plus’’. 
3
(c) PART OF GENERAL BUSINESS CREDIT.—Section 
4
38(b) of such Code is amended by striking ‘‘plus’’ at the 
5
end of paragraph (32), by striking the period at the end 
6
of paragraph (33) and inserting ‘‘, plus’’, and by adding 
7
at the end the following new paragraph: 
8
‘‘(34) the domestic medical and drug manufac-
9
turing credit determined under section 45U(a).’’. 
10
(d) CREDIT ALLOWED AGAINST ALTERNATIVE MIN-
11
IMUM TAX.—Section 38(c)(4)(B) of such Code is amended 
12
by redesignating clauses (x) through (xii) as clauses (xi) 
13
through (xiii), respectively, and by inserting after clause 
14
(ix) the following new clause: 
15
‘‘(x) the credit determined under sec-
16
tion 45U,’’. 
17
(e) CLERICAL AMENDMENT.—The table of sections 
18
for subpart D of part IV of subchapter A of chapter 1 
19
of such Code is amended by adding at the end the fol-
20
lowing new item: 
21
‘‘Sec. 45U. Domestic medical and drug manufacturing credit.’’. 
(f) EFFECTIVE DATE.—The amendments made by 
22
this section shall apply to taxable years beginning after 
23
December 31, 2020. 
24
19:08 Nov 24, 2020
H14
321 
•HR 14 IH
SEC. 8002. QUALIFYING ADVANCED MEDICAL MANUFAC-
1
TURING EQUIPMENT CREDIT. 
2
(a) IN GENERAL.—Subpart E of part IV of sub-
3
chapter A of chapter 1 of the Internal Revenue Code of 
4
1986 is amended by adding at the end the following new 
5
section: 
6
‘‘SEC. 48D. QUALIFYING ADVANCED MEDICAL MANUFAC-
7
TURING EQUIPMENT CREDIT. 
8
‘‘(a) IN GENERAL.—For purposes of section 46, the 
9
qualifying advanced medical manufacturing equipment 
10
credit determined under this section for any taxable year 
11
is the applicable percentage of the basis of any qualifying 
12
advanced medical manufacturing equipment placed in 
13
service during such taxable year. 
14
‘‘(b) APPLICABLE PERCENTAGE.—For purposes of 
15
subsection (a), the applicable percentage is— 
16
‘‘(1) 30 percent in the case of equipment which 
17
is placed in service before January 1, 2028, 
18
‘‘(2) 20 percent in the case of equipment which 
19
is placed in service during calendar year 2028, 
20
‘‘(3) 10 percent in the case of equipment which 
21
is placed in service during calendar year 2029, and 
22
‘‘(4) 0 percent in the case of equipment which 
23
is placed in service after December 31, 2029. 
24
‘‘(c) QUALIFYING ADVANCED MEDICAL MANUFAC-
25
TURING EQUIPMENT.—For purposes of this section, the 
26
19:08 Nov 24, 2020
H14
322 
•HR 14 IH
term ‘qualifying advanced medical manufacturing equip-
1
ment’ means property of a character subject to the allow-
2
ance for depreciation— 
3
‘‘(1) which is machinery or equipment that is 
4
designed and used to manufacture a— 
5
‘‘(A) drug (as such term is defined in sec-
6
tion 201(g)(1) of the Federal Food, Drug, and 
7
Cosmetic Act), 
8
‘‘(B) device (as such term is defined in sec-
9
tion 201(h) of such Act), or 
10
‘‘(C) biological product (as such term is 
11
defined in section 351(i) of the Public Health 
12
Service Act), 
13
‘‘(2) which has been identified by the Secretary 
14
(after consultation with the Secretary of Health and 
15
Human Services) as machinery or equipment that— 
16
‘‘(A) incorporates novel technology or uses 
17
an established technique or technology in a new 
18
or innovative way, or 
19
‘‘(B) that can improve medical product 
20
quality, address shortages of medicines, and 
21
speed time-to-market, 
22
‘‘(3) which is placed in service in the United 
23
States by the taxpayer, and 
24
19:08 Nov 24, 2020
H14
323 
•HR 14 IH
‘‘(4) with respect to which depreciation is allow-
1
able. 
2
‘‘(d) CERTAIN
QUALIFIED
PROGRESS
EXPENDI-
3
TURES RULES MADE APPLICABLE.—Rules similar to the 
4
rules of subsections (c)(4) and (d) of section 46 (as in 
5
effect on the day before the enactment of the Revenue 
6
Reconciliation Act of 1990) shall apply for purposes of 
7
this section. 
8
‘‘(e) REGULATIONS.—The Secretary shall prescribe 
9
such regulations or other guidance as may be necessary 
10
to carry out the purposes of this section, including regula-
11
tions which prevent abuse or fraud.’’. 
12
(b) TREATMENT UNDER BASE EROSION TAX.—Sec-
13
tion 59A(b)(1)(B)(ii) of such Code, as amended by section 
14
8001 of this Act, is further amended by striking ‘‘plus’’ 
15
at the end of subclause (II), by redesignating subclause 
16
(III) as subclause (IV), and by inserting after subclause 
17
(II) the following new subclause: 
18
‘‘(III) the credit allowed under 
19
section 46 for the taxable year which 
20
is properly allocable to the qualifying 
21
advanced 
medical 
manufacturing 
22
equipment credit determined under 
23
section 48D(a), plus’’. 
24
19:08 Nov 24, 2020
H14
324 
•HR 14 IH
(c) PART OF INVESTMENT CREDIT.—Section 46 of 
1
such Code is amended by striking ‘‘and’’ at the end of 
2
paragraph (5), by striking the period at the end of para-
3
graph (6) and inserting ‘‘, and’’, and by adding at the 
4
end the following new paragraph: 
5
‘‘(7) the qualifying advanced medical manufac-
6
turing equipment credit.’’. 
7
(d) CLERICAL AMENDMENT.—The table of sections 
8
for subpart D of part IV of subchapter A of chapter 1 
9
of such Code is amended by adding at the end the fol-
10
lowing new item: 
11
‘‘Sec. 48D. Qualifying advanced medical manufacturing equipment credit.’’. 
(e) EFFECTIVE DATE.—The amendments made by 
12
this section shall apply to periods after the date of the 
13
enactment of this section under rules similar to the rules 
14
of section 48(m) of the Internal Revenue Code of 1986 
15
(as in effect on the date of the enactment fo the Revenue 
16
Reconciliation Act of 1990). 
17
SEC. 8003. NEW MEDICAL RESEARCH EXPENDITURE COM-
18
19
SEARCH ACTIVITIES. 
20
(a) IN GENERAL.—Section 41(a) of the Internal Rev-
21
enue Code of 1986 is amended by striking ‘‘and’’ at the 
22
end of paragraph (2), by striking the period at the end 
23
of paragraph (3) and inserting ‘‘, and’’, and by adding 
24
at the end the following new paragraph: 
25
19:08 Nov 24, 2020
H14
325 
•HR 14 IH
‘‘(4) 14 percent of specified medical research 
1
expenditures.’’. 
2
(b) SPECIFIED
MEDICAL
RESEARCH
EXPENDI-
3
TURES.—Section 41(f) of such Code is amended by adding 
4
at the end the following new paragraph: 
5
‘‘(7) SPECIFIED MEDICAL RESEARCH EXPENDI-
6
TURES.— 
7
‘‘(A) IN
GENERAL.—The term ‘specified 
8
medical research expenditures’ means amounts 
9
paid or incurred for qualified research with re-
10
spect to any qualified countermeasure. 
11
‘‘(B) QUALIFIED COUNTERMEASURE.—The 
12
term ‘qualified countermeasure’ has the mean-
13
ing given to such term in section 319F–1(a)(2) 
14
of the Public Health Service Act (42 U.S.C. 
15
247d–6a(a)(2)).’’. 
16
(c) DENIAL OF DOUBLE BENEFIT.— 
17
(1) TAXABLE YEARS BEGINNING BEFORE JANU-
18
ARY 1, 2021.—In the case of specified medical re-
19
search expenditures (as defined in section 41(f)(7) 
20
of such Code (as added by this section)) paid or in-
21
curred in taxable years beginning before January 1, 
22
2021— 
23
(A) such expenditures shall be treated in 
24
the same manner as qualified research expenses 
25
19:08 Nov 24, 2020
H14
326 
•HR 14 IH
and basic research expenses under section 
1
280C(c)(1) of such Code (as in effect on the 
2
day before the enactment of the Tax Cuts and 
3
Jobs Act), and 
4
(B) the amount determined under section 
5
280C(c)(2)(A) (as in effect on such day) for the 
6
taxable year shall be increased by the amount 
7
of credit determined for the taxable year under 
8
section 41(a)(4) (as added by this section). 
9
(2) TAXABLE YEARS BEGINNING AFTER DECEM-
10
BER 31, 2020.—Section 280C(c)(1) of such Code is 
11
amended by striking ‘‘section 41(a)(1)’’ and insert-
12
ing ‘‘paragraphs (1) and (4) of section 41(a)’’. 
13
(d) CONFORMING AMENDMENT.—Section 41(f)(1) of 
14
such Code is amended by striking ‘‘and amounts paid or 
15
incurred to energy research consortiums’’ each place it ap-
16
pears and inserting ‘‘, amounts paid or incurred to energy 
17
research consortiums, and specified medical research ex-
18
penditures’’. 
19
(e) EFFECTIVE DATE.—The amendments made by 
20
this section shall apply to amounts paid or incurred after 
21
the date of the enactment of this Act, in taxable years 
22
ending after such date. 
23
19:08 Nov 24, 2020
H14
327 
•HR 14 IH
SEC. 8004. REFUNDABLE PORTION OF RESEARCH CREDIT 
1
FOR SMALL BUSINESSES ENGAGING IN SPEC-
2
IFIED MEDICAL RESEARCH. 
3
(a) IN GENERAL.—Section 41 of the Internal Rev-
4
enue Code of 1986 is amended by adding at the end the 
5
following new subsection: 
6
‘‘(i) REFUNDABLE
FOR
SMALL
BUSI-
7
NESSES ENGAGING IN SPECIFIED MEDICAL RESEARCH.— 
8
‘‘(1) IN GENERAL.—At the election of a medical 
9
research small business, the portion of the credit de-
10
termined under this section for the taxable year 
11
which is properly allocable to specified medical re-
12
search shall be treated (other than for purposes of 
13
section 280C) as a credit allowed under subpart C 
14
(and not this subpart). 
15
‘‘(2) MEDICAL RESEARCH SMALL BUSINESS.— 
16
For purposes of this subsection, the term ‘medical 
17
research small business’ means any domestic C cor-
18
poration— 
19
‘‘(A) which conducts any specified medical 
20
research during the taxable year, and 
21
‘‘(B) the gross receipts of which (deter-
22
mined under the rules of subsection (c)) for the 
23
taxable year do not exceed $1,000,000. 
24
‘‘(3) SPECIFIED
MEDICAL
RESEARCH.—For 
25
purposes of this subsection, the term ‘specified med-
26
19:08 Nov 24, 2020
H14
328 
•HR 14 IH
ical research’ means any qualified research with re-
1
spect to qualified countermeasures (as defined in 
2
section 319F–1(a)(2) of the Public Health Service 
3
Act (42 U.S.C. 247d–6a(a)(2))). 
4
‘‘(4) ELECTION.—Any election under this sub-
5
section for any taxable year— 
6
‘‘(A) shall specify the amount of the credit 
7
to which such election applies, 
8
‘‘(B) shall be made on or before the due 
9
date (including extensions) of the return of tax 
10
for the taxable year, 
11
‘‘(C) may not be made for any taxable year 
12
with respect to any portion of the credit deter-
13
mined under this section with respect to which 
14
an election is made under subsection (h), and 
15
‘‘(D) may be revoked only with the consent 
16
of the Secretary. 
17
‘‘(5) REGULATIONS.—The Secretary shall pre-
18
scribe such regulations for purposes of this sub-
19
section as may be necessary or appropriate for de-
20
termining proper allocation to specified medical re-
21
search of the portion of any credit allowed to a tax-
22
payer for a taxable year under this section.’’. 
23
19:08 Nov 24, 2020
H14
329 
•HR 14 IH
(b) CONFORMING AMENDMENT.—Section 1324(b) of 
1
title 31, United States Code, is amended by inserting 
2
‘‘41(i),’’ after ‘‘6428,’’. 
3
(c) EFFECTIVE DATE.—The amendments made by 
4
this section shall apply to taxable years beginning after 
5
December 31, 2020. 
6
SEC. 8005. EXCEPTION FROM PASSIVE LOSS RULES FOR IN-
7
VESTMENTS 
IN 
SPECIFIED 
MEDICAL 
RE-
8
SEARCH SMALL BUSINESS PASS-THRU ENTI-
9
TIES. 
10
(a) IN GENERAL.—Subsection (c) of section 469 of 
11
the Internal Revenue Code of 1986 is amended by redesig-
12
nating paragraphs (4) through (7) as paragraphs (5) 
13
through (8), respectively, and by inserting after paragraph 
14
(3) the following new paragraph: 
15
‘‘(4) SPECIFIED
MEDICAL
RESEARCH
ACTIVI-
16
TIES.— 
17
‘‘(A) IN GENERAL.—The term ‘passive ac-
18
tivity’ shall not include any qualified medical re-
19
search activity of the taxpayer carried on by a 
20
specified medical research small business pass- 
21
thru entity. 
22
‘‘(B) TREATMENT OF LOSSES AND DEDUC-
23
TIONS.— 
24
19:08 Nov 24, 2020
H14
330 
•HR 14 IH
‘‘(i) IN GENERAL.—Losses or deduc-
1
tions of a taxpayer in connection with 
2
qualified medical research activities carried 
3
on by a specified medical research small 
4
business pass-thru entity shall not be 
5
treated as losses or deductions, respec-
6
tively, from a passive activity except as 
7
provided in clause (ii) and subparagraph 
8
(C). 
9
‘‘(ii) LIMITATION.—Clause (i) shall 
10
apply to losses and deductions of a tax-
11
payer in connection with a specified med-
12
ical small business pass-thru entity for a 
13
taxable year only to the extent that the ag-
14
gregate losses and deductions of the tax-
15
payer in connection with qualified medical 
16
research activities of such entity for such 
17
taxable year do not exceed the portion of 
18
the taxpayer’s adjusted basis in the tax-
19
payer’s ownership interest in such entity 
20
that is attributable to money or other 
21
property contributed— 
22
‘‘(I) in exchange for such owner-
23
ship interest, and 
24
19:08 Nov 24, 2020
H14
331 
•HR 14 IH
‘‘(II) specifically for use in con-
1
nection with qualified medical re-
2
search activities. 
3
For purposes of the preceding sentence, 
4
the taxpayer’s basis shall not include any 
5
portion of such basis which is attributable 
6
to an increase in a partner’s share of the 
7
liabilities of a partnership that is consid-
8
ered under section 752(a) as a contribution 
9
of money. 
10
‘‘(C) TREATMENT OF CARRYOVERS.—Sub-
11
paragraph (B)(i) shall not apply to the portion 
12
of any loss or deduction that is carried over 
13
under subsection (b) into a taxable year other 
14
than the taxable year in which such loss or de-
15
duction arose. 
16
‘‘(D) QUALIFIED MEDICAL RESEARCH AC-
17
TIVITY.—For purposes of this paragraph, the 
18
term ‘qualified medical research activity’ means 
19
any qualified research (within the meaning of 
20
section 41(d)) with respect to qualified counter-
21
measures (as defined in section 319F–1(a)(2) 
22
of the Public Health Service Act (42 U.S.C. 
23
247d–6a(a)(2))). 
24
19:08 Nov 24, 2020
H14
332 
•HR 14 IH
‘‘(E) 
SPECIFIED
MEDICAL
RESEARCH 
1
SMALL
BUSINESS
PASS-THRU
ENTITY.—For 
2
purposes of this paragraph, the term ‘specified 
3
medical research small business pass-thru enti-
4
ty’ means any domestic pass-thru entity for any 
5
taxable year if— 
6
‘‘(i) more than 80 percent of such en-
7
tity’s expenditures on qualified research for 
8
such taxable year are paid or incurred in 
9
connection with qualified medical research 
10
activities, and 
11
‘‘(ii) the gross receipts (as determined 
12
under the rules of section 41(h)(3)) of 
13
such entity for the taxable year (and each 
14
preceding taxable year) is less than 
15
$1,000,000. 
16
‘‘(F) CAPITAL EXPENDITURES TAKEN INTO 
17
ACCOUNT FOR EXPENDITURES TEST.—An ex-
18
penditure shall not fail to be taken into account 
19
under subparagraph (E)(i) merely because such 
20
expenditure is chargeable to capital account. 
21
‘‘(G) PASS-THRU
ENTITY.—For purposes 
22
of this paragraph, the term ‘pass-thru entity’ 
23
means any partnership, S corporation, or other 
24
19:08 Nov 24, 2020
H14
333 
•HR 14 IH
entity identified by the Secretary as a pass-thru 
1
entity for purposes of this paragraph. 
2
‘‘(H) AGGREGATION RULES.— 
3
‘‘(i) IN GENERAL.—All persons treat-
4
ed as a single employer under subsection 
5
(a) or (b) of section 52, or subsection (m) 
6
or (o) of section 414, shall be treated as a 
7
single entity for purposes of subparagraphs 
8
(E) and (F)(iii). 
9
‘‘(ii) 
LIMITATION
WHERE
ENTITY 
10
WOULD NOT QUALIFY.—No entity shall be 
11
treated as a specified medical research 
12
small business pass-thru entity unless such 
13
entity qualifies as such both with and with-
14
out the application of clause (i).’’. 
15
(b) MATERIAL PARTICIPATION NOT REQUIRED.— 
16
Paragraph (5) of section 469(c) of the Internal Revenue 
17
Code of 1986, as redesignated by subsection (a), is amend-
18
ed by striking ‘‘and (3)’’ in the heading and text and in-
19
serting ‘‘, (3), and (4)’’. 
20
(c) CERTAIN RESEARCH-RELATED DEDUCTIONS AND 
21
CREDITS
OF SPECIFIED MEDICAL RESEARCH SMALL 
22
BUSINESS PASS-THRU ENTITIES ALLOWED
FOR PUR-
23
24
19:08 Nov 24, 2020
H14
334 
•HR 14 IH
(1) DEDUCTION FOR RESEARCH AND EXPERI-
1
MENTAL EXPENDITURES.—Paragraph (2) of section 
2
56(b) of the Internal Revenue Code of 1986 is 
3
amended by adding at the end the following new 
4
subparagraph: 
5
‘‘(E) EXCEPTION FOR SPECIFIED MEDICAL 
6
RESEARCH SMALL BUSINESS PASS-THRU ENTI-
7
TIES.—In the case of a specified medical re-
8
search small business pass-thru entity (as de-
9
fined in section 469(c)(4)), this paragraph shall 
10
not apply to any amount allowable as a deduc-
11
tion under section 174(a).’’. 
12
(2) ALLOWANCE
OF
CERTAIN
RESEARCH-RE-
13
LATED
CREDITS.—Subparagraph (B) of section 
14
38(c)(4) of such Code is amended by redesignating 
15
clauses (ii) through (ix) as clauses (iii) through (x), 
16
respectively, and by inserting after clause (i) the fol-
17
lowing new clause: 
18
‘‘(ii) the credit of an individual tax-
19
payer determined under section 41 to the 
20
extent attributable to a specified medical 
21
research small business pass-thru entity 
22
(as defined in section 469(c)(4)),’’. 
23
(d) EXCEPTION TO LIMITATION ON PASS-THRU OF 
24
RESEARCH CREDIT.—Subsection (g) of section 41 of such 
25
19:08 Nov 24, 2020
H14
335 
•HR 14 IH
Code is amended by adding at the end the following: 
1
‘‘Paragraphs (2) and (4) shall not apply with respect to 
2
any specified medical research small business pass-thru 
3
entity (as defined in section 469(c)(4)).’’. 
4
(e) EFFECTIVE DATE.—The amendments made by 
5
this section shall apply to losses and credits arising in tax-
6
able years beginning after December 31, 2020. 
7
SEC. 8006. TEMPORARY CARRYOVER FOR HEALTH AND DE-
8
PENDENT CARE FLEXIBLE SPENDING AR-
9
RANGEMENTS. 
10
(a) IN GENERAL.—With respect to the 2020 plan 
11
year for any health flexible spending arrangement or any 
12
dependent care flexible spending arrangement, an em-
13
ployer may elect to amend its cafeteria plan to permit any 
14
unused amounts remaining in such flexible spending ar-
15
rangement at the end of such plan year to be carried over 
16
to the 2021 plan year, pursuant to rules similar to the 
17
rules established for health flexible spending arrangements 
18
under Internal Revenue Service Notice 2013–71. 
19
(b) RETROACTIVE APPLICATION.—An employer shall 
20
be permitted to amend its cafeteria plan to effectuate the 
21
rule described in subsection (a), provided that such 
22
amendment— 
23
(1) is adopted before January 1, 2021; and 
24
19:08 Nov 24, 2020
H14
336 
•HR 14 IH
(2) provides that the rule described in such sub-
1
section shall be in effect as of the first day of the 
2
2020 plan year. 
3
(c) DEFINITIONS.—Any term used in this section 
4
which is also used in section 125 of the Internal Revenue 
5
Code of 1986 or the regulations thereunder shall have the 
6
same meaning as when used in such section or regulations. 
7
SEC. 8007. INCREASE IN EXCLUSION FOR EMPLOYER-PRO-
8
VIDED DEPENDENT CARE ASSISTANCE. 
9
(a) IN GENERAL.—Section 129(a)(2) of the Internal 
10
Revenue Code of 1986 is amended by adding at the end 
11
the following new subparagraph: 
12
‘‘(D) SPECIAL RULE FOR 2020 AND 2021.— 
13
In the case of any taxable year beginning dur-
14
ing 2020 or 2021, subparagraph (A) shall be 
15
applied by substituting ‘$10,500 ($5,250’ for 
16
‘$5,000 ($2,500’.’’. 
17
(b) EFFECTIVE DATE.—The amendment made by 
18
this section shall apply to taxable years beginning after 
19
December 31, 2019. 
20
(c) RETROACTIVE PLAN AMENDMENTS.—A plan or 
21
other arrangement that otherwise satisfies all applicable 
22
requirements of sections 106, 125, and 129 of the Internal 
23
Revenue Code of 1986 (including any rules or regulations 
24
thereunder) shall not fail to be treated as a cafeteria plan 
25
19:08 Nov 24, 2020
H14
337 
•HR 14 IH
or dependent care flexible spending arrangement merely 
1
because such plan or arrangement is amended pursuant 
2
to a provision under this section and such amendment is 
3
retroactive, if— 
4
(1) such amendment is adopted no later than 
5
the last day of the plan year in which the amend-
6
ment is effective, and 
7
(2) the plan or arrangement is operated con-
8
sistent with the terms of such amendment during 
9
the period beginning on the effective date of the 
10
amendment and ending on the date the amendment 
11
is adopted. 
12
SEC. 8008. TEMPORARY INCREASE IN CONTRIBUTION LIM-
13
ITS FOR HEALTH SAVINGS ACCOUNTS. 
14
(a) IN GENERAL.—Section 223(b) of the Internal 
15
Revenue Code of 1986 is amended by adding at the end 
16
the following new paragraph: 
17
‘‘(9) INCREASE IN MONTHLY LIMITATIONS FOR 
18
TAXABLE YEARS 2020 AND 2021.—In the case of any 
19
month during a taxable year which begins after De-
20
cember 31, 2019, and before January 1, 2022, the 
21
dollar amount in effect under subparagraph (A) or 
22
(B) of paragraph (2) for such month shall be twice 
23
the amount otherwise applicable under such sub-
24
paragraph, as determined— 
25
19:08 Nov 24, 2020
H14
338 
•HR 14 IH
‘‘(A) before application of paragraph (3), 
1
‘‘(B) after application of subsection (g), 
2
and 
3
‘‘(C) without regard to this paragraph.’’. 
4
(b) EFFECTIVE DATE.—The amendment made by 
5
this section shall apply with respect to taxable years begin-
6
ning after December 31, 2019. 
7
SEC. 8009. TEMPORARY ALLOWANCE OF PAYMENTS FOR 
8
EMPLOYMENT-RELATED 
EXPENSES 
UNDER 
9
HEALTH SAVINGS ACCOUNTS. 
10
(a) IN GENERAL.—Section 223(d)(2) of the Internal 
11
Revenue Code of 1986 is amended by adding at the end 
12
the following new subparagraph: 
13
‘‘(E) INCLUSION
OF
EMPLOYMENT-RE-
14
LATED
EXPENSES
FOR
TAXABLE
YEARS
2020 
15
AND
2021.—In the case of any taxable year 
16
which begins after December 31, 2019, and be-
17
fore January 1, 2022, the term ‘qualified med-
18
ical expenses’ includes, with respect to an ac-
19
count beneficiary, any amounts paid by such 
20
beneficiary for employment-related expenses (as 
21
defined in section 21(b)(2)) which are incurred 
22
during such taxable year.’’. 
23
(b) CONFORMING AMENDMENT.—Section 21(c) of 
24
the Internal Revenue Code of 1986 is amended by insert-
25
19:08 Nov 24, 2020
H14
339 
•HR 14 IH
ing ‘‘and any amounts paid or distributed out of a health 
1
savings account which are used exclusively to pay expenses 
2
described in section 223(d)(2)(E) which are incurred by 
3
the taxpayer during such taxable year’’ before the period 
4
at the end of the second sentence. 
5
(c) EFFECTIVE DATE.—The amendments made by 
6
this section shall apply with respect to taxable years begin-
7
ning after December 31, 2019. 
8
SEC. 8010. TREATMENT OF DIRECT PRIMARY CARE SERV-
9
ICE ARRANGEMENTS. 
10
(a) IN GENERAL.—Section 223(c)(1) of the Internal 
11
Revenue Code of 1986 is amended by adding at the end 
12
the following new subparagraph: 
13
‘‘(D) TREATMENT
OF
DIRECT
PRIMARY 
14
CARE SERVICE ARRANGEMENTS.— 
15
‘‘(i) IN GENERAL.—A direct primary 
16
care service arrangement shall not be 
17
treated as a health plan for purposes of 
18
subparagraph (A)(ii). 
19
‘‘(ii) DIRECT PRIMARY CARE SERVICE 
20
ARRANGEMENT.—For purposes of this 
21
paragraph— 
22
‘‘(I) IN GENERAL.—The term ‘di-
23
rect primary care service arrange-
24
ment’ means, with respect to any indi-
25
19:08 Nov 24, 2020
H14
340 
•HR 14 IH
vidual, an arrangement under which 
1
such individual is provided medical 
2
care (as defined in section 213(d)) 
3
consisting solely of primary care serv-
4
ices provided by primary care practi-
5
tioners 
(as 
defined 
in 
section 
6
1833(x)(2)(A) of the Social Security 
7
Act, determined without regard to 
8
clause (ii) thereof), if the sole com-
9
pensation for such care is a fixed peri-
10
odic fee. 
11
‘‘(II) LIMITATION.—With respect 
12
to any individual for any month, such 
13
term shall not include any arrange-
14
ment if the aggregate fees for all di-
15
rect primary care service arrange-
16
ments (determined without regard to 
17
this subclause) with respect to such 
18
individual for such month exceed 
19
$150 (twice such dollar amount in the 
20
case of an individual with any direct 
21
primary care service arrangement (as 
22
so determined) that covers more than 
23
one individual). 
24
19:08 Nov 24, 2020
H14
341 
•HR 14 IH
‘‘(iii) CERTAIN
SERVICES
SPECIFI-
1
CALLY
EXCLUDED
FROM
TREATMENT
AS 
2
PRIMARY
CARE
SERVICES.—For purposes 
3
of this subparagraph, the term ‘primary 
4
care services’ shall not include— 
5
‘‘(I) procedures that require the 
6
use of general anesthesia, and 
7
‘‘(II) laboratory services not typi-
8
cally administered in an ambulatory 
9
primary care setting. 
10
The Secretary, after consultation with the 
11
Secretary of Health and Human Services, 
12
shall issue regulations or other guidance 
13
regarding the application of this clause.’’. 
14
(b) DIRECT PRIMARY CARE SERVICE ARRANGEMENT 
15
FEES
TREATED
AS
MEDICAL
EXPENSES.—Section 
16
223(d)(2)(C) of the Internal Revenue Code of 1986 is 
17
amended by striking ‘‘or’’ at the end of clause (iii), by 
18
striking the period at the end of clause (iv) and inserting 
19
‘‘, or’’, and by adding at the end the following new clause: 
20
‘‘(v) any direct primary care service arrangement.’’. 
21
(c) INFLATION ADJUSTMENT.—Section 223(g)(1) of 
22
the Internal Revenue Code of 1986 is amended— 
23
(1) by inserting ‘‘, (c)(1)(D)(ii)(II),’’ after 
24
‘‘(b)(2),’’ each place such term appears, and 
25
19:08 Nov 24, 2020
H14
342 
•HR 14 IH
(2) in subparagraph (B), by inserting ‘‘and 
1
(iii)’’ after ‘‘clause (ii)’’ in clause (i), by striking 
2
‘‘and’’ at the end of clause (i), by striking the period 
3
at the end of clause (ii) and inserting ‘‘, and’’, and 
4
by inserting after clause (ii) the following new 
5
clause: 
6
‘‘(iii) in the case of the dollar amount 
7
in subsection (c)(1)(D)(ii)(II) for taxable 
8
years beginning in calendar years after 
9
2020, ‘calendar year 2019’.’’. 
10
(d) REPORTING OF DIRECT PRIMARY CARE SERVICE 
11
ARRANGEMENT FEES ON W–2.—Section 6051(a) of the 
12
Internal Revenue Code of 1986 is amended by striking 
13
‘‘and’’ at the end of paragraph (16), by striking the period 
14
at the end of paragraph (17) and inserting ‘‘, and’’, and 
15
by inserting after paragraph (17) the following new para-
16
graph: 
17
‘‘(18) in the case of a direct primary care serv-
18
ice 
arrangement 
(as 
defined 
in 
section 
19
223(c)(1)(D)(ii)) which is provided in connection 
20
with employment, the aggregate fees for such ar-
21
rangement for such employee.’’. 
22
(e) EFFECTIVE DATE.— 
23
(1) IN GENERAL.—Except as provided under 
24
paragraph (2), the amendments made by this section 
25
19:08 Nov 24, 2020
H14
343 
•HR 14 IH
shall apply to months beginning after December 31, 
1
2019, in taxable years ending after such date. 
2
(2) INFLATION
ADJUSTMENT.—The amend-
3
ments made by subsection (c) shall apply to taxable 
4
years beginning in calendar years beginning after 
5
December 31, 2020. 
6
SEC. 8011. ALLOW BOTH SPOUSES TO MAKE CATCH-UP CON-
7
TRIBUTIONS TO THE SAME HSA ACCOUNT. 
8
(a) IN GENERAL.—Paragraph (5) of section 223(b) 
9
of the Internal Revenue Code of 1986 is amended to read 
10
as follows: 
11
‘‘(5) SPECIAL RULE FOR MARRIED INDIVIDUALS 
12
WITH FAMILY COVERAGE.— 
13
‘‘(A) IN GENERAL.—In the case of individ-
14
uals who are married to each other, if both 
15
spouses are eligible individuals and either 
16
spouse has family coverage under a high de-
17
ductible health plan as of the first day of any 
18
month— 
19
‘‘(i) the limitation under paragraph 
20
(1) shall be applied by not taking into ac-
21
count any other high deductible health 
22
plan coverage of either spouse (and if such 
23
spouses both have family coverage under 
24
separate high deductible health plans, only 
25
19:08 Nov 24, 2020
H14
344 
•HR 14 IH
one such coverage shall be taken into ac-
1
count), 
2
‘‘(ii) such limitation (after application 
3
of clause (i)) shall be reduced by the ag-
4
gregate amount paid to Archer MSAs of 
5
such spouses for the taxable year, and 
6
‘‘(iii) such limitation (after application 
7
of clauses (i) and (ii)) shall be divided 
8
equally between such spouses unless they 
9
agree on a different division. 
10
‘‘(B) TREATMENT
OF
ADDITIONAL
CON-
11
TRIBUTION AMOUNTS.—If both spouses referred 
12
to in subparagraph (A) have attained age 55 
13
before the close of the taxable year, the limita-
14
tion referred to in subparagraph (A)(iii) which 
15
is subject to division between the spouses shall 
16
include the additional contribution amounts de-
17
termined under paragraph (3) for both spouses. 
18
In any other case, any additional contribution 
19
amount determined under paragraph (3) shall 
20
not be taken into account under subparagraph 
21
(A)(iii) and shall not be subject to division be-
22
tween the spouses.’’. 
23
19:08 Nov 24, 2020
H14
345 
•HR 14 IH
(b) EFFECTIVE DATE.—The amendment made by 
1
this section shall apply to taxable years beginning after 
2
December 31, 2019. 
3
SEC. 8012. REPEAL OF CEILING ON DEDUCTIBLE AND OUT- 
4
OF-POCKET EXPENSES UNDER A HIGH DE-
5
DUCTIBLE HEALTH PLAN. 
6
(a) IN GENERAL.—Subparagraph (A) of section 
7
223(c)(2) of the Internal Revenue Code of 1986 is amend-
8
ed to read as follows: 
9
‘‘(A) HIGH DEDUCTIBLE HEALTH PLAN.— 
10
The term ‘high deductible health plan’ means a 
11
health plan which has an annual deductible 
12
which is not less than— 
13
‘‘(i) $1,000 for self-only coverage, and 
14
‘‘(ii) twice the dollar amount in clause 
15
(i) for family coverage.’’. 
16
(b) CONFORMING AMENDMENTS.— 
17
(1) Subparagraph (D) of section 223(c)(2) of 
18
the Internal Revenue Code of 1986 is amended to 
19
read as follows: 
20
‘‘(D) 
SPECIAL
RULE
FOR
NETWORK 
21
PLANS.—In the case of a plan using a network 
22
of providers, such plan’s annual deductible for 
23
services provided outside of such network shall 
24
19:08 Nov 24, 2020
H14
346 
•HR 14 IH
not be taken into account for purposes of sub-
1
section (b)(2).’’. 
2
(2) Clause (ii) of section 223(g)(1)(B) of such 
3
Code is amended by striking ‘‘each dollar amount in 
4
subsection (c)(2)(A)’’ and inserting ‘‘the dollar 
5
amount in subsection (c)(2)(A)(i)’’. 
6
(c) EFFECTIVE DATE.—The amendments made by 
7
this section shall apply with respect to taxable years begin-
8
ning after December 31, 2019. 
9
SEC. 8013. ON-SITE EMPLOYEE CLINICS. 
10
(a) IN GENERAL.—Paragraph (1) of section 223(c) 
11
of the Internal Revenue Code of 1986, as amended by sec-
12
tion 8010 of this Act, is amended by adding at the end 
13
the following new subparagraph: 
14
‘‘(E) SPECIAL
RULE
FOR
QUALIFIED 
15
ITEMS AND SERVICES.— 
16
‘‘(i) IN
GENERAL.—For purposes of 
17
subparagraph (A)(ii), an individual shall 
18
not be treated as covered under a health 
19
plan described in subclauses (I) and (II) of 
20
such subparagraph merely because the in-
21
dividual is eligible to receive, or receives, 
22
qualified items and services— 
23
‘‘(I) at a healthcare facility lo-
24
cated at a facility owned or leased by 
25
19:08 Nov 24, 2020
H14
347 
•HR 14 IH
the employer of the individual (or of 
1
the individual’s spouse), or 
2
‘‘(II) at a healthcare facility op-
3
erated primarily for the benefit of em-
4
ployees of the employer of the indi-
5
vidual (or of the individual’s spouse). 
6
‘‘(ii) QUALIFIED ITEMS AND SERVICES 
7
DEFINED.—For purposes of this subpara-
8
graph, the term ‘qualified items and serv-
9
ices’ means the following: 
10
‘‘(I) Physical examination. 
11
‘‘(II) Immunizations, including 
12
injections of antigens provided by em-
13
ployees. 
14
‘‘(III) Drugs or biologicals other 
15
than a prescribed drug (as such term 
16
is defined in section 213(d)(3)). 
17
‘‘(IV) Treatment for injuries oc-
18
curring in the course of employment. 
19
‘‘(V) Preventive care for chronic 
20
conditions (as defined in clause (iv)). 
21
‘‘(VI) Drug testing. 
22
‘‘(VII) 
Hearing 
or 
vision 
23
screenings and related services. 
24
19:08 Nov 24, 2020
H14
348 
•HR 14 IH
‘‘(iii) AGGREGATION.—For purposes 
1
of clause (i), all persons treated as a single 
2
employer under subsection (b), (c), (m), or 
3
(o) of section 414 shall be treated as a sin-
4
gle employer. 
5
‘‘(iv) PREVENTIVE CARE FOR CHRON-
6
IC CONDITIONS.—For purposes of this sub-
7
paragraph, the term ‘preventive care for 
8
chronic conditions’ means any item or 
9
service specified in the Appendix of Inter-
10
nal Revenue Service Notice 2019–45 which 
11
is prescribed to treat an individual diag-
12
nosed with the associated chronic condition 
13
specified in such Appendix for the purpose 
14
of preventing the exacerbation of such 
15
chronic condition or the development of a 
16
secondary condition, including any amend-
17
ment, addition, removal, or other modifica-
18
tion made by the Secretary (pursuant to 
19
the authority granted to the Secretary 
20
under paragraph (2)(C)) to the items or 
21
services specified in such Appendix subse-
22
quent to the date of enactment of this sub-
23
paragraph.’’. 
24
19:08 Nov 24, 2020
H14
349 
•HR 14 IH
(b) EFFECTIVE DATE.—The amendments made by 
1
this section shall apply to months in taxable years begin-
2
ning after the date of enactment of this Act. 
3
SEC. 8014. ADJUSTMENT OF MEDICAL EXPENSE DEDUC-
4
TION. 
5
(a) IN GENERAL.—Section 213 of the Internal Rev-
6
enue Code of 1986 is amended— 
7
(1) in subsection (a), by striking ‘‘10 percent’’ 
8
and inserting ‘‘7.5 percent’’, and 
9
(2) by striking subsection (f) and inserting the 
10
following: 
11
‘‘(f) TEMPORARY SPECIAL RULE.—In the case of any 
12
taxable year beginning after December 31, 2019, and end-
13
ing before January 1, 2022, subsection (a) shall be applied 
14
with respect to a taxpayer by substituting ‘5 percent’ for 
15
‘7.5 percent’.’’. 
16
(b) EFFECTIVE DATE.—The amendments made by 
17
this section shall apply to taxable years beginning after 
18
December 31, 2019. 
19
SEC. 8015. HEALTHY WORKPLACE TAX CREDIT. 
20
(a) IN GENERAL.—In the case of an employer, there 
21
shall be allowed as a credit against applicable employment 
22
taxes for each calendar quarter an amount equal to 50 
23
percent of the sum of— 
24
19:08 Nov 24, 2020
H14
350 
•HR 14 IH
(1) the qualified employee protection expenses 
1
paid or incurred by the employer during such cal-
2
endar quarter, 
3
(2) the qualified workplace reconfiguration ex-
4
penses paid or incurred by the employer during such 
5
calendar quarter, 
6
(3) the qualified workplace technology expenses 
7
paid or incurred by the employer during such cal-
8
endar quarter, and 
9
(4) the qualified workplace training expenses 
10
paid or incurred by the employer during such cal-
11
endar quarter. 
12
(b) LIMITATIONS AND REFUNDABILITY.— 
13
(1) OVERALL DOLLAR LIMITATION ON CRED-
14
IT.— 
15
(A) IN
GENERAL.—The amount of the 
16
credit allowed under subsection (a) with respect 
17
to any employer for any calendar quarter shall 
18
not exceed the excess (if any) of— 
19
(i) the applicable dollar limit with re-
20
spect to such employer for such calendar 
21
quarter, over 
22
(ii) the aggregate credits allowed 
23
under subsection (a) with respect to such 
24
19:08 Nov 24, 2020
H14
351 
•HR 14 IH
employer for all preceding calendar quar-
1
ters. 
2
(B) APPLICABLE
DOLLAR
LIMIT.—The 
3
term ‘‘applicable dollar limit’’ means, with re-
4
spect to any employer for any calendar quarter, 
5
the sum of— 
6
(i) $1,000, multiplied so much of the 
7
average number of employees employed by 
8
such employer during such calendar quar-
9
ter as does not exceed 500, plus 
10
(ii) $750, multiplied by so much of 
11
such average number of employees as ex-
12
ceeds 500 but does not exceed 1,000, plus 
13
(iii) $500, multiplied by so much of 
14
such average number of employees as ex-
15
ceeds 1,000. 
16
(2) 
CREDIT
LIMITED
TO
EMPLOYMENT 
17
TAXES.—The credit allowed by subsection (a) with 
18
respect to any calendar quarter shall not exceed the 
19
applicable employment taxes (reduced by any credits 
20
allowed under subsections (e) and (f) of section 
21
3111 of the Internal Revenue Code of 1986, sections 
22
7001 and 7003 of the Families First Coronavirus 
23
Response Act, and section 2301 of the CARES Act) 
24
on the wages paid with respect to the employment 
25
19:08 Nov 24, 2020
H14
352 
•HR 14 IH
of all the employees of the eligible employer for such 
1
calendar quarter. 
2
(3) REFUNDABILITY OF EXCESS CREDIT.— 
3
(A) IN GENERAL.—If the amount of the 
4
credit under subsection (a) exceeds the limita-
5
tion of paragraph (2) for any calendar quarter, 
6
such excess shall be treated as an overpayment 
7
that shall be refunded under sections 6402(a) 
8
and 6413(b) of the Internal Revenue Code of 
9
1986. 
10
(B) TREATMENT OF PAYMENTS.—For pur-
11
poses of section 1324 of title 31, United States 
12
Code, any amounts due to the employer under 
13
this paragraph shall be treated in the same 
14
manner as a refund due from a credit provision 
15
referred to in subsection (b)(2) of such section. 
16
(c) 
QUALIFIED
EMPLOYEE
PROTECTION
EX-
17
PENSES.—For purposes of this section, the term ‘‘quali-
18
fied employee protection expenses’’ means amounts paid 
19
or incurred by the employer for— 
20
(1) testing employees of the employer for 
21
COVID–19 (including on a periodic basis), 
22
(2) equipment to protect employees of the em-
23
ployer 
from 
contracting 
COVID–19, 
including 
24
masks, gloves, and disinfectants, and 
25
19:08 Nov 24, 2020
H14
353 
•HR 14 IH
(3) cleaning products or services (whether pro-
1
vided by an employee of the taxpayer or a cleaning 
2
service provider) related to preventing the spread of 
3
COVID–19. 
4
(d) QUALIFIED WORKPLACE RECONFIGURATION EX-
5
PENSES.—For purposes of this section— 
6
(1) IN GENERAL.—The term ‘‘qualified work-
7
place reconfiguration expenses’’ means amounts paid 
8
or incurred by the employer to design and recon-
9
figure retail space, work areas, break areas, or other 
10
areas that employees or customers regularly use in 
11
the ordinary course of the employer’s trade or busi-
12
ness if such design and reconfiguration— 
13
(A) has a primary purpose of preventing 
14
the spread of COVID–19, 
15
(B) is with respect to an area that is lo-
16
cated in the United States and that is leased or 
17
owned by the employer, 
18
(C) is consistent with the purpose of the 
19
property immediately before the reconfigura-
20
tion, 
21
(D) is commensurate with the risks faced 
22
by the employees or customers or is consistent 
23
with recommendations made by the Centers for 
24
19:08 Nov 24, 2020
H14
354 
•HR 14 IH
Disease Control and Prevention or the Occupa-
1
tional Safety and Health Administration, 
2
(E) is completed pursuant to a reconfig-
3
uration plan and no comparable reconfiguration 
4
plan was in place before March 13, 2020, and 
5
(F) is completed before January 1, 2021. 
6
(2) REGULATIONS.—The Secretary shall pre-
7
scribe such regulations and other guidance as may 
8
be necessary or appropriate to carry out the pur-
9
poses of this subsection, including guidance defining 
10
primary purpose and reconfiguration plan. 
11
(e) QUALIFIED
WORKPLACE
TECHNOLOGY
EX-
12
PENSES.—For purposes of this section— 
13
(1) IN GENERAL.—The term ‘‘qualified work-
14
place technology expenses’’ means amounts paid or 
15
incurred by the employer for technology systems 
16
that employees or customers use in the ordinary 
17
course of the employer’s trade or business if such 
18
technology system— 
19
(A) has a primary purpose of preventing 
20
the spread of COVID–19, 
21
(B) is used for limiting physical contact 
22
between customers and employees in the United 
23
States, 
24
19:08 Nov 24, 2020
H14
355 
•HR 14 IH
(C) is commensurate with the risks faced 
1
by the employees or customers or is consistent 
2
with recommendations made by the Centers for 
3
Disease Control and Prevention or the Occupa-
4
tional Safety and Health Administration, 
5
(D) is acquired by the taxpayer after 
6
March 12, 2020, and is not acquired pursuant 
7
to a written binding contract entered into be-
8
fore such date, and 
9
(E) is placed in service by the taxpayer be-
10
fore January 1, 2021. 
11
(2) TECHNOLOGY SYSTEMS.—The term ‘‘tech-
12
nology systems’’ means computer software (as de-
13
fined in section 167(f)(1)) and qualified techno-
14
logical equipment (as defined in section 168(i)(2)). 
15
(3) REGULATIONS.—The Secretary shall pre-
16
scribe such regulations and other guidance as may 
17
be necessary or appropriate to carry out the pur-
18
poses of this subsection, including guidance defining 
19
primary purpose. 
20
(f) QUALIFIED WORKPLACE TRAINING EXPENSES.— 
21
For purposes of this section, the term ‘‘qualified workplace 
22
training expenses’’ means amounts paid or incurred by the 
23
employer for education and training with respect to indus-
24
try best practices that ensure— 
25
19:08 Nov 24, 2020
H14
356 
•HR 14 IH
(1) the health and safety of employees in the 
1
workplace with respect to COVID–19, and 
2
(2) the prevention of the spread of COVID–19 
3
in the workplace. 
4
(g) OTHER DEFINITIONS.—For purposes of this sec-
5
tion— 
6
(1) APPLICABLE
EMPLOYMENT
TAXES.—The 
7
term ‘‘applicable employment taxes’’ means the fol-
8
lowing: 
9
(A) The taxes imposed under section 
10
3111(a) of the Internal Revenue Code of 1986. 
11
(B) So much of the taxes imposed under 
12
section 3221(a) of such Code as are attrib-
13
utable to the rate in effect under section 
14
3111(a) of such Code. 
15
(2) COVID–19.—Except where the context 
16
clearly indicates otherwise, any reference in this sec-
17
tion to COVID–19 shall be treated as including a 
18
reference to the virus which causes COVID–19. 
19
(3) SECRETARY.—The term ‘‘Secretary’’ means 
20
the Secretary of the Treasury or the Secretary’s del-
21
egate. 
22
(4) OTHER TERMS.—Any term used in this sec-
23
tion (other than subsection (b)(1)(B)) which is also 
24
used in chapter 21 or 22 of the Internal Revenue 
25
19:08 Nov 24, 2020
H14
357 
•HR 14 IH
Code of 1986 shall have the same meaning as when 
1
used in such chapter. 
2
(h) CERTAIN GOVERNMENTAL EMPLOYERS.—This 
3
credit shall not apply to the Government of the United 
4
States, the government of any State or political subdivi-
5
sion thereof, or any agency or instrumentality of any of 
6
the foregoing. 
7
(i) SPECIAL RULES.— 
8
(1) AGGREGATION RULE.—All persons treated 
9
as a single employer under subsection (a) or (b) of 
10
section 52 of the Internal Revenue Code of 1986, or 
11
subsection (m) or (o) of section 414 of such Code, 
12
shall be treated as one employer for purposes of this 
13
section. 
14
(2) DENIAL OF DOUBLE BENEFIT.— 
15
(A) IN
GENERAL.—Rules similar to the 
16
rules of paragraphs (1) and (2) of section 
17
280C(b) shall apply for purposes of this section. 
18
(B) EXPENSES NOT TAKEN INTO ACCOUNT 
19
MORE
THAN
ONCE.—Any qualified workplace 
20
reconfiguration expense or qualified workplace 
21
technology expense shall not be treated as a 
22
qualified employee protection expense and any 
23
qualified workplace technology expense shall not 
24
19:08 Nov 24, 2020
H14
358 
•HR 14 IH
be treated as a qualified workplace reconfigura-
1
tion expense. 
2
(3) THIRD-PARTY PAYORS.—Any credit allowed 
3
under this section shall be treated as a credit de-
4
scribed in section 3511(d)(2) of such Code. 
5
(4) ELECTION NOT TO HAVE SECTION APPLY.— 
6
This section shall not apply with respect to any eligi-
7
ble employer for any calendar quarter if such em-
8
ployer elects (at such time and in such manner as 
9
the Secretary may prescribe) not to have this section 
10
apply. 
11
(j) TRANSFERS TO CERTAIN TRUST FUNDS.—There 
12
are hereby appropriated to the Federal Old-Age and Sur-
13
vivors Insurance Trust Fund and the Federal Disability 
14
Insurance Trust Fund established under section 201 of 
15
the Social Security Act (42 U.S.C. 401) and the Social 
16
Security Equivalent Benefit Account established under 
17
section 15A(a) of the Railroad Retirement Act of 1974 
18
(45 U.S.C. 231n–1(a)) amounts equal to the reduction in 
19
revenues to the Treasury by reason of this section (without 
20
regard to this subsection). Amounts appropriated by the 
21
preceding sentence shall be transferred from the general 
22
fund at such times and in such manner as to replicate 
23
to the extent possible the transfers which would have oc-
24
19:08 Nov 24, 2020
H14
359 
•HR 14 IH
curred to such Trust Fund or Account had this section 
1
not been enacted. 
2
(k) TREATMENT OF DEPOSITS.—The Secretary shall 
3
waive any penalty under section 6656 of the Internal Rev-
4
enue Code of 1986 for any failure to make a deposit of 
5
any applicable employment taxes if the Secretary deter-
6
mines that such failure was due to the reasonable anticipa-
7
tion of the credit allowed under this section. 
8
(l) REGULATIONS AND GUIDANCE.—The Secretary 
9
shall prescribe such regulations and other guidance as 
10
may be necessary or appropriate to carry out the purposes 
11
of this section, including— 
12
(1) with respect to the application of the credit 
13
under subsection (a) to third-party payors (including 
14
professional employer organizations, certified profes-
15
sional employer organizations, or agents under sec-
16
tion 3504 of the Internal Revenue Code of 1986), 
17
regulations or other guidance allowing such payors 
18
to submit documentation necessary to substantiate 
19
the amount of the credit allowed under subsection 
20
(a), and 
21
(2) regulations or other guidance to prevent 
22
abusive transactions. 
23
19:08 Nov 24, 2020
H14
360 
•HR 14 IH
(m) APPLICATION.—This section shall only apply to 
1
amounts paid or incurred after March 12, 2020, and be-
2
fore January 1, 2021. 
3
TITLE IX—MEDICARE 
4
PROVISIONS 
5
Subtitle A—Telehealth 
6
SEC. 9001. REMOVING CERTAIN GEOGRAPHIC AND ORIGI-
7
NATING SITE RESTRICTIONS ON THE FUR-
8
NISHING OF TELEHEALTH SERVICES UNDER 
9
THE MEDICARE PROGRAM. 
10
Section 1834(m)(4)(C) of the Social Security Act (42 
11
U.S.C. 1395m(m)(4)(C)) is amended— 
12
(1) in clause (i), by inserting ‘‘, with respect to 
13
services furnished on or after January 1, 2024,’’ 
14
after ‘‘telecommunications system and’’; and 
15
(2) in clause (ii)(X), by inserting ‘‘, with re-
16
spect to services furnished on or after January 1, 
17
2024,’’ after ‘‘but’’. 
18
SEC. 9002. MAKING PERMANENT FQHC AND RHC TELE-
19
HEALTH PAYMENTS. 
20
Section 1834(m)(6) of the Social Security Act (42 
21
U.S.C. 1395m(m)(8)), as so redesignated by section 2(7), 
22
is amended— 
23
(1) in the header, by striking ‘‘DURING EMER-
24
GENCY PERIOD’’; 
25
19:08 Nov 24, 2020
H14
361 
•HR 14 IH
(2) in subparagraph (A), in the matter pre-
1
ceding clause (i), by striking ‘‘During’’ and inserting 
2
‘‘With respect to services furnished on or after the 
3
first day of’’; and 
4
(3) in subparagraph (B)(i), by striking ‘‘during 
5
such emergency period’’. 
6
SEC. 9003. EXPANDING THE LIST OF PRACTITIONERS ELIGI-
7
BLE TO FURNISH TELEHEALTH SERVICES. 
8
Section 1834(m) of the Social Security Act (42 
9
U.S.C. 1395m(m)) is amended— 
10
(1) in paragraph (1), by striking ‘‘described in 
11
section 1842(b)(18)(C)’’ and inserting ‘‘as defined in 
12
paragraph (4)(E)’’; 
13
(2) in paragraph (3)(B), by inserting ‘‘de-
14
scribed in subparagraph (C) of such section’’ after 
15
‘‘practitioners’’; and 
16
(3) in paragraph (4), by amending subpara-
17
graph (E) to read as follows: 
18
‘‘(E) PRACTITIONER.—The term ‘practi-
19
tioner’ means a practitioner described in section 
20
1842(b)(18)(C) and includes, with respect to 
21
services furnished before January 1, 2024, any 
22
supplier (other than a physician) permitted to 
23
receive payment for a telehealth service under 
24
this section as of the date of the enactment of 
25
19:08 Nov 24, 2020
H14
362 
•HR 14 IH
this subparagraph pursuant to a waiver in ef-
1
fect as of such date under section 1135.’’. 
2
SEC. 9004. ALLOWING FOR THE PROVISION OF TELE-
3
HEALTH SERVICES VIA AUDIO-ONLY TELE-
4
COMMUNICATIONS SYSTEMS. 
5
Section 1834(m)(4) of the Social Security Act (42 
6
U.S.C. 1395m(m)(4)) is amended by adding at the end 
7
the following new subparagraph: 
8
‘‘(G) TELECOMMUNICATIONS SYSTEM.— 
9
‘‘(i) IN
GENERAL.—The term ‘tele-
10
communications system’ includes, in the 
11
case of a telehealth service furnished by a 
12
qualified provider (as defined in clause (ii)) 
13
to an individual located at an originating 
14
site before January 1, 2024, a communica-
15
tions system consisting of only audio capa-
16
bilities, but only if such individual does not 
17
have access to a communications system 
18
with audio-visual capabilities at such site. 
19
‘‘(ii) 
QUALIFIED
PROVIDER.—For 
20
purposes of clause (i), the term ‘qualified 
21
provider’ means, with respect a telehealth 
22
service furnished to an individual, a physi-
23
cian or practitioner who— 
24
19:08 Nov 24, 2020
H14
363 
•HR 14 IH
‘‘(I) furnished to such individual 
1
an item or service (other than such 
2
telehealth service) for which payment 
3
was made under any group health 
4
plan (as defined in section 2791 of 
5
the Public Health Service Act), health 
6
insurance coverage (as so defined), 
7
Federal health care program (as de-
8
fined in section 1128B(f)), or the 
9
health care program under chapter 89 
10
of title 5, United States Code, during 
11
the 3-year period ending on the date 
12
such telehealth service was furnished; 
13
or 
14
‘‘(II) is in the same practice (as 
15
determined by tax identification num-
16
ber) of a physician or practitioner who 
17
furnished such an item or service to 
18
such individual during such period.’’. 
19
SEC. 9005. MAKING PERMANENT THE SAFE HARBOR FOR 
20
ABSENCE OF DEDUCTIBLE FOR TELEHEALTH. 
21
(a) IN GENERAL.—Section 223(c)(2)(E) of the Inter-
22
nal Revenue Code of 1986 is amended by striking ‘‘In the 
23
case of plan years beginning on or before December 31, 
24
2021, a’’ and inserting ‘‘A’’. 
25
19:08 Nov 24, 2020
H14
364 
•HR 14 IH
(b) CERTAIN COVERAGE DISREGARDED.—Section 
1
223(c)(1)(B)(ii) of the Internal Revenue Code of 1986 is 
2
amended by striking ‘‘(in the case of plan years beginning 
3
on or before December 31, 2021)’’. 
4
SEC. 9006. REMOVING REQUIREMENT FOR FACE-TO-FACE 
5
VISITS BETWEEN HOME DIALYSIS PATIENTS 
6
AND PHYSICIANS. 
7
(a) IN GENERAL.—Section 1881(b)(3)(B) of the So-
8
cial Security Act (42 U.S.C. 1395rr(b)(3)(B)) is amend-
9
ed— 
10
(1) in clause (i), by striking ‘‘clauses (ii) and 
11
(iii)’’ and inserting ‘‘clause (ii)’’; 
12
(2) in clause (ii), by inserting ‘‘or (iv)’’ after 
13
‘‘clause (iii)’’; 
14
(3) by moving clause (iii) 6 ems to the left; and 
15
(4) by adding at the end the following new 
16
clause: 
17
‘‘(iv) Clause (ii) shall not apply to monthly end stage 
18
renal disease-related clinical assessments furnished before 
19
January 1, 2024, in the case of an individual who has 
20
received in-person training with respect to home dialysis.’’. 
21
(b) WAIVER AUTHORITY.— 
22
(1) IN GENERAL.—Notwithstanding any provi-
23
sion of section 1135 of the Social Security Act (42 
24
U.S.C. 1320b–5), the Secretary of Health and 
25
19:08 Nov 24, 2020
H14
365 
•HR 14 IH
Human Services may, with respect to a specified 
1
waiver (as defined in paragraph (2)), continue such 
2
waiver in effect for any period of time before Janu-
3
ary 1, 2024. 
4
(2) DEFINITION.—In this subsection, the term 
5
‘‘specified waiver’’ means a waiver in effect on the 
6
date of the enactment of this Act that, with respect 
7
to any provision of title XVIII of the Social Security 
8
Act (42 U.S.C. 1395 et seq.) that requires an in-per-
9
son visit with a provider of services or supplier (as 
10
such terms are defined in section 1861 of such Act 
11
(42 U.S.C. 1395x)) as a prerequisite for payment of 
12
any item or service under such title or for any other 
13
purpose, modifies such provision to allow such visit 
14
to be conducted through the use of telehealth. 
15
SEC. 9007. REPORT ON TELEHEALTH PAYMENT INTEGRITY. 
16
Not later than 1 year after the date of the enactment 
17
of this Act, the Inspector General of the Department of 
18
Health and Human Services shall review claims for pay-
19
ment for telehealth services furnished under the Medicare 
20
program during the emergency period described in section 
21
1135(g)(1)(B) of the Social Security Act (42 U.S.C. 
22
1320b–5(g)(1)(B)) and submit to Congress a report on 
23
any instances of waste, fraud, or abuse identified through 
24
such review. 
25
19:08 Nov 24, 2020
H14
366 
•HR 14 IH
SEC. 9008. INCREASING FUNDING FOR REVIEW OF TELE-
1
HEALTH CLAIMS. 
2
There are authorized to be appropriated to the In-
3
spector General of the Department of Health and Human 
4
Services $10,000,000 for fiscal years 2021 through 2023 
5
for purposes of conducting audits and other oversight ac-
6
tivities with respect to payments made under section 
7
1834(m) of the Social Security Act (42 U.S.C. 
8
1395m(m)). 
9
SEC. 9009. TELEHEALTH RESOURCES. 
10
Not later than 6 months after the last day of the 
11
emergency period described in section 1135(g)(1)(B) of 
12
the Social Security Act (42 U.S.C. 1320b–5(g)(1)(B)), the 
13
Secretary of Health and Human Services shall develop and 
14
make available to physicians (as defined in section 1861(r) 
15
of such Act (42 U.S.C. 1395x(r))) and practitioners (as 
16
defined in section 1834(m)(4)(E) of such Act (42 U.S.C. 
17
1395m(m)(4)(E))) educational resources and training ses-
18
sions on requirements relating to the furnishing of tele-
19
health services under section 1834(m) of such Act (42 
20
U.S.C. 1395m(m)). 
21
19:08 Nov 24, 2020
H14
367 
•HR 14 IH
Subtitle B—Protecting Access to 
1
Innovation During COVID–19 
2
SEC. 
9011. 
AUTHORIZING 
THE 
EXTENSION 
OF 
PASS- 
3
THROUGH STATUS UNDER THE MEDICARE 
4
PROGRAM FOR CERTAIN DRUGS AND DE-
5
VICES IMPACTED BY COVID–19. 
6
Section 1833(t)(6) of the Social Security Act (42 
7
U.S.C. 1395l(t)(6)) is amended by adding at the end the 
8
following new subparagraph: 
9
‘‘(K) 
AUTHORITY
TO
EXTEND
PASS- 
10
THROUGH
STATUS
FOR
CERTAIN
DRUGS
AND 
11
DEVICES IMPACTED BY COVID–19.— 
12
‘‘(i) IN
GENERAL.—Notwithstanding 
13
the preceding provisions of this paragraph, 
14
in the case of an eligible drug or device (as 
15
defined in clause (iv)), if the Secretary de-
16
termines, prior to or on the date of the ex-
17
piration of pass-through status for such 
18
drug or device (or, in the case of such a 
19
drug or device whose pass-through status 
20
expired before the date of the enactment of 
21
this subparagraph, not later than 30 days 
22
after such date), that the cost of such drug 
23
or device is unable to be accurately cal-
24
culated due to the effects of COVID–19, 
25
19:08 Nov 24, 2020
H14
368 
•HR 14 IH
the Secretary may extend the pass-through 
1
status of such eligible drug or device in ac-
2
cordance with clause (ii). 
3
‘‘(ii) 
EXTENSION.—The 
Secretary 
4
may extend the pass-through status of an 
5
eligible drug or device described in clause 
6
(i) with respect to which a determination 
7
has been made under such clause— 
8
‘‘(I) in the case of a drug or de-
9
vice whose period of pass-through sta-
10
tus expired during the emergency pe-
11
riod 
described 
in 
section 
12
1135(g)(1)(B) before the date of the 
13
enactment of this subparagraph, for a 
14
period beginning on the first day after 
15
such period of up to the number of 
16
days occurring during such period 
17
during which such drug or device had 
18
pass-through status; 
19
‘‘(II) in the case of a drug or de-
20
vice whose period of pass-through sta-
21
tus would otherwise expire during 
22
such emergency period on or after 
23
such date of enactment— 
24
19:08 Nov 24, 2020
H14
369 
•HR 14 IH
‘‘(aa) for the remainder of 
1
such period; and 
2
‘‘(bb) for a period beginning 
3
on the first day after such period 
4
of up to the number of days oc-
5
curring during such period dur-
6
ing which such drug or device 
7
had pass-through status (not tak-
8
ing into account any extension of 
9
such status pursuant to this sub-
10
clause); and 
11
‘‘(III) in the case of a drug or 
12
device not described in subclause (I) 
13
or (II), by the number of days occur-
14
ring during such emergency period 
15
during which such drug or device had 
16
pass-through status. 
17
‘‘(iii) SPECIAL RULES FOR ALREADY- 
18
EXPIRED
DRUGS
AND
DEVICES.—In the 
19
case of an eligible drug or device described 
20
in clause (ii)(I) for which payment under 
21
this subsection was packaged into a pay-
22
ment for a covered OPD service (or group 
23
of services) and whose period of pass- 
24
19:08 Nov 24, 2020
H14
370 
•HR 14 IH
through status is extended in accordance 
1
with such clause, the Secretary— 
2
‘‘(I) shall, for the period during 
3
which such extension is in effect for 
4
such drug or device— 
5
‘‘(aa) remove, during such 
6
period, the packaged costs of 
7
such drug or device (as deter-
8
mined by the Secretary) from the 
9
payment amount under this sub-
10
section for the covered OPD serv-
11
ice (or group of services) with 
12
which it is packaged; and 
13
‘‘(bb) not make any adjust-
14
ments to payment amounts under 
15
this subsection for a covered 
16
OPD service (or group of serv-
17
ices) for which no costs were re-
18
moved under subclause (I); and 
19
‘‘(II) may not, when calculating 
20
the cost of such drug or device at the 
21
end of such extension, take into ac-
22
count claims for such drug or device 
23
made while such drug or device was 
24
so packaged. 
25
19:08 Nov 24, 2020
H14
371 
•HR 14 IH
‘‘(iv) ELIGIBLE DRUG OR DEVICE DE-
1
FINED.—For purposes of this subpara-
2
graph, the term ‘eligible drug or device’ 
3
means a drug, biological, or device with 
4
pass-through status in effect during any 
5
portion of the emergency period described 
6
in section 1135(g)(1)(B) that will not be 
7
(or was not) separately payable upon the 
8
expiration of such status, but only if, in 
9
the case of a drug or biological, such drug 
10
or biological— 
11
‘‘(I) was payable based upon the 
12
wholesale acquisition cost of such 
13
drug or biological in lieu of the aver-
14
age sales price of such drug or biologi-
15
cal on the first date of such emer-
16
gency period; and 
17
‘‘(II) will be (or was) packaged 
18
into a payment for a covered OPD 
19
service (or group of services) upon ex-
20
piration of such status.’’. 
21
19:08 Nov 24, 2020
H14
372 
•HR 14 IH
Subtitle C—Reducing Unnecessary 
1
Senior Hospitalizations 
2
SEC. 9021. SNF-BASED PROVISION OF PREVENTIVE ACUTE 
3
CARE AND HOSPITALIZATION REDUCTION 
4
PROGRAM. 
5
Title XVIII of the Social Security Act is amended by 
6
adding at the end the following new section: 
7
‘‘SEC. 
1899C. 
SNF-BASED 
PROVISION 
OF 
PREVENTIVE 
8
ACUTE CARE AND HOSPITALIZATION REDUC-
9
TION PROGRAM. 
10
‘‘(a) ESTABLISHMENT.—There is established a pro-
11
gram to be known as the ‘SNF-based Provision of Preven-
12
tive Acute Care and Hospitalization Reduction Program’ 
13
(in this section referred to as the ‘Program’), to be admin-
14
istered by the Secretary, for purposes of reducing unneces-
15
sary hospitalizations and emergency department visits by 
16
allowing qualified group practices (as defined in section 
17
1877(h)(4)) on or after January 1, 2022, to furnish items 
18
and services identified under subsection (b)(3) to individ-
19
uals entitled to benefits under part A and enrolled under 
20
part B residing in qualified skilled nursing facilities. 
21
‘‘(b) OPERATION
OF PROGRAM.—Under the Pro-
22
gram, the Secretary shall provide for the following: 
23
19:08 Nov 24, 2020
H14
373 
•HR 14 IH
‘‘(1) Certification of skilled nursing facilities as 
1
qualified skilled nursing facilities under subsection 
2
(c)(1). 
3
‘‘(2) Certification of group practices as quali-
4
fied group practices under subsection (c)(2). 
5
‘‘(3) Identification of minimum required non-
6
surgical items and services furnished at a hospital 
7
emergency department that may be safely furnished 
8
by a qualified group practice at a qualified skilled 
9
nursing facility under the Program, as determined 
10
as clinically appropriate by the Secretary, and that 
11
such qualified group practice shall offer to furnish 
12
under the Program. 
13
‘‘(4) Annual identification of additional items 
14
and services furnished at a hospital emergency de-
15
partment that may be safely furnished by a qualified 
16
group practice at a qualified skilled nursing facility 
17
under the Program during a year and that such 
18
qualified group practice may offer to furnish under 
19
the Program during such year. 
20
‘‘(5) Establishment of qualifications for non-
21
physician employees who may furnish such items 
22
and services at a qualified skilled nursing facility. 
23
Such qualifications shall include the requirement 
24
that such an employee— 
25
19:08 Nov 24, 2020
H14
374 
•HR 14 IH
‘‘(A) be certified in basic life support by a 
1
nationally recognized specialty board of certifi-
2
cation or equivalent certification board; and 
3
‘‘(B) have— 
4
‘‘(i) 
clinical 
experience 
furnishing 
5
medical care— 
6
‘‘(I) in a skilled nursing facility; 
7
‘‘(II) in a hospital emergency de-
8
partment setting; or 
9
‘‘(III) as an employee of a pro-
10
vider or supplier of ambulance serv-
11
ices; or 
12
‘‘(ii) a certification in paramedicine. 
13
‘‘(6) Payment under this title for items and 
14
services identified under paragraph (3) or (4) fur-
15
nished by such qualified group practices at such a 
16
facility in amounts determined under subsection (d). 
17
‘‘(c) CERTIFICATIONS.— 
18
‘‘(1) QUALIFIED
SKILLED
NURSING
FACILI-
19
TIES.—For purposes of this section, the Secretary 
20
shall certify a skilled nursing facility as a qualified 
21
skilled nursing facility if the facility submits an ap-
22
plication in a time and manner specified by the Sec-
23
retary and meets the following requirements: 
24
19:08 Nov 24, 2020
H14
375 
•HR 14 IH
‘‘(A) The facility has on-site diagnostic 
1
equipment necessary for a qualified group prac-
2
tice to furnish items and services under the 
3
Program and real-time audio and visual capa-
4
bilities. 
5
‘‘(B) The facility has at least one indi-
6
vidual who meets the qualifications described in 
7
paragraph (5) or a physician present 24 hours 
8
a day and 7 days a week to work with the 
9
qualified group practice. Such individual may 
10
be a member of the staff of the qualified skilled 
11
nursing facility or of the qualified group prac-
12
tice. 
13
‘‘(C) The facility ensures that residents of 
14
such facility, upon entering such facility, are al-
15
lowed to specify in an advanced care directive 
16
whether the resident wishes to receive items 
17
and services furnished at the facility under the 
18
Program in a case where communication with 
19
the resident is not possible. 
20
‘‘(D) The facility ensures that individuals 
21
to be furnished such items and services under 
22
the Program at such facility have the oppor-
23
tunity, at their request, to instead be trans-
24
ported to a hospital emergency department. 
25
19:08 Nov 24, 2020
H14
376 
•HR 14 IH
‘‘(E) The facility is not part of the Special 
1
Focus Facility program of the Centers for 
2
Medicare & Medicaid Services (although the fa-
3
cility may, at the discretion of the Secretary, be 
4
a candidate for selection under such program). 
5
Nothing in this paragraph shall affect the require-
6
ments under section 1819(b)(4). 
7
‘‘(2) QUALIFIED GROUP PRACTICES.—For pur-
8
poses of this section, the Secretary shall certify a 
9
group practice as a qualified group practice for a pe-
10
riod of 3 years if the group practice submits an ap-
11
plication in a time and manner specified by the Sec-
12
retary and meets the following requirements: 
13
‘‘(A) The group practice offers to furnish 
14
all minimum required items and services identi-
15
fied under subsection (b)(3) under the Pro-
16
gram. 
17
‘‘(B) The group practice submits a notifi-
18
cation to the Secretary annually specifying 
19
which (if any) additional items and services 
20
identified under subsection (b)(4) for a year the 
21
group practice will offer to furnish for such 
22
year under the Program. 
23
‘‘(C) The group practice ensures that only 
24
individuals who meet the qualifications estab-
25
19:08 Nov 24, 2020
H14
377 
•HR 14 IH
lished under subsection (b)(5) or a physician 
1
who is part of such group practice may furnish 
2
such minimum required items and services and 
3
such additional items and services. 
4
‘‘(D) The group practice ensures that, in 
5
the case where such minimum required items 
6
and services or such additional items and serv-
7
ices are furnished by such an individual, such 
8
individual furnishes such minimum required 
9
items and services or additional items and serv-
10
ices under the supervision, either in-person or 
11
through the use of telehealth (not including 
12
store-and-forward technologies), of— 
13
‘‘(i) a physician— 
14
‘‘(I) who is board certified or 
15
board eligible in emergency medicine, 
16
family medicine, geriatrics, or internal 
17
medicine; or 
18
‘‘(II) who has been certified by a 
19
nationally recognized specialty board 
20
of certification or equivalent certifi-
21
cation board in basic life support; 
22
‘‘(ii) a nurse practitioner who has 
23
been certified by a nationally recognized 
24
specialty board of certification or equiva-
25
19:08 Nov 24, 2020
H14
378 
•HR 14 IH
lent certification board in basic life sup-
1
port; or 
2
‘‘(iii) a physician assistant who has 
3
been certified by a nationally recognized 
4
specialty board of certification or equiva-
5
lent certification board in basic life sup-
6
port. 
7
‘‘(E) With respect to any year in which the 
8
qualified group practice would participate in the 
9
Program, the Chief Actuary for the Centers for 
10
Medicare & Medicaid Services determines that 
11
such participation during such year will not re-
12
sult in total estimated expenditures under this 
13
title for such year being greater than total esti-
14
mated expenditures under such title for such 
15
year without such participation. 
16
‘‘(d) PAYMENTS.— 
17
‘‘(1) IN GENERAL.—For 2022 and each subse-
18
quent year, the Secretary shall develop a schedule of 
19
payments to apply for items and services identified 
20
under paragraph (3) or paragraph (4) of subsection 
21
(b) furnished during such year under the Program. 
22
Such payments shall be in lieu of any other pay-
23
ments that may be made under this title for such 
24
items and services. 
25
19:08 Nov 24, 2020
H14
379 
•HR 14 IH
‘‘(2) SHARED SAVINGS.—In the case of a year 
1
for which the Secretary determines that participa-
2
tion in the Program resulted in a reduction in ex-
3
penditures under this title compared to what such 
4
expenditures would have been without such partici-
5
pation, the Secretary shall— 
6
‘‘(A) pay to such qualified group practice 
7
an amount equal to 37.5 percent of the esti-
8
mated amount of such reduction; and 
9
‘‘(B) in the case of each qualified skilled 
10
nursing facility where such qualified group 
11
practice furnished items and services under the 
12
Program during such year— 
13
‘‘(i) if the qualified skilled nursing fa-
14
cility has at least a three-star rating under 
15
the Five Star Quality Rating System (or a 
16
successor system), pay to the facility an 
17
amount that bears the same ratio to 12.5 
18
percent of the estimated amount of such 
19
reduction as the amount of expenditures 
20
under the Program for such items and 
21
services furnished with respect to individ-
22
uals at such facility by such qualified 
23
group practice during such year bears to 
24
the total amount of expenditures under the 
25
19:08 Nov 24, 2020
H14
380 
•HR 14 IH
Program for such items and services fur-
1
nished with respect to all individuals by 
2
such qualified group practice during such 
3
year; and 
4
‘‘(ii) in the case of a qualified skilled 
5
nursing facility that is not described in 
6
clause (i), retain in the Federal Hospital 
7
Insurance Trust Fund under section 1817 
8
the amount that the facility would have 
9
been paid pursuant to clause (i) if the fa-
10
cility were described in such clause until 
11
such time as the facility has at least a 
12
three-star rating under the Five Star Qual-
13
ity Rating System (or a successor system), 
14
at which point the Secretary shall pay such 
15
amount to the facility. 
16
‘‘(3) ADVANCED ALTERNATIVE PAYMENT MOD-
17
ELS.—Paragraph (2) shall not apply to items and 
18
services furnished to an individual entitled to bene-
19
fits under part A and enrolled under part B for 
20
whom shared savings would otherwise be attributed 
21
through an advanced alternative payment model as 
22
authorized under section 1115A or section 1899. 
23
‘‘(e) EVALUATION.— 
24
19:08 Nov 24, 2020
H14
381 
•HR 14 IH
‘‘(1) IN GENERAL.—With respect to a qualified 
1
group practice and a qualified skilled nursing facil-
2
ity, not later than 6 months after such group prac-
3
tice begins furnishing items and services under the 
4
Program (or, in the case of a qualified skilled nurs-
5
ing facility, not less than 6 months after a qualified 
6
group practice first furnishes such items and serv-
7
ices at such facility), and not less than once every 
8
2 years thereafter, the Secretary shall evaluate such 
9
qualified group practice and such qualified facility 
10
using information received under paragraph (2) on 
11
such criteria as determined appropriate by the Sec-
12
retary. 
13
‘‘(2) REPORTING OF INFORMATION.—In a time 
14
and manner specified by the Secretary, a qualified 
15
group practice and a qualified skilled nursing facility 
16
shall submit to the Secretary a report containing the 
17
following information with respect to items and serv-
18
ices furnished under the Program during a reporting 
19
period (as specified by the Secretary): 
20
‘‘(A) The number of individuals with re-
21
spect to whom such group practice furnished 
22
such items and services in such period (or, in 
23
the case of a qualified skilled nursing facility, 
24
the number of individuals with respect to whom 
25
19:08 Nov 24, 2020
H14
382 
•HR 14 IH
such a group practice furnished such items and 
1
services at such facility in such period). 
2
‘‘(B) The number of such individuals who 
3
were admitted to a hospital or treated in the 
4
emergency department of a hospital within 24 
5
hours of being furnished such items and serv-
6
ices. 
7
‘‘(C) Other information determined appro-
8
priate by the Secretary. 
9
‘‘(3) LOSS OF QUALIFIED CERTIFICATION.— 
10
‘‘(A) IN
GENERAL.—Not later than 3 
11
months after a determination described in this 
12
sentence is made, the Secretary may revoke the 
13
certification of a qualified skilled nursing facil-
14
ity or a qualified group practice made under 
15
subsection (c) if— 
16
‘‘(i) the Chief Actuary of the Centers 
17
for Medicare & Medicaid Services deter-
18
mines that the participation of such skilled 
19
nursing facility or such group practice in 
20
the Program during a year resulted in 
21
total expenditures under this title for such 
22
period being greater than total expendi-
23
tures under such title would have been 
24
19:08 Nov 24, 2020
H14
383 
•HR 14 IH
during such period without such participa-
1
tion; or 
2
‘‘(ii) a facility is selected for the Spe-
3
cial Focus Facility program or, if the facil-
4
ity is a candidate for the Special Focus 
5
Facility program, the Secretary determines 
6
that the participation of such facility in the 
7
Program should be terminated. 
8
‘‘(B) EXCLUSION FROM CERTIFICATION.— 
9
‘‘(i) IN GENERAL.—In the case that 
10
the Secretary revokes the certification of a 
11
qualified skilled nursing facility or a quali-
12
fied group practice under subparagraph 
13
(A), such skilled nursing facility or such 
14
group practice shall be ineligible for certifi-
15
cation as a qualified skilled nursing facility 
16
or a qualified group practice (as applica-
17
ble) under subsection (c) for the applicable 
18
period (as defined under clause (ii)). 
19
‘‘(ii) 
APPLICABLE
PERIOD
DE-
20
FINED.—In this subparagraph, the term 
21
‘applicable period’ means— 
22
‘‘(I) if the revocation of a facility 
23
or group practice under subparagraph 
24
(A) is due to the application of clause 
25
19:08 Nov 24, 2020
H14
384 
•HR 14 IH
(i) of such subparagraph, a 1-year pe-
1
riod beginning on the date of such 
2
revocation; and 
3
‘‘(II) in the revocation of a facil-
4
ity under subparagraph (A) is due to 
5
the application of clause (ii) of such 
6
subparagraph, the period beginning 
7
on the date of such revocation and 
8
ending on the date on which the facil-
9
ity graduates from the Special Focus 
10
Facility program (or, in the case of a 
11
facility that is a candidate for such 
12
program, the date on which the facil-
13
ity is no longer such a candidate, as 
14
determined by the Secretary). 
15
‘‘(f) DETERMINATION
OF BUDGET NEUTRALITY; 
16
TERMINATION OF PROGRAM.— 
17
‘‘(1) DETERMINATION.—Not later than July 1, 
18
2027, the Chief Actuary of the Centers for Medicare 
19
& Medicaid Services shall determine whether the 
20
Program has resulted in an increase in total expend-
21
itures under this title with respect to the period be-
22
ginning on January 1, 2022, and ending on Decem-
23
ber 31, 2026, compared to what such expenditures 
24
19:08 Nov 24, 2020
H14
385 
•HR 14 IH
would have been during such period had the Pro-
1
gram not been in operation. 
2
‘‘(2) TERMINATION.—If the Chief Actuary 
3
makes a determination under paragraph (1) that the 
4
Program has resulted in an increase in total expend-
5
itures under this title, the Secretary shall terminate 
6
the Program as of January 1 of the first year begin-
7
ning after such determination.’’. 
8
TITLE X—APPROPRIATIONS 
9
APPROPRIATIONS 
10
SEC. 10001. The following sums are hereby appro-
11
priated, out of any money in the Treasury not otherwise 
12
appropriated, for the fiscal year ending September 30, 
13
2021, and for other purposes, namely: 
14
Subtitle A—Health Programs 
15
DEPARTMENT OF HEALTH AND HUMAN 
16
SERVICES 
17
OFFICE OF THE SECRETARY 
18
PUBLIC HEALTH AND SOCIAL SERVICES EMERGENCY 
19
FUND 
20
(INCLUDING TRANSFER OF FUNDS) 
21
For an additional amount for ‘‘Public Health and So-
22
cial Services Emergency Fund’’, $31,000,000,000, to re-
23
main available until September 30, 2025, to prevent, pre-
24
pare for, and respond to coronavirus, domestically or 
25
19:08 Nov 24, 2020
H14
386 
•HR 14 IH
internationally, including the development of necessary 
1
countermeasures and vaccines, prioritizing platform-based 
2
technologies with United States-based manufacturing ca-
3
pabilities, 
the 
purchase 
of 
vaccines, 
therapeutics, 
4
diagnostics, necessary medical supplies, as well as medical 
5
surge capacity, addressing blood supply chain, workforce 
6
modernization, telehealth access and infrastructure, initial 
7
advanced manufacturing, novel dispensing, enhancements 
8
to the United States Commissioned Corps, and other pre-
9
paredness and response activities: Provided, That funds 
10
appropriated under this paragraph in this title may be 
11
used to develop and demonstrate innovations and enhance-
12
ments to manufacturing platforms to support such capa-
13
bilities: Provided further, That the Secretary of Health 
14
and Human Services shall purchase vaccines developed 
15
using funds made available under this paragraph in this 
16
title to respond to an outbreak or pandemic related to 
17
coronavirus in quantities determined by the Secretary to 
18
be adequate to address the public health need: Provided 
19
further, That products purchased by the Federal Govern-
20
ment with funds made available under this paragraph in 
21
this title, including vaccines, therapeutics, and diagnostics, 
22
shall be purchased in accordance with Federal Acquisition 
23
Regulation guidance on fair and reasonable pricing: Pro-
24
vided further, That the Secretary may take such measures 
25
19:08 Nov 24, 2020
H14
387 
•HR 14 IH
authorized under current law to ensure that vaccines, 
1
therapeutics, and diagnostics developed from funds pro-
2
vided in this title will be affordable in the commercial mar-
3
ket: Provided further, That in carrying out the previous 
4
proviso, the Secretary shall not take actions that delay the 
5
development of such products: Provided further, That the 
6
Secretary shall ensure that protections remain for individ-
7
uals enrolled in group or individual health care coverage 
8
with pre-existing conditions, including those linked to 
9
coronavirus: Provided further, That products purchased 
10
with funds appropriated under this paragraph in this title 
11
may, at the discretion of the Secretary of Health and 
12
Human Services, be deposited in the Strategic National 
13
Stockpile under section 319F–2 of the Public Health Serv-
14
ice Act: Provided further, That of the amount appropriated 
15
under this paragraph in this title, not more than 
16
$2,000,000,000 shall be for the Strategic National Stock-
17
pile under section 319F–2(a) of such Act: Provided fur-
18
ther, That funds appropriated under this paragraph in this 
19
title may be transferred to, and merged with, the fund 
20
authorized by section 319F–4, the Covered Counter meas-
21
ure Process Fund, of the Public Health Service Act: Pro-
22
vided further, That of the amount appropriated under this 
23
paragraph in this title, not more than $2,000,000,000, to 
24
remain available until September 30, 2023, shall be for 
25
19:08 Nov 24, 2020
H14
388 
•HR 14 IH
activities to improve and sustain State medical stockpiles: 
1
Provided further, That of the amount appropriated under 
2
this paragraph in this title, $20,000,000,000 shall be 
3
available to the Biomedical Advanced Research and Devel-
4
opment Authority for necessary expenses of manufac-
5
turing, production, and purchase, at the discretion of the 
6
Secretary, of vaccines, therapeutics, diagnostics, and small 
7
molecule active pharmaceutical ingredients, including the 
8
development, translation, and demonstration at scale of 
9
innovations in manufacturing platforms: Provided further, 
10
That funds in the previous proviso may be used for the 
11
construction or renovation of United States-based next 
12
generation manufacturing facilities, other than facilities 
13
owned by the United States Government: Provided further, 
14
That amounts provided in the eleventh proviso may be for 
15
necessary expenses related to the sustained on-shore man-
16
ufacturing capacity for public health emergencies: Pro-
17
vided further, That of the amount appropriated under this 
18
paragraph in this title, $6,000,000,000 shall be for activi-
19
ties to plan, prepare for, promote, distribute, administer, 
20
monitor, and track coronavirus vaccines to ensure broad- 
21
based distribution, access, and vaccine coverage: Provided 
22
further, That the Secretary shall coordinate funding and 
23
activities outlined in the previous proviso through the Di-
24
rector of the Centers for Disease Control and Prevention: 
25
19:08 Nov 24, 2020
H14
389 
•HR 14 IH
Provided further, That the Secretary, through the Director 
1
of the Centers for Disease Control and Prevention, shall 
2
report to the Committees on Appropriations of the House 
3
of Representatives and the Senate within 60 days of the 
4
date of enactment of this title on a comprehensive 
5
coronavirus vaccine distribution strategy and spend plan 
6
that includes how existing infrastructure will be leveraged, 
7
enhancements or new infrastructure that may be built, 
8
considerations for moving and storing vaccines, guidance 
9
for how States and health care providers should prepare 
10
for, store, and administer vaccines, nationwide vaccination 
11
targets, funding that will be distributed to States, how an 
12
informational campaign to both the public and health care 
13
providers will be executed, and how the vaccine distribu-
14
tion plan will focus efforts on high risk, underserved, and 
15
minority populations: Provided further, That such plan 
16
shall be updated and provided to the Committees on Ap-
17
propriations of the House of Representatives and the Sen-
18
ate 90 days after submission of the first plan: Provided 
19
further, That the Secretary shall notify the Committees 
20
on Appropriations of the House of Representatives and the 
21
Senate 2 days in advance of any obligation in excess of 
22
$50,000,000, including contracts and interagency agree-
23
ments, from funds provided in this paragraph in this title: 
24
Provided further, That funds appropriated under this 
25
19:08 Nov 24, 2020
H14
390 
•HR 14 IH
paragraph in this title may be used for the construction, 
1
alteration, or renovation of nonfederally owned facilities 
2
for the production of vaccines, therapeutics, diagnostics, 
3
and medical supplies where the Secretary determines that 
4
such a contract is necessary to secure sufficient amounts 
5
of such supplies: Provided further, That not later than 30 
6
days after enactment of this title, and every 30 days there-
7
after until funds are expended, the Secretary shall report 
8
to the Committees on Appropriations of the House of Rep-
9
resentatives and the Senate on uses of funding for Oper-
10
ation Warp Speed, detailing current obligations by De-
11
partment or Agency, or component thereof broken out by 
12
the coronavirus supplemental appropriations Act that pro-
13
vided the source of funds: Provided further, That the plan 
14
outlined in the previous proviso shall include funding by 
15
contract, grant, or other transaction in excess of 
16
$20,000,000 with a notation of which Department or 
17
Agency, and component thereof is managing the contract: 
18
Provided further, That such amount is designated by the 
19
Congress as being for an emergency requirement pursuant 
20
to section 251(b)(2)(A)(i) of the Balanced Budget and 
21
Emergency Deficit Control Act of 1985. 
22
For an additional amount for ‘‘Public Health and So-
23
cial Services Emergency Fund’’, $16,000,000,000, to re-
24
main available until September 30, 2023, to prevent, pre-
25
19:08 Nov 24, 2020
H14
391 
•HR 14 IH
pare for, and respond to coronavirus, domestically or 
1
internationally, which shall be for necessary expenses for 
2
testing, contact tracing, surveillance, containment, and 
3
mitigation to monitor and suppress COVID–19, including 
4
tests for both active infection and prior exposure, includ-
5
ing molecular, antigen, and serological tests, the manufac-
6
turing, procurement and distribution of tests, testing 
7
equipment and testing supplies, including personal protec-
8
tive equipment needed for administering tests, the devel-
9
opment and validation of rapid, molecular point-of-care 
10
tests, and other tests, support for workforce, epidemiology, 
11
to scale up academic, commercial, public health, and hos-
12
pital laboratories, to conduct surveillance and contact 
13
tracing, support development of COVID–19 testing plans, 
14
and other related activities related to COVID–19 testing: 
15
Provided, That of the amount appropriated under this 
16
paragraph in this title, not less than $15,000,000,000 
17
shall be for States, localities, territories, Tribes, Tribal or-
18
ganizations, urban Indian health organizations, or health 
19
service providers to Tribes for necessary expenses for test-
20
ing, contact tracing, surveillance, containment, and miti-
21
gation, including support for workforce, epidemiology, use 
22
by employers, elementary and secondary schools, child 
23
care facilities, institutions of higher education, long-term 
24
care facilities, or in other settings, scale up of testing by 
25
19:08 Nov 24, 2020
H14
392 
•HR 14 IH
public health, academic, commercial, and hospital labora-
1
tories, and community-based testing sites, health care fa-
2
cilities, and other entities engaged in COVID–19 testing, 
3
and other related activities related to COVID–19 testing, 
4
contact tracing, surveillance, containment, and mitigation: 
5
Provided further, That the amount provided in the pre-
6
ceding proviso shall be made available within 30 days of 
7
the date of enactment of this title: Provided further, That 
8
the amount identified in the first proviso under this para-
9
graph in this title shall be allocated to States, localities, 
10
and territories according to the formula that applied to 
11
the Public Health Emergency Preparedness cooperative 
12
agreement in fiscal year 2019: Provided further, That not 
13
less than $500,000,000 shall be allocated in coordination 
14
with the Director of the Indian Health Service, to Tribes, 
15
Tribal organizations, urban Indian health organizations, 
16
or health service providers to Tribes: Provided further, 
17
That the Secretary of Health and Human Services (re-
18
ferred to in this paragraph as the ‘‘Secretary’’) may sat-
19
isfy the funding thresholds outlined in the first and fourth 
20
provisos under this paragraph in this title by making 
21
awards through other grant or cooperative agreement 
22
mechanisms: Provided further, That the Governor or des-
23
ignee of each State, locality, territory, Tribe, or Tribal or-
24
ganization receiving funds pursuant to this title shall up-
25
19:08 Nov 24, 2020
H14
393 
•HR 14 IH
date their plans, as applicable, for COVID–19 testing and 
1
contact tracing submitted to the Secretary pursuant to the 
2
Paycheck Protection Program and Health Care Enhance-
3
ment Act (Public Law 116–139) and submit such updates 
4
to the Secretary not later than 60 days after funds appro-
5
priated in this paragraph in this title have been awarded 
6
to such recipient: Provided further, That not later than 
7
60 days after the date of enactment, and every quarter 
8
thereafter until funds are expended, the Governor or des-
9
ignee of each State, locality, territory, Tribe, or Tribal or-
10
ganization receiving funds shall report to the Secretary on 
11
uses of funding, detailing current commitments and obli-
12
gations broken out by the coronavirus supplemental appro-
13
priations Act that provided the source of funds: Provided 
14
further, That not later than 15 days after receipt of such 
15
reports, the Secretary shall summarize and report to the 
16
Committees on Appropriations of the House of Represent-
17
atives and the Senate on States’ commitments and obliga-
18
tions of funding: Provided further, That funds an entity 
19
receives from amounts described in the first proviso in this 
20
paragraph may also be used for the rent, lease, purchase, 
21
acquisition, construction, alteration, renovation, or equip-
22
ping 
of 
nonfederally 
owned 
facilities 
to 
improve 
23
coronavirus preparedness and response capability at the 
24
State and local level: Provided further, That such amount 
25
19:08 Nov 24, 2020
H14
394 
•HR 14 IH
is designated by the Congress as being for an emergency 
1
requirement pursuant to section 251(b)(2)(A)(i) of the 
2
Balanced Budget and Emergency Deficit Control Act of 
3
1985. 
4
Subtitle B—General Provisions–This Title 
5
SEC. 10101. Each amount appropriated or made 
6
available by this title is in addition to amounts otherwise 
7
appropriated for the fiscal year involved. 
8
SEC. 10102. No part of any appropriation contained 
9
in this title shall remain available for obligation beyond 
10
the current fiscal year unless expressly so provided herein. 
11
SEC. 10103. Unless otherwise provided for by this 
12
title, the additional amounts appropriated by this title to 
13
appropriations accounts shall be available under the au-
14
thorities and conditions applicable to such appropriations 
15
accounts for fiscal year 2020. 
16
SEC. 10104. In this title, the term ‘‘coronavirus’’ 
17
means SARS–CoV–2 or another coronavirus with pan-
18
demic potential. 
19
SEC. 10105. Each amount designated in this title by 
20
the Congress as being for an emergency requirement pur-
21
suant to section 251(b)(2)(A)(i) of the Balanced Budget 
22
and Emergency Deficit Control Act of 1985 shall be avail-
23
able (or rescinded or transferred, if applicable) only if the 
24
19:08 Nov 24, 2020
H14
395 
•HR 14 IH
President subsequently so designates all such amounts 
1
and transmits such designations to the Congress. 
2
SEC. 10106. Any amount appropriated by this title, 
3
designated by the Congress as an emergency requirement 
4
pursuant to section 251(b)(2)(A)(i) of the Balanced Budg-
5
et and Emergency Deficit Control Act of 1985 and subse-
6
quently so designated by the President, and transferred 
7
pursuant to transfer authorities provided by this title shall 
8
retain such designation. 
9
SEC. 10107. (a) STATUTORY PAYGO SCORECARDS.— 
10
The budgetary effects of this title shall not be entered on 
11
either PAYGO scorecard maintained pursuant to section 
12
4(d) of the Statutory Pay As-You-Go Act of 2010. 
13
(b) SENATE PAYGO SCORECARDS.—The budgetary 
14
effects of this title shall not be entered on any PAYGO 
15
scorecard maintained for purposes of section 4106 of H. 
16
Con. Res. 71 (115th Congress). 
17
(c) CLASSIFICATION
OF BUDGETARY EFFECTS.— 
18
Notwithstanding Rule 3 of the Budget Scorekeeping 
19
Guidelines set forth in the joint explanatory statement of 
20
the committee of conference accompanying Conference Re-
21
port 105–217 and section 250(c)(7) and (c)(8) of the Bal-
22
anced Budget and Emergency Deficit Control Act of 1985, 
23
the budgetary effects of this title shall be estimated for 
24
purposes of section 251 of such Act. 
25
19:08 Nov 24, 2020
H14
396 
•HR 14 IH
(d) ENSURING NO WITHIN-SESSION SEQUESTRA-
1
TION.—Solely for the purpose of calculating a breach with-
2
in a category for fiscal year 2020 pursuant to section 
3
251(a)(6) or section 254(g) of the Balanced Budget and 
4
Emergency Deficit Control Act of 1985, and notwith-
5
standing any other provision of this title, the budgetary 
6
effects from this title shall be counted as amounts des-
7
ignated as being for an emergency requirement pursuant 
8
to section 251(b)(2)(A) of such Act. 
9
This title may be cited as the ‘‘Coronavirus Response 
10
Additional Supplemental Appropriations Act, 2020’’. 
11
Æ 
19:08 Nov 24, 2020
H14
